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Aqui nesta praia onde 
Não há nenhum vestígio de impureza, 
Aqui onde há somente  
Ondas tombando ininterruptamente, 
Puro espaço e lúcida unidade, 
Aqui o tempo apaixonadamente 
Encontra a própria liberdade. 
 





“We know accurately only when we know little; doubt grows with knowledge.”  
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 Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS) 
physiologic role remain controversial. Central nervous system and behavioral effects have 
been described. DHEA and DHEAS have been hypothesised to play a role in cortical 
organization and brain maturation and suggested to have memory, attention and mood 
enhancement effects in humans. A neuro-stimulatory action and an anti-cortisol 
mechanism of action may contribute to those effects. Moreover, the balance between 
DHEA and DHEAS may modulate their effects in the central nervous system. The objective 
of this thesis was to explore behavioral correlates of DHEA and DHEAS in humans, in 
particular regarding personality, stress response, working memory and emotion. 
Relations at the performance and brain processing levels were explored. DHEA response 
to the performance of cognitive tasks was also analyzed.  
 In study I we explored the relation between DHEAS and both pituitary-adrenal axis 
reactivity and personality in human subjects of both genders. This was a retrospective 
study of 120 patients assisted at the endocrine outpatient department of a public central 
Portuguese hospital, before medical treatment. Personality was evaluated with the 
Minnesota Multiphasic Personality Inventory (MMPI) and the pituitary-adrenal axis 
reactivity was assessed with the corticotrophin releasing hormone (CRH) test. Baseline 
serum DHEAS was inversely related to peak/baseline cortisol response to CRH infusion. 
DHEAS reactivity in the CRH test was directly related to the Deviant Behavior triad and 
type A personality. These results suggest higher DHEAS levels may be a protective factor 
against an excessive cortisol response under stressful situations and personality may be 
related to DHEAS reactivity. 
 In studies II and III DHEA, DHEAS and cortisol relations to working memory and 
distraction were studied by recording the electroencephalogram of 23 young women 
performing a discriminatory (no working memory load) or 1-back (working memory load) 
task in an audio-visual oddball paradigm. We measured salivary DHEA, DHEAS and cortisol 
both before each task and at 30 and 60 min intervals. In study II, we showed that under 
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working memory load, a higher baseline cortisol/DHEA ratio was related to higher 
distraction as indexed by an enhanced novelty-P3. This suggests that cortisol may lead to 
increased distraction whereas DHEA may hinder distraction by leading to lower 
processing of the distractor. An increased DHEA production with consecutive cognitive 
tasks was found, and higher DHEA responses attributed to working memory load were 
related to enhanced working memory processing as indexed by an enhanced visual P300. 
Overall, the results suggest that in women DHEA may oppose cortisol effects, reducing 
distraction and that a higher DHEA response may enhance working memory at the 
electrophysiological level. In study III we used that same group of subjects and protocol to 
analyze the DHEAS/DHEA ratio relation to involuntary attention during the performance 
of a working memory task. Higher DHEAS/DHEA ratio was related to enhanced auditory 
novelty-P3 amplitudes during the performance of the working memory task, but there 
was no significant relation to visual P300 amplitudes, novelty-P3 latencies or visual P300 
latencies. Therefore, a relation between higher DHEAS/DHEA ratio and enhanced 
involuntary attention to the surrounding world without a deleterious effect on working 
memory processing is suggested. These results also suggest that the balance between 
DHEAS and DHEA may modulate attentional resources and the importance of the 
sulfotransferase and sulfatase activity in the modulation of DHEA and DHEAS central 
nervous system effects. 
 In study IV we explored DHEAS, DHEA and cortisol relations to the processing of 
negative emotional stimuli at behavioral and brain levels by recording the 
electroencephalogram of 21 young women while performing a visual task with implicit 
neutral or negative emotional content in an audio-visual oddball paradigm. For each 
condition, salivary DHEA, DHEAS and cortisol were measured before performing the task, 
and at 30 and 60 min intervals. DHEA increased after task performance, independently of 
the implicit emotional content. With implicit negative emotion, higher DHEAS/DHEA and 
DHEA/cortisol ratios before task performance were related to shorter visual P300 
latencies suggesting faster brain processing under a negative emotional context. In 
addition, higher DHEAS/DHEA ratios were related to reduced visual P300 amplitudes, 
indicating less processing of the negative emotional stimuli. With this study, we could 
show that at the electrophysiological level, higher DHEAS/DHEA and DHEA/cortisol ratios 
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were related to shorter stimulus evaluation times, suggesting less interference of the 
implicit negative content of the stimuli with the task. Furthermore, higher DHEAS/DHEA 
ratios were related to reduced processing of negative emotional stimuli which may 
eventually constitute a protective mechanism against negative information overload. 
 In conclusion, these studies showed several behavioral correlates of DHEA and 
DHEAS. Additionally, the results suggest anti-cortisol effects of DHEA and DHEAS and the 
importance of the balance between DHEAS and DHEA. DHEA levels increased after the 
performance of cognitive tasks, more so after a working memory load than a no working 
memory load task, suggesting that cognitive tasks may modulate DHEA levels. Higher 
baseline DHEAS levels were related to reduced cortisol response to CRH suggesting a 
protective effect during the stress response. In addition, significant new findings were 
described regarding DHEA and DHEAS relations to working memory, emotion and 
attention at the brain processing level. Those results suggest DHEA may eventually 
oppose cortisol effects reducing distraction while higher DHEAS/DHEA ratios may 
enhance involuntary attention to the surrounding world during the performance of 
working memory tasks with no evident deleterious effects on the working memory load 
task in course. On the other hand, higher DHEA response may enhance working memory 
at the electrophysiological level. Regarding emotional processing, higher DHEAS/DHEA 
and DHEA/cortisol ratios may be related to less interference of the implicit negative 
content of the stimuli and higher DHEAS/DHEA ratios were related to reduced processing 
of negative emotional stimuli which may eventually protect against negative information 
overload. In short, results suggest DHEAS levels may be related to personality and 
reduced cortisol stress response while studies at brain processing level suggest DHEA 
and/or DHEAS may enhance working memory / attention and reduce the processing of 
negative information. 
 





A desidroepiandrosterona (DHEA) é sintetizada nas suprarrenais, mas também nas 
gónadas e ao nível do sistema nervoso central. É reversivelmente convertida em 
desidroepiandrosterona-sulfato (DHEAS) por ação de uma sulfotransferase, quer na 
periferia, quer no sistema nervoso central. DHEA e DHEAS são hormonas abundantes nos 
primatas, em especial nos seres humanos e a concentração de ambas é maior no sistema 
nervoso central que na circulação periférica. A forma como é regulada a sua síntese não 
está definida, mas as suas concentrações aumentam em situações de stress agudo e 
reduzem em situações de stress crónico. A partir da quarta década de vida as suas 
concentrações reduzem-se progressivamente e níveis mais reduzidos relacionam-se com 
maior morbilidade e mortalidade, independentemente da idade. 
 Os efeitos fisiológicos e os mecanismos de ação da DHEA e DHEAS são ainda 
controversos. Contudo, muitos estudos têm sugerido efeitos ao nível do sistema nervoso 
central. Foi colocada a hipótese de contribuírem para a organização cortical e 
desenvolvimento cerebral e em particular, têm sido sugeridos efeitos benéficos em 
relação à memória, atenção e humor. Níveis mais elevados de DHEAS, DHEA ou da razão 
DHEA/cortisol foram relacionados com melhor desempenho cognitivo, menos sintomas 
depressivos e níveis mais elevados de bem-estar. Tem sido colocada a hipótese de esses 
efeitos serem mediados em parte, através de mecanismos de ação anti-cortisol e neuro-
estimulantes. De facto, a nível molecular a DHEA e sobretudo a DHEAS são agonistas 
glutamatérgicos e antagonistas gabaminérgicos. Para além disso, a razão entre níveis de 
DHEA e DHEAS poderá eventualmente modular os efeitos destas hormonas ao nível do 
sistema nervoso central. Os efeitos eletrofisiológicos da DHEA e DHEAS em seres 
humanos são essencialmente desconhecidos e a sua relação com a personalidade ou 
fenótipo endócrino de resposta ao stress não estão bem definidos.  
O objetivo desta tese foi explorar relações da DHEA ou DHEAS com variáveis 
comportamentais em seres humanos adultos. Em particular foram estudadas relações 
com a personalidade, resposta ao stress, memória de trabalho e emoções. Foram 
estudadas relações ao nível do desempenho e do processamento cerebral. Foram 
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exploradas eventuais relações opostas às do cortisol, bem como os efeitos do balanço 
entre os níveis de DHEAS e DHEA. Foram ainda analisadas as respostas da DHEA à 
realização de tarefas cognitivas.  
No estudo I explorámos a relação da concentração de DHEAS com a reatividade 
hipófise-suprarrenal e o perfil de personalidade em adultos de ambos os géneros. Foi um 
estudo retrospetivo que incluiu 120 doentes assistidos na consulta externa de um 
hospital público terciário, antes do início de terapêutica médica. Foi avaliada a 
personalidade utilizando o Inventário de Personalidade Multifásico do Minnesota (MMPI) 
e a reatividade do eixo hipófise-suprarrenal utilizando a prova da corticoliberina (CRH). A 
concentração de corticotrofina (ACTH) relacionou-se diretamente com a concentração 
sérica de DHEAS basal, e em conjunto com a idade e o género explicaram 34% da 
variabilidade da concentração de DHEAS. A concentração de DHEAS basal relacionou-se 
inversamente com a resposta pico/basal do cortisol na prova de CRH. A reatividade da 
DHEAS na prova de CRH relacionou-se diretamente com a pontuação obtida na tríade de 
Problemas de Comportamento e personalidade tipo A. Estes resultados sugerem que 
concentrações mais elevadas de DHEAS poderão constituir um fator protetor contra uma 
resposta excessiva do cortisol em situações de stress. Por outro lado, sugerem a 
existência de uma relação entre a personalidade e a reatividade da DHEAS. 
No estudo II explorámos a relação das concentrações de DHEA, DHEAS e cortisol 
com a memória de trabalho e distração ao nível do desempenho e do processamento 
cerebral. Com essa finalidade, registámos o eletroencefalograma de 23 jovens adultas do 
sexo feminino enquanto realizavam uma tarefa discriminativa (sem utilização da memória 
de trabalho) e outra com a utilização de memória de trabalho. Essas tarefas eram visuais 
e antes de cada estímulo visual eram administrados estímulos auditivos, 20% dos quais 
eram novos e tinham o objetivo de causar distração (paradigma de "oddball"). Medimos a 
DHEA, DHEAS e o cortisol salivares antes de cada tarefa e aos 30 e 60 min. Durante a 
tarefa com utilização de memória de trabalho, razões cortisol/DHEA mais elevadas 
relacionaram-se com deflexões "P3-novidade" (em inglês, novelty-P3) mais amplas, 
traduzindo maior distração. Este resultado sugere que o cortisol poderá causar maior 
distração enquanto que a DHEA poderá reduzir essa distração através da redução do 
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processamento desse estímulo distrativo. Encontrámos uma elevação das concentrações 
de DHEA com a realização das duas tarefas cognitivas consecutivas, maior com a 
realização da tarefa com memória de trabalho que com a realização da tarefa 
discriminativa. Para além disso, uma maior resposta da DHEA devida à realização da 
tarefa com memória de trabalho, relacionou-se com um maior incremento na amplitude 
da P300 visual devida à memória de trabalho, traduzindo assim um melhor 
processamento dessa memória de trabalho. Globalmente, estes resultados sugerem que 
nas mulheres, a DHEA poderá opor-se aos efeitos do cortisol, reduzindo a distração e que 
maiores reatividades da DHEA se relacionam com melhor memória de trabalho ao nível 
eletrofisiológico. 
No estudo III utilizámos o protocolo anterior para analisar a relação entre a razão 
DHEAS/DHEA e a atenção involuntária durante a execução de uma tarefa envolvendo 
memória de trabalho. Verificámos que razões DHEAS/DHEA mais elevadas se 
relacionaram com amplitudes maiores da deflexão auditiva P3-novidade durante a 
realização de uma tarefa visual envolvendo memória de trabalho. Contudo, a razão 
DHEAS/DHEA não se relacionou com a amplitude da P300 visual, a latência da P3-
novidade ou a latência da P300 visual. Estes resultados sugerem que o balanço entre 
DHEAS e DHEA pode modular a atenção involuntária. Especificamente, os resultados 
sugerem que razões DHEAS/DHEA mais elevadas podem aumentar o processamento 
involuntário de estímulos auditivos sem um efeito deletério no processamento da 
memória de trabalho visual em curso. A manutenção da atenção involuntária em relação 
ao mundo envolvente durante a realização de tarefas envolvendo a utilização de 
memória de trabalho pode ser um mecanismo protetor importante. Os recursos da 
atenção são limitados e estes resultados sugerem que o balanço entre DHEAS e DHEA 
pode modular esses recursos bem como sugerem a importância da atividade da 
sulfotransferase e sulfatase na modulação desses efeitos. 
No estudo IV explorámos as relações da DHEAS, DHEA e cortisol com o 
processamento de estímulos com conteúdo emocional negativo, ao nível do 
comportamento e do processamento cerebral. Foi registado o eletroencefalograma de 21 
jovens adultas enquanto realizavam uma tarefa com conteúdo emocional implícito neutro 
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ou negativo, utilizando um paradigma de "oddball" audiovisual. A tarefa alvo era visual e 
os estímulos auditivos, dos quais 20% eram sons novos, pretendiam causar distração. Em 
cada condição, foram doseadas a DHEA, DHEAS e cortisol antes da realização da tarefa e 
aos 30 e 60 min. A concentração de DHEA aumentou após a realização da tarefa, 
independentemente do conteúdo emocional. Razões DHEAS/DHEA e DHEA/cortisol mais 
elevadas antes da execução da tarefa com conteúdo emocional implícito negativo 
relacionaram-se com latências mais curtas da P300 visual, sugerindo um processamento 
cerebral mais rápido em contexto emocional negativo. Para além disso, razões 
DHEAS/DHEA mais elevadas relacionaram-se com amplitudes da P300 visual mais 
reduzidas, indicando menor processamento do estímulo emocional negativo. Com este 
estudo mostrámos que ao nível eletrofisiológico, razões DHEAS/DHEA e DHEA/cortisol 
mais elevadas se relacionaram com tempos de avaliação do estímulo mais curtos, 
sugerindo menor interferência pelo conteúdo implícito negativo dos estímulos. Também, 
razões DHEAS/DHEA mais elevadas relacionaram-se com menor processamento dos 
estímulos negativos, o que pode constituir um mecanismo protetor contra o excesso de 
informação negativa. 
Concluindo, estes estudos revelaram relações da DHEA e DHEAS com variáveis 
comportamentais. Os resultados sugerem efeitos anti cortisol da DHEA e DHEAS e a 
importância do balanço entre os níveis de DHEAS e DHEA. As concentrações de DHEA 
aumentaram com a execução de tarefas cognitivas, sugerindo que essas tarefas podem 
modular as concentrações de DHEA. Concentrações basais mais elevadas de DHEAS 
relacionaram-se com menor resposta do cortisol à CRH sugerindo um efeito protetor 
durante a resposta ao stress. Encontrámos também relações entre DHEAS e o perfil de 
personalidade. Para além disso, encontrámos resultados novos no que respeita às 
relações da DHEA e DHEAS com o processamento cerebral. Esses resultados sugerem que 
ao nível eletrofisiológico, a DHEA poderá opor-se aos efeitos do cortisol, reduzindo a 
distração; que razões DHEAS/DHEA mais elevadas poderão aumentar a atenção 
involuntária em relação ao meio envolvente, sem um efeito deletério no processamento 
da memória de trabalho; e que uma maior resposta da DHEA poderá melhorar o 
processamento dessa memória de trabalho. No que respeita ao processamento 
emocional, os resultados sugerem que razões DHEAS/DHEA e DHEA/cortisol mais 
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elevadas se relacionam com menor interferência do conteúdo implícito negativo dos 
estímulos e que razões DHEAS/DHEA mais elevadas se relacionam com menor 
processamento do conteúdo emocional negativo, o que poderá constitui um mecanismo 
protetor contra os efeitos deletérios do excesso de informação negativa. Portanto, os 
resultados sugerem que a DHEAS se relaciona com a personalidade e menor resposta do 
cortisol ao stress, enquanto os estudos ao nível do processamento cerebral sugerem que 
a DHEA e/ou DHEAS poderão melhorar a memória de trabalho / atenção e reduzir o 
processamento de informação com conteúdo emocional negativo.  
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Introduction/Literature Review:  
Dehydroepiandrosterone and Dehydroepiandrosterone-
sulphate as Neuroactive Steroids 
In humans, dehydroepiandrosterone-sulphate (DHEAS) is the most abundant 
hormone in the peripheral circulation (1; 2). Brain levels of dehydroepiandrosterone 
(DHEA) and DHEAS are higher than peripheral circulation levels (3; 4) and both forms of 
the hormone are synthesized in the adrenals, but also in the central nervous system (1). 
DHEA and DHEAS [DHEA(S)] regulation and its physiological effects are still a matter of 
debate (5; 6; 7). Nevertheless, stressful stimuli increase DHEA and DHEAS levels in the 
acute setup (8) whereas chronic stress decreases DHEA and DHEAS levels (9; 10; 11). 
DHEAS levels are also higher in early adulthood and dramatically decrease with aging (2; 
12), reaching a nadir by the time many diseases of aging become more prevalent. Besides, 
lower DHEAS levels are related to higher morbidity and mortality even after age 
adjustment (2; 13).  
Although DHEA and DHEAS are steroid hormones, no high affinity nuclear receptor 
has been found for them (5; 6; 7; 14). On the other hand, DHEA and DHEAS effects 
mediated by binding to cytoplasmic receptors were described. In the brain, these 
hormones modulate synaptic transmission. They present a general neuro stimulatory 
effect mainly as glutamatergic agonist and gabaminergic antagonist (1; 3) and general 
biological actions of DHEA and/or DHEAS involve neuronal survival, neurite growth, 
neurogenesis, anti-oxidant, anti-inflammatory and anti-glucocorticoid effects (7). It was 
hypothesised that DHEA and DHEAS may play a role in cortical organization (15) and brain 
maturation (16). At the behavioral level, higher DHEA, DHEAS or DHEA-to-cortisol ratios 
were related to improved attention, cognition and mood (17; 18; 19; 20). 
The previous findings raised the hypothesis that restoring DHEA to youthful levels 
might protect the brain from cognitive decline or improve cognition, improve mood and 
even extend life span. In this regard, DHEA and DHEAS were evaluated in the treatment of 
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neuropsychiatric disorders, with published reports appearing as early as 1952 (21; 22). 
Since the late 1980s, a growing amount of studies addressing pre-clinical aspects and 
some controlled clinical trials with DHEA administration were performed (23). Regarding 
the effects of DHEA administration, until the present date, the studies failed to show 
consistent beneficial effects on cognition but suggest beneficial effects of DHEA 
administration on mood. Although the knowledge of neurobiological actions of DHEA and 
DHEAS is rapidly growing, the neurofunctional correlates of DHEA and DHEAS are mostly 
unknown. In fact, only a very small number of studies addressed the effects of DHEA on 
brain processing, both at the electrophysiological level (mostly since the late 1990s) (24) 
and functional neuroimaging level (since the early 2010s) (25). 
This review will address the following DHEA and DHEAS aspects as neurosteroids: 
1) molecular structure, synthesis and distribution; 2) concentrations along the life span; 3)
molecular mechanisms of action and cellular effects; 4) cognitive and neuropsychiatric 
effects; 5) electrophysiological and neuroimaging correlates. 
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Synthesis and distribution 
Dehydroepiandrosterone (also designated as prasterone) is a steroid hormone. It is 
derived from the cyclopentanoperhydrophenanthrene structure, which is composed of 
three cyclohexane rings and a single cyclopentane ring (figure 1.A). Its International Union 
of Pure and Applied Chemistry (IUPAC) designation is 3β-hydroxyandrost-5-en-17-one or 
5-androsten-3β-ol-17-one (26). DHEA possesses a hydroxyl group at position C3 (figure
1.B) while DHEAS has a sulphate group in that position (figure 1.C).
DHEA and DHEAS are synthesized in the adrenals, gonads and central nervous system. 
The adrenals are responsible for most of its synthesis in both genders, but while in 
women, the gonads are a minor source, in adult men, the testes secrete approximately 
10-25% of DHEA and 5% of DHEAS (27; 28). The brain is believed to produce only small
amounts of peripheral DHEA and DHEAS levels (27; 28; 29). 
B. C.
A.
Figure 1: Cyclopentanoperhydrophenanthrene structure (A), dehydroepiandrosterone (B) and 
dehydroepiandrosterone-sulphate (C) chemical structure. 
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DHEA synthesis in the adrenals and gonads 
In the periphery, DHEA is mostly synthesized in the adrenals but also in the 
gonads. In the adrenals it is synthesized in the adrenal cortex, mostly in the zona 
reticularis (to a lesser degree it can be synthesized in the zona fasciculata). In the ovary, it 
is produced in the thecal cells (30) and in the testis it is produced by the Leydig cells.  
Cholesterol is the precursor of all adrenal and gonadic steroids, either internalized 
in steroidogenic cells by receptor mediated endocytosis or synthesized de novo within 
those cells (31).  Within the steroidogenic cells (adrenal cortical cells, theca cells, theca-
interstitial cells and Leydig cells), the intracellular cholesterol is transported from the 
outer to the inner mitochondrial membrane, a process that is mediated by the 
steroidogenic acute regulatory protein (StAR) (32). This transport of cholesterol across the 
mitochondrial membrane is the initial rate-limiting step in adrenal steroidogenesis (33; 
34). The placental steroidogenic cells are an exception because they do not express StAR 
and directly utilize the mitochondrial cholesterol side chain cleavage enzyme (a 
cytochrome P450 enzyme) to initiate steroidogenesis (the protein MLN64 is one 
candidate for a factor mediating the transport of cholesterol into placental mitochondria) 
(35). In the mitochondria of adrenal and other steroidogenic cells in general, the 
cholesterol is converted to pregnenolone by cytochrome P450 side chain cleavage 
enzyme (P450scc, desmolase or CYP11A1). The steroidogenesis involves the action of 
other cytochrome P450 enzymes. The cholesterol side-chain cleavage enzyme and the 
11β-hydroxylase (CYP11B) enzymes are mitochondrial enzymes and require an electron 
shuttle system to hydroxylate steroids. The 17α-hydroxylase (CYP17) and 21-hydroxylase 
(CYP21A2) are microsomal-endoplasmic reticulum enzymes and involve a distinct electron 
shuttle system (cytochrome b5, a flavoprotein) (34; 35). 
The pathway for DHEA synthesis is mostly identical in the adrenals and gonads. 
After the synthesis of pregnenolone by the action of the P450scc (CYP11A1) enzyme, CYP 
17α-hydroxylase hydroxylates pregnenolone to form 17-hydroxypregnenolone. Then, the 
CYP17 also possesses 17,20-lyase activity and this activity converts 17-
hydroxypregnenolone into DHEA, which is a C19 androgen (figure 2) (34). The synthesis of 
adrenal androgens occurs mostly in the reticularis zone. Additionally, DHEA is sulfated to 
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DHEAS in the adrenal zona reticularis. DHEA is liposoluble and can easily cross biological 
membranes, but DHEAS, having a sulfate group, does not (2; 36).  
Besides androgens, the adrenals produce two other main types of hormones: 
glucocorticoids and mineralocorticoids, see figure 3 (34; 35; 37). 
Figure 2: Biochemical pathway for DHEA synthesis. SCC - cholesterol side chain cleavage enzyme (CYP11A1); 
17α-OH - 17α-hydroxylase enzyme; 17,20-lyase - 17,20-lyase enzyme. 
Figure 3: Adrenal steroidogenesis. Three main types of hormones are produced by the adrenals: 
glucocorticoids, mineralocorticoids and androgens. SCC - cholesterol side chain cleavage enzyme (CYP11A1); 
17α-OH/17,20-lyase - 17α-hydroxylase/17,20-lyase enzyme (CYP17); 3β-HSD - 3β-hydroxysteroid 
dehydrogenase enzyme (HSD3B); 21OH - 21-hydroxylase enzyme (CYP21A2); DOC – deoxycorticosterone; 
11βOH - 11-hydroxylase (CYP11B1); 11βOH/18OH/18CH3OX – aldosterone synthase (CYP11B2), which has 
11β-hydroxylase (11βOH), 18-hydroxylase (18OH) and 18-methyl oxidase (18CH3OX) activity; black arrows 
indicate the predominant pathways. 
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In the fetal adrenal, because of relative lack of 3β-HSD and high sulfotransferase 
activity, DHEA and DHEAS are the main steroids produced by the adrenal. The fetal 
adrenal has considerable sulfotransferase activity but little steroid sulfatase activity, also 
favoring conversion of DHEA to DHEAS. The resulting DHEAS is secreted, 16α-
hydroxylated in the fetal liver (by the hydroxilase CYP3A7) (38; 39), and then acted on by 
placental 3βHSD1, 17βHSD1, and P450 aromatase to produce estriol. Small amounts of 
DHEA and DHEAS bypass the liver and are not 16α-hydroxylated, and hence yield estrone 
and estradiol. Estrogens in turn, further inhibit adrenal 3βHSD activity, providing a 
feedback system to promote production of DHEAS (40; 41). 
As mentioned, the gonads secrete DHEA although in much lower levels then the 
adrenals. The main hormonal products of the normal ovaries of reproductive age women 
are progesterone and estradiol. Accordingly, the preferential pathways are to convert 
pregnenolone into progesterone and estradiol (figure 4) (30). In the testis, testosterone is 
the main steroid produced (35; 42; 43), see figure 5. 
Figure 4: Steroidogenic pathway in the ovary. DHEA is synthesized as an intermediary metabolite. SCC - 
cholesterol side chain cleavage enzyme; 17α-OH/17,20-lyase - 17α-hydroxylase/17,20-lyase enzyme; 3β-
HSD - 3β-hydroxysteroid dehydrogenase enzyme type II; 17βOH – 17β-hydroxysteroid dehydrogenase type 
1 enzyme; arom – aromatase.  
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Figure 5: Steroidogenesis in human testis. SCC - cholesterol side chain cleavage enzyme; 17α-OH/17,20-
lyase - 17α-hydroxylase/17,20-lyase enzyme; 3β-HSD - 3β-hydroxysteroid dehydrogenase enzyme type II; 
17βOH – 17β-hydroxysteroid dehydrogenase type 3 enzyme; black arrows indicate the predominant 
pathway in humans. 
DHEA and DHEAS interconversion, secretion, peripheral metabolism and excretion 
As mentioned, DHEA is sulfated to DHEAS in the adrenal reticularis zone. This 
sulfation reaction is reversibly mediated by the hydroxysteroid sulfotransferase enzyme 
(SULT2A1), which is a cytosolic enzyme (44; 45). Human cytosolic sulfotransferases 
transfer the sulfuryl group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the 
hydroxyl group of DHEA (46). The equilibrium constant for this reaction strongly favours 
DHEAS synthesis (Keq = 1.3 x 103), DHEA is the concentration-limiting substrate and 
nucleotide (3',5'-diphosphoadenosine, PAP) release is the rate-limiting step (46). In the 
presence of increasing DHEA concentration, there is partial substrate inhibition by DHEA: 
in that condition, DHEA excess causes it to add more quickly to the enzyme-PAP complex, 
trapping a greater fraction of PAP in a dead-end complex (DHEA-enzyme-PAP). Therefore, 
as the DHEA concentration increases, the rate determining step in this reaction shifts 
from PAP release from the enzyme-PAP complex (K off = 1.2 s-1 ) to PAP release from the 
dead-end complex (DHEA-enzyme-PAP) (K off = 0.48 s-1) (46).  
Of note, DHEA-sulfotransferase (SUL2A1) is also expressed in liver (hepatocytes) 
and a smaller amount is expressed in the gastrointestinal tract (small intestine mucosa 
and parietal cells of the gastric glands) (47; 48; 49; 50). SUL2A1 expressed in the human 
liver is responsible for sulfation of bile acids and circulating hydroxysteroids (51; 52; 53; 
44), including DHEA. The DHEA-sulfotransferase present in human adrenal and liver show 
similar physical, biochemical and kinetic properties (47). In humans, the sulfotransferases 
expression in non-gonadal tissues is identical in both genders (in contrast, rodents show 
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sex-related differences) (48). Several nuclear receptors might regulate SULT2A1 
expression in liver (peroxisome proliferator-activated receptor-α; pregnane X receptor; 
constitutive androstane receptor, vitamin D receptor, liver X receptors, farnesoid 
receptor, retinoid-related orphan receptors) while Estrogen-Related Receptor-α is 
suggested to play a major role in the regulation of SULT2A1 expression in the human 
adrenal (48). 
As mentioned, DHEA can easily cross biological membranes. On the contrary, the 
transport mechanism for adrenal cell export of DHEAS into the circulation is not well 
understood. The Organic Solute Transporter α - Organic Solute Transporter β (OSTα-
OSTβ) is a heteromeric carrier abundantly expressed in the human adrenal gland which 
may play a role in the export of DHEAS from the adrenal cell (54). It is also expressed in a 
variety of other tissues, including the small intestine, colon, liver, biliary tract and kidney 
(54). In polarized epithelial cells, OSTα-OSTβ protein is localized in the basolateral 
membrane and functions in the export or uptake of bile acids and steroids (54).  
DHEAS may be converted back to DHEA by a steroid-sulfatase (STS) (steroid sulfo-
hydrolase) enzyme. The steroid-sulfatase gene is X-linked and escapes X inactivation in 
humans (55). Its expression was observed in the adrenal, liver, adipose tissue, brain, 
placenta, gonads, uterus, skin and other peripheral tissues (56; 57; 58; 59; 60). STS is 
localized in the endoplasmic reticulum, with evidence suggesting that its active site is 
located within the endoplasmic reticulum membrane and that facilitated transport of 
DHEAS across the ER membrane may not be required for STS activity (61). Therefore, 
cycling of DHEA and DHEAS (and other steroids and their sulfates) may occur as a result of 
steroid sulfotransferases and steroid sulfatases activity. Higher concentration of 
phosphate reduces the velocity of STS reaction and other sulfated steroids (namely 
pregnenolone sulfate) functioning as competitive inhibitors of this enzyme (58; 62; 63). 
In young adults, the adrenals secrete about 4mg of DHEA and 25mg of DHEAS daily 
(64). DHEA and DHEAS in the peripheral circulation do not bind significantly to sex 
hormone binding globulin. They bind to albumin, although DHEAS binding to albumin 
seems non-specific (64). Overall, in the adrenals and other peripheral tissues, 64-74% of 
the DHEAS produced each day is converted back to DHEA, while only 6-13% of the DHEA 
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produced is metabolized to DHEAS (28; 64; 65; 66). DHEA and DHEAS can be converted to 
other steroids in the adrenals, ovaries and testis and released into the peripheral 
circulation (64; 67). Secreted DHEA and DHEAS can also be converted to other steroids in 
several peripheral target tissues (like the skin, adipose tissue, liver, bone), although in 
many cases, probably with no significant release into the general peripheral circulation 
(intracrinology) (5; 64). In particular, DHEA and DHEAS can be converted into androgens 
(Δ4-androstenedione, testosterone, 5α-dihydrotestosterone), estrogens (Δ5-
androstenediol and those resulting from the aromatization of testosterone and Δ4-
androstenedione - estradiol, estrone) and other DHEA derivatives (16α-, and 7α/β-
oxygenated DHEA derivatives) (36; 64).  
As a result of the previous findings, circulating DHEAS may be seen as a reservoir 
for DHEA, with conversion by sulfotransferases occurring in several tissues (5). Besides 
that, the fact that DHEAS and DHEA may be converted to other active steroids gave rise to 
the hypothesis that DHEA and DHEAS effects could be mediated by its conversion to 
androgens, estrogens and other metabolites and not direct effects of DHEA or DHEAS (5; 
68). To note, the high DHEA and DHEAS concentrations found in human peripheral 
circulation are not reproduced in other animals. The peripheral concentration of DHEA 
and DHEAS in monkeys is much lower than that in humans and in most other laboratory 
animals, particularly rodents, the peripheral concentration of these hormones is very low 
(7; 64). This is also suggestive that DHEA and DHEAS might play a partcular role in the 
human species. 
Again, although DHEA is expected to freely cross membranes of target cells, 
another issue was whether DHEAS, a hydrophilic steroid, can enter the specific target 
cells. To that concern, transport systems were described. The Organic Anion Transporting 
Polypeptide (OATP) family has broad and overlapping substrate specificities and in 
particular, some members of the Organic Anion Transporting Polypeptide (OATP) family 
were described to occur in the liver, kidney, testis, small intestine, thymus, placenta and 
other tissues and mediate the trans-epithelial / transmembrane uptake of DHEAS and 
estrone sulfate (69; 70; 71). Besides, a specific steroid-sulfate transporter, the sodium-
dependent Organic Anion Transporter (SOAT), can mediate DHEAS cellular inward in the 
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testis (69). SOATs are expressed in other tissues namely in vesicular structures in neurons 
of the central and peripheral nervous system, but a transport function was not yet 
detected, namely no transport of DHEAS by SOATs was detected in those cells (72). 
Besides, OATPs were detected in salivary glands, but no transport of DHEAS by OATPs in 
those cells was described (73). On the other hand, it was described that DHEAS squeezes 
through the tight junctions between salivary glands and DHEAS concentrations in saliva 
are therefore dependent on serum concentration and salivary flow rate (74). 
Renal and biliary excretion of DHEA and DHEAS do occur. Renal excretion accounts 
for 51-73% of the elimination of DHEAS and its metabolites (28). Besides the direct 
excretion of DHEAS and DHEA, renal excretion products include androsterone sulfate, 
etiocholanolone sulfate, androsterone glucuronoside and etiocholanolone glucuronoside 
(75; 76). The half-life of DHEA is similar to cortisol and most other steroid hormones. It is 
estimated to take 15-30 min, for a metabolic clearance rate (MCR) of approximately 2,000 
L / day. On the contrary, the half-life of DHEAS is much longer, 7-10 h, and the MCR is low, 
5-20 L/day (36; 64). As a consequence, the plasma concentration of DHEA is not much
different from that of other adrenal steroids, but it is several times less abundant than 
DHEAS. DHEA concentration is in several nmol/L (2-9 μg/dL, 7-31 nmol/L), while the 
concentration of DHEAS is in several μmol/L (50-250 μg/dL, 1.3-6.8 μmol/L) (64; 77). Of 
note cortisol molar concentration in the peripheral circulation is about 10 times higher 
than DHEA concentration (morning cortisol: 5-25 μg/dL, 140-690nmol/L) (77).  
DHEAS concentration is 20-30% lower in women, therefore the DHEAS/DHEA ratio 
is also lower in women (64). The ratios for the conversion of DHEAS and androsterone 
sulfate to DHEA, are both significantly higher for women than men (78). Plasma levels of 
DHEA are only a little higher in women than in men [in Bird et al. study (78), levels were 
8.50 ± 0.95 and 8.75 ± 1.01 ng/ml for men and women, respectively]. Concluding from the 
above stated, the X-linked sulfatase activity, which escapes X-inactivation, may explain or 
contribute to this difference. There is no sex difference in the binding of DHEA and DHEAS 
to plasma proteins and this is also reflected in the lack of sex difference in the MCRs (78). 
Nevertheless, women probably excrete more DHEAS and DHEA through urine when 
compared to men (73±5.5% in women and 51±3.5% in men), while men excrete more 
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DHEAS and DHEA though the bile than women (79). Circadian rhythm of DHEA is identical 
to that of cortisol, eventually related to ACTH stimulation of DHEA synthesis. DHEAS levels 
on the contrary, due to its long half-life, remain stable 24h a day under normal conditions 
(64). 
DHEA synthesis in the brain 
Neurosteroids are steroids that can be synthesized de novo in the nervous system 
from sterol precursors (1). This notion was proposed in 1981. Interestingly, this came to 
light after the observation that DHEA and DHEAS were present in the adult rat brain. At 
that time, it was an unexpected finding since the rodents steroidogenic glands do not 
secrete significant amounts of DHEA. As a sequence to that observation, the nervous 
system steroidogenesis was discovered (80) and DHEA and DHEAS were known to be 
neurosteroids. However, it is still not clear where and how DHEA and DHEAS are 
synthesized in the central nervous system. 
Corpéchot et al. (80) performed a series of experiments showing that DHEAS levels 
in brain were independent of its peripheral synthesis. DHEAS concentrations in the brain 
tissue largely exceeded DHEA concentrations in the brain tissue and DHEAS 
concentrations in plasma. Furthermore, there is an anterior to posterior DHEA and DHEAS 
brain gradient (3; 80; 81). DHEA concentrations are higher in the anterior brain, while 
DHEAS concentrations are higher in the posterior brain. In a post-mortem study of human 
brains, subjects 76 to 93 years old (nine women and one man), DHEA concentrations 
were found to be higher in the prefrontal lobe (29 nmol/kg) than in other brain regions 
(16 nmol/kg in the parietal lobe, 13 nmol/kg in the temporal cortex, 17 nmol/kg in the 
cerebellum and 19 nmol/kg in the corpus callosum) (4). Mice also have higher DHEA 
concentrations in the anterior brain (0.42±0.10 ng/g in anterior brain and 0.12±0.03 ng/g 
in posterior brain) (80). On the contrary, DHEAS concentration in rats are higher in the 
posterior (4.89±1.06 ng/g) than in the anterior brain tissue (1.58±0.14 ng/g) (3; 80) and 
peripheral concentrations of DHEAS in rats are lower than the central ones (0.26±0.13 
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ng/mL) (80). In humans, DHEA levels are also about 6.5 time higher in brain than in the 
plasma of subjects of similar age (4). 
Of note, DHEA concentrations in human brain tissue (homogenates) are higher 
than plasma concentrations, but cerebrospinal fluid concentrations are lower than 
plasma concentrations, about 5.4% of plasma concentrations (cortisol levels in the 
cerebrospinal fluid are also about 5.8% of plasma concentrations) (82). Despite the fact 
that DHEAS is expected to penetrate less into the cerebrospinal fluid than DHEA (0.03% of 
circulating DHEAS is expected to cross the blood brain barrier) (83), in adults, the levels of 
DHEAS in the cerebrospinal fluid are still higher than those of DHEA (82). DHEA-to-DHEAS 
molar ratio was estimated to be about 0.01 in plasma and 0.52 in the cerebrospinal fluid 
(in the peripheral circulation DHEAS levels are 100 or more times higher than those of 
DHEA and about 5-10 times those of cortisol; DHEAS levels in the cerebrospinal fluid are 
about 1/3 of cortisol levels) (82). Gooddyer et al. studied the relative levels of DHEA, 
DHEAS and cortisol in the  blood and saliva of adolescents (84), and found a similar 
relationship to that described by Guazzo et al. between blood and cerebrospinal fluid 
levels (82), hence suggesting that  transport  into  the  brain  and  saliva might be, to  this 
extent, comparable, and that salivary levels may therefore give a reasonable 
representation to those in the cerebrospinal fluid (82). 
Several studies suggest that central nervous system DHEAS levels do not depend 
on adrenal secretion. Injections for 3 days of long-acting preparations of corticotrophin, 
to stimulate adrenal steroidogenesis, or of dexamethasone to inhibit endogenous 
adrenocorticotropic hormone (ACTH) secretion, were not accompanied by clear-cut 
changes in brain DHEAS (1; 80). Also, brain DHEAS was unchanged one day after 
castration, whereas testosterone completely disappeared from the brain. Also, no 
difference was observed in brain DHEAS levels when castrated adrenalectomized male 
rats were compared 15 days after operation with sham operated controls (1; 80). Taking 
into account that the rat steroidogenic glands do not secrete significant amounts of DHEA 
and peripheral concentrations of DHEA and DHEAS are very low (7; 64), these results 
suggest that in rats, DHEA and DHEAS may be produced mainly in the brain. Moreover, 
mice have higher DHEA concentrations in brain than in plasma (7).  
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The same conclusion cannot be directly applied to humans, since DHEA and DHEAS 
are abundant in brain but also in peripheral circulation. In human beings, brain DHEA 
might be derived from both local synthesis and peripheral synthesis (7). DHEA may cross 
the blood-brain barrier and be converted to DHEAS in the brain. On the contrary, DHEAS 
can enter and leave the brain through specific transport systems but the flux of DHEAS is 
believed to be mainly from the brain to the peripheral circulation and not the opposite 
(85). Accordingly, in subjects not taking steroid medication, DHEA and DHEAS levels in 
blood and cerebrospinal fluid were directly related (82). DHEA levels were shown to 
decrease in plasma and cerebrospinal fluid in subjects receiving steroid therapy while 
DHEAS levels decreased in the plasma but not in the cerebrospinal fluid in subjects also 
receiving steroid therapy (82). Furthermore, in those subjects receiving steroid therapy, 
cortisol levels in plasma were directly related to cerebrospinal fluid levels, but there was 
no relation between plasma and cerebrospinal fluid levels of DHEA or DHEAS (82), further 
suggesting that DHEA and DHEAS may be synthesized in the central nervous system. 
 The synthesis of DHEA in the central nervous system is believed to follow 
essentially the same metabolic pathway (3; 86) as the peripheral synthesis. Pregnenolone 
is derived from cholesterol after side chain cleavage by cytochrome P450scc. Then, 
cytochrome P450 CYP17, a 17α-hydroxylase with 17,20-lyase activity catalyses the 
conversion of pregnenolone to 17α-hydroxypregnenolone and DHEA. Finally, 
hydroxysteroid sulfotransferase enzyme (SULT2A1 and SULT1E1) convert DHEA to DHEAS. 
This is a reversible reaction, hence, DHEAS can also be converted back to DHEA (by the 
activity of steroid sulfatase enzyme) in the central nervous system. 
Whether or not StAR also participates in brain steroidogenesis, or whether brain 
steroidogenesis, like that in the placenta, is independent of StAR, remains controversial 
(35). The mRNAs for StAR and P450scc are co-localized in several regions of the rat brain 
(87), and StAR mRNA is found in various regions of the human brain (88). In the 
developing rat, StAR mRNA is found glial and neuronal steroidogenic cells, in the 
hippocampus, thalamus, cortex, pons and the striatum, with an intracellular pattern, 
consistent with a mitochondrial localization. In the adult, StAR protein was detected in 
the same tissues (89). P450scc was also expressed in the same cells (89).  
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Mutations in StAR resulted in adrenal insufficiency (lipoid congenital adrenal 
hyperplasia) and is lethal (89), but neither StAR knockout mice nor human patients with 
lipoid congenital adrenal hyperplasia have a phenotype attributable to altered central 
nervous system (CNS) function, therefore suggesting the existence of a StAR-independent 
mechanism for steroidogenesis. As mentioned before, the placental steroidogenic cells do 
not express StAR and utilize a StAR independent pathway. One proposed hypothesis is 
that a proportion of steroids may be generated from oxysterols in the brain (89). The 
brain produces significant levels of oxysterols (like 24-hydroxycholesterol) and these can 
not only regulate StAR expression but also freely diffuse into the mitochondria and be 
directly converted to steroids (89; 90; 91). This could represent an alternative pathway for 
the synthesis and regulation of neurosteroid levels (89; 90; 91).   
Pregnenolone and its sulfate ester concentrations in the rat brain are about 10 
times higher than DHEA concentrations and about 10 times higher than plasma 
pregnenolone concentrations (92). The presence of immunoreactivity for P450scc protein 
(which converts cholesterol to pregnenolone) was initially found in the white matter in 
rat and human brain, and in glial cell cultures of the newborn rat forebrain (93) and later 
in several regions of the brain, especially neurons in the hippocampus (86; 87), this was 
established since 1987. N-methyl-D-aspartate (NMDA) stimulation promoted Ca2+ influx 
and the synthesis of pregnenolone in rat hippocampal neurons, suggesting that 
pregnenolone synthesis in the hippocampus may be stimulated and regulated by 
glutamate mediated synaptic communication (86).  
P450 CYP17, the key enzyme in the production of DHEA, is found throughout the 
developing mouse brain (94; 95; 96). Zwain and Yen (97) demonstrated for the first time 
in 1999 that the neonatal rat brain expressed P450 CYP17 steroidogenic enzyme. More 
precisely, they demonstrated that hypothalamic and cortical astrocytes in vitro expressed 
the P450 CYP17 steroidogenic enzyme and were able to synthesize and secrete DHEA and 
metabolize this hormone to testosterone and estradiol in a dose-dependent manner. 
These cortical neurons in vitro expressed a very low level of P450 CYP17 mRNA and 
produced a small amount of DHEA (97). Hypothalamic astrocytes produce DHEA at a level 
three times higher than that produced by cortical astrocytes (97). On the contrary, 
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oligodendrocytes neither express the messenger RNA nor produce DHEA (97). In the adult 
mouse brain, P450 CYP17 was found in the hippocampus (98) and spinal cord (99). In the 
hippocampus, it was localized to pyramidal neurons and granule cells of the dentate gyrus 
(in both cases, localized in pre- and post-synaptic locations and in the endoplasmic 
reticulum) (98). In the spinal cord, cytochrome P450c17 was found in neurons and glial 
cells (99). Of note, mRNA transcripts of the several steroidogenic enzymes necessary for 
DHEA synthesis were found in the hippocampus, although in very low levels (86). P450 
CYP17 mRNA transcripts in the embryonic mouse brain (94) and in the hippocampus of 
adult male rats are low, about 1/200th of the expression found in the testis (7; 86; 98). 
Similar to the stimulation of pregnenolone synthesis, the activity of P450 CYP17 in the 
hippocampus was enhanced by exposing neurons to NMDA (98). The synthesis of DHEA 
from pregnenolone in frog brains was also inhibited by ketoconazole, a known inhibitor of 
the P450 CYP17 (7). 
People with P450 CYP17 gene mutations have sexual infantilism in phenotypic 
females (due to lack of sex steroid precursors and 46,XY subjects also have female 
infantile external genitalia), hypertension, and hypokalemia (100; 101). There are no 
reported neonatal neurological problems in those subjects, eventually because they 
obtain sufficient quantities of 17-hydroxylated steroids from their mothers during 
prenatal development. Adults with P450 CYP17 gene mutations are not well studied with 
regards to neuropsychiatric illness, although this could be complicated with the possible 
psychological effects of disturbed sexual development. In mouse, studies with knock out 
of this gene were also uninformative, as the P450c17−/− mice died by embryonic day 7, 
and the cause of this early lethality was unknown (102). 
An alternative pathway for DHEA synthesis in the brain might exist. In that 
respect, Prasad et al. (1994) (103) and Cascio et al. (1998) (104) suggested an alternative 
pathway for DHEA synthesis in the brain, which was independent of P450scc activity and 
involved hydroperoxide intermediates. Prasad et al. found evidence of the presence of 
sterol hydroperoxides or peroxides in brain extracts, that in the presence of FeSO4, 
increased DHEA concentrations (103). That Fe2+ effect is observed even in the absence of 
CYP17 activity (105). To a much lesser extent, several reagents like triethylamine, HCl, 
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FeCl3, Pb(OAc)4 also increased DHEA concentrations (103). Prasad et al. proposed a 
"hydroperoxide pathway", in which an unknown cholesterol metabolite present in brain 
would serve as the precursor for pregnenolone and DHEA synthesis (103; 104).  
Prasad et al. also proposed that this transient complex could serve as a precursor 
of an organic soluble sterol hydroperoxide, sterol cyclic peroxides, and/or other di-
substituted sterol peroxides, steroid-O-O-R (where the radical R is not H) (103). Then, the 
authors proposed that one possibility was that this complex could be converted into the 
isolable 20-hydroperoxide, the 20,22-cycloperoxide, or the 17,20-cycloperoxide by 
enzymes that could be specific for hormone synthesis. Possibly through the action of a 
different enzyme, the 17-hydroperoxide of cholesterol could be the product of the sterol 
and 17,20-dioxetane, which eventually could be the source of the 17-ketosteroid 
dehydroepiandrosterone (103). Therefore, in this hypothesized pathway, the 
peroxidation of cholesterol could be catalyzed by enzymes, different from the 
cytochrome P450scc. These authors also propose that if the path cholesterol - cholesterol 
peroxide - dehydroepiandrosterone does exist in the brain or even in the steroid-
producing endocrine glands, then it would undoubtedly be associated with its own 
regulatory system (trophic factors, etc.) and could therefore represent a new aspect of 
steroidogenesis (103). 
Cascio et al. (104) used rat glioma tumor cells and found that FeSO4 induced the 
synthesis of DHEA (and pregnenolone) in those cells, even in the presence of specific 
inhibitors of P450scc and/or P450c17. The authors suggested that the synthesis of DHEAS 
and pregnenolone might result from the fragmentation of in situ-formed tertiary 
hydroperoxides. When exogenous pregnenolone along with FeSO4 were added to those 
tumor cell microsomes, the amount of DHEA formed was (5 to 10 times) higher than in 
controls, indicating that Fe2+ facilitated the conversion of pregnenolone to DHEA. 
Treatment of those cells with KI, NaBH4 or HIO4 also resulted in increased DHEA synthesis, 
suggesting that the precursor of DHEA in those cells was a steroid in which C17 and C20 
were oxygenated (1; 104). In that alternative pathway, for instance, the precursor 17-
hydroperoxide of pregnenolone (17-hydroperoxi-pregnenlone), would convert to 17-
hydroxy-pregnenolone by the addition of KI; then when treated with NaBH4 would result 
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in pregn-5-en-3β,17,20-triol; and when treated with HIO4 would result in the formation of 
DHEA (104). Contrary to the observations made in brain extracts, the treatment of rat 
adrenal or testis extracts with Fe2+ did not increase pregnenolone or 
dehydroepiandrosterone production (103), suggesting that the effect was tissue specific. 
Moreover, the enhancement of DHEA formation by Fe2+, was somehow specific, as it was 
not observed for progesterone (104).  
In accordance with the previous alternative pathway, oxidative stress is proposed 
to contribute to DHEA synthesis in Alzheimer´s Disease and other neurodegenerative 
diseases linked to oxidative stress (106). DHEA levels in Alzheimer Disease central nervous 
system and cerebrospinal fluid are significantly higher than in age-matched controls, 
although serum levels are lower than in the cerebrospinal fluid, and not significantly 
different from age-matched controls (107). FeSO4 increases DHEA synthesis, more in 
controls than in Alzheimer Disease patients, suggesting the presence of a precursor of 
DHEA in controls (107). It is proposed that in the brain with Alzheimer Disease, DHEA is 
formed by oxidative stress metabolism of that precursor (107). A lower DHEA formation 
in response to FeSO4 would be a marker of Alzheimer Disease (107). Also, the DHEA 
variation after oxidation was correlated with the patients' cognitive and mental status 
(106). Besides ferrous sulfate, beta-amyloid peptide (a pro-oxidant) also enhanced the 
synthesis of DHEA by CYP17 independent pathway (107; 108; 109). This also points to the 
hypothesis that DHEA synthesis may involve oxygenated hydroxyperoxides, as free 
radicals and oxidative stress enhance DHEA synthesis while anti-oxidants reduce that 
synthesis (109; 110).    
Conversion of DHEA into DHEAS has been shown to occur in rats, monkeys and 
human brains. In fact, a low activity of DHEA sulfotransferase (SULT2A1) was detected in 
several regions of rat brain (pons, hypothalamus, olfactory bulb, cortex, hippocampus, 
thalamus, basal ganglia and cerebellum), with the highest level found in the 
hypothalamus and pons (111; 112; 113). The question remains to be answered, whether 
this low activity of DHEA sulfotransferase is responsible for the formation of the high 
DHEAS concentrations found elsewhere in the brain. This sulfotransferase (SULT2A1) 
catalyzes the conversion of DHEA to DHEAS and it is identical to the one expressed in the 
18 
 
liver. Another sulfotransferase, SULT2B1a, is also expressed in rat (114) and human brain 
(115). SULT2A1 and SULT2B1 are both encoded in chromosome 19 (19q13.3) (116; 45). In 
contrast to the substrate specificity of SULT2A1, SULT2B1a and SULT2B1b (SULT2B1a is 
expressed mostly in the brain and spinal cord, while SULT2B1b is expressed in the skin 
and several other peripheral tissues and weakly expressed in the CNS) catalyze the 
sulfonation of several 3beta-hydroxysteroids with high catalytic efficiency (cholesterol, 
pregnenolone, dehydroepiandrosterone, dihydrotestosterone). As mentioned, DHEAS 
levels in rats did not change after corticotrophin, dexamethasone medication, 
adrenalectomy or orchiectomy (80). On the contrary, stress conditions increased DHEAS 
levels in brain, even after adrenalectomy plus orchiectomy, thus suggesting that DHEAS 
formation in the rat brain may depend on local mechanisms independent of peripheral 
glands (80). 
 Due to its hydrophilic nature, DHEAS does not readily cross the blood brain 
barrier. This transport, in both directions, is mediated by organic anion transporting 
peptides (OATPs) (85), which, in brain, are expressed in the blood-brain barrier 
endothelial cells and blood-cerebrospinal fluid barrier epithelial cells (117). DHEAS is 
predominantly transported outside of the brain. In one study, only 0.03% of peripherally 
injected DHEAS reached the rat brain (83) while the efflux of DHEAS outside of the brain 
was tenfold greater than its influx (efflux was a saturable process with a Michaelis 
constant, K(m) of 32.6 μM, efflux clearance was 118 μl/min.g of brain; influx had a K(m) of 
34.4 microM, influx clearance was 11.4 μl/min.g of brain) (85). That DHEAS efflux was 
inhibited by taurocholate, cholate, sulfobromophthalein, and estrone-3-sulfate and 
DHEAS influx was inhibited by digoxin (and DHEAS inhibited digoxin influx) (85). The influx 
of DHEAS (in mouse brain capillary endothelial cells) after a 30 min interval was 
significantly increased under ATP-depleted conditions, further suggesting that the efflux 
may be an energy-dependent process (85). The fact that DHEAS is predominantly 
transported out of the brain, also suggests that DHEAS found in the brain may be most 
likely due to local synthesis (7). 
As stated before, DHEA can be further metabolized to androgens and estrogens in 
the brain. P450 aromatase activity was found in hypothalamic tissues (118) and 
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hypothalamic astrocytes were shown to be three times more active than cortical 
astrocytes in the synthesis and metabolism of DHEA to estradiol (97), thus suggesting that 
DHEA may be involved in the regulation of hypothalamic neuronal function, particularly 
gonadotrophin releasing hormone (GnRH) neurons, whether directly or indirectly through 
its metabolite, estradiol. 
Brain tissues are further able to metabolize DHEA to its hydroxylated metabolites, 
7α-hydroxy-DHEA and 7β-hydroxy-DHEA, leading to the formation of androstenediol and 
androstenetriol (81). Astrocytes were reported to be involved in the formation of DHEA 
metabolites in the brain (81). Besides that, CYP7B1, which converts DHEA into 7-hydroxy-
DHEA in brain, was found to be highly expressed in pyramidal neurons in human 
hippocampal sections (119).  
Thus, DHEA is synthesised in the adrenals and gonads, but also in the central 
nervous system (1; 2; 68; 120; 121; 122). A sulfotransferase reversibly converts DHEA into 
DHEAS in the adrenals, liver and brain (80; 111; 112; 113; 115). DHEAS is the most 
abundant hormone in the human peripheral circulation and DHEAS concentrations largely 
exceed DHEA concentrations both in the peripheral circulation and in brain tissue (80). 
DHEA and DHEAS concentrations in the central nervous system are higher than their 
concentration in the peripheral circulation, with higher DHEA concentrations in prefrontal 
than posterior brain regions, whereas DHEAS concentrations are higher in the posterior 
than in the anterior brain tissue (3; 4; 80). DHEA is lipid soluble and may easily cross 
biologic membranes (2; 122) whereas DHEAS does not. DHEA has a short half-life, 
whereas DHEAS has a long half-life (5; 36; 123). 
20 
Changes along the life span and regulation 
Fetal life 
In the fetus, the adrenal steroidogenesis occurs primarily within the inner fetal zone 
(124; 125). In that period of life, there is a relative lack of 3β-HSD and Δ4,5 isomerase 
activity and high sulfotransferase activity (126; 127). Accordingly, the fetal adrenals 
cannot synthesize progesterone and in that period DHEA and DHEAS are the major 
products of adrenal steroidogenesis. Part of the DHEAS originating from the adrenals, is 
transported to the fetal liver for 16-hydroxylation. DHEA, DHEAS and 16-hydroxy-DHEAS, 
are then aromatized to estrogens by placental trophoblast [DHEA is a substract for 
estrone (E1) synthesis, DHEAS is converted to estradiol (E2), and 16-hydroxy-DHEAS is 
converted to estriol (E3)].  
Proliferation into the fetal and definitive adrenal zones are stimulated by 
fibroblast growth factor and epidermal growth factor (EGF). The fetal adrenal expresses 
high levels of insulin-like growth factor-II (IGF-II) mRNA and protein, which respond to 
ACTH (128; 129). IGF-II augments ACTH-stimulated expression of CYP11A1 (P450scc), 
CYP17 and 3β-HSD and stimulates cortisol and DHEAS synthesis in the fetal cortex, 
suggesting a role in adrenal regulation during fetal and postnatal life (128). Nevertheless, 
according to the pattern of adrenal maturation, it is also suggested that cortisol is 
synthesized the novo from cholesterol in the adrenal, but only after the 30th week of 
gestation (128).  
ACTH concentrations are higher throughout gestation than in postnatal life and its 
levels fall near the term of gestation. Midgestation fetal ACTH are high (about 250 pg/mL, 
55 pmol/L) and stimulate maximum fetal steroidogenesis. Thus, ACTH stimulates the 
adrenal cortex considerably to produce pregnenolone, DHEA and their sulfate conjugates 
(130). Prolactin (PRL) and other peptides were also suggested to selectively stimulate 
adrenal androgen production (131). Low amounts of cortisol are produced by the fetal 
adrenal. Fetal cortisol is converted to cortisone mostly through 11β-HSD in fetal tissues, 
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and also levels of cortisone in the fetus at midgestation were found to be fourfold to 
fivefold higher than cortisol levels (130). Cortisone is a relatively inactive glucocorticoid, 
and this metabolism protects the anabolic milieu of the fetus because cortisol can retard 
both placental and fetal growth (132). On the other hand, studies with animal cultures 
suggest that DHEA and DHEAS might influence neocortical organization (15). 
The ACTH feedback control of adrenal steroidogenesis matures during the second 
half of gestation and the early neonatal period. Dexamethasone can suppress the human 
fetal pituitary-adrenal axis at term but not at 18-20 weeks of gestation (131). With 
advancing gestation, increased production of estradiol in the placenta, induces placental 
11β-HSD activity resulting in a decrease in cortisol levels of maternal origin reaching the 
fetus and culminating in the ontogenesis of fetal ACTH production and de novo 
production of cortisol by the fetal adrenal gland (131). Cortisol is necessary to prepare the 
fetus for extra uterine survival (namely for lung surfactant synthesis, hepatic enzymes 
maturation, maturation of transport processes of the small intestine, ductus arteriosus 
closure, increased methylation of norepinephrine to epinephrine, increased conversion of 
T4 to T3) (130), therefore, during the last 10 weeks of gestation there is an increase in 
cortisol levels in the fetus as a result of increased secretion and reduced conversion of 
cortisol to cortisone (130). Then, at birth ACTH, DHEAS, cortisol and cortisone levels 
sharply decrease (130). The failure of the rising cortisol to suppress plasma ACTH during 
the last weeks of gestation may be due to altered sensitivity of glucocorticoid negative 
feedback (133), but presently little is understood about the regulation of hypothalamic-
pituitary-adrenal (HPA) function during late gestation and at term (133).   
Childhood and adolescence 
After birth, DHEAS levels decline rapidly during the first year of life and are 
maintained at a minimum level until around 6-8 years old (134). Concerning DHEA, its 
levels are relatively high after the first month of life and then decline more slowly, to 
reach a minimum level in girls between 5 and 7 years and in boys between 5 and 9 years 
of age (134). DHEA and DHEAS levels remain low until adrenarche starts, around six to 
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eight years of age (skeletal age 6 to 8 years). In contrast to the zona fasciculata, the 
expression of 3β-HSD and Δ4,5 isomerase type 2 and their activity in the zona reticularis is 
very low, whereas the expression and activity of the sulfotransferase is high. Around 6 to 
8 years of age, the DHEA and DHEAS are secreted from the zona reticularis of the adrenal 
cortex and their serum concentrations then begin to rise (135; 136). Those levels continue 
to rise through early adulthood (137). Around 14-16 years old, boys reach higher DHEAS 
levels than girls (137), but DHEA levels are not higher in boys than in girls (134). In fact, 
higher DHEA levels were found in girls 11-15 years old when compared to boys in the 
same age group (134). In the peripheral circulation, DHEA has a diurnal rhythm similar to 
that of cortisol while DHEAS shows less variation and is a practical biochemical marker of 
adrenarche (135; 136). 
During that period, there is a parallel increase in DHEA and DHEAS levels in blood 
and the cerebrospinal fluid (82). Guazzo et al. compared DHEAS-to-DHEA ratios in 
subjects below 18 years old (3-16 years old) and adults and found DHEAS-to-DHEA ratios 
of 124 and 136 in the peripheral circulation, 1.6 and 2.9 in the cerebrospinal fluid (CSF), in 
subjects below 18 years old and adults respectively (82). Those authors found a decrease 
in cortisol-to-DHEA and cortisol-to-DHEAS ratios in the CSF during adolescence and young 
adulthood, contrary to the increased ratios found in old subjects (82). However, although 
there are low levels of DHEA and DHEAS during early childhood, they also found lower 
levels of cortisol in the CSF during early childhood when compared to young adults and 
higher CSF cortisol levels in the elderly when compared to young adults (82). Therefore, 
the increased CSF cortisol observed in the elderly were not observed during early 
childhood (82).  
The adrenal androgens contribute to the growth of pubic and axillary hair. Besides 
that, the elevation of DHEA prior to the first signs of puberty led to the suggestion that 
DHEA may play a role in the maturation of the hypothalamic-hypophyseal-gonadal axis 
(138). By extraglandular metabolism, the adrenal androgens contribute to physiologically 
active testosterone and estradiol. However, the mechanism that triggers the secretion of 
DHEA is not known and there is no consistent support for a role of adrenal androgens in 
determining the onset of puberty. In fact, most patients with premature adrenarche do 
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not have precocious puberty; children with adrenal insufficiency usually have normal 
onset and progression of puberty when given adequate glucocorticoid and 
mineralocorticoid replacement therapy (139; 140). Also the transient increase in height 
velocity that occurs in middle childhood (6 to 7 years) cannot be attributed to adrenarche. 
This spurt lasts about two years and then terminates, while DHEAS continues to increase. 
Instead, it is hypothesized that that spurt is probably related to the cyclic pattern of 
prepubertal growth and/or genetic factors (141).  
Although its meaning is an unsolved issue, the changes in DHEA and DHEAS levels 
through life are unique and do not match other steroid hormones. Focal islands of 
reticular tissue and then a continuous reticular zone develop during adrenarche (140). 
DHEAS concentrations are related to the growth of the zona reticularis and the increase in 
adrenal volume with age (140). This last step in the adrenal zonation is characterized by: 
1) low level of expression of 3β-HSD/Δ4,5 isomerase type 2 and cytochrome P450 CYP21
mRNAs and enzyme activities (142; 143); 2) high activity of the DHEA sulfotransferase 
enzyme (143); 3) increase in 17,20-lyase activity of P450 CYP17, the enzyme that catalyzes 
both the activity and synthesis of cytochrome b5; and 4) expression of major 
histocompatibility complex class II (human leukocyte antigen DR, HLA-DR) antigens (144). 
The fetal adrenal cortex contains the first three characteristics, while the HLA-DR antigens 
were not expressed. 
Several epidemiologic related associations with DHEA levels have been found 
raising interesting hypothesis about DHEA teleological meaning, but in most cases, causal 
relationships are not established. DHEA is a neurosteroid, and along with adrenarche, 
there is a simultaneous parallel increase in cortical maturation from approximately age six 
to the middle twenties, suggesting that adrenarche may influence brain development. 
DHEAS may increase the activity of the amygdala and hippocampus and promote 
synaptogenesis within the cortex. It may influence memory, emotions, anxiety, resilience 
and increase social interaction with unfamiliar individuals. In summary, it might 
eventually play a role in human brain maturation (16). Of note, besides humans, 
adrenarche was shown to occur only in great apes and to some extent, also in Old World 
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monkeys (145; 146; 147), also suggesting that it evolved to promote brain development 
(147). 
The zona reticularis has an increased ratio of 17,20-lyase to 17α-hydroxylase 
activity. That ratio increased by increased phosphorylation of serine and threonine 
residues on the CYP17enzyme (148) and by the abundance of redox partners such as 
cytochrome P450 oxidoreductase and cytochrome b5, which preferentially promotes 
17,20-lyase activity by allosterically affecting the interaction between CYP17 and P450 
oxidoreductase (149; 150). These studies suggest a mechanism that may be involved in 
the relative increment of 17,20-lyase activity in the zona reticularis, although not in its 
regulation. 
No definitive major factors regulating DHEAS synthesis have been identified. 
Nevertheless, ACTH may be a necessary stimulus for DHEA adrenal secretion. This is 
evidenced by the low levels of DHEA found in cases of ACTH deficiency or resistance 
(151). In fact, CRH stimulates corticotrophin secretion and in turn corticotrophin is a 
stimulus for cortisol and DHEA secretion (152). CRH also directly stimulates the 
expression of CYP17 by fetal adrenal cortical cells (153) as well as fetal, pubertal and adult 
adrenal androgen secretion. This was evidenced by studies showing that CRH stimulated 
dexamethasone-suppressed adrenal to secrete DHEA and DHEAS within three hours (154; 
155). Nevertheless, there is a 20-fold increase in DHEAS levels between the onset of 
adrenarche and midpuberty but there is no concomitant increase in cortisol levels.  
Evidence of the dissociation between adrenal androgen and glucocorticoid 
regulation and secretion are the differential suppression by dexamethasone and 
differential changes in adrenarche (only DHEA increases), aging (only DHEA decreases), 
starvation, anorexia nervosa and chronic illness (DHEA decreases with no change or 
increase in cortisol levels) as well as in the age related response to ACTH (only DHEA and 
DHEAS response decline with age). Accordingly, the action of an unidentified factor is 
hypothesized, which would be an adrenal androgen stimulating hormone (AASH, also 
called cortical androgen stimulating hormone, CASH) (140; 156; 157).  This factor could 
originate from the pituitary, the adrenal or an extra-adrenal source and might explain the 
dissociation of adrenal androgen and glucocorticoid secretion. 
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Leptin in vitro also stimulates 17,20-lyase activity and 17α-hydroxylase activity, 
suggesting a role in adrenarche (158), although there is no clinical evidence to suggest a 
pivotal role of leptin in adrenarche. Nevertheless, an increase in body mass index (BMI) 
was related to an increase in DHEAS levels during adrenarche, suggesting that the 
nutritional status may play a role in the regulation of adrenarche (159). 
Adulthood and old age 
In the adult human DHEAS is the most abundant steroid in the peripheral 
circulation and, as mentioned, brain tissue levels are even higher than in peripheral 
circulation ones. Its levels in peripheral circulation are about 300 times higher than those 
of DHEA, in relation to its longer half-life, difficulty to cross plasma membranes and lower 
clearance rate (36; 160). Curiously, most laboratory animals have low circulating 
concentrations of DHEA and DHEAS. Concentrations comparable to those in humans are 
found only in great apes and Old World monkeys (161; 162), and not all primates share 
this characteristic (1; 2; 163). Nevertheless, the rodent brains still have appreciable 
concentrations of DHEA, although lower than those found in human brains (1.5 and 0.4 
nmol/kg in the anterior and posterior rat brain; 29.4 and 16.9 nmol/kg in anterior and 
posterior human brain) (4; 80). 
During adulthood and old age, DHEAS levels are higher in males than in females. 
Unlike DHEAS, unconjugated DHEA levels are not higher in men (134). On the contrary, 
significantly higher levels of DHEA were found in women in the premenopausal period 
(between 36 and 45 years of age) and in the older group (after 60 years of age) (134). The 
age- and sex-related dependencies are different between DHEAS and DHEA, suggesting 
an eventual variable secretion and dynamics of their interconversion (134). In both 
genders, DHEA and DHEAS levels both in plasma and cerebrospinal fluid peak in early 
adulthood (in the mid-twenties) and then generally, but progressively decreasing with age 
(82; 164). Its mean levels decrease to about 1 to 4% per year in men (12; 165) and about 
2% per year in women between 40 and 80 years old (12). By 65 to 70 years old, DHEA and 
DHEAS levels are about 20% of those in early adulthood (12). This progressive decline in 
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circulating levels of DHEA and DHEAS has been called by several authors as adrenopause 
(166; 167). Of note, one study suggested that 15% of women and 5% of men showed an 
increase instead of a decrease in DHEAS levels over a 10 to 14 year follow up (12). 
Besides, a transient increase in DHEAS concentrations was described in women 
transitioning into menopause along with its associated increase in gonadotrophins (168; 
169). And a DHEA increase was also found in women in the premenopausal period (36-45 
years of age) (134). 
 Along with the age-related decline in DHEA and DHEAS levels, there is a parallel 
decline in CSF levels of DHEA and DHEAS (82). On the contrary, there is an increase in CSF 
cortisol-to-DHEA molar ratio with aging. Those ratios for 70 years old were four times 
those for 20 years old (79). Nevertheless, there may be an attenuated decline in CSF 
levels of DHEA and DHEAS with age when compared to the peripheral circulation decline, 
and the age decline in CSF levels may be much lower for DHEAS when compared to DHEA 
(82). Guazzo et al. found that the CSF levels of DHEA in the 60 to 85 years old group of 
subjects was half those in the 19 to 40 years old group, while the blood levels declined to 
about one third of those in the 19-40 years old group; but concerning DHEAS, in the 
oldest group of subjects, those levels in the CSF were 80% of those in the younger adults 
(82). In older individuals with relatively high CSF cortisol and low DHEA(S), the molar ratio 
was 5-10 times higher than in young adults aged around 20 years old (82). 
 The CYP3A group of enzymes (which includes CYP3A4) are abundantly expressed 
in liver, being responsible for the metabolism of several pharmacologic medications. 
CYP3A7 enzyme is expressed mostly in human fetal liver and is normally silenced after 
birth. This enzyme carries a similar role in fetus as CYP3A4 in adults. It oxidizes several 
compounds, including steroids, fatty acids and xenobiotics, and it plays an important role 
in the 16α-hydroxylation of DHEA and DHEAS. There is a common polymorphism in this 
gene (CYP3A7*1C) that causes the persistence of its enzymatic activity during adult life. 6 
to 8% of the population are heterozygous carriers of this polymorphism resulting in about 
half the serum DHEAS levels and identical serum DHEA levels compared with homozygous 
carriers of the reference allele (170). Nevertheless, although those subjects have lower 
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DHEAS levels than controls, there is no evidence that they have an earlier beginning in 
diseases related to aging. 
DHEA and DHEAS levels reach a nadir by the time many diseases of old age peak 
its prevalence. Moreover, lower DHEA and DHEAS levels were related with higher 
morbidity and mortality even after age adjustment (2; 13). In a long time (27 years) 
period follow-up study, lower baseline DHEAS levels were also predictive of shorter 
longevity independently of other risk factors such as age, blood pressure or fasting 
glucose levels (171).  Either specific effects or a cortisol antagonism has been evoked to 
account for those associations (17; 172). Importantly, DHEA and DHEAS levels gradually 
decrease over time whereas corticotrophin secretion and cortisol levels remain largely 
unchanged in older subjects. Accordingly, the ratio of DHEA to cortisol and DHEAS to 
cortisol decline with age. Some authors proposed that this decline in DHEA and DHEAS 
occur due to a reduction in the number of functional zona reticularis cells in the adrenal 
cortex rather than due to regulation by some central hypothalamic pacemaker of aging 
(173). 
The sulfotransferase activity is downregulated during infection, inflammation and 
the euthyroid sick syndrome (174; 175; 176). The acute-phase response and T3 levels 
have also been shown to modulate the DHEA sulfotransferase activity. TNF and IL-1 
mediated inhibitory effects of lipopolysaccharides (LPS) on SULT2A1 at the mRNA level 
(174) could provide a possible mechanism by which infection and inflammation are
associated with reduced serum levels of DHEAS. On the other hand, SULT2A1 enzyme has 
been reported to be regulated by two transcription factors, the steroidogenic factor 1 
(SF1) and GATA in the human adrenal gland. SF1 on the other hand was also found to be 
indirectly up-regulated by T3 (175). This could eventually contribute to the low DHEAS 
levels that we usually find in patients with euthyroid sick syndrome. Additionally, cAMP 
may enhance the synthesis of cortisol, DHEA and the sulfotranstransferase activity (176) 
while, in patients with chronic liver disease, the dehydroepiandrosterone-sulfotransferase 
concentrations and its activity in liver are reduced (177). 
As mentioned before, DHEA and DHEAS are precursors to peripherally synthesized 
androgens and estrogens in target tissues such as the brain, bone, skin and adipose 
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tissue. In this regard, some authors propose that DHEA and DHEAS are inactive precursors 
and that their actions are mainly exerted after conversion to active androgens and 
estrogens in peripheral target tissues (intracrinology) (178; 179). In this case, these 
actions are exerted inside the cells where the active steroids are synthesized and those 
active steroids are not released to the general circulation. 
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Mechanisms of action and cellular effects 
Molecular effects 
Steroid hormones in general act by binding to nuclear or cytoplasmic receptors. 
Cytoplasmic receptors usually translocate into the nucleus and for both cytoplasmic and 
nuclear receptors, the complex hormone-receptor bind to steroid responding elements in 
the deoxyribonucleic acid (DNA) (7). Nevertheless, to date, no nuclear steroid receptor 
with high affinity for either DHEA or DHEAS has been found and the exact molecular 
mechanisms by which DHEA and DHEAS operate are not fully understood (7). Also, there 
is no evidence that DHEA or its active metabolites bind to the glucocorticoid receptor or 
interfere with glucocorticoid hormone binding with its receptor (180; 181). Some of DHEA 
and DHEAS effects may be mediated after conversion to estrogens and other androgens 
in target tissues, that later have effects on their respective receptors (7). Besides, 
although no specific membrane receptor was found for DHEA and DHEAS, these 
molecules were shown to have affinity for several membrane receptors that could affect 
their action (3; 7).  
In cell membranes in the brain, DHEA and DHEAS modulate ion-gated channel 
neurotransmitter receptors N-methyl-D-aspartate (NMDA) and γ-aminobutyric acid type 
A (GABA-A) receptors (86; 110). DHEA and DHEAS present in general a neurostimulatory 
effect: presynaptic actions include glutamate, acetylcholine and norepinephrine release 
and postsynaptic actions include sigma 1 receptor agonism, N-methyl-D-aspartate 
(NMDA) receptor agonism, γ-aminobutyric acid type A (GABA-A) receptor antagonism and 
inhibition of voltage-gated calcium currents (1; 3). Although DHEA and DHEAS may 
influence the release of several neurotransmitters at the synaptic terminals, they act 
primarily through postsynaptic receptors (1). 
Presynaptic actions of DHEAS include spontaneous glutamate release and 
inhibition of serotonin (5HT)-evoked glutamate release in the prelimbic cortex, as well as 
spontaneous glutamate, acetylcoline (Ach) and NMDA-evoked norepinephrine (NE) 
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release in the hippocampus. Post-synaptic actions of DHEAS include GABA-A receptor 
antagonism with reduction of inhibitory postsynaptic currents and reduction of decay 
time constants at the ventral midbrain, sigma-1 receptor agonism with inhibition of 
persistent sodium currents in the prefrontal cortex, pain facilitation at the spinal cord, 
NMDA-induced neuronal excitability in the hippocampus and inhibition of voltage-gated 
calcium currents in the hippocampus CA1 region (3). 
The GABA-A receptor complex contains a central chloride anion conduction pore. 
Several substances interact with this receptor complex. It binds GABA and drugs like 
muscinol, gabaxadol and bicuculline. Also, besides DHEA and DHEAS, other steroids and 
drugs like picrotoxin, benzodiazepines, barbiturates and ethanol bind at allosteric sites of 
the GABA-A receptor, modulating its activity. The NMDA receptor is an ionotropic 
glutamate receptor (ion channel), nonselective to several cations, allowing the voltage-
dependent flow of Na+ and small amounts of Ca2+ into the cell and K+ out of the cell. 
Again, numerous substances are known to interact with the NMDA receptor. It has got 
several regulatory and functional binding sites, including the glutamate (recognition) site, 
the glycine (co-activator) site, and a site within its ion channel that binds phencyclidine 
and the noncompetitive antagonist MK-801 (dizocilpine) (182; 183). Agonists include 
NMDA (which selectively binds to this receptor), aspartic acid, glutamic acid, serine, 
alanine, nebostinel, DHEA, DHEAS and pregnenolone sulfate (120) amongst others; 
antagonists include ethanol, nitrous oxide, methadone and tramadol; and modulators 
include Na+, K+, Ca2+ and H+ concentrations. Sigma-1 receptors modulate Ca2+ release and 
voltage gated K+ channels amongst its other actions. Tryptaminergic amines, DHEA, 
DHEAS, pregnenolone and pregnenolone sulfate may activate this receptor. 
By acting as GABA-A receptor antagonists and sigma-1/NMDA receptor agonists in 
neuronal membranes, several intraneuronal effects of DHEA and DHEAS were described 
(7). DHEA inhibits Ca2+ influx into the mitochondria; DHEA increases kinase activity of Akt 
and decreases apoptosis, while DHEAS decreases Akt and increases apoptosis; DHEAS 
increases tyrosine hydroxylase mRNA and protein, leading to increased catecholamine 
synthesis;  DHEA and DHEAS stimulate actin depolymerization and submembrane actin 
filament disassembly, thereby increasing secretion of catecholamines dopamine and 
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norepinephrine from secretory vesicles; DHEA and DHEAS inhibit reactive oxygen species 
(ROS) activation of transcription mediated by NF-κB; DHEA inhibits nuclear translocation 
of the glucocorticoid receptors; these hormones also inhibit stress-activated protein 
kinase 3 (SAPK3) translocation and 11β-hydroxysteroid dehydrogenase type 1 activity (7). 
DHEA and DHEAS may either directly act at the NMDA receptor level or bind to 
sigma-1 receptors with posterior NMDA receptor activation (7). Several intracellular 
actions of sigma-1 receptor activation by DHEAS were suggested. DHEAS activation of 
sigma-1 receptor was found to inhibit persistent sodium currents, an effect that was 
mediated through Gi protein and protein kinase C (3; 7). Other pathways might also be 
involved in sigma-1 signaling, namely inositol triphosphate (IP3) receptors and Ca2+ 
signaling, mitogen-activated protein kinase (MAPK), phospholipase C, c-Jun N-terminal 
kinase, Ras/Raf/MAPK pathways, and norepinephrine release (3).  
DHEA and DHEAS act as noncompetitive antagonists at the GABA-A receptor (184; 
185; 186; 187) and as positive allosteric modulators of the NMDA receptor (188; 189). 
Binding assays indicate that DHEA can bind with high affinity on membranes isolated from 
rat hippocampal cells (Kd=61.9 nM) (DHEA bind normal human adrenal chromaffin cells 
with a Kd=0.1 nM) (211). DHEA and DHEAS actions at GABA-A and NMDA receptors were 
observed at micromolar concentrations (and some at nanomolar concentrations) (29; 
190; 191). DHEA and DHEAS may act at distinct sites of the GABA-A receptor (192). DHEAS 
may bind at the barbiturate site of the GABA-A receptor complex (187). Also, DHEAS but 
not DHEA, competitively inhibits the binding of TBPS to GABA-A, suggesting that the 
noncompetitive inhibition of DHEAS on GABA-A responses may be mediated by attaching 
to the picrotoxin/TBPS (T-butyl-bicyclo-phosphorothionate) binding site of the GABA-A 
receptor complex (187). 
DHEAS produces a concentration-dependent block of GABA-induced currents with 
IC50 of 13 μM and 10 μM respectively, in cultured neurons from the ventral 
mesencephalon (192; 193) and cortical neurons (187). DHEA was much less potent in 
inhibiting GABA-induced currents: Cl- influx was reduced by 13% at 10 μM and by 33% at 
100 μM concentrations (187). The presence of the γ subunit in GABA-A receptor may 
enhance the efficacy of DHEAS without altering its binding affinity (194). A saturating 
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concentration of DHEAS blocked approximately 75 % of currents mediated by GABA-A 
receptor, which is composed of human α1, β1, and γ2S subunits, whereas the inhibition 
was only 35 % in GABA-A receptor containing only α1 and β1 subunits (194). Long-term 
exposure of GABA-A receptors to DHEAS did not produce changes in receptor expression 
and functional coupling, thus suggesting that DHEAS does not induce tolerance and 
dependence by acting at this receptor (195).  
High micromolar concentrations of DHEAS inhibited muscimol and flunitrazepam 
binding to GABA-A receptors in rat brain membranes, primarily by reducing their binding 
affinities (192). On the other hand, pregnenolone sulfate, pentobarbital and 
phenobarbital interacted with the GABA-A receptor, inhibiting the binding of DHEAS (192; 
120). Concerning sigma-1 receptors, at nanomolar concentrations, DHEAS enhanced and 
pegnenolone sulfate reduced the sigma-1 mediated response to NMDA (196). Haloperidol 
(a sigma antagonist) and progesterone prevented that effect of DHEAS on sigma-1 
mediated NMDA-evoked response (norepinephrine release, in that study) (196). Pertussis 
toxin, which inactivates sigma-1 mediated Gi function, also suppressed the effect of 
DHEAS (196). Besides, chronic treatment with nandrolone may also change the affinity of 
DHEAS to the sigma-1 receptor (197). 
DHEAS effect on the NMDA receptor may facilitate long-term potentiation 
induction and increase the number of NMDA binding sites in the hippocampus and cortex 
of the rat brain (3). Nevertheless, in some non-hippocampal regions, DHEA and DHEAS 
may inhibit glutamate transmission also through sigma transmission, as sigma 
transmission was shown to reduce NMDA-induced effects in the striatum (198); and 
DHEAS may also inhibit serotonin-evoked glutamate release via activation of sigma-1 
receptor in the pyramidal cells of the prelimbic cortex (199).  
Acute and chronic effects of DHEA and DHEAS in the modulation of the synaptic 
function may be mediated by different receptors: DHEAS induces short-term potentiation 
(STP) in rat hippocampus through postsynaptic effects at the metabotrophic glutamate 
receptor (200), whereas long-term potentiation (LTP) is induced in rat hippocampus and 
cortex through sigma-1 and NMDA postsynaptic receptors and NMDA-induced [Ca2+]i 
increase (201; 202; 203; 204). DHEA and DHEAS effect may also vary according to their 
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concentration. As an example, low DHEAS concentrations may inhibit presynaptic 
serotonin-evoked glutamate release in the prelimbic cortex, whereas higher DHEAS 
concentrations can promote spontaneous glutamate release (205). Therefore, the effects 
of DHEA and DHEAS on neurotransmitter release are complex, depending on factors such 
as the brain region involved, presynaptic functional state and hormone concentration (3; 
206). 
Sulfated steroids in general possibly act as endogenous neuromodulators (207) 
and the balance between DHEAS and DHEA has been suggested to influence brain 
functioning. Bearing this in mind, it is important to note that DHEAS has a much more 
potent excitatory action than DHEA (NMDA agonism and specially gabaminergic 
antagonism) and that it may account for some differential effects of both forms of the 
hormone (1; 184; 196). DHEAS, but not DHEA, also enhances cholinergic function. In fact, 
it increases acetylcholine (ACh) release from rat hippocampal neurons (208) and this 
effect may also be mediated through sigma 1 receptors, because it is blocked by a sigma 1 
antagonist (209). Inhibiting the conversion of DHEAS to DHEA in rats also increased the 
hippocampal ACh release (210). Notably, several studies suggest that the balance 
between DHEAS and DHEA may influence brain functioning (7; 207). Hence, the 
simultaneous evaluation of DHEA and DHEAS may uncover more information than the 
individual examination of either form of that hormone. 
Working memory rely on glutamatergic transmission (211), raising the hypothesis 
that DHEA and DHEAS might play a role on working memory. On the other hand, DHEA 
and DHEAS antidepressive effects might be partially mediated via GABAergic receptor 
antagonism (212) and sigma 1 receptors agonism. In fact, the GABAergic system can 
mediate depression (213) and other selective sigma-1 receptor agonists are known to 
cause antidepressant-like effects on rats (214). As mentioned, in this regard, DHEAS has a 
much more potent NMDA agonism and specially gabaminergic antagonism action than 
DHEA (1; 184; 196).  
The alteration in the mechanisms involving the activity of the calcium-
phospholipid-dependent protein kinase C (PKC) is believed to be an important cellular 
change associated with brain aging (namely regarding the decline in memory and 
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attention) (215). There is defective activation of PKC-dependent pathways during aging 
which is due to a defective mechanism of translocation of the kinase due to reduced 
levels of the major anchoring protein RACK-1 (receptor for activated C kinase) and there is 
also experimental evidence that DHEA can revert the alteration of RACK-1 anchoring 
protein expression (215). 
Besides the above mentioned receptors, DHEA and DHEAS effects on other 
receptors were described. There is evidence of DHEA binding with high affinity (Kd=49nM) 
receptors on endothelial cell plasma membranes, where its actions seem to be mediated 
through Gi protein-coupled receptors, activating the endothelial nitric-oxide synthase, 
eNOS (191; 216). DHEA may also act on cytoskeleton components. Regarding this, DHEA 
was found to bind to microtubule-associated protein 2C (MAP2C). This protein is 
expressed at early development stages and also in the adult retina and the olfactory bulb. 
Of note, in these two tissues, neurogenesis persists in the adult (217). DHEA and DHEAS 
may also act at the peroxisome proliferator-activated receptor (PPARα), pregnane 
receptor, androstanol receptor and estrogen receptor β (6; 218; 219). 
Besides the classical slow genomic effects, rapid non-genomic effects of 
glucocorticoids were observed at the hypothalamus, hippocampus, amygdala and 
prefrontal cortex (220). These effects involve mineralocorticoid and glucocorticoid 
receptors and membrane-associated mechanisms, which are not direct but conditional 
effects, facilitating or inhibiting the signaling of ion channels, receptors and 
neurotransmitters, thus modulating the threshold of neuronal activation (220). 
The mainly neuro-excitatory effects of DHEA and DHEAS on GABA-A and NMDA 
receptors do not suggest a direct anti-cortisol or anti-stress effect at this level. In that 
respect, cortisol effects at GABA-A and NMDA receptor binding sites are less evident than 
those found in DHEA and DHEAS. Most studies failed to find any effect of glucocorticoids 
on GABA-A receptor mediated responses (120), although a study by Majewska (190) 
suggested that glucocorticoids may play a role in the modulation of neuronal excitability 
via interactions with the GABA receptor complex. T-butyl-bicyclo-phosphorothionate 
(TBPS) blocks the GABA-A receptor mediated Cl--current response (221) and Majewska 
also found that at low nanomolar concentrations of glucocorticoids potentiate TBPS 
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binding (20-50% above control), whereas at high nanomolar and micromolar 
concentrations glucocorticoids slightly reduced TBPS binding (190). Regarding NMDA 
receptors, a low dose of dexamethasone (which caused a decrease in serum cortisol 
levels) reduced by 20% the NMDA affinity for the antagonist MK-801 in the newborn lamb 
(but not at other developmental stages of the lamb), thus suggesting that exposure to 
corticosteroids during a critical period could have significant effects on the developing 
brain (182). Other studies found either an increase in the apparent number of NMDA 
receptors (with unchanged Kd) (222; 223) or no effects of glucocorticoids on NMDA 
receptor binding (224; 225). 
 DHEA and DHEAS binding to a NMDA and GABA-A receptor negative neural crest-
derived rat sympathoadrenal cells was observed to occur with high affinity, possible at a 
Gi coupled receptor (IC50 of 1.3nM for DHEAS and 1.5nM for DHEA) (191). 
Glucocorticoids (cortisol and dexamethasone) and androgens (testosterone and 
dihydrotestosterone) affinity for that receptor was also tested and found to be 10 to 15-
fold lower than that of DHEA, displacing 70% and 60% of DHEA binding at a concentration 
of 1μM respectively (191). Also, the anti-apoptotic effect that was observed for DHEA and 
DHEAS in that study, was not observed for those steroids (191). That observation suggest 
the hypothesis that cortisol and androgens may act as weak endogenous antagonist of 
DHEA at that non-NMDA and non-GABA-A receptor level (191). 
 
Neuronal effects 
 Biological actions of DHEA and DHEAS involve neuroprotection, neurogenesis, 
neurite growth and apoptosis. Several studies suggest a neuroprotective effect of DHEA 
and DHEAS. After spinal cord injury, mice treated with DHEA had better locomotor 
recovery, more white matter at the site of injury and a reduced area of reactive gliosis 
surrounding the lesion (226). Rats submitted to forebrain ischemia showed reduced 
hippocampal CA1 injury if they were treated with DHEA when compared to rats treated 
with placebo (227). Similarly, rabbits treated with DHEAS also had increased tolerance to 
ischemia (228). In the like manner, in vitro studies found DHEA and DHEAS protective 
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effects after oxygen-deprivation (229; 230). It was therefore proposed that this effect was 
mediated though GABA-A receptor antagonism (228) and that the effect of DHEAS is 
dose-dependent, with higher concentrations providing more neuroprotective effects 
(230).  
Another mechanism for DHEA and DHEAS neuroprotective effect was shown to be 
the protection from glutamate, NMDA excitotoxicity (230; 231; 232). This last finding was 
unexpected since DHEA and DHEAS also have NMDA receptor agonist activity. However, it 
was proposed that these hormones may be neuroprotective against NMDA toxicity 
through other pathways (233; 234). Although not completely understood in the case of 
DHEA, studies suggest that the protection might involve the inhibition of nitric oxide 
production and the reduction of intracellular Ca2+ overload (thus preventing Ca2+ influx 
into the mitochondria) whereas DHEAS protective effect could somehow be mediated via 
the sigma 1 receptor (235). 
It is also important to note that while low doses (10-8 – 10-7 M) of DHEA increased 
neuronal survival, intermediate doses (10-6 – 10-4 M) had less effect, and high DHEA 
concentrations (500nM and micromolar concentrations) were neurotoxic in rat primary 
cortex and hippocampus. This deleterious effect may be mediated through DHEA 
inhibition of the respiratory chain (236; 237). On the contrary, other studies found that 
DHEAS had no effect on the neuronal cultures viability (238) and when incubated with 
neuroblastoma cells, DHEAS antagonized the neurotoxic effect of DHEA (238). Given the 
higher concentrations of DHEAS than DHEA in the central nervous system, the authors 
assume that the higher concentrations of DHEAS (10-100 nM) in vivo may prevent DHEA 
induced neurotoxicity (238). We don’t know how this DHEAS effect was mediated nor do 
we know if the effect of DHEA and DHEAS was mediated by different receptors. 
Nevertheless, these data suggest that in some situations DHEA and DHEAS may have 
distinct and sometimes opposing effects (7).  
Both DHEA and DHEAS were also shown to promote neurogenesis, neurite growth 
and neuronal survival. DHEA promoted neurogenesis in the dentate gyrus (239). It is not 
known whether this effect is mediated through brain-derived neurotrophic factor (BDNF), 
but a study did reveal that DHEA and DHEAS administration modulated the levels of 
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BDNF, which is a nerve growth factor. In this regard, the effects of each hormone were 
different: after DHEA administration, the BDNF levels decreased in the hippocampus, did 
not change in the amygdala but increased BDNF in the hypothalamus; after DHEAS 
administration, the BDNF levels were initially reduced in the hippocampus and then they 
increased in the hippocampus and amygdala and reduced in the hypothalamus (240). 
DHEA and DHEAS increased neuronal differentiation and reduced astroglial proliferation 
rates in cultures of mouse brain cells (241). 
In what concerns neurite growth, DHEA and DHEAS effects also differed: using 
embryonic neocortical neurons, DHEA preferentially increased axonal length whereas 
DHEAS increased dendritic growth (15). In the case of DHEA, it was suggested that this 
effect was mediated through NMDA receptors (15). The DHEA and DHEAS effects in 
neurite growth may lead to the formation of specific neuronal synapses networks in the 
rat neocortex (242). Noting that P450 CYP17 is expressed in the cortical subplate, a region 
enrolled in guiding the thalamic fibers to their cortical targets, Compagnone and Mellon 
purposed that DHEAS might play a role in the brain development of the rat embryo (189).  
In adult rats, DHEA increased synapse formation in the hippocampus (243), 
although this effect was likely mediated through aromatization to estradiol (243). In what 
concerns neuronal survival, DHEA and DHEAS increased neuronal survival of embryo and 
adult cultures of rat and human neurons, namely from the human cortex (244; 241; 245). 
In the case of DHEA, the results suggest that the effect may be mediated through NMDA 
and sigma 1 receptors (246). DHEA and DHEAS enhancement of glial survival in rat 
embryo cell cultures was also observed (245).  
DHEA and DHEAS may also modulate apoptosis. The activation of the serine-
threonine protein kinase B or Akt has been previously shown to inhibit apoptosis, 
enhancing neuronal survival (247). In this regard, DHEA activated the serine-threonine 
protein kinase B protecting from apoptosis; on the contrary, DHEAS decreased the serine-
threonine protein kinase B increasing apoptosis (248). In the same way, DHEA but not 
DHEAS, decreased neuronal death due to NMDA neurotoxicity (249). Once again, this 
suggests that the balance between DHEA and DHEAS is important for the maintenance of 
the nervous system. On the contrary, both DHEA and DHEAS promoted chromaffin and 
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pheocromocytoma cells survival (250). Of note, these cells do not have functional GABA-A 
or NMDA receptors and mechanisms other than NMDA or NOS inhibition may be 
involved, namely coupled G-protein mechanisms (216). 
 
Chromaffin cell effects 
DHEA and DHEAS where shown to stimulate the secretion of catecholamines from 
rat pheocromocitoma cells (251) and DHEAS was shown to stimulate dopamine (DA) 
release from rat hypothalamic cultures (252). Besides stimulating secretion, DHEAS but 
not DHEA, stimulated catecholamine production (253) and DHEAS was shown to increase 
tyrosine hydroxylase protein concentration (this last effect was not studied for DHEA) 
(253). Accordingly, non-transcriptional effects of DHEA in the chromaffin tissue and non-
transcriptional as well as transcriptional effects of DHEAS in that tissue were suggested.  
DHEA and DHEAS do not directly stimulate the proliferation of chromaffin cells, 
but they modulate the proliferation induced by growth factors. They increase the 
proliferation induced by some growth factors and decrease the proliferation induced by 
other growth factors (122; 254). Besides, DHEA and DHEAS may also play a role in 
chromaffin tissue differentiation: using rat pheocromocitoma cells, they inhibited 
neuronal proliferation and promoted differentiation towards a more neuroendocrine 
phenotype (251).  
Overall, the findings suggest that DHEA and DHEAS production in the adrenal 
cortex might increase catecholamine production as well as release and modulate the 
proliferation and differentiation of chromaffin cells in adrenal medulla. Some authors 
proposed that DHEA and DHEAS might eventually have similar effects in catecholamine 
producing neurons in the central nervous system (7). These results are unexpected and 
counter-intuitive if we take into account the anti-cortisol and anti-stress effects of DHEA 
and DHEAS. On the other hand, most effects of DHEA and DHEAS at neuronal membrane 
receptors were also neurostimulant and the effects of these hormones were probably 
more than just anti-cortisol. 
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Antioxidant and anti-inflammatory effects 
Antioxidant, anti-inflammatory and immunomodulatory effects of DHEA and 
DHEAS have also been proposed. In hippocampal tissues (from rat and human species), 
DHEA protected against toxicity induced by hydrogen peroxide, sodium nitroprusside and 
ferrous sulfate (255). In Alzheimer's disease, DHEA protected against oxidative stress and 
amyloid β protein toxicity (231; 255; 256). Studying diabetes models, DHEA decreased 
oxidative stress radicals, increased the antioxidant glutathione (GSH) and antioxidant 
enzymes (GSH-peroxidase and catalase) in the rat hippocampus (257). Likewise, DHEA 
inhibited the transcription factor NF-kB (which is pro-inflammatory) in those diabetic rats 
(257). DHEA and DHEAS administration to PPARα -/- knockout mice had less antioxidant 
and anti-inflammatory effects than its administration to wild type PPARα +/+ mice 
suggesting that DHEA and DHEAS antioxidant and anti-inflammatory effects might be 
mediated through PPARα (258). 
 The administration of DHEA to rats decreased the proinflammatory cytokine 
tumor necrosis factor (TNF) α (259). In rat brain glial cell cultures, DHEA inhibited the 
production of TNFα and interleukin (IL)-6 (another proinflammatory cytokine) (259). 
DHEA and DHEAS inhibits NF-kB transcription in hepatocyte cell cultures, both basally and 
through TNFα stimulation (260). On the other hand, TNFα also induced NF-kB and this 
pathway inhibits the nuclear receptor steroidogenic factor (SF)-1 activation of P450 CYP17 
transcription (261). This is due to competition between NF-kB and SF-1 for binding to the 
P450 CYP 17 promoter. Thus, the proinflammatory cytokines TNFα and NF-kB probably 
inhibit DHEA production while DHEA and DHEAS inhibit TNFα and NF-kB transcription.  
Anti-glucocorticoid effects 
Several levels of evidence point towards anti-glucocorticoid effects of DHEAS and 
particularly DHEA. However, the mechanism of this anti-glucocorticoid effect is not clear. 
Possible mechanisms accounting for this DHEA effect are the inhibition of 11β-
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hydroxysteroid dehydrogenase (11β-HSD) type 1 and up-regulation of 11β-HSD type 2, 
therefore reducing the conversion of cortisone to cortisol (which is the active 
glucocorticoid) and enhancing the conversion of cortisol to cortisone, respectively (262; 
263). In fact, DHEA inhibited 11β-HSD type 1 mRNA expression and enzyme activity but 
up-regulated 11β-HSD type 2 mRNA expression and enzyme activity (262; 263).  
The mechanisms for this effect may involve the modulation of the 
phosphatidylinositol-3 kinase/Protein kinase B-dependent pathway with a shift in 
expression from the transcription factor CCAAT/enhancer-binding protein (C/EBP)-α to 
C/EBP-β (262; 263). C/EBP-α is a strong activator of HSD11B1 and a weak activator of 
HSD11B2 whereas C/EBP-β acts in an opposite way and preferentially stimulates HSD11B2 
expression (262; 263). Of note, these effects were not in any way mediated by DHEA 
metabolism to estradiol or to testosterone (262). On the other hand, in the brain, DHEA 
can be converted into 7α-hydroxy-DHEA or 7β-hydroxy-DHEA. In vitro, these metabolites 
can act as anti-glucocorticoids through competitive inhibition of 11β-HSD1, thus limiting 
the conversion of cortisone into cortisol (264). 11β-HSD type 1 is widely expressed (in 
liver, adipose tissue, muscle, pancreatic islets, adult brain, inflammatory cells, and 
gonads) (265). Interestingly, its expression is elevated in the ageing brain, increasing 
active glucocorticoid levels and 11β-HSD type 1 deficiency or selective inhibition of 11β-
HSD type 1 improving cognitive function with ageing (265).  
Contrary to what might be expected, there is no evidence that DHEA or its active 
metabolites interfere with glucocorticoid hormone binding with its receptor (180; 181) 
and there is also conflicting evidence regarding the interference of DHEA on cellular 
trafficking of the glucocorticoid receptor into the nucleus (181; 231). Nevertheless, 
prolonged treatment with DHEA may decrease the relative concentration of the 
glucocorticoid receptor (266) and reduce its baseline glucocorticoid-receptor dependent 
transcriptional activity (267). In that regard, it was suggested that maybe DHEA could 
interfere with glucocorticoid receptor binding to glucocorticoid responsive element 
sequence, counteracting cortisol effects (268). 
At the cellular level, several other studies showed that DHEA is protective against 
the neurotoxic effects of corticosterone (262), both in vitro and in vivo. Corticosterone 
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treatment decreased neurogenesis in the rat dentate gyrus whereas DHEA administration 
antagonized that effect (239). Corticosterone induced hippocampal neurotoxicity in 
primary rat tissue cultures, whereas DHEA prevented that neurotoxicity (236). In that 
study, DHEA reduced the corticosterone-induced nuclear translocation of stress-activated 
protein kinase 3 (SAPK3), which might be important in the sequence of events leading to 
either neuronal death or its survival (236).  
In another in vitro study, DHEA protected against glutamate toxicity (231). 
Neurons treated with glutamate showed increase nuclear localization of glucocorticoid 
receptors (GR) and DHEA treatment suppressed the nuclear localization of glucocorticoid 
receptors (GR) in that condition. These results suggest that the inhibition of GR 
translocation into the nucleus is a possible mechanism of DHEA’s anti-glucocorticoid 
effects (231). Low levels of glucocorticoids are known to facilitate plasticity and 
hippocampus-dependent memory mostly through mineralocorticoid activation, while the 
absence or very high levels of glucocorticoids inhibit plasticity, mostly through 
glucocorticoid receptors effects (220) while DHEAS antagonized the memory 
deteriorating neurotoxic effects of cortisol in the hippocampus (3; 269). Hence, the 
simultaneous evaluation of DHEA, DHEAS and cortisol may uncover more information 
than the individual examination of either steroid. 
Reactivity to psychological stimuli 
As mentioned, DHEA is synthesized in response to ACTH, even if another unknown 
stimulating factor may exist. Accordingly, several studies have shown that DHEA and 
DHEAS are synthesized in response to acute psychological stressful stimuli. Nevertheless, 
acute and chronic stress have different effects on DHEA and DHEAS levels: acute stress is 
related to an increase in DHEA and DHEAS levels (8; 270; 271) while chronic stress 
decreases baseline DHEA and DHEAS levels (9; 10; 272; 273; 274). Also, in subjects under 
chronic stress, the acute DHEAS response to a superimposed psychological stress is 
reduced (11). Of note, although DHEAS has a long half-life and is present in high 
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concentrations in humans, short term increases in peripheral levels of DHEAS have been 
described in response to acute stimuli (8; 11; 271; 275). 
DHEA and DHEAS response to emotional stimuli is mostly unexplored, but a study 
by Hamilton and Meston (275) showed that DHEAS levels rose after the visualization of a 
movie with positive emotional content. A direct influence of cognitive processing on 
DHEAS and DHEA levels or the influence of negative emotional stimuli on DHEA or DHEAS 
levels were mostly unexplored. Interestingly, in a previous study we showed that 
corticotrophin releasing hormone (CRH) levels increased with the visualization of 
emotionally significant movies, more so in a movie of negative rather than positive 
emotional content (276). Of note, although in that study we found no significant relation 
between baseline CRH and ACTH, cortisol or DHEAS levels (276) [eventually because most 
CRH in the peripheral circulation may have originated from central extra-hypothalamic 
origins (277)], hypothalamic CRH is expected to stimulate corticotrophin secretion and in 
turn corticotrophin is a stimulus for cortisol and DHEA secretion by the adrenal (152). 
Although not completely understood, a differential regulation of DHEA and 
cortisol responses exist, suggesting that DHEA may be an anti-stress hormone. In that 
concern, Boudarene et al. (278) described a direct relation between DHEAS and cortisol 
responses during the performance of cognitive tasks but nevertheless those differential 
responses of each hormone depended on the subjects’ anxiety level. Most studies 
addressing pathological conditions, described that higher anxiety levels were related to 
higher cortisol-to-DHEA or cortisol-to-DHEAS ratios (279; 280; 281). Boudarene et al. 
(278) also studied subjects without mental disorders and varying levels of anxiety, and
found that the level of anxiety was related to the following profile of endocrine response 
after the performance of cognitive tasks: subjects with high anxiety levels in the State-
Trait Anxiety Inventory (STAI) (282) had increased cortisol reactivity and subjects with low 
anxiety levels showed an exclusive increase in DHEAS levels. The authors suggested that 
the antagonism in DHEAS and cortisol might be related to a competition in their synthesis 
and release by the adrenal gland. In a different setting, military subjects who reported 
fewer psychological symptoms of dissociation when exposed to an acute stress, also 
43 
showed higher DHEAS-to-cortisol ratios (270) and increased DHEA response during an 
acute stress (283). 
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Cognitive and neuropsychiatric effects 
DHEA and DHEAS levels decline with aging, chronic stress, inflammation and illness 
(82; 284; 285). Although lower DHEA and DHEAS are related to higher morbidity and 
mortality independent of age (2; 171; 286), it is not known whether DHEA and DHEAS are 
pathophysiologically directly related to the manifestations of aging and illness. Allostasis 
refers to the state in which the physiological systems of the body fluctuate to meet 
demands from external forces (287). It emphasizes the dynamic behavioral and 
physiological mechanisms that are used to anticipate or cope with environmental change 
in order to maintain body function (288). Allostasis involves mostly the sympathetic 
nervous system and HPA axis responses (allostatic responses) (287). These responses are 
activated whenever the body faces a challenge (such as infection, danger or any other 
physical or psychological stress) and stop when the danger passes away (287). 
Nevertheless, body responses may be beneficial, impose significant costs or cause harm 
(288). In particular, long time duration stressors (chronic stress) change neural and 
neuroendocrine responses, dysregulating allostatic mechanisms and resulting in 
deleterious effects on the body (287; 288; 289). 
Allostatic load is a measure of the cumulative physiological burden to the body, 
resulting from that repeated or chronic stress over time (290). McEvan and Stellar 
proposed that higher allostatic load is responsible for increased "wear and tear" of the 
body, thus increasing the chances of developing disease (289). The term allostatic 
overload is also used to refer to the point above which the body starts to suffer negative 
physiological consequences due to the activation of allostatic mechanisms (288; 291). Ten 
biological parameters are included to calculate allostatic load scores: DHEAS, cortisol, 
epinephrine, norepinephrine, high density lipoprotein cholesterol (HDLc), total 
cholesterol, waist-to-hip ratio, glycated hemoglobin, systolic and diastolic blood pressure 
(292). Notably, low DHEAS and high cortisol levels contribute to higher allostatic load 
scores (111; 292) and people with higher allostatic load at baseline have a higher 
probability of experiencing declines in physical and cognitive functioning and higher 
incidence of cardiovascular disease (287). Also, higher allostatic load scores, strongly 
predict cardiovascular disease, in fact more so, than the use of traditional cardiovascular 
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risk factors alone (111; 292). Besides the general relation of DHEAS to allostatic load, 
several other interesting relations of DHEA and DHEAS to cognitive and neuropsychiatric 
parameters were also described. Unfortunately, in most cases those relations are not 
systematic nor conclusive, hence they do not elucidate the exact physiological effect of 
DHEA and DHEAS and also do not establish a cause-effect relation.  
Memory, cognition and quality of life 
Some studies suggest that DHEA and particularly DHEAS might be implicated in 
age-associated memory deficits. One clue came from the fact that DHEA and DHEAS 
decrease with aging, reaching the lowest levels to the time when memory and other 
cognitive capacities deteriorate. Of note, cortisol levels do not decrease with age. With 
advanced age, higher cortisol-to-DHEA and cortisol-to-DHEAS levels are found, raising the 
hypothesis that the balance between DHEA or DHEAS and cortisol might be relevant to 
memory and cognition. In fact, several studies found correlations between higher DHEA, 
DHEAS, DHEA-to-cortisol or DHEAS-to-cortisol ratios and better cognitive functioning in 
healthy adults and aging individuals (293; 294; 295) and these relations were independent 
of age. 
Higher DHEAS levels were correlated to better executive functioning, working 
memory and concentration capacity in a group of 295 women aged 21 to 77 years old 
(293), whereas higher cortisol-to-DHEA ratios were related to more confusion and poorer 
visuospatial memory performance in older males (295). Also, greater cognitive 
deterioration was observed in elderly men and women who showed larger decreases in 
plasma DHEAS-to-cortisol ratios over time, although changes in DHEAS concentrations 
alone were not significantly correlated with cognitive change (296). A group of frail, 
institutionalized elderly people did not differ from independent community-dwelling 
controls in serum concentrations of cortisol or DHEAS, but did have significantly lower 
DHEAS-to-cortisol ratios (294). Again, this evidence suggests the importance of the 
balance between DHEA or DHEAS and cortisol, therefore implying anti-cortisol effects of 
DHEA and DHEAS. 
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 Nevertheless, other studies found no relation between DHEA or DHEAS levels 
alone or their decline and cognitive function. This occurred in studies for both genders, 
adults as well as aging subjects (18; 297; 298). Finally, some studies in elderly women also 
found significant relationship between higher DHEA or DHEA levels and worse cognitive 
function (299; 300). 
 Many studies found a direct relation between lower DHEA or DHEAS levels and 
poor quality of life, namely poor life satisfaction, psychosocial stress and functional 
limitations (2; 20; 298; 300; 301; 302; 303; 304; 305; 306; 307; 308; 309). Lower DHEAS 
levels were also related to higher perceived stress scores (274; 306). On the other hand, 
individuals with higher DHEAS levels had a higher probability of living independently and 
men with higher DHEAS levels had lower probability of having organic brain syndromes 
(310). Higher DHEAS levels were also related to higher vitality ratings in pre-menopausal 
women, but were not related to well-being scores in post-menopausal women (113). In 
male subjects, higher DHEAS levels were related to indulging in more leisure activities and 
greater enjoyment in these activities (311) while females with higher DHEAS levels had 
greater sexual gratification (312; 313). 
 DHEAS effects on cognition could be mediated through several actions. The 
administration of a sulfatase inhibitor was shown to increase DHEAS levels (by 88%), with 
consequent increases in acetylcholine release in the hippocampus and a reduction of 
scopolamine-induced amnesia (208). This study suggests that DHEAS enhances cholinergic 
function and that could eventually be a mechanism to enhance memory (208). Although 
the study did not test it, it simultaneously raises the hypothesis that higher DHEAS-to-
DHEA ratios could eventually benefit memory. DHEA and DHEAS could also potentially 
improve memory through antiglucocorticoid actions (as DHEA and DHEAS antagonize the 
deleterious effect of cortisol on memory) (314) or sigma-1 receptor agonism (as sigma-1 
antagonists can impair memory) (209; 315). Besides, cognitive effects could also be 
mediated through NMDA agonism or GABA-A antagonism (316). 
Higher DHEA, DHEAS or DHEA-to-cortisol levels were related to improved 
attention (317), lower perceived stress and improved performance under stressful 
conditions (17; 283; 318), again suggesting the importance of the cortisol/DHEA ratio (7; 
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269; 319). On the other hand, concerning attention, steroid sulfatase inhibition in mice 
(reducing the conversion of DHEAS into DHEA), was shown to impair accuracy under 
attention demanding conditions (320), and subjects with steroid sulfatase deficiency had 
higher rates of attention deficit hyperactivity disorder, with predominant inattentive 
symptoms (55; 321; 322). Nevertheless, methylphenidate administered to boys with 
attention deficit hyperactivity disorder has been shown to increase serum levels of both 
DHEAS and DHEA and simultaneously produce marked clinical improvement (323). 
Therefore, a relation between higher DHEAS-to-DHEA ratio or reduced DHEA and reduced 
attention was suggested, while the previous studies concerning memory suggested a 
relation between higher DHEAS levels and enhanced memory raising the hypothesis to 
test an eventual relationship between higher DHEAS-to-DHEA ratio and enhanced 
memory. 
Concerning the potential effects of treatment, DHEAS administration to mice, 
enhanced memory retention, meliorated the effects of several memory-blocking agents 
(309) and improved working memory (324). Interestingly, in mice, DHEA and DHEAS
administration demonstrated a dose-dependent inverted U-shaped effect on memory, 
with the lowest doses of DHEA or DHEAS showing no effect on memory, intermediate 
doses improving memory retention and the highest doses showing no effect at all (325). 
Nevertheless, in humans there is no evidence of a beneficial effect of DHEA 
supplementation on cognitive performance in healthy middle-age or elderly subjects 
(295; 326; 327). In fact, DHEA administration to human subjects showed inconclusive 
results on memory and attention (328; 329; 319; 330; 331). There is still the hypothesis 
that DHEA supplementation may eventually protect stress induced impairments in 
memory. In that concern, in one study of elderly subjects, DHEA supplementation 
impaired the recall of material learned before the stress but had an enhanced effect on 
attention after stress (327). These results are however, difficult to interpret and do not 
support a direct anti-glucocorticoid effect of DHEA on hippocampal mediated memory 
functions (327). It is also important to note that high quality studies using DHEA 
treatment for more than one year and involving a large number of participants, that could 




 Other authors tested the effects of DHEA administration to patients with 
Addison's disease. In that condition, results are not consensual. Some studies found 
positive results with improvements in overall well-being (333), mood, anxiety, depression, 
obsessive-compulsive traits, hostility and exhaustion (334), or improvements in self-
esteem, mood and fatigue, but not in cognitive function (335). Those positive results were 
found only after three to four months’ treatment (334; 335). DHEA treatment for six 
months to patients with hypopituitarism also resulted in improved psychological well-
being compared to placebo (336). Nevertheless, another study was even longer (9 
months) but did not find any positive results of DHEA administration to patients with 
Addison's disease (337). Interestingly, this study however used 25mg DHEA whereas the 
previously mentioned studies pertaining to Addison's disease and hypopituitarism used 
50mg DHEA daily. 
 
Personality 
 Personality trait characteristics of each individual develop in childhood and remain 
relatively stable over time (338). The same occurs with the HPA axis phenotype, 
concerning both baseline levels and reactivity patterns (339), and some relations between 
personality traits and HPA axis phenotype have been described in what concerns the 
ACTH and cortisol reactivity (339; 340; 341; 342; 343; 344; 345; 346; 347; 348; 349). In 
general, positive psychological traits were related to reduced HPA axis reactivity to an 
acute stress (350). Subtlety to profound changes may however occur in personality 
according to individual experiences (338) and, the HPA axis may show endocrine plasticity 
according to those experiences. For instance, neonatal stress or repeated stress could 
change this axis activity in the long term (351; 352). However, the relation between 
personality trait and DHEA or DHEAS responses to stress are not known. 
 Over a period of months to a few years, DHEAS levels during adulthood are also 
relatively stable in the same individual while showing large interindividual differences 
(353; 354). Also, DHEA and DHEAS are believed to influence cortical organization. Yet, the 
relationship between DHEA or DHEAS and personality is mostly unknown. Low plasma 
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DHEA and DHEAS levels have been related to chronic stress states but the relation 
between DHEA or DHEAS and anxiety trait is not established. Nevertheless, individuals 
with low anxiety trait scores were shown to have an increase in DHEAS levels after a 
psychological stress (without a concomitant increase in cortisol levels), whereas high 
anxiety trait individuals showed mostly an increase in cortisol levels (282).  
One study found lower DHEAS levels in individuals with higher Type A behavior 
scores (355). Of note, Type A personality individuals have hypothalamic-pituitary-
adrenocortical axis and sympathetic nervous system hyperactivity, and accordingly, they 
have higher cortisol and catecholamine levels, which might be the mediators of the 
higher cardiovascular risk, related to Type A personality (355). Interestingly, while chronic 
stress reduces DHEAS levels (274), a stress reducing program was also shown to increase 
DHEAS levels (356).  
Another study also suggested that DHEAS might contribute to greater sensation-
seeking and monotony-avoidant traits. In that study, individuals with higher DHEAS levels 
had higher scores in impulsivity and sensation-seeking-related personality scales, 
suggesting more disinhibited behavior in the social sphere, increased interest in sports 
and activities involving some danger with an increased need for change (357). 
Depression 
DHEA and DHEAS antidepressive effects may be partially mediated via GABAergic 
receptor antagonism (212) and sigma 1 receptors agonism. In fact, the GABAergic system 
can mediate depression (213), and other selective sigma 1 receptor agonists can cause 
antidepressant-like effects on rats (214). As noted, DHEAS has a much more potent 
excitatory action than DHEA (NMDA agonism and specially gabaminergic antagonism) and 
that may account for some differential effects of both forms of the hormone (1; 184; 
196). But besides glutamate, sigma-1 and gabaminergic modulatory effects, DHEA and 
DHEAS effects in neurogenesis and neuroprotection, catecholamine, anti-glucocorticoid, 
anti-inflammatory and anti-oxidant effects could also contribute to or underlie the 
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relationship between these hormones and depression (121; 358; 359; 360; 361; 362; 363; 
364). 
Higher DHEAS concentrations and DHEA-to-cortisol ratios have been related to 
lower prevalence of depression, lower depression ratings and higher well-being scores 
(18; 20; 365; 366; 367; 368). Low serum DHEAS levels were also found in dysthymic 
patients (369). There are also several inconsistent and contradictory results in the 
literature, showing either reduced, unaltered (370; 371; 372; 373) or increased (374; 375) 
levels of DHEA or DHEAS in depressed patients. In fact, the evidence for a relation 
between DHEA levels alone and depression is less consistent than the evidence that 
suggest a relation between higher DHEAS concentrations or DHEA-to-cortisol ratios and 
lower depression ratings. Lower concentrations of both DHEAS and DHEA were found in 
peri-menopausal depressed women (376) and lower DHEA concentrations during 
pregnancy and postpartum period were found in relation to higher postpartum ratings of 
depression (377). But also, in a study assessing both DHEA and DHEAS, depressed patients 
had low DHEAS but normal DHEA concentrations (308). Yet in another study, patients 
with depression had increased DHEA plasma concentrations, which paralleled elevations 
in plasma cortisol (374). These results point towards the importance of DHEA-to-cortisol 
and DHEAS-to-DHEA balance. 
In fact, several groups have found that DHEA-to-cortisol ratios, rather than 
concentrations of either hormone alone, discriminated more accurately depressed from 
non-depressed individuals, with lower DHEA-to-cortisol ratios seen in depression (84; 
304; 365; 366; 378; 379; 380), in untreated depressed patients and in patients who 
remained depressed after several months (381; 382). It was hence suggested that 
elevated DHEA and DHEAS relative to cortisol levels, may counteract the negative effects 
of high cortisol on mood (360; 381). Moreover, controlled trials of DHEA therapy have 
reported significant and positive effects on mood (362; 383; 384; 385). Those mood 
improvements were related to increases in the circulating concentrations of DHEA and 
DHEAS and to increases in their ratios with cortisol, again suggesting anti-glucocorticoid 
effects of DHEA. Although controlled trials of DHEA administration in depression have 
consistently reported significant antidepressant effects, large-scale, long-term and 
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comparative studies (with established antidepressant drugs) are still missing. Such studies 
will be necessary before an eventual role for DHEA administration in depression 
management can be established. 
Anxiety 
DHEA and DHEAS gabaminergic antagonist effects could underline the relation 
between DHEA and DHEAS and anxiety disorders (185; 186; 386). Higher concentrations 
of DHEA or DHEAS-to-cortisol ratios were reported in patients with panic disorder (387; 
388) than in healthy individuals. Nevertheless, no relation was found between social
anxiety disorder (social phobia) and DHEA or DHEAS concentrations (389). 
Several studies consistently found increased DHEA and DHEAS concentrations 
(193; 390; 391) as well as higher DHEA-to-cortisol and DHEAS-to-cortisol ratios (193; 390; 
392; 393) in patients with post-traumatic stress disorder (PTSD). Nevertheless, these 
studies suggest that the increase in DHEA and DHEAS in PTSD and other stress conditions 
may be salutary. In that regard, in men with PTSD, higher DHEA and DHEAS levels were 
related to symptom improvement and better coping (390). In women with PTSD, 
increased DHEA response to ACTH was correlated with less PTSD symptoms (393). Also 
pointing to a beneficial effect of higher DHEA levels, subjects whose DHEA concentrations 
increased during treatment had decreased symptoms, whereas those whose DHEA levels 
decreased during treatment, did not improve (394). Apart from PTSD, in other stress 
conditions, higher DHEA, DHEAS, DHEA-to-cortisol, DHEAS-to-cortisol levels or DHEAS 
increases, were related to fewer dissociative symptoms and better performance under 
stress (270; 395; 396). Overall, higher DHEA and DHEAS levels are proposed to be 
adaptive, contributing to resilience, less deleterious effects of stress and better 
performance under stress (270; 318; 397; 398; 390). 
Five patients with treatment-resistant PTSD and low DHEAS concentrations were 
treated with 7-keto-DHEA in an open label study (7-keto-DHEA is not converted to 
testosterone or estrogen and it has higher anti-glucocorticoid activity than DHEA). All five 
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patients showed improved symptoms within days (399). On the contrary, DHEA 
supplementation did not have beneficial results during stressful military training (400).  
  
Schizophrenia 
 There are reports of decreased (401; 402; 403) and increased (404; 405; 406) 
concentrations of DHEA and DHEAS in patients with schizophrenia. Some studies also 
found increased levels of DHEA and low levels of DHEAS (407) whereas other studies 
showed opposite results, i.e. decreased DHEA and increased DHEAS levels (408). So, it is 
difficult to draw conclusions regarding DHEA and DHEA alterations in schizophrenia. One 
study measured post-mortem tissue DHEA concentrations and found higher DHEA 
concentrations in the posterior cingulate and parietal cortex of schizophrenics than in 
control subjects (409).  
 There are several types of schizophrenia, with different symptoms and this could 
account for the incongruent results described. In schizophrenic patients, correlations 
were specifically found between lower DHEA and DHEAS and negative symptoms (410), 
cognitive impairment (411; 412), depressive and hostility symptoms (280) and anxiety 
symptoms (406). Two studies suggest that administering DHEA to schizophrenic patients 
significantly decreased negative symptoms (independently of anxiety or depression) and 
did not change positive symptoms (413; 414). A few studies also suggest that DHEA 
treatment may have a beneficial effect in extrapyramidal motor symptoms and 
parkinsonian symptoms (414; 415) whereas another study did not confirm those 
beneficial results (416), although in this last study, the patients presented higher baseline 
DHEA concentrations than in the previous studies. 
 
Addiction 
 Drug addiction is characterized by loss of control over drug consumption. Drug 
addicts present a chronic stress pattern of the HPA axis function (with increased CRH, 
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decreased ACTH, increased cortisol and impaired cortisol feedback loop) (417; 418; 419). 
After cocaine discontinuation, cortisol concentrations decreased while DHEAS levels 
increased (420) and cocaine abusers who relapse had lower DHEAS levels than the ones 
who did not relapse (421). Moreover, patients with higher DHEAS levels showed better 
treatment responses (422). In fact, DHEAS may play a role in morphine tolerance and 
dependence: DHEA administration to rats prevented the development of tolerance to the 
antinociceptive effect of morphine and prevented morphine dependence (423; 424). 
DHEAS modulates dopamine, glutamate, sigma-1 and GABA-A receptors. Both 
these receptors may be relevant to drug abuse. Hence, DHEAS effects on addiction could 
be mediated through modulation of these receptors. Besides, DHEA is also a negative 
modulator of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, 
which may attenuate behavioral sensitization, drug self-administration and contribute to 
glutamate homeostasis (425; 426). 
Dementia 
DHEA and DHEAS effects in dementia could be mediated through their effects on 
sigma-1 receptors (209), cholinergic transmission (208; 427), and amyloid β protein (256). 
Again, divergent results exist concerning DHEA and DHEAS levels in dementia. Increased 
(428; 429; 430; 431; 432; 433; 434), unchanged (435; 436; 437) and decreased (438; 439; 
440; 441) levels of DHEA and DHEAS were reported in serum/plasma and cerebrospinal 
fluid in patients with dementia (mostly patients with Alzheimer’s disease). On the other 
hand, DHEA-to-cortisol and DHEAS-to-cortisol ratios more frequently discriminate 
demented patients from controls, than the levels of either hormone alone (442; 443; 444; 
445; 446) and DHEAS-to-DHEA ratios may also be more relevant than either hormone 
alone (447). Lower DHEA-to-cortisol ratios were correlated with more cognitive 
impairment (441; 446; 448) and smaller hippocampal volume, as evaluated by magnetic 
resonance imaging (MRI) (448). Also, lower DHEAS-to-DHEA ratios were found in the 
cerebrospinal fluid of demented patients when compared to controls (447). 
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Hippocampal volume and hippocampal perfusion are correlated to peripheral 
DHEAS concentrations (449; 450). Hippocampal perfusion was also found to be directly 
related to DHEAS-to-cortisol ratios but this relation was dependent on DHEAS 
concentrations and not on cortisol concentrations alone (450). Thus, it is hypothesized 
that diminished DHEAS concentrations in the central nervous system are involved in the 
pathophysiology of Alzheimer’s disease. DHEAS concentrations in the hypothalamus, 
striatum and cerebellum of Alzheimer’s disease patients were also lower than in controls 
(451). On the contrary, increased DHEA concentrations (cerebrospinal fluid and tissue 
concentrations) were found in Alzheimer’s patients, in the hippocampus, hypothalamus 
and frontal cortex (107) and these findings may point towards the importance of DHEAS-
to-DHEA ratios. These findings agree with preclinical findings in which DHEAS antagonized 
the neurotoxic effect of DHEA in neuroblastoma cells (238) and inhibiting the conversion 
of DHEAS to DHEA resulted in increased acetylcholine concentrations in the hippocampus 
and improved memory in rats (209; 210; 452). These findings also point towards the 
importance of the sulfotransferase activity. Reduced activity of the sulfotransferase 
would lead to a reduced synthesis of DHEAS (453) and this could be involved in the 
pathophysiology of Alzheimer’s disease.  
It is also interesting to note that Alzheimer's disease and other neurodegenerative 
disorders present an increased oxidative stress (106). Pro-oxidant agents, such as 
amyloid-β peptide may induce an alternative pathway to DHEA synthesis (independent of 
CYP17 enzyme activity) in these patients (105; 106; 108). This could explain the higher 
DHEA levels found in Alzheimer's disease patients and the fact that treatment of 
Alzheimer disease patient’s serum with Fe2+ induced a much smaller increase in DHEA 
levels when compared to control patients (105; 106; 108). Also, DHEA variation after 
oxidation correlated with the patients' cognitive and mental status (108). 
Some authors also hypothesize that the conversion of DHEA to 7α-hydroxy-DHEA 
is relevant in the pathophysiology of Alzheimer’s disease. 7α-hydroxy-DHEA has more 
potent anti-glucocorticoid and neuroprotective effects than DHEA (454) and lower 
expression of the gene coding for the enzyme that converts DHEA to 7α-hydroxy-DHEA 
(455), as well as lower plasma 7α-hydroxy-DHEA concentrations were found in patients 
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with Alzheimer’s disease (456). Also interesting, 7α-hydroxy-DHEA does not interfere with 
glucocorticoid binding to its receptor but was found to be a substrate for 11β-
hydroxysteroid dehydrogenase type 1 with kinetic parameters favoring the conversion of 
7α-hydroxy-DHEA to 7β-hydroxy-DHEA over the production of active glucocorticoids 
(457). 
 To the present date, there is not enough evidence to support the use of DHEA 
supplementation in dementia. Studies are scarce, with a small number of participants and 
inconsistent results. In one open-label study with DHEAS administration, three out of 
seven patients with multi-infarct dementia had an improvement in their daily activities 
and emotional disturbances, and in two of the four patients the improvement was 
reflected in the electroencephalogram (EEG) (428). In another randomized study, 58 
patients with Alzheimer's disease were treated with DHEA (50 mg twice daily) or placebo. 
After three to six months’ treatment, there was only a trend towards DHEA superiority on 
cognitive ratings (458). On the other hand, a study of 27 women with mild to moderate 
cognitive impairment (Mini-Mental State Examination, MMSE) showed positive results of 
DHEA treatment (25 mg once daily during six months). In this case, DHEA administration 
increased cognitive scores and maintained basic activities of daily living score, while 
cognition and basic activities of daily living deteriorated in the control group. More 





Electrophysiological and neuroimaging correlates 
Auditory distraction and visual event-related potentials (ERPs) correlates of working 
memory and emotion 
Auditory ERPs are characterized by brainstem potentials, followed by middle 
latency potentials and then cortical potentials. Brainstem potentials occur within a short 
latency of 1 to 10 ms and consist of several positive waves recorded at the vertex. These 
potentials are elicited by the presentation of external sensory stimuli, independent of 
subjects’ collaboration and correspond to surface measurements of the sequential 
activity of the auditory nerve, the cochlear nuclei, the superior olives, the lateral 
lemniscus, the inferior colliculus and the medial geniculate nucleus (460; 461; 462). 
Middle latency potentials appear between 10 and 50 ms after the stimulus onset (463) 
and probably correspond to the neural activity of the thalamic nuclei and initial stages of 
the temporal region of the auditory cortex activity. Finally, cortical auditory potentials 
occur from about 60 to 300 ms after the beginning of the stimulus (see figure 6). 
Typically, these potentials initially include N1 and P2 components, which are sensorial or 
perceptive (464; 465), corresponding to the activity in the primary and associative areas 
of the temporal and parietal cortex and reflecting the analysis of the physical 
characteristics of the stimulus. When individuals are performing cognitive tasks involving 
the allocation of attention resources, there are negative potentials superimposed to N1 
and P2. These negative potentials are designated attention-related negativity or 
processing negativity (466; 467). The P3 component (P300) is a cognitive, late, positive 
potential, occurring between 250 and 1000 ms after the stimulus (465; 464). 
The P300 family of components reflects the cognitive updating of information, 
activation of working memory, the process of categorization of comparing with models 
stored in the memory and the contextual updating of information (468; 469; 470). These 
cognitive potentials are dependent of the individual experience and may occur even 
without stimulus (471). The contextual updating or memory recovery can be an 
automated process or a controlled process (465). Whereas the automated processes 
occur without the subject’s attention, the controlled processes are voluntary and elicit 
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much more increased P300 amplitudes than automated processes (472). The P300 
latencies depend on the process of stimulus classification. It can be correlated to reaction 
times (473) or not (474), because the reaction times may depend on the selection of the 
motor response and the time to carry it out (475). 
Figure 6: Typical cortical components elicited to an auditory stimulus. s – seconds after stimulus 
presentation. 
Auditory distraction event-related potentials (ERPs) characteristically present an 
auditory N1/mismatch negativity (N1/MMN) enhancement, reflecting the brain response 
to a detectable difference in a repetitive acoustic stimulus that leads to attention capture, 
being elicited even if the auditory stimulus is irrelevant for the task (476; 477; 478). It is 
followed by a novelty-P3 (nov-P3) reflecting the effective orientation of attention (477; 
479; 480). There is an early (P3a) and a late (P3b) phase of this component. The P3a is 
prominent on the frontal area of the brain in response to unexpected novelty which 
suggests an orientation reflex and the P3b is prominent in the parietal areas of the brain 
in response to stimuli that are of unlikely probability of being presented and thus, require 
reiteration of the categorization process (481). The P3, particularly the P3b, is sensitive to 
attentional (477; 482) and emotional context manipulations (483). Subsequently, the re-
orienting negativity (RON) reflects the re-orientation of attention back to the task (484; 
485; 486; 487). 
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In visual event-related potentials (see figure 7), the potentials derived from 
subcortical structures (superior colliculus, lateral geniculate nucleus of the thalamus) are 
observed only to a limited extent. Around 40 ms a small amplitude negative polarity peak 
can be observed reflecting the stage of subcortical analysis. A second peak around 80 ms 
(also designated first component, C1 or PN/80), of positive or negative polarity reflects 
the processing in the primary visual area. It is followed by the P1 sensory component, 
around 100 to 140 ms after the stimulus, and is believed to reflect the activity of the 
extrastriate visual cortex (488; 489; 490; 491; 492) and fusiform gyrus (493). C1 and P1 
amplitude and latency can be modulated by the stimulus frequency, quadrant of 
stimulation, luminance and contrast (494; 495; 496). P1 shows hemispheric asymmetry 
and its amplitude is modulated by attention and expectancy (497; 498).  
After P1, a negative sensory N1 and other negative deflections (N2) follow. There 
are several visual N1 subcomponents. The earliest subcomponent peaks around 100 to 
150 ms at anterior electrode sites. There are at least two posterior N1 components that 
typically peak 150 to 300 ms after stimulus presentation, one originating from parietal 
cortex and the other from lateral occipital cortex. They are strongly affected by attention 
(497; 498; 499; 500; 501) and were designated as selection negativity or processing 
negativity (467; 502). In particular, faces elicit a particular potential between 150 and 200 
ms, the vertex positive potential (VPP) (503) and a more negative potential at lateral 
occipital electrode sites (the N170, as it peaks around 170 ms), especially over the right 
hemisphere (504; 505), when compared to non-face stimuli. Although not fully 
ascertained, it is hypothesized that the VPP and N170 may be the opposite sides of the 
same dipole (505; 506).  
The cognitive components related to visual target processing, include the N2b and 
P300. The N2b is a negative deflection originated by the task-relevant stimulus. Then, the 
P300 (visP300), starting around 300 ms after the visual stimulus, reflects the conscious 
processing of the visual stimulus (472; 507; 508) and is sensitive to attention allocation, 
cognitive and motivational factors (472; 509). The general characteristics mentioned 
above regarding the P300 family, apply to visual P300. Of note, increased attention 
allocation elicits increased P1, N1, N2 and P300 amplitudes, whereas irrelevant visual 
stimuli elicit deflections of reduced amplitude. 
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Figure 7: Typical event related potential components elicited to a visual stimulus. s – seconds after stimulus 
presentation. 
Attention is a limited resource (510; 511; 512). There are voluntary or endogenous 
(top-down) and involuntary or exogenous (bottom-up) mechanisms of control of 
attention. Exogenous mechanisms are driven by the stimulus. They play a role for 
instance, when a salient stimuli irrelevant to the task captures attention (513). On the 
other hand, voluntary mechanisms modulate brain responses related to target stimuli 
(514; 515). But there are interactions between these endogenous and exogenous 
mechanisms of attention control. Involuntary attention to exogenous stimuli disrupt 
responses to target stimuli in a bottom-up way (477; 479; 509; 516) while 
automatic/exogenous processes can also be modulated in a top-down way (517; 518). 
In particular, working memory functions based on prefrontal cortex may provide 
top-down signals to other brain structures (519; 520; 521) and modulate involuntary 
attention processing at primary sensory areas of the cortex (for example, reducing early 
responses to a distractor) (514; 522; 523). Another factor that may modulate involuntary 
attention in a top-down way is the emotional context. Several studies suggest that ventral 
prefrontal areas play a role on emotional processing (509; 524; 525) and in the top-down 
regulation of attention (526; 527). 
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Working memory load processing is expected to be more difficult than no working 
memory load processing, leading to worse performance and a reduced P300. This 
decrease in P300 is thought to reflect less processing of the task-relevant stimuli (472; 
507; 508). As noted, working memory load can also modulate involuntary auditory 
distraction. In several studies, working memory load resulted in either increased (528; 
529; 530; 531; 532) or decreased auditory distraction (508; 533). During no working 
memory load processing, control mechanisms reduce interferences from distractors, 
whereas higher cognitive load processing, namely working memory load processing, may 
override that capacity (528).  
Emotional stimuli (in particular of threatening, fearful or anger content) elicit 
stronger and faster attention capture than non-emotional ones (509; 534; 535; 536; 537; 
538; 539) and consequently interfere with the processing of concomitant stimuli, either 
within the same sensory modality (534; 540) or across sensory modalities. Accordingly, 
task-irrelevant emotional stimuli deteriorate performance (509). Nevertheless, the visual 
P300 is enhanced by the emotive content of images, as subjects remain engaged in the 
emotional content processing at the expense of processing the relevant aspects of the 
task (509). Emotional faces and International Affective Picture System (IAPS) images have 
been reported to elicit similar hemodynamic responses in emotion-sensitive areas, such 
as the amygdala, ventromedial prefrontal and visual cortices (541). Nevertheless, in 
studies using faces, some authors have found visual P300 enhancement by fearful faces 
(542), while others reported no changes in P300 amplitude (543). The type of emotional 
content of the stimuli is also relevant. Carretié et al. (537) found that the N2 was 
significantly elicited only by positive or non-emotional stimuli and not by negative stimuli. 
Nevertheless, contrary to what might be initially expected, a negative emotional context 
may enhance involuntary auditory distraction (early and late novelty-P3) processing (483; 
509; 544). This suggests that acoustic novelty processing is enhanced under a potentially 
harming environment (544). On the contrary, auditory distraction (involuntary attention 
to novel auditory stimuli) deteriorates performance under an emotional context (477; 
479; 509; 516).  
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Neural networks of memory and emotions 
The memory processes involve information encoding, storing and retrieval. 
Encoding includes receiving and processing the information, implying that the 
information is transformed into physical and chemical stimuli. Then the information is 
stored into short term (working memory) or long term memory. Retrieval refers to the 
process by which stored information is recalled, coming back to consciousness in 
response to some trigger point.  
Sensory memory lasts less than ten seconds after the sensory stimulus is 
delivered. It is an automatic (not cognitive) process (545) and the decay of this memory 
information can be prevented by rehearsal (545). Short-term memory allows recall for 
several seconds to about one minute. This type of memory is limited to about 3 to 5 items 
(546) and may be increased by chunking (grouping) items, a concept that was initially
purposed by Miller in 1956 (547). Although this author proposed that people can 
remember about seven chunks in short term memory, it is now believed that the correct 
number is four (546).  
In 1974, Baddeley and Hitch proposed a three-component model of working 
memory: the central executive, the phonological loop and the visuo-spatial sketchpad 
(548). Latter, Baddeley introduced a fourth component into this model: the episodic 
buffer (548). In this model, the central executive is a supervisory system that channels 
information to and from the other three components; the phonological loop stores verbal 
content (by rehearsing sounds or words in a continuous loop) and the visuo-spatial 
sketchpad stores visuo-spatial data. The episodic buffer is dedicated to linking 
information across domains (like verbal, visual and spatial) and is attributed to have links 
to long-term memory. Working memory has limited capacity and provides temporary 
storage of information held in a multimodal code, which is capable of binding information 
from the subsidiary systems and from long-term memory, into a unitary episodic 
representation. Conscious awareness is assumed to be the principal mode of retrieval 
from the buffer. In this modified model, working memory is used both to process 
information and to allow the transient storage of information (549). 
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Contrary to short term memory, long term memory can store large quantities of 
information for a long period of time (sometimes the whole life). There are different kinds 
of long-term memory representation (549). Declarative (explicit) memory implies the 
conscious recall of information and it includes semantic, episodic and visual memory 
among others (549). Non-declarative memory (procedural, implicit) uses unconscious 
aspects of previous experiences and is involved in several motor skills. Accordingly, 
multiple memory systems exist, not just two kinds (550). Non-declarative memory 
includes skills and habits, simple forms of conditioning, emotional learning, priming and 
perceptual learning, as well as forms of behavioral plasticity such as habituation and 
sensitization (550). Non-declarative memories are shaped by past events and influence 
our behavior conferring each person dispositions, habits and preferences that are 
inaccessible to their conscious recollection (550). 
The internal representation of memory includes the expression of memory at the 
conscious or behavioral level and the underlying physical and chemical changes at the 
neuronal level. Short-term memory is supported by transient patterns of neuronal 
communication whereas long-term memory is maintained by more stable and permanent 
changes in neural connections widely spread throughout the brain. Encoding of working 
memory involves spiking of individual neurons induced by sensory input, which persists 
after the sensory input extinguishes (551; 552). Memory consolidation, referring to the 
process by which a newly formed and unstable memory (working memory) is transformed 
into a stable long-term memory, involves underlying physical and chemical changes in the 
neural tissue, called memory engrams. Some authors propose that a specific pattern of 
connectivity of engram cells may be crucial for memory consolidation and that 
strengthened synapses in these cells critically contribute to the memory retrieval process 
(553). This internal representation of memory is also subject to reactivation and 
reconstruction. Upon their retrieval, consolidated long-term memories may enter a 
transient special state, in which they might become prone to change (reconsolidation) 
(554). 
 At the cellular level, pyramidal cells and interneurons within the cerebral cortex 
interact during working memory processes. Most interneurons use the inhibitory 
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neurotransmitter GABA as their neurotransmitter, whereas pyramidal cells use the 
excitatory amino acids and pyramidal–nonpyramidal interactions, which may be critical to 
the formation of memory fields. Dopamine innervation, which is also abundant in the 
prefrontal cortex, has inhibitory actions on prefrontal cortical neurons by interacting with 
those other neurotransmitter systems, notably with the excitatory neurotransmitter 
glutamate, the inhibitory neurotransmitter GABA, and the cholinergic neurotransmitters, 
thereby regulating working memory (555). 
Long-term memory involves long-term potentiation (LTP) or spike-timing-
dependent plasticity (STDP) with long term changes in synaptic transmission and neurons 
(552).  Synaptic changes in long-term memory consolidation may involve protein 
synthesis in the medial temporal lobe (MTL), allowing MTL-independent memory 
processes to spread through a large portion of the brain that could act over months to 
years. In this process, consolidation is probably a reiterated process with repeated 
activation of the memories instead of a one-time process (556). As mentioned, after 
consolidation, long-term memories become labile and are again updated during retrieval, 
thus requiring another phase of protein synthesis to be maintained (557). Whenever a 
memory is reactivated this reconsolidation process is necessary for the memory to persist 
(557). Evidence comes from post-retrieval studies, in which the treatment with protein 
synthesis inhibitors during that period, lead to amnestic states (554; 556; 557). Long-term 
memory formation and maintenance may also involve DNA methylation (558). DNA 
methylation is associated with transcriptional silencing, it is involved in lifelong molecular 
information storage during development and it was shown to be dynamically regulated in 
the adult nervous system (558). 
Short-term memory depends on regions of the temporal lobe (in particular the 
hippocampus), the frontal lobe (especially dorsolateral prefrontal cortex) and the parietal 
lobe. Consolidation depends on several structures of the medial temporal lobe and 
diencephalic midline region and lesions within those structures impair memory causing 
amnesia (550). These medial temporal lobe structures include the hippocampus (dentate 
gyrus, CA3, CA1 region and subicular complex) and the adjacent entorhinal, perirhinal, 
and parahippocampal cortices, which make up much of the parahippocampal gyrus; and 
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midline diencephalic regions include the dorsomedial nucleus of the thalamus and the 
mammillary bodies of the hypothalamus (550). 
The hippocampus is essential for learning new information, meaning the 
consolidation of information from short-term to long-term memory. It does not seem to 
store information itself, but without the hippocampus, new memories are unable to be 
stored into long-term memory (559) and attention would be reduced. The hippocampus 
may be involved in changing neural connections during the months after the initial 
learning. It is also involved in memory retrieval processes (560). The hippocampus 
receives information from different parts of the cortex (secondary and tertiary sensory 
areas that have already processed the information) and sends information, to different 
parts of the brain. Hippocampal lesions damage memory storage and cause memory loss, 
namely loss of memory for the events that happened shortly before the hippocampal 
lesion. 
A volume loss in the hippocampus of ~40% or above (for instance after an anoxic 
event) impairs memory and this reduction in hippocampal volume (estimated by MRI), 
may indicate a nearly complete loss of hippocampal neurons (550). Moreover, within the 
hippocampus, specific CA1 lesions also confer important memory impairment (550). 
These CA1 field lesions, importantly disrupt hippocampal function, as information 
processing, that begins at the dentate gyrus and ends in the subiculum and entorhinal 
cortex must pass through this region of the hippocampus (550). The CA3a,b subregion of 
the hippocampus plays an important role in the encoding of new spatial information 
within short-term memory with a duration of seconds to minutes (561). 
The PFC and the hippocampus interact during working memory, particularly with 
increased task demands (562). That hippocampus-PFC pathway involves a monosynaptic 
projection between these two structures and multisynaptic connections (involving the 
nucleus reuniens, nucleus accumbens, basolateral amygdala and ventral tegmental area) 
(562). Pyramidal and local GABAergic neurons in the medial PFC are directly targeted by 
hippocampal and thalamic glutamatergic afferents (562). Those afferents cause excitatory 
and/or inhibitory postsynaptic potentials in neocortical pyramidal neurons. The 
hippocampus-PFC pathway has synaptic plasticity, as repetitive stimulation in the ventral 
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subiculum or CA1 region of the hippocampus induces LTP or long-term depression in the 
PFC (562). The hippocampus inputs to prelimbic/infralimbic PFC may be essential for 
spatial information processing. Of note, the hippocampus and PFC are required for spatial 
learning, and the PFC is more important in primates than in rodents (562).  
 Pathologies like posttraumatic stress disorder, depression, autism and Alzheimer's 
disease are believed to share disruptions in the hippocampus-PFC functional connectivity 
(562; 563). Glucocorticoid and mineralocorticoid receptors are heavily expressed in the 
hippocampus, medial PFC and amygdala. Stress also modulates the hippocampus-medial 
PFC interactions during working memory: increased corticosteroids after stress cause a 
shift of memory retrieval from the dorsal hippocampus (non stress condition) to the 
medial PFC (stress condition) (562). Depressive patients show reduced hippocampus-PFC 
connectivity and reduced plasticity in the hippocampus-PFC pathway (562). In sum, the 
hippocampus-PFC connectivity is important in cognitive processes like working memory, 
memory consolidation and emotion regulation and stress may modulate that connectivity 
(562; 563). 
 Working memory encompasses both processing and storage functions and there 
may be multiple working memory domains, each located in a different anatomical 
subdivision of the prefrontal cortex of both human and nonhuman primates, each having 
its own specialized processing and content specific storage mechanism. As mentioned, 
long-term memory records also involve multiple regions and each neocortical region 
operates within a very specific domain, meaning that each region stores only specific 
features of an experience (550). For instance, neurons in visual area store the visual 
memory of a multisensory experience while neurons in auditory areas store the auditory 
memory of that experience (550). Then, remembering involves the coordinated 
reactivation of those distributed neocortical regions (550; 564). The same cortical areas 
are consistently activated in humans during immediate experiences (working memory) or 
when the person accesses information from long-term storage in the same domain (555). 
For newly formed memories, the reactivation process depends on the hippocampus and 
related structures, but for the memories that are fully consolidated, the reactivation 
process can occur independently in the neocortex (550). Whereas the medial temporal 
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lobe structures encode and consolidate broad type of memories, each neocortical region 
stores specific features of an experience. Therefore, a lesion in a specific region of the 
neocortex simultaneously causes an anterograde and retrograde memory impairment in 
the respective specific domain (for instance achromatopsia, amusia or prosopagnosia- 
impaired facial recognition) (550). 
Medial temporal lobe structures are thought to be important for declarative 
memory, specifically for the formation of memory and maintenance of that type of 
memory for a period of time after learning (550). That consolidation process can take 
years (550). It is not certain whether these structures are necessary for other domains of 
memory like working memory or perceptual memory (550). Medial temporal lobe 
structures are not the ultimate storage sites for acquired memories. Memories that 
initially require the integrity of medial temporal lobe structures are reorganized as time 
passes after learning and gradually become independent of these structures (550). This 
was evidenced by findings in a patient with bilateral medial temporal lobe resection, 
previously carried out due to epilepsy (550). He retained memory for events that 
occurred more than three years before the surgery. The period of three years retrograde 
amnesia provided an indication of how long that process takes (550). 
 Patients with medial temporal or diencephalic lesions both exhibit memory 
deficits, and some authors hypothesize it might be because diencephalic nuclei and tracts 
(the medial dorsal nucleus and the adjacent internal medullary lamina; the 
mammillothalamic tract and its target, the anterior thalamic nuclei) are anatomically 
related to the medial temporal lobe (550). The perirhinal cortex originates projections to 
the medial dorsal nucleus that enter through the internal medullary lamina, while the 
hippocampal formation projects both to the anterior nuclei and mammillary nuclei (550). 
One cause of diencephalic amnesia is alcohol related Korsakoff’s syndrome (550). 
Recognition memory involves recollection and familiarity. Familiarity means that a 
component of an experience was presented, but the subject may have no other 
additional information about that component (550; 565). Some authors propose that the 
hippocampus and the perirhinal cortex contribute to recollection and familiarity (550; 
566) whereas others propose that the hippocampus selectively support recollection and
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that perirhinal cortex selectively supports familiarity (550; 567). There is an age-related 
cognitive decline in operations dependent on the hippocampus and prefrontal cortical 
circuits (568). Nevertheless, that age-related memory decline is different in normal aging 
and in Alzheimer patients. One of Alzheimer’s Disease characteristics is loss of episodic 
memory and it was suggested that damage of the connections between the entorhinal 
cortex and hippocampus could play an important role in the memory impairment of 
Alzheimer's Disease (569; 570). Specifically, the CA1 region of the hippocampus was 
suggested to be the minimal region that is required for acquisition of episodic memory 
and some pathways were proposed that may connect the CA1 region of the hippocampus 
to the entorhinal cortex, namely through the dentate gyrus (571). Notably, neurogenesis 
in the dentate gyrus was also suggested to be involved in the formation of new memories 
in adults (570; 571).  
 Damage to the entorhinal cortex and hippocampal region in Alzheimer Disease is 
associated with the appearance of senile plaques and neurofibrillary tangles. 
Nevertheless, the relation between the appearance of those plaques and memory 
decline, is not clear, as some subjects have plaques but no cognitive impairment and the 
plaques could eventually reflect a protective, possibly antioxidant response to the 
primary pathogenesis (570). To explain that discrepancy, some authors proposed that the 
maintenance of an alternative neural circuitry could eventually prevent cognitive decline 
in some subjects with plaques and that the proportion of Aβ or tau protein molecules 
present in different areas of the brain could be important for the maintenance of 
cognitive functions (570). 
 Stress involves the activation of the sympathetic nervous system and the HPA axis. 
The sympathetic nervous system results in rapid release (essentially immediate) of 
epinephrine and norepinephrine from the adrenal medulla while the HPA axis results in a 
somehow slower (within minutes) release of corticosteroids from the adrenal cortex (572; 
573). Catecholamines and corticosteroids influence the hippocampus, prefrontal cortex 
(PFC), and amygdala, thereby influencing memory. The hippocampus and the PFC (which 
is responsible for working memory and higher-order cognitive function), both have high 
density corticosteroid receptors, making them susceptible to the effects of stress (573).  
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Glucocorticoids bind to mineralocorticoid and glucocorticoid receptors (574). They 
bind mineralocorticoid receptors with 6-10 times higher affinity than glucocorticoid 
receptors (574). The result is that in humans, during the afternoon, glucocorticoids 
occupy more than 90% of mineralocorticoid receptor, but only 10% of glucocorticoid 
receptors (574). Yet, during stress or the morning peak of glucocorticoid secretion, 
mineralocorticoid receptors are saturated and 67-74% of glucocorticoid receptors are also 
occupied (574). This is also relevant, due to the distribution of these two types of 
receptors in the brain: mineralocorticoid receptors are present in the limbic system 
(hippocampus, parahippocampal gyrus, entorhinal and insular cortices) and glucocorticoid 
receptors are present in subcortical (paraventricular nucleus and other hypothalamic 
nuclei, the hippocampus and parahippocampal gyrus) and cortical structures, with a 
preferential distribution in the prefrontal cortex (574). 
There is a U-shaped relationship between glucocorticoid levels and hippocampal 
plasticity and learning. Moderate levels of glucocorticoids are believed to enhance these 
parameters whereas high glucocorticoid levels, as the ones following stress, may impair 
hippocampal plasticity and memory storage (575; 576). Excessive stress or long term rises 
in glucocorticoids and catecholamines were shown to impair encoding processes in the 
hippocampus and memory recall (577; 578). Glucocorticoid excess result in excessive 
calcium influx and negative effects on cellular function, which may be both rapid non-
genomic effects and slow gene-dependent effects (573). 
Long-term potentiation (LTP) is a long-lasting enhancement of synaptic efficacy 
that results from high-frequency stimulation (HFS) of afferent fibers and is believed to 
underlie memory formation (573; 579). Memory formation involves the strengthening of 
neural connections and a lasting pattern of altered synaptic weights (573). LTP-inducing 
events in close proximity may compete for memory formation but the brain, having 
limited resources will select the more important information (573). Stress induced LTP, 
identical to that necessary for memory formation, allows the formation of the memory 
related to the stress experience (573). In fact, in the hippocampus, stress and LTP 
increase gene induction, increase NMDA and AMPA receptor activity, increase levels of 
neurotrophins (BDNF) and increase glutamate and intracellular calcium levels (573). 
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Stress may then impair subsequent LTP induction and learning, but the memory for the 
stressful event remains intact (573; 580). As mentioned, NMDA receptor antagonists, 
impair LTP induction and also prevent stress effects on hippocampus-dependent learning 
and LTP (581).  
 Glucocorticoids rapidly raise hippocampal CA1 neurons excitability via 
nongenomic mineralocorticoid receptors, probably in pre- and postsynaptic membranes. 
Hours later, gene-mediated effects result in enhanced calcium influx and impaired LTP, 
which slowly normalize hippocampal activity and preserve stress induced information. 
Noradrenaline also interact with glucocorticoids in the hippocampus for these effects 
(582). Therefore, the effects of stress on memory formation are time dependent. Stress 
facilitates hippocampal memory function during the first minutes after stress onset. In 
that period there is stress induced glutamate release and glutamatergic receptors are 
over-stimulated, leading to a posterior refractory period, caused by glutamatergic 
receptors desensitization and glucocorticoids gene-dependent activity, and during which 
LTP induction is less probable (573). This may be adaptive, as it allows the brain to form a 
solid memory of the stress related information without the interference of other 
cognitive processes (573). Accordingly, stress will enhance memory when a learning event 
occurs in the same context as the stress event, and this results from shared neural circuits 
simultaneously forming memories for the learning event and stress event.  
 On the contrary, if a learning event occurs outside the context of a stress event, or 
if the events are temporally separated, encoding for this unrelated information would be 
impaired as the neural circuits necessary for memory formation being previously 
saturated would compromise the hippocampus into a refractory state (573; 579). This will 
simultaneously protect the hippocampus from glutamate excess neurotoxicity (573). 
Stress effect on the retrieval of previously learned information may also result from the 
interference of the formation of the stress memory with retrieval of another memory 
(573). In the same way, LTP may produce retrograde amnesia for previously learned 
information  (583). 
 In 1884, emotions were defined by William James as subjective experiences. He 
proposed that stimuli trigger activity in the autonomic nervous system, and that activity 
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would produce an emotional experience in the brain. In his theory, the physiological 
response was the emotion (584). Carl Lange proposed a similar theory and argued that 
"we feel sad because we cry, angry because we strike, afraid because we tremble, and 
neither we cry, strike, nor tremble because we are sorry, angry, or fearful, as the case 
may be" (585; 586). This was the James-Lange theory of emotions. Currently, emotions 
are believed to involve several components, such as subjective experiences, cognitive 
processes, expressive behaviors, psychophysiological changes and instrumental behaviors 
(586). The processing of complex emotional information in one sensory modality can 
strongly affect emotion processing of another modality during very early stages of neural 
processing, as well as self-reported emotions (587). The concept of multimodality, apply 
to emotional stimuli processing, such as audiovisual stimuli (587). 
Paul Ekman found that basic emotions could be identified by facial expressions 
across different cultures. In the 1970s, he proposed a classification that included six 
groups of basic emotions: anger, disgust, fear, happiness, sadness and surprise (588). 
Besides facial expressions, emotions may be expressed by gaze and tears and autonomic 
responses such as pupil-dilation, eye blinks, blushing and sweating that can hardly be 
controlled or regulated by the sender (589). These autonomic expressions of arousal such 
as pupil dilation are less prone to cognitive control than facial expressions (589). Thus, 
facial muscle actions, although unconscious, are possible to control or regulate by ‘top–
down’ cognitive processes (589). Instead, autonomic expressions of arousal are much 
harder to control and more driven in a bottom-up fashion (589). 
Emotional processing is related to the limbic system. This was initially suggested 
by the work of Broca in 1878 (590), Papez in 1937 (591) and MacLean in 1952 (592). The 
limbic system includes the hypothalamus, cingulate cortex and hippocampus amongst 
other structures. A large amount of evidence subsequently confirmed that limbic 
structures are directly related to emotion, but non-limbic structures have also been found 
to play an important role in emotional processing. The following limbic structures are 
currently thought to be involved in emotion (593): amygdalae, thalamus, hypothalamus, 
hippocampus, fornix, mammillary bodies, olfactory bulbs and cingulate gyrus. Besides, the 
following non-limbic structures are also believed to be involved in emotion: basal ganglia, 
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prefrontal cortex, ventral striatum, insular cortex and cerebellum (594; 595; 596; 597; 
598).  
 In particular, the amygdalae are involved in detecting, evaluating and learning 
emotionally important aspects of our surroundings, particularly those involving fear and 
other negative emotions (560; 599; 600); the thalamus is involved in relaying sensory and 
motor signals to the cerebral cortex; the hypothalamus synthesizes and releases 
neurotransmitters which can affect mood, reward and arousal (601); the hippocampus is 
mainly involved in memory and is implicated in memory retrieval that is used to evaluate 
affective stimuli (560); the cingulate gyrus (different parts of this structure have different 
functions) is involved in affect, visceromotor control, response selection, skeletomotor 
control, visuospatial processing and memory access. Of note, the anterior cingulate 
cortex (part of the cingulate gyrus) may be involved in conscious emotional awareness 
and in the start of motivated behavior (602). Besides, the anterior cingulate cortex is also 
thought to play a central role in attention (603) and demanding cognitive tasks (602). 
 Concerning non-limbic structures involved in emotion processing, the basal ganglia 
are thought to play a role in motivation (594); the orbitofrontal cortex may be involved in 
decision making taking into account the influence of emotion (595); the prefrontal cortex 
is believed to play a critical role in the regulation of emotion and behavior by anticipating 
the consequences of our actions as well as in maintaining emotions over time and 
organizing behavior towards specific goals (597); the nucleus accumbens is part of the 
ventral striatum, which is thought to be involved in the experience of goal-directed 
positive emotion, namely, individuals with addictions, experience increased activity in this 
area when they encounter the object of their addiction; insular cortex is thought to play a 
critical role in the bodily experience of emotion, as it is connected to other brain 
structures that regulate the body’s autonomic functions; the cerebellum is involved in 
emotional regulation (598), it is hypothesized that it may be involved in the activation of 
redundant alternative limbic structures in response to fearful stimuli or that it is involved 
in the regulation of the neural response to the rewarding stimuli (604; 605; 606). 
 The amygdala is involved in emotional memory and emotions also have a memory 
enhancement effect (emotionally charged events are better remembered than non-
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emotionally charged ones) (607; 608). Accordingly, patients with amygdala lesions don't 
have an emotional enhancement of memory (573). Whereas a stress inherent to the 
experience enhances memory  (609; 610), variable and more complex results were found 
for stress extrinsic to the learning experience (573; 611). Considering extrinsic stress, it 
showed variable effects on encoding (612; 613), beneficial effects on consolidation (614) 
and deleterious effects on long-term memory retrieval (573). The amygdala also 
facilitates memory operations in other regions, including the hippocampus and prefrontal 
cortex and emotion–memory interactions occur at various stages of information 
processing, from the initial encoding and consolidation of memory, to their long-term 
retrieval (607). 
Hormones and neurotransmitters are involved in emotions' modulation, namely 
cortisol, noradrenaline, dopamine, serotonin, oxytocin and GABA (573; 615). Mild and 
short lasting increases in glucocorticoids enhance short and long-term memory for both 
emotionally arousing and emotionally neutral information (220; 574). Stress effect at the 
amygdala level preferentially facilitates memory for arousing, potentially more important 
emotional information, at the cost of less memory for neutral, potentially less important 
information (573; 615). Short-term increases in the stress hormones cortisol and 
epinephrine affect the amygdala, enhancing the storage of information. Lesions of the 
amygdala and the stria terminalis block the effects of post-training administration of 
epinephrine and glucocorticoids on memory (616). This supports the notion that stress 
hormones affect the amygdala to enhance memory related to emotions (616). In rats, 
memory is enhanced by post-training intra-amygdala infusions of drugs that activate 
beta-adrenergic and glucocorticoid receptors as well as injections of GABAergic 
antagonists and opioid receptor antagonists (616). On the contrary, infusion of beta-
adrenergic blockers into the amygdala blocked the memory-modulating effects of 
epinephrine, glucocorticoids and drugs affecting opiate and GABAergic systems (616). 
Also interesting is the fact that metyrapone, an 11β-hydroxylase inhibitor (therefore 
inhibiting cortisol synthesis), prior to training, also block the memory-enhancing effects of 
epinephrine, thus suggesting some interaction between cortisol and epinephrine (617). In 
women, differences in sexually dimorphic tasks along the menstrual cycle are small and 
difficult to replicate, but emotion-related changes are found in relation with 
progesterone, with higher levels associated with increased amygdala reactivity and 
increased emotional memory (618). 
The mesocorticolimbic system, consisting, at its core, of the ventral tegmental 
area, the nucleus accumbens, and medial prefrontal cortex, is involved in positively 
motivated behaviors and reinforcement learning (reward) (619). Dopamine neurons in 
the ventral tegmental area and their targets in the nucleus accumbens and the medial 
prefrontal cortex are believed to play a central role in this reward system (619). More 
recently, this system is also recognized to be involved in punishment and negative 
reinforcement and it is assumed that different subtypes of nucleus accumbens neurons 
(Dopamine D1-receptor vs Dopamine D2-receptor expressing neurons) might exert 
opposing influences over reward or punishment directed behavior (619). Besides 
dopamine input, the nucleus accumbens also receives glutamate input from regions 
including the prefrontal cortex, amygdala, and hippocampus. Also, nucleus accumbens 
GABAergic neurons (which account for the majority of the neurons in this region) might 
contribute to the encoding of rewarding and aversive states (620). Oxytocin appears to 
modulate the dopaminergic activity within the mesocorticolimbic dopamine system, 
being important not only for reward and motivated behavior but also for the expression 
of affiliative behaviors (621). The endocannabinoid system modulates neural activity and 
synaptic functions in brain regions involving rewards (ventral tegmental area, striatum, 
amygdala, and prefrontal cortex) (622). 
Rewarding behaviors such as sexual activity, eating, nursing, parenting, social 
interactions and play activity are strongly conserved in evolution and they are essential 
for development and survival (622). Dysfunction of the mesocorticolimbic reward system 
is involved in addiction, schizophrenia, depression and other mood disorders (619). In 
particular, the dopaminergic system is involved in neurologic and psychiatric pathologies 
showing impaired emotional processes like Parkinson disease, schizophrenia, autism, 
Attention Deficit Hyperactivity Disorder, Huntington disease and frontal lobe lesions 
(623). Additionally, the administration of dopaminergic agonists/antagonists in those 
conditions, also modulate those emotional processes (623). 
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Electrophysiological correlates of DHEA and DHEAS 
DHEA and DHEAS relations to memory processing at the electrophysiological level 
are little known as only a few studies in humans, focused on DHEA and DHEAS 
electrophysiological effects in what concerns memory. Also, DHEA and DHEAS relations to 
emotional processing at the electrophysiological level are not known. Wolf et al. (24) 
studied the effects of DHEA replacement on short term memory ERPs. The participants 
were old men and the authors reported an increase in P3 amplitude after DHEA 
replacement, reflecting an enhancement of information updating. Alhaj et al. (624) 
administered DHEA to young men and used low-resolution brain electromagnetic 
tomography (LORETA) imaging. In this study, DHEA treatment reduced cortisol levels, 
improved episodic memory recollection and mood and modified the ERPs associated with 
retrieval. Another study found that lower DHEA levels were correlated to longer P300 
latencies (625) in women aged 40 to 69 years old and men aged 60 to 69 years old. In this 
study, the authors found no significant relation between DHEA levels and memory or 
attention scores. Studying sleep, Friess et al. (626) found that DHEA administration 
increased rapid eye movement sleep and electroencephalogram (EEG) power in the sigma 
frequency range, suggesting a role of DHEA in memory storage.  
Studies in rats further suggest an effect of DHEAS on synaptic plasticity. A study 
with evoked field responses and single-unit activity in anesthetized rats suggested that 
DHEAS application suppresses hippocampal recurrent inhibition and synchronizes 
neuronal activity to theta rhythm (627). Of note, rat theta rhythms are likely involved in 
mechanisms of learning and memory (628; 629). They are very strong in rodent 
hippocampus and entorhinal cortex during learning and memory retrieval, and are 
believed to be vital to the induction of long-term potentiation, a potential cellular 
mechanism of learning and memory (630; 631). The entorhinal cortex is the rat’s main 
interface between hippocampus and neocortex, playing an important role in memory 
formation and consolidation. 
Besides, DHEAS was shown to reduce the threshold pulse number for long-term 
potentiation (LTP) in hippocampal CA1 pyramidal cells through the amplification of NMDA 
receptor signaling (201; 202). In contrast, DHEA had no facilitating effect on the induction 
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of LTP. Thus, it is suggested that chronically administered DHEAS (but not DHEA) plays a 
priming role in inducing a facilitated synaptic plasticity, probably via chronic activation of 
sigma1 receptor in rat hippocampal cells (201). Then, the authors evaluated the effects of 
DHEAS administration in rat ischemic forebrains. In this study, the repetitive 
administration of DHEAS after reperfusion prevented the impairment of LTP produced by 
ischemia and this effect was possibly mediated through sigma-1 activation (203). On the 
contrary, Diamond et al. (632) found an enhancement of primed burst but not of LTP 
after a single dose administration of DHEAS to rats. The enhanced primed burst was 
achieved after the administration of intermediate doses of DHEAS but not of the lower or 
highest dose of DHEAS tested. These results also suggest that non-repetitive 
administration of DHEAS could enhance memory by facilitating the induction of neural 
plasticity, although through this different mechanism. 
Concerning glucocorticoids, whereas mild or short-lasting increases in cortisol due 
to stress may protect the body, promote adaptation and have beneficial effects on 
attention and memory, higher cortisol levels or long term increases are related to poorer 
executive functioning, poorer learning and memory and less cognitive flexibility (220; 633; 
634; 635; 636; 637; 638). Working memory (WM) depends on prefrontal cortex activity, 
and this is modulated by glucocorticoids: prefrontal cortex-dependent working memory is 
enhanced by acute stress and inhibited by chronic stress (220; 639; 640; 641).  
At the electrophysiological level, cortisol administration increased attention in 
healthy subjects, as indicated by increased amplitudes of the vertex components of the 
auditory evoked potentials (642). Also, higher cortisol levels during acute stress were 
related to reduced auditory distraction as indexed by reduced MMN amplitudes (643). 
Regarding memory, higher cortisol levels were related to impaired working memory 
(decreased frontal theta activity) (644), modified anterior-posterior distribution of the 
memory-related electrophysiological responses (increased P600 amplitude in anterior 
leads and reduced amplitude over posterior leads; P600 is an electrophysiological index of 
recognition memory and hippocampal activity) (645) and modified laterality of episodic 
memory retrieval (500-1400 ms) (646). Cortisol also interferes with error detection 
processes: a single dose of cortisol administration (but not episodic administration) 
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increases error rates in a choice response task with associated quantitative changes in 
incorrect-response ERPs (647). Concerning emotional processing, hydrocortisone 
administration increased the processing of angry faces in highly anxious individuals as 
indicated by increased amplitudes of early (P150) and late (P3) event-related potentials 
(648).  
Neuroimaging correlates of DHEA, DHEAS and cortisol 
A vast number of neuroimaging studies were performed in the last decade using 
mostly functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography 
(PET). These studies provided important information regarding the neurobiology and 
neurochemistry of memory, emotions and other aspects pertaining to the functioning of 
the human central nervous system. In contrast, only a few studies addressed the neural 
network correlates of DHEA and DHEAS. 
Magri et al. (448) studied human participants and found that higher cortisol-to-
DHEAS ratios were correlated with cognitive impairment and smaller hippocampal 
volume, as measured by magnetic resonance imaging (MRI). In the study by Alhaj et al. 
(624) in which DHEA was administered to young men and resulted in modified ERPs and
improved episodic memory recollection, low-resolution brain electromagnetic 
tomography (LORETA) imaging also showed that DHEA treatment led to a trend towards 
an early differential activation of the anterior cingulate cortex (ACC). The authors 
concluded that those effects of DHEA appear to be via neuronal recruitment of the 
steroid sensitive ACC, which may be involved in pre-hippocampal memory processing. 
DHEA and DHEAS effects on cerebral regions specifically involved in emotional 
processing including the amygdale, hippocampus, insula and anterior cingulated cortex 
have also been suggested (240; 649; 650). However, little research has explored the 
neural correlates of DHEA and DHEAS with respect to emotion and mood. Concerning 
DHEA relations to emotional neuroimaging, Sripada et al. (25) performed a functional MRI 
study to investigate the effect of DHEA administration on emotion regulation 
neurocircuits. The DHEA administration reduced the activity in the amygdala and 
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hippocampus, increased the connectivity between these two regions and enhanced the 
activity in the rostral anterior cingulated cortex during emotion processing. Moreover, the 
DHEA administration reduced the negative affect and the memory accuracy for emotional 
stimuli. Hence, those results suggest that DHEA may downregulate the negative emotions 
induced by aversive stimuli by reducing the activity in regions associated with the 
generation of negative emotions (amygdala and hippocampus) and enhance the activity 
in regions linked to regulatory processes. The authors did not exclude whether the effects 
of DHEA administration were mediated by other DHEA derivatives, namely DHEAS and 
androsterone. Of note, DHEA administration produced an increase in DHEA and DHEAS in 
serum and salivary levels, without a simultaneous change in cortisol levels. Sripada et al. 
(651) also studied the effects of DHEA in resting networks and found that DHEA
administration to humans reduced the connectivity between amygdala and periamygdala 
and between amygdala and insula (in fMRI). In this study, reductions of amygdala to 
precuneus connectivity were associated with less self-reported negative affect. Therefore, 
DHEA effects on emotion processing neurocircuits differed from its effects on resting 
networks and so the authors purposed that DHEA may shift the balance between salience 
network and default network, a finding that could provide insight into the neurocircuitry 
of anxiety related psychopathology. 
Adrenarche coincides with the emergence of the pro-social and neurobehavioral 
skills of middle childhood and may therefore represent a human-specific stage of 
development. DHEA appears to modulate the process of cortical maturation during 
middle childhood: DHEA levels were associated with increases in cortical thickness of the 
left dorsolateral prefrontal cortex, right temporoparietal junction, right premotor and 
right entorhinal cortex between the ages of 4-13 years, a period marked by the 
androgenic changes of adrenarche (652). DHEA and testosterone were also related to 
cortical thickness of the right cingulate cortex and occipital pole and this was most 
significant in prepubertal subjects (652).  
Important brain remodeling pursued during adolescence, was shown by 
longitudinal studies using MRI (653; 654). It has been hypothesized that these changes 
may be related to increases in adrenal and gonadal hormones (655; 656; 657; 658) and 
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gonadal hormones are known to have organizational and activation effects on limbic 
structures and association cortex of animals (659). Concomitantly, social behavior, change 
dramatically during adolescence: there is increased self-consciousness, increase in 
complex and important relationships, including romantic and sexual relationships, and 
improvement in relation to understanding others (660; 661). Mentalizing, meaning the 
ability to recognize and interpret the feelings, intentions, beliefs and desires of others 
(662) is important for all social behaviors. Social emotions (like guilt or embarrassment)
are emotions that require mentalizing about others and their reactions to one’s actions. 
In contrast, basic emotions (like disgust or fear) do not require mentalizing. The network 
of brain regions recruited during mentalizing tasks comprises the dorsomedial prefrontal 
cortex (DMPFC), posterior superior temporal sulcus at the temporo-parietal junction and 
the anterior temporal cortex.  The signal in the DMPFC during mentalizing tasks decreases 
with age across adolescence, while signal in temporal regions increases during the same 
period (663; 664; 665; 666). 
Goddings et al. (667) compared brain regions activated during social emotion and 
a basic emotional condition. The authors used fMRI and measured testosterone, estradiol 
and DHEA. In this study, the contrast between social versus basic emotion resulted in 
activity within the social brain network, including dorsomedial prefrontal cortex (DMPFC), 
the posterior superior temporal sulcus, and the anterior temporal cortex in both 
hemispheres. Increased hormone levels (independent of age) were associated with higher 
left anterior temporal cortex activity during social emotion processing. More specifically, 
this relation was significant for testosterone and there was a trend for DHEA and 
estradiol. More advanced age (independent of hormone levels) was associated with lower 
DMPFC activity during social emotion processing (667). Klapwijk et al. (668) studied 
adolescent girls and found enhanced functional connectivity between the DMPFC and the 
left anterior temporal cortex during social relative to basic emotion processing 
independent of age. These authors also found that estradiol concentrations were 
associated with increased functional connectivity between the DMPFC and the right 
temporo-parietal junction during social related to basic emotion processing, independent 
of age but they did not find any relation between DHEA levels and the mentalizing 
network. 
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Concerning glucocorticoids' effects, as mentioned, mild or short-lasting increases 
in cortisol due to stress have beneficial effects on attention and memory, whereas higher 
cortisol levels or long term increases are related to poorer learning and memory and less 
cognitive flexibility (220; 633; 634; 635; 636; 637; 638). Increased cortisol levels during 
perception or encoding led to better memory performance and brain regions involved in 
the modulation of this process were medial temporal lobe regions such as amygdala and 
hippocampus, the anterior cingulate cortex and other parts of the prefrontal cortex (PFC) 
(669). Increased cortisol levels during the maintenance of items in working memory also 
increased the activity in prefrontal cortex and posterior parietal cortex (670). 
Corticosteroids' slow effects appear to improve working memory performance and 
increase neuronal activity during working memory performance in the dorsolateral 
prefrontal cortex depending on working memory load. Thereby, up to a certain level, the 
slow actions of corticosteroids seem to facilitate adequate higher-order cognitive 
functioning, which may support recovery in the aftermath of stress exposure (671). On 
the contrary, in this study, no effects of corticosteroids' rapid actions were observed 
during working memory performance in the dorsolateral prefrontal cortex (671). 
Nevertheless, other studies observed rapid, non-genomic effects of glucocorticoids, 
namely at the hypothalamus, hippocampus, amygdala and prefrontal cortex (220). These 
effects may involve mineralocorticoid and glucocorticoid receptors and membrane-
associated mechanisms, but are not directly induced by glucocorticoids (220). Instead, 
glucocorticoids play permissive or conditional effects, in facilitating or inhibiting the 
signaling of ion channels, receptors and neurotransmitters, thus modulating the threshold 
of neuronal activation (220). 
Contrary to the effects of mild and short lasting increases in cortisol levels, very 
high or sustained increases in cortisol levels may be deleterious for memory processes. 
While prefrontal cortex-dependent working memory is enhanced by acute stress, it is 
inhibited by chronic stress (633; 639; 640; 641). Important stress accompanied by very 
high cortisol levels during retrieval led to impaired memory retrieval (669) and the 
administration of cortisol also delayed and impaired implicit learning performance (672). 
Moreover, higher cortisol levels were correlated to lower hippocampal volume formation 
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(673). It is hypothesized that glucocorticoids that are released during stress, damage 
neurons that are located in the hippocampal region of the brain. The CA1 neurons found 
in the hippocampus are destroyed due to glucocorticoids, decreasing the release of 
glucose and the reuptake of glutamate. This high level of extracellular glutamate allows 
calcium to enter NMDA receptors which in return kills neurons. 
Finally, glucocorticoids may also modulate the brains emotional network. High 
cortisol levels during consolidation of emotional material involve increased amygdala and 
hippocampus activation (669). Nevertheless, acute increases in cortisol levels due to 
stress seem to reduce hippocampal activation to fearful faces (674), increasing the 
activity in the dorsal anterior cingulate cortex and Brodmann's area 8 (675) and reducing 
the amygdala-hippocampal connectivity (676) [on the contrary, as noted before, DHEA 
administration increased the connectivity between these two regions (651)]. Regarding 
amygdala responsivity, cortisol can rapidly desensitize amygdala responsivity to negative 
stimuli and this was related to an altered coupling of the amygdala with the medial 
prefrontal cortex. There is a posterior slow normalization of amygdala responsivity and 
amygdala to prefrontal cortex connectivity. These results reveal a temporarily fine-tuned 
mechanism that is critical for avoiding amygdala overshoot during stress and enabling 
adequate recovery thereafter (677). 
Contrary to short time and small increases in cortisol levels, the effects of chronic 
increases in cortisol levels, have desensitizing and deleterious effects on brain emotional 
processes that could be related to depression and anxiety disorders (678). Repetitive 
glucocorticoid administration increased self-reported negative emotions (679). Depressed 
subjects showed decreased cortisol sensitivity and simultaneous subgenual hyperactivity 
while glucocorticoids administration to these subjects decreased subgenual cingulate 
activity evoked by sadness (680). Cushing's syndrome patients made more errors in 
categorizing facial expressions and had less activation in left anterior superior temporal 
gyrus, a region important in emotion processing. Thus they showed altered activation of 
brain structures relevant to emotion perception, processing and regulation, similar to the 
performance decrements and brain regions shown to be dysfunctional in major 
depressive disorder (681). Using Fluorodeoxyglucose (FDG)-positron emission 
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tomography (FDG-PET) to study anxious temperament monkeys, Shackman et al. (682) 
found that elevated activity in the lateral anterior hippocampus was selective to 
individuals with high levels of hypothalamic–pituitary–adrenal (HPA) axis activity. 
Increased distress and anxiety and high cortisol levels were also correlated to increased 
PFC activation in pregnant women (683). Cortisol effects in the activation of brain 
memory and emotional processes also showed some lateralization effects and differences 
according to gender (669; 684; 685). 
In sum, higher baseline DHEA levels were related to higher hippocampal volume, 
increases in cortical thickness of the prefrontal cortex, temporoparietal junction, 
premotor and entorhinal cortex, cingulate cortex and occipital pole. During episodic 
memory recollection, DHEA administration was related to an early differential activation 
of the anterior cingulate cortex. Regarding emotional processing, DHEA administration 
was related to reduced activity in the amygdala and hippocampus, increased connectivity 
between these two regions and enhanced activity in the rostral anterior cingulated cortex 
whereas in the resting state DHEA administration reduced the connectivity between 
amygdala and periamygdala and between amygdala and insula. There was also a trend 
towards a relation between higher DHEA levels during adolescence and increased left 
anterior temporal cortex activity during social emotion processing. 
On the other hand, cortisol modulates memory processes enhancing activity in the 
prefrontal cortex, amygdala, hippocampus, anterior cingulate cortex and posterior 
parietal cortex. Prefrontal cortex-dependent working memory is enhanced by small acute 
cortisol increases, but inhibited by chronic cortisol increases and higher cortisol levels are 
correlated to lower hippocampal volume. Cortisol increases amygdala, hippocampus and 
anterior cingulate cortex activation during the processing of emotional material but acute 
physiological increases in cortisol also reduce hippocampal activation to fearful stimuli, 
reduce the amygdala to hippocampal connectivity and amygdala to prefrontal cortex 
connectivity. Chronic increased cortisol levels were related to more errors in the 
categorization of emotional stimuli, less activation in left anterior superior temporal 
gyrus, increased activity in the lateral anterior hippocampus and altered prefrontal 




Overall, research results suggest that DHEA and DHEAS might play a role in cortical 
organization, enhance memory and attention and protect against depression. 
Nevertheless, results are not consensual. Moreover, DHEA and DHEAS relations to 
personality are not established and their electrophysiological effects concerning 
attention, working memory and emotional processing are mostly unexplored. 
Neurostimulant and anti-cortisol effects of DHEA and DHEAS have been proposed to 
contribute to their central nervous system effects. Also, the balance between DHEAS and 
DHEA may influence those effects, but most studies did not address this parameter. 
Finally, DHEA and DHEAS increase in response to acute stress but it is not known whether 

















Aims and Hypothesis 
The objective of this doctoral thesis was to explore behavioral and 
electrophysiological correlates DHEA and DHEAS. In particular, we aimed to explore 
relations to personality profile and cognitive and emotional processing at the 
performance and electrophysiological level. Additionally, we wanted to explore DHEA and 
DHEAS responses to stress and to the performance of cognitive and emotionally loaded 
tasks. In every case, we wanted to explore evidence of anti-cortisol effects of DHEA and 
DHEAS and effects of DHEAS-to-DHEA balance.  
Study I 
Personality traits are individual behavioral characteristics which are established 
early in childhood and remain relatively stable over time (338). The same occurs with the 
HPA axis phenotype, meaning that each person has characteristic and relatively stable 
baseline levels and reactivity pattern (339). Stressful events experienced in the neonatal 
period or early years of life may have long-term effects on the HPA axis phenotype, 
personality, and upon the future development of psychosomatic diseases (351; 352; 574; 
686). Also, personality has been related to hypothalamic-pituitary-adrenal axis phenotype 
(339; 343; 344; 345; 346; 347; 348; 349) in what concerns the ACTH and cortisol reactivity 
(340; 341; 342; 344) with positive psychological traits generally being related to reduced 
cortisol reactivity to an acute stress (350). 
Previous evidence of DHEA and DHEAS effects on cortical organization (15), 
cortical maturation (16), synaptic transmission (3; 7; 120) and behavior (18; 20; 317; 365; 
366) raise the hypothesis that DHEA and DHEAS may be related to personality profile.
There is however, scarce evidence showing a relationship between DHEAS and 
personality (355; 357). There is also evidence suggesting that DHEA and DHEAS levels may 
increase in response to an acute psychological stress (8; 270; 271) and evidence 
suggesting anti-cortisol effects of DHEA and DHEAS (17; 687), but the relation between 
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pituitary-adrenal axis (HPA) phenotype in what concerns the DHEA and DHEAS response 
and personality has not been established. 
The objective of this study was to explore the relation between DHEAS and both 
personality traits and pituitary-adrenal axis reactivity in humans. To address this 
objective, personality was evaluated with the Minnesota Multiphasic Personality 
Inventory (MMPI) (688) and the pituitary-adrenal axis reactivity was assessed with the 
CRH test. The main hypotheses were that higher DHEAS levels and/or DHEAS reactivity 
may be related to lower Type A personality and Neurotic Triad scores and to higher 
Deviant Behavior scores. DHEAS opposite to cortisol reactivity to CRH infusion is 
expected. 
Study II 
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS) 
have been suggested to have memory enhancement effects in humans (317; 451). A 
neuro-stimulatory action and an anti-cortisol mechanism of action may contribute to that 
relation (17; 283; 318). The aim of this study was to test whether DHEA and DHEAS levels 
are related to distraction and Working Memory at the electrophysiological level, as 
evidence for their neurophysiologic effects using Event-Related Brain Potentials (ERPs) is 
scarce (24; 624; 645) and to test whether these endocrine levels are modulated by 
Working Memory (WM) load. The specific a priori hypotheses were: 1) higher 
endogenous DHEA and DHEAS levels may prevent involuntary distraction and enhance 
cognitive performance; 2) DHEA and DHEAS putatively beneficial effects may be 
translated at the neurophysiological level; 3) DHEA and DHEAS effects may be largely 
antagonistic from those of high baseline cortisol; and 4) cognitive tasks using Working 
Memory load may be a stimulus for DHEA and DHEAS production.  
To test these hypotheses, we measured the relation between DHEA, DHEAS and 
cortisol on one hand, and the cognitive performance and brain responses, using a well-
established auditory-visual distraction paradigm (477; 479; 689) on the other hand. The 
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protocol included task irrelevant sounds, some of which were aimed to cause distraction 
and a visual task including working memory manipulation. In this paradigm, unexpected 
auditory novel sounds caused distraction and were expected to deteriorate performance 
and elicit a novelty-P3 enhancement (477; 479; 480). Typically, the task with working 
memory load is more difficult for the subjects, leading to worse performance and a 
reduced P300, reflecting less processing of the task-relevant visual stimulus (472; 507; 
508). 
Study III 
Higher DHEA and DHEAS levels have been related to enhanced working memory 
and attention (317; 451). However, the administration of DHEA returned inconclusive 
effects on working memory and attention (319; 328; 329; 330; 331) and the relation 
between both forms of the hormone may modulate their effects in the central nervous 
system (447). The aim of this study was to test whether DHEAS-to-DHEA ratio modulates 
working memory and involuntary attention during the performance of a working memory 
task at the electrophysiological level. Our hypotheses were that higher DHEAS-to-DHEA 
levels may enhance working memory and/or involuntary attention, and that these effects 
translate at the electrophysiological level. 
To test these hypotheses, we measured baseline DHEAS and DHEA and brain 
responses, using a well-established auditory-visual distraction paradigm (477; 479; 689). 
The protocol included task irrelevant sounds, some of which were novel and aimed to 
cause involuntary attention and a visual task including working memory manipulation. 
Involuntary distraction by novel sounds elicits a novelty-P3 enhancement and was 
expected to deteriorate performance (477; 479; 480). The processing of the relevant 
visual stimulus elicits a P300 component. Working memory load tasks, being more 
difficult than discriminative tasks, led to worse performance, typically eliciting a reduced 
P300 and also reduced involuntary attention (472; 507; 508). 
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Study IV 
DHEA and DHEAS may have mood enhancement effects: higher DHEAS 
concentrations and DHEA/cortisol ratio have been related to lower depression scores (18; 
20; 365; 366) and controlled trials of DHEA administration have reported significant 
antidepressant effects (364; 383; 384). 
The aim of this study was to explore whether DHEA and DHEAS levels were related 
to involuntary attention and emotional stimuli processing at the performance and brain 
levels and, on the other hand, if an emotional challenge would alter DHEA and DHEAS 
levels. Furthermore, we wanted to examine the relation of DHEA and DHEAS with cortisol 
levels. The a priori hypotheses were: 1) higher endogenous DHEAS and DHEA levels as 
well as higher DHEA-to-cortisol and DHEAS-to-DHEA levels may protect from involuntary 
distraction and enhance brain processing and performance under a negative emotional 
context; 2) DHEAS and DHEA effects may be largely antagonistic from those of baseline 
cortisol; 3) in the short term, a negative emotional context might be a stimulus for DHEA 
and cortisol secretion.  
To test these hypotheses, we used a visual task with a neutral or negative 
emotional context and unexpected auditory novel sounds aimed to cause distraction. In 
this paradigm, the negative emotional context was expected to elicit an increased 
attention capture when compared to non-emotional faces (534) and consequently 
deteriorate performance (483). Furthermore, auditory distraction by novel sounds was 
expected to elicit a novelty-P3 component in the electroencephalogram (EEG) and also 
deteriorate performance (477; 479; 509; 516). We recorded performance parameters, the 
EEG and took saliva samples in order to determine the hormonal levels before and after 
the task. We explored DHEA, DHEAS, cortisol, DHEA/cortisol ratio and DHEAS/DHEA ratio 
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Abstract 
Objectives: Dehydroepiandrosterone-sulphate (DHEAS) physiologic relevance remains 
controversial. However, several central nervous system and behavioural effects of DHEAS 
have been described. We explored the relation between DHEAS and both pituitary-
adrenal axis reactivity and personality in human subjects. Design: We studied 120 
consecutive patients assisted at the out patient endocrine department of a public central 
hospital before medical treatment. Personality was evaluated with the Minnesota 
Multiphasic Personality Inventory (MMPI) and the pituitary-adrenal axis reactivity was 
assessed with the CRH test. Results: Baseline DHEAS was inversely related to peak/basal 
cortisol (parcial r=–0.454, p<0.05) response to CRH infusion. DHEAS reactivity in the CRH 
test was directly related to the Deviant Behaviour triad (BD) (r=0.257, p<0.05) and type A 
personality (AP) (r=0.295, p<0.05). Basal ACTH was directly related to baseline DHEAS 
(r=0.366, p<0.001) and together with age and gender explained 34% of DHEAS variability. 
Conclusions: DHEAS may be a protective factor against an excessive cortisol response 
when people are under stress situations. Personality may be related to DHEAS reactivity. 




Objetivos: Os efeitos fisiológicos da desidroepiandrosterona-sulfato (DHEAS) são ainda 
controversos. Contudo, têm sido descritos efeitos ao nível do sistema nervoso central e 
efeitos comportamentais. Explorámos a relação entre os níveis de DHEAS e a reatividade 
do eixo hipófise-suprarrenal e a personalidade. Participantes e Métodos: Estudámos 120 
doentes consecutivos, assistidos na consulta externa de um serviço de endocrinologia de 
um hospital público central, antes de qualquer tratamento médico. A personalidade foi 
avaliada com o Inventário de Personalidade Multifásico do Minnesota (MMPI). A 
reatividade hipófise-suprarrenal foi avaliada pela prova da corticoliberina (CRH). 
Resultados: Os níveis basais de DHEAS relacionaram-se inversamente com a resposta 
pico/basal do cortisol (r parcial=-0,454; p<0,05) na prova da CRH. A reatividade da DHEAS 
na prova da CRH relacionou-se diretamente com a tríade de Problemas do 
Comportamento (r=0,257; p<0,05) e com a personalidade tipo A (r=0,295; p<0,05). Os 
níveis de ACTH basais relacionaram-se diretamente com os níveis de DHEAS (r=0,366; 
p<0,001). A idade, género e os níveis de ACTH em conjunto, explicaram 34% da 
variabilidade nos níveis de DHEAS. Conclusões: A DHEAS poderá ter um papel protetor 
contra uma resposta excessiva do cortisol em situações de stress. Os resultados sugerem 
ainda que a personalidade se relaciona com a reatividade da DHEAS.  
Palavras chave: DHEAS; cortisol; personalidade; stress; reatividade da DHEAS; prova da 
CRH. 
 
Abreviations: AP - Type A Personality; AUC - Area Under the Curve; AUC/h - Area Under 
the Curve/hour; BD - Behaviour Deviant Triad; GABA-A - Gamma-Aminobutyric Acid Type 
A; Receptor K-S - Kolmogorov-Smirnov; MMPI - Minnesota Multiphasic Personality 
Inventory; NMDA - N-methyl-D-aspartate receptor; NT - Neurotic Triad; PD - Psychotic 





In humans dehydroepiandrosterone-sulphate (DHEAS) is the most abundant 
hormone in the peripheral circulation. Its normal levels (2–10 μmol/L) are more than 20 
times those of cortisol or thyroxine, more than 100 times those of testosterone, growth 
hormone and prolactin and more than 10,000 times those of aldosterone, estradiol or 
insulin. On the other hand, most laboratory animals have only negligible amounts of 
DHEAS. Even primates have much lower levels than humans (Berr et al. 1996).  
DHEA is mostly synthesised in the adrenals and gonads, either as the final 
androgen-like compound or as an intermediate in the synthesis of androgens. However, it 
is also synthesised in the central nervous system (Paul & Purdy 1992; Berr et al. 1996; 
Baulieu & Robel 1998; Reddy & Kulkarni 1998; Labrie et al. 2003; Sicard et al. 2007). A 
sulphotransferase reversibly converts DHEA into DHEAS, and the sulphated form is by far 
the most abundant in the peripheral circulation. Nevertheless, the nonsulphated form is, 
however, much more lipossoluble and may easily cross biologic membranes presenting a 
much larger distribution that includes the central nervous system (Berr et al. 1996; Sicard 
et al. 2007). DHEA has a short half-life – 1 to 3 hours – as opposed to DHEAS that has a 
long half-life – 10 to 20 hours (Legrain et al. 2000; Muniyappa et al. 2006; Komesaroff 
2008).  
No definitive factors regulating DHEAS synthesis have been so far identified. 
DHEAS physiological effects and teleological meaning are unclear and controversial. At 
the clinical level DHEAS levels are higher in males and dramatically decrease with age – in 
the seventh decade they are about 20% of those in the third decade (Berr et al. 1996; 
Kimonides et al. 1998; Laughlin & Barrett-Connor 2000; Tannenbaum et al. 2004; Sicard et 
al. 2007). Furthermore, DHEAS levels relate to morbidity and mortality even after age 
correction (Berr et al. 1996; Gruenewald et al. 2006; Sicard et al. 2007). Either specific 
effects or more generally a cortisol antagonism has been invoked to account for those 
associations (Akinola & Mendes 2008; Wemm et al. 2010).  
Regarding DHEAS effects, initial evidence resulted mainly from large observational 
studies on the elderly and post-menopausal women – The Rancho Bernardo Study, 
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Baltimore Longitudinal Study of Aging and Personnes Agées Quid (PAQUID) – studies with 
DHEAS replacement in the elderly – DHEAge Study – and smaller clinical studies of 
patients with primary adrenal failure (Barrett-Connor & Edelstein 1994; Berr et al. 1996; 
Wolf et al. 1997; Barrett-Connor et al. 1999; Baulieu et al. 2000; Schlienger et al. 2002; 
Legrain & Girard 2003; Hougaku et al. 2006; O’Donnell et al. 2006). Nevertheless, during 
the last years, more and more evidence regarding DHEAS effects in adolescents and 
adults has been collected.  
Similar to other neurosteroids, specific central nervous system effects have been 
described for DHEAS. DHEAS seems to modulate cognitive function and higher levels of 
this hormone are related to better results regarding memory, learning and resilience 
(Barrett-Connor & Edelstein 1994; Morley et al. 1997; Compagnone & Mellon 1998; 
Reddy & Kulkarni 1998; Morrow 2007; Sicard et al. 2007; Wemm et al. 2010); to higher 
well being scores and less depression (Moralès et al. 1994; Wolf et al. 1997; Barrett-
Connor et al. 1999; Schlienger et al. 2002; Dallman et al. 2003; Akinola & Mendes 2008) 
and to higher resistance to the deleterious effects of a stressful situation (Reddy & 
Kulkarni 1998; Morrow 2007; Morgan et al. 2009; Yoon et al. 2009).  
At the molecular level DHEAS has a general neurostimulatory effect via 
gabaminergic antagonism [Gamma-Aminobutyric Acid Type A Receptor (GABAA) 
antagonism] and glutaminergic agonism [N-methylD-aspartate receptor (NMDA) sigma-1 
agonism] (Paul & Purdy 1992; Baulieu & Robel 1998; Reddy & Kulkarni 1998; Morrow 
2007). Neurotrophic effects have also been described and DHEA and DHEAS may 
contribute to neocortical organization (Baulieu & Robel 1998; Compagnone & Mellon 
1998; Beck & Handa 2004; Suzuki et al. 2004). Moreover, DHEA and DHEAS 
neuroprotective effects after hypoxia have been documented and lower levels of those 
hormones in older adults could contribute to the enhanced cerebral vulnerability to 
vascular lesion or other neural insults (Kimonides et al. 1998).  
The concept of endocrine phenotypes in endocrine research assumes that with 
regard to hormone levels, intersubject variability is much larger than intrasubject 
variability throughout the time (Bertagna et al. 1994; Coste et al. 1994). It is also 
postulated that these endocrine phenotypes are established at the beginning of one’s life. 
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A second related concept is that one of endocrine plasticity, meaning that endocrine 
responses nonrandomly change throughout the time according to previous experiences 
(Chrousos et al. 1988; Chrousos 1992; Levine 1993). In what concerns behavioural 
endocrine research personality traits are also individual features established quite early in 
life. A relation between cortisol and the hypothalamic-pituitary-adrenal axis reactivity and 
personality has been established (Chrousos et al. 1988; Chrousos 1992; Kirshbaum et al. 
1992; Levine 1993; Bertagna et al. 1994; Castanon & Morméde 1994; George et al. 2010; 
Wirtz et al. 2010); however, this relation was less studied in what concerns DHEAS 
(Thomas et al. 1994).  
The Minnesota Multiphasic Personality Inventory (MMPI) is well validated in the 
general population and, in addition to its importance in the psychiatric setting, it can also 
be used to interpret classic personality dimensions (Costa et al. 1986). In the 
corticotropin-releasing hormone (CRH) test, pituitary-adrenal response to CRH 
administration is classically measured with ACTH and cortisol determinations as an index 
of the stress response. The CRH test has been extensively used in psychoneuroendocrine 
research of several psychiatric and psychosomatic disorders (Gold et al. 1986; Demitrack 
et al. 1991; Chrousos & Gold 1992) and previous studies from our research team found 
out significant relations between personality and pituitary-adrenal response to CRH 
administration in common clinical disorders (Martins et al. 2001; Martins et al. 2002; 
Martins et al. 2004).  
The above evidence suggests the existence of a relation between DHEAS and 
behaviour, namely with personality and stress response. In the current study we explored 
the relation between DHEAS and both personality traits and pituitary-adrenal axis 
reactivity in humans. 
Patients and Methods 
We analysed retrospectively the records of 120 consecutive patients in which CRH 
test and personality evaluation with the MMPI were included in the clinical workout. 
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Patients belong to several diagnostic groups. Clinical condition was not further taken into 
account for this study but diagnostic group was retained as a baseline variable in the 
statistical analysis, so that only significant results after correction for this potential 
confounding variable are reported. The study protocol was approved by the Hospital 
Ethical Committee and informed written consent was obtained for every patient. The 
data used was obtained before beginning medical treatment.  
Age, gender, height and weight without shoes or coats were recorded. The 
Portuguese translation of the MMPI (Montenegro 1982) was filled by the participants 
after one of the authors’ complete and detailed instructions. The participants remained 
alone in a quiet room for the entire procedure. Scores were obtained according to MMPI 
authors’ instructions. To avoid the use of multiple comparisons, only conventionally 
defined type A personality (AP) and superordinate traits were used – neurotic triad (NT): 
hypochondriasis (Hs) + depression (D) + hysteria (Hy); psychotic dyad (PD): paranoia (Pa) + 
schizophrenia (Sc) and behaviour-deviant triad (BD): psychopathic deviate (Pd) + 
masculinity-femininity (Mf) + hypomania (Ma) (Butcher et al. 1990; Greene 1991). The 
original MMPI version was used instead of the revised one (MMPI-2) since the MMPI-2 
translation had not been validated yet.  
The CRH test was performed the following week, after an overnight fast. In all 
cases a venous line was obtained in the antecubital region, the participant lying in the 
supine position; after a 15 to 20 min period of adaptation a venous blood sample was 
collected – time 0. CRH was then slowly infused in 1 to 2min (human CRH, 100 μg, CRH 
Ferring GmHb, Kiel, Germany); further blood samples were obtained at 15, 30, 60 and 120 
min. All samples were immediately refrigerated at +4 °C and sent to the Endocrine 
Laboratory after test completion. ACTH and cortisol were measured at 0, 15, 30, 60 and 
120 min, DHEAS was measured at 0, 30 and 60 min and prolactin (PRL) was only 
measured at baseline.  
Immunoradiometric assay (IRMA) and enzymelinked immunoassay (ELISA) 
methods were used for ACTH (IRMA, Nichols Institute, San Juan Capistrano, CA), PRL 
(IRMA, Diagnostc Products Corporation, Los Angeles, CA), DHEAS and cortisol (ELISA, 
Diagnostic Products Corporation, Los Angeles, CA) measurements which were performed 
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in the hospital central laboratory. Intra- and interassay variation coefficients were less 
than 10% in every case.  
Statistical analysis was carried out with the use of the Statistical Package for the 
Social Sciences Program (SPSS, version 16.0). Results are presented as the mean±standard 
deviation (sd) or as percentage as appropriate. The area under the curve (AUC) was 
computed according to the trapezoidal rule (Rowland & Tozer 1995). Mean values per 
hour were computed. The normal distribution of continuous variables was verified by the 
Kolmogorov-Smirnov (K-S) goodness of fit test. Non normal distributed variables were log 
transformed prior to analysis. However, for the sake of simplicity when no differences 
were found, results regarding the non-transformed variables are presented. The Chi-
Square test was used to compare the distribution of non-continuous variables between 
selected groups, factorial analysis of variance (ANOVA) to compare continuous variables 
between selected groups and Multiple linear regression analysis to explore the relation 
between continuous variables. The limit of statistical significance was selected at 0.05.  
Results 
All patients’ results are summarized in Tables 1–3. Basal DHEAS was different 
among diagnostic groups – F(4,119)=3.959, p<0.005 – with hirsute subjects presenting 
significantly higher basal DHEAS values – 237±113 μg/dL – when compared to all other 
diagnostic groups. There were no differences in ACTH, cortisol and PRL among diagnostic 
groups.  
Mean baseline DHEAS was 158±99 [20–554] μg/dL and presented a distribution 
not significantly different from the normal one, K-S test Z=0.862, ns. DHEAS levels were 
higher in males when compared to females – 207±87 μg/dL vs 151±99 μg/dL, t=2.088, 
p<0.05. DHEAS levels were inversely related to age – r=0.444, p<0.001, even after gender 
correction, the regression equation being DHEAS=272.493–3.736 × age. Together gender 
and age accounted for 27% of DHEAS variability. DHEAS levels were not significantly 
related to body mass index (BMI) or body weight.  
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[min-max] or % 
Age (years)   33±12 [18-57] 
Gender F/M (%)   87/13 
BMI (kg/m2)   27.7±9.0 [14.5-60.1] 
DHEAS (μg/dL) 35-430 158±99 [20-554] 
ACTH (pg/mL) 0-46 19±14 [1-90] 
PRL (ng/mL) 2-29 11±7 [2-33] 
Cortisol (μg/dL) 4-23 18±9 [4-51] 
 







0’ 21±16 19±9 177±106 
15’ 52±74 b 22±8 c - 
30’ 50±58 c 23±8 c 177±114 
60’ 31±31 a 24±9 c 176±107 
120’ 16±18 a 18±10 - 
AUC 32±36 b 22±8 c 176±107 
       AUC units are pg/mL.h for ACTH, μg/dL.h for cortisol, and μg/dL.h for DHEAS. 
       Value different from basal, a p<0.05, b p<0.01, c p<0.001. 
 
      Table 3. Superordinate traits and AP score (MMPI). 
 Mean±sd 
Neurotic Triad (NT) score 164±30 
Psychotic Dyad (PD) score 115±22 
Behaviour-Deviant triad (BD) score 158±23 
Type A Personality (AP) (%) 38±16 
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DHEAS levels were significantly related to ACTH – r=+0.366, p<0.001 – and PRL – 
r=+0.233, p<0.05 – but not to cortisol. However, ACTH and PRL were interrelated and 
when both variables were included in the analysis only ACTH remained as a significant 
factor. This relation persists even after age, gender and diagnostic group correction. Age, 
gender and ACTH account for 34% of DHEAS variability.  
Baseline ACTH was significantly related to the peak ACTH (r=+0.490, p<0.001) and 
peak cortisol (r=+0.246, p<0.05) responses during the CRH test. Baseline cortisol was 
strongly related to the peak cortisol response (r=+0.782, p<0.001). Baseline DHEAS was 
not related to the peak ACTH or peak cortisol response in the CRH test but baseline 
DHEAS was inversely related to the peak/baseline cortisol response (parcial r=–0.454, 
p<0.05) after age, gender, baseline ACTH and baseline cortisol correction (multiple linear 
correlation including peak/baseline cortisol, age, gender, baseline ACTH and baseline 
cortisol, total r=0.631, p<0.005) (Figure 1). DHEAS was not related to peak/baseline ACTH 
response. 















Figure 2: Relation between DHEAS reactivity and BD triad. 
(µg/dL.h) 
(µg/dL.h) 
Figure 3: Relation between DHEAS reactivity and type A Personality. 
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Baseline DHEAS was inversely related to NT score – r=–0.355, p<0.001 – but not to 
PD or BD triad. However, this relation was no longer significant when age correction was 
carried out; in fact, age was directly related to NT – r=+0.443, p<0.001. Nevertheless, the 
DHEAS response in the CRH test (evaluated as the AUC) was significantly and directly 
related to BD triad and type A personality – simple linear correlation respectively 
r=+0.257, p<0.05 and r=+0.295, p<0.05 (Figure 2 and 3) – and that relation remains 
significant even after age and diagnostic group correction. As noted, DHEAS average 
levels have not significantly changed after the CRH test. Despite this, DHEAS response was 
highly variable in what concerns the individual level (–73 μg/dL to +317 μg/dL). 
Discussion 
This is an observational retrospective study, whose objective is to explore the 
relation between DHEAS and both personality and pituitary-adrenal axis reactivity in adult 
humans.  
We used several specific diagnostic groups. As noted before only results remaining 
significant independently of age and diagnostic group are reported. Only DHEAS and not 
DHEA measurements were used. We expected a stronger relation between DHEAS and 
more stable parameters as age, gender, basal hypothalamic-pituitary-adrenal (HPA) axis 
activity and personality as that hormone has a longer half-life. On the contrary, acute 
changes might be more easily detected with DHEA, namely after CRH administration.  
The predominance of female participants (87%) reflects the population assisted in 
the Endocrine outpatient department. Even so, DHEAS levels were significantly higher 
(37%) in males, as it was expected (Berr et al. 1996; Baulieu et al. 2000; Laughlin & 
Barrett-Conner 2000; Tannenbaum et al. 2004; Gruenewald et al. 2006). 
The mean age was 33 years old (the sample was 18 to 57 years old) and DHEAS 
levels were inversely related to age as it has extensively been described in the literature 
(Berr et al. 1996; Lane et al. 1997; Morley et al. 1997; Kimonides et al. 1998; Legrain & 
Girard 2003; Sicard et al. 2007). We found a 1.4% mean decline in DHEAS levels per year 
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while other authors had previously described a decline of about 2% per year during 
adulthood and higher decline rates in post-menopausal women and older men (Laughlin 
& Barrett-Connor 2000; Tannenbaum et al. 2004; Labrie et al. 2005).  
Age explained 20% of DHEAS variability, gender explained 4% of DHEAS variability 
and age and gender together explained 27% of DHEAS variability. Both factors have been 
extensively identified as relevant factors for DHEAS levels.  
DHEAS levels were also significantly and directly related to basal ACTH 
independently of age, gender and diagnostic group; ACTH explains 14% of DHEAS 
variability. Age, gender and ACTH accounted for 34% of DHEAS variability. This is a 
relatively new finding since ACTH had not been generally considered as a relevant factor 
both for DHEAS and adrenal androgen production. In fact, chronic stress is generally 
associated with increased cortisol levels and decreased DHEAS levels. Moreover, it should 
be noted that despite the ACTH response, no DHEAS response was found in the CRH test, 
even if dexamethasone suppression decreases both cortisol and DHEAS. All this points out 
the complexity of the relation between ACTH and DHEAS until a putative cortical 
androgen stimulating hormone (CASH) is still to be identified. 
As a group, and despite the ACTH response, mean DHEAS levels did not change in 
the CRH test suggesting no acute effect of ACTH on DHEAS levels. Taking into account the 
high DHEAS levels and long DHEAS half-life, it may be necessary a longer ACTH rise to 
increase DHEAS levels (Berr et al. 1996). However, individually DHEAS response was 
highly variable. Baseline ACTH was strongly and directly related to the peak ACTH 
response and was also directly related to the peak cortisol response and baseline cortisol 
was strongly related to the peak cortisol response suggesting that baseline HPA axis 
activity is a strong determinant of the response to CRH. In more detail, baseline ACTH 
levels seem to be a major determinant of either ACTH or cortisol response.  
An interesting finding is the fact that baseline ACTH is related to both ACTH or 
cortisol peak levels but not to ACTH or cortisol peak/ baseline ratio suggesting that ACTH 
does not modulate the intensity of the response, but only that those subjects with higher 
baseline ACTH and cortisol levels naturally reach higher peak ACTH and cortisol levels. 
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The influence of DHEAS seems much more subtle. Baseline DHEAS was not related to the 
peak ACTH or peak cortisol response in the CRH test. Similarly, it was not related to 
peak/baseline ACTH response in CRH test but it was inversely related to the peak/baseline 
cortisol response (after age, gender, baseline ACTH and baseline cortisol correction). 
Those results suggest that DHEAS may reduce the magnitude of the cortisol response 
independently of baseline ACTH or cortisol levels. There is some previous evidence that 
DHEAS may indeed down-regulate cortisol levels (Kimonides et al. 1998; Gruenewald et 
al. 2006; Morrow 2007; Akinola & Mendes 2008).  
Lower DHEAS was related to higher NT scores. The relation between DHEAS and 
NT score persisted after diagnostic group correction. However, that relation was no 
longer significant after age correction, and in fact, age was directly related to NT score. 
This is rather surprising not only because personality is generally considered as a stable 
personal characteristic established at a very early stage of life but also because this is a 
rather young sample. On the other hand, it seems plausible that aging, bringing about 
morbidity and mortality of both the patient and their relationships, should be associated 
with increased hypochondriac and depressive scores, two of the three components of the 
neurotic triad. Whatever the reason may be, aging is associated with increased NT scores 
(Zuckerman 1994) and decreased DHEAS baseline levels and that seems to be the reason 
for the spurious relation between DHEAS and NT. Disappointingly, baseline DHEAS levels 
were not significantly related to any of the selected psychometric variables and this 
points out the insensitivity of baseline endocrine levels. 
However, DHEAS reactivity in the CRH test is significantly related to BD triad and 
Type A personality and both relations persist independently from age, gender and 
diagnostic group. As noted before neuroendocrine reactivity in the CRH test (regarding 
the ACTH and cortisol response) has been previously shown to be related to other 
psychometric variables. The apparent paradox is that although there does not seem to be 
any DHEAS response in the CRH test (evaluated by the mean), the DHEAS response is 
significantly related to psychometric variables. In fact, although the mean DHEAS does 
not change in the CRH test, individually considered peak DHEAS – baseline DHEAS 
changes deeply from –73 to + 317 μg/mL. In short, higher DHEAS responses are 
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associated with Type A behaviour and BD triad (psychopathic deviation + hypomania + 
masculinity-femininity) and more specifically with Pd score (data not shown).  
To conclude, we found that DHEAS significantly changes according to gender and 
age. Moreover, we also noticed that: 1) baseline DHEAS is significantly modulated by 
ACTH; 2) baseline DHEAS significantly modulates the intensity of the cortisol response in 
the CRH test; 3) DHEAS reactivity is a factor for BD triad and Type A behaviour. In short, 
baseline DHEAS relates to stress response and DHEAS reactivity relates to personality. 
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Abstract 
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEAS) have 
been reported to have memory enhancement effects in humans. A neuro-stimulatory 
action and an anti-cortisol mechanism of action may contribute to that relation. In order 
to study DHEA, DHEAS and cortisol relations to working memory and distraction, we 
recorded the electroencephalogram of 23 young women performing a discrimination (no 
working memory load) or 1-back (working memory load) task in an audio-visual oddball 
paradigm. We measured salivary DHEA, DHEAS and cortisol both before each task and at 
30 and 60 min. Under working memory load, a higher baseline cortisol/DHEA ratio was 
related to higher distraction as indexed by an enhanced novelty P3. This suggests that 
cortisol may lead to increased distraction whereas DHEA may hinder distraction by 
leading to less processing of the distractor. An increased DHEA production with 
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consecutive cognitive tasks was found and higher DHEA responses attributed to working 
memory load were related to enhanced working memory processing as indexed by an 
enhanced visual P300. Overall, the results suggest that in women DHEA may oppose 
cortisol effects reducing distraction and that a higher DHEA response may enhance 
working memory at the electrophysiological level. 
Key-words: dehydroepiandrosterone; dehydroepiandrosterone-sulphate; cortisol; 
working memory; auditory distraction; dehydroepiandrosterone response; event-related-
potentials. 
Resumo 
Têm sido descritos efeitos benéficos da desidroepiandrosterona (DHEA) e 
desidroepiandrosterona-sulfato (DHEAS) na memória em seres humanos. Uma ação 
neuroestimulante bem como efeitos anti-cortisol da DHEA e DHEAS, poderão contribuir 
para essa relação. O objetivo deste estudo foi avaliar as relações da DHEA, DHEAS e 
cortisol com a memória e a distração. Para isso, gravámos o eletroencefalograma de 23 
jovens do género feminino, enquanto realizavam uma tarefa discriminativa (sem 
memória de trabalho) e outra tarefa com memória de trabalho, usando um paradigma 
audiovisual (de tipo "oddball"), em que a tarefa alvo é visual e a distração é auditiva. 
Medimos a DHEA, DHEAS e cortisol na saliva, antes de cada tarefa e aos 30 e 60 min. 
Durante a realização da tarefa com memória de trabalho, uma razão cortisol/DHEA basal 
mais elevada, relacionou-se com uma deflexão “P3-novidade” mais ampla, indicando 
maior distração. Esta relação sugere que o cortisol se poderá aumentar a distração 
enquanto que a DHEA poderá reduzir essa distração, através da redução do 
processamento do estímulo distrativo. Verificou-se uma maior secreção de DHEA com a 
realização das duas tarefas cognitivas consecutivas. Uma maior a reatividade da DHEA 
atribuível à memória de trabalho, relacionou-se com uma maior amplitude da deflexão 
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P300 visual, sugerindo um maior processamento da memória de trabalho. Globalmente, 
estes resultados sugerem que nas mulheres, a DHEA poderá opor-se aos efeitos do 
cortisol, reduzindo a distração e que uma maior resposta da DHEA, poderá melhorar a 
memória de trabalho, ao nível eletrofisiológico. 
Palavras-chave: desidroepiandrosterona; desidroepiandrosterona-sulfato; cortisol; 
memória de trabalho; distração auditiva; reactividade da desidroepiandrosterona; 
potenciais evocados. 
Introduction 
Dehydroepiandrosterone-sulphate (DHEAS) is the most abundant steroid in the 
peripheral circulation and it is much more abundant in humans than in any other species 
[1,2,3,4,5,6,7]. Circulating levels dramatically decrease with aging. Moreover, lower levels 
are related to higher morbidity and mortality ratios even when corrected for age [2,8]. 
 DHEA is mostly synthesized in the adrenals whereas the gonads represent a minor 
source of this hormone. However, DHEA is also synthesized in the central nervous system 
[3], where its concentrations are higher than in the peripheral circulation [3,9,10]. In both 
peripheral and central compartment, a sulpho-transferase reversibly converts DHEA to 
DHEAS, restricting its distribution and prolonging its half-life [2,3].  
Several central effects concerning cognitive performance and stress response have 
been described for DHEA and DHEAS. Higher levels were related to increased memory 
and attention scores [9,11] and improved performance in stressful conditions [12,13,14], 
whereas low levels were found in Alzheimer’s disease [15]. However, DHEA 
administration in older subjects showed inconclusive results [5,16,17,18,19].  
On the other hand, stressful stimuli also modulate DHEA and DHEAS levels: acute 
stress is related to an increase in DHEA and DHEAS levels [20,21,22,23] whereas chronic 
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stress decreases baseline DHEA and DHEAS levels [24,25,26,27,28], as well as the acute 
DHEAS response to a superimposed psychological stress [29]. Yet, a direct influence of 
cognitive processing on DHEA or DHEAS levels has not been studied.  
At the molecular level, DHEA and DHEAS have a general neuro-stimulatory effect: 
presynaptic actions include glutamate, acetylcholine and norepinephrine release and 
postsynaptic actions include sigma 1 receptor agonism with subsequent N-methyl-D-
aspartate (NMDA) receptor activation, gabaminergic antagonism and inhibition of 
voltage-gated calcium currents [3,9,10]. Nevertheless, DHEA and DHEAS molecular effects 
are not exactly the same and several studies suggest that the balance between them may 
influence brain functioning [9,30]. As an example, DHEAS has more potent antagonistic 
effects at the c-aminobutyric acid type A receptor (GABA-A receptor) than DHEA [31,32]. 
Hence, the simultaneous evaluation of DHEA and DHEAS may uncover more information 
than the individual examination of either form of that steroid.  
Concerning glucocorticoids, whereas mild or short-lasting increases in cortisol due 
to stress may protect the body, promote adaptation and have beneficial effects on 
attention and memory, higher cortisol levels or long term increases are related to poorer 
executive functioning, poorer learning and memory and less cognitive flexibility 
[33,34,35,36,37,38,39]. In particular, working memory (WM) depends on prefrontal 
cortex activity, which is modulated by glucocorticoids: prefrontal cortex-dependent 
working memory is enhanced by acute stress and inhibited by chronic stress [35,40]. The 
relation between glucocorticoids and cognitive functioning is bidirectional: 
glucocorticoids impact cognitive function and cognitive processing has been shown to 
influence glucocorticoid secretion [41].  
Several levels of evidence suggest that DHEA and DHEAS may counterbalance 
cortisol effects: a higher DHEA/cortisol ratio has been related to better performance 
under stress [14] and DHEAS antagonized the memory deteriorating neurotoxic effects of 
cortisol in the hippocampus [10,42]. More generally, DHEA and DHEAS decrease with 
aging, whereas cortisol does not. Consequently, the cortisol/DHEA ratio increases and 
may be involved both in the cognitive impairments and in the particular vulnerability to 
stress damage that seems to characterize the elderly [5,9,42].  
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The aim of the present study was to test whether DHEA and DHEAS levels are 
modulated by WM load and whether these endocrine levels are related to distraction and 
WM at the electrophysiological level, as evidence for their neurophysiologic effects using 
Event-Related Brain Potentials (ERPs) is scarce [43,44,45]. The specific a priori hypotheses 
were: 1) higher endogenous DHEA and DHEAS levels may prevent involuntary distraction 
and enhance cognitive performance; 2) DHEA and DHEAS putatively beneficial effects 
may be translated at the neurophysiological level; 3) DHEA and DHEAS effects may be 
largely antagonistic from those of high baseline cortisol; and 4) WM load may be a 
stimulus for DHEA and DHEAS production.  
To test these hypotheses, we measured the relation between DHEA, DHEAS and 
cortisol on one hand and the cognitive performance and brain responses, using a well-
established auditory-visual distraction paradigm [46,47,48] on the other. The protocol 
includes task irrelevant sounds, some of which are aimed to cause distraction and a visual 
task including working memory manipulation. 
Subjects and Methods 
Ethics Statement 
The experimental protocol was approved by the ethical committees of the 
University of Barcelona and Lisbon Medical School and it was conducted according to the 
principles of the Declaration of Helsinki. All the subjects gave their written informed 
consent before entering the study. 
Subjects 
28 healthy female volunteers (undergraduated Psychology students) performed 
the study protocol. In order to ensure a higher homogeneity in androgen levels, only 
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women were included. The subjects were young (18 to 25 years old, mean 20±0.5 years 
old) and presented a normal body mass index (21.8±0.5 kg/m2). All the participants had a 
normal or corrected to-normal vision and none reported auditory deficits. None of the 
participants reported a past history of neurologic, psychiatric, endocrine or oral diseases. 
All the subjects were right-handed. Four subjects were under hormonal contraception. No 
other medications were allowed. Regular or binge alcohol consumption were exclusion 
criteria and subjects were asked not to consume alcohol in the twelve hours before the 
experimental protocol. Regular tobacco consumption as well as illicit drug consumption 
were further exclusion criteria. Prior to the experimental session, subjects completed the 
State-Trait Anxiety Inventory [49] and all showed a normal range of state and trait anxiety 
levels. Five subjects were discarded from the analysis due to technical problems with 
electroencephalogram (EEG) recordings or endocrine measurements. 
Task and Procedure 
The experimental sessions were held in the afternoon, beginning at 2–3 pm. An 
adapted version of a well-established auditory-visual distraction task [46,47,50] was 
presented, based on the protocol used by SanMiguel et al. (2008) [51]. In this protocol, 
two visual tasks were performed: one task without working memory load (WM0) and 
another one with working memory load (WM1). In the present experiment, the two tasks 
were performed two hours apart from each other (from onset to onset) and the order of 
the tasks was counterbalanced across participants. Each task lasted about 15 minutes, 
and consisted of two blocks of 250 trials each (plus five initial trials that were excluded 
from the analyses). A short pause was allowed between blocks.  
Participants sat in a comfortable chair in a dimly lit and electrically and acoustically 
shielded room. In the discrimination task (WM0) subjects had to decide whether the two 
digits appearing on the screen were the same (11 and 22) or different (12 and 21), see 
figure 1A. In the WM1 task (1-back task) subjects had to decide whether the left or right 
digit (counterbalanced across subjects) on the screen was the same as the left or right 
digit of the previous trial (figure 1B). Thus, they had to keep one digit in working memory 
until the next trial, answering to every trial, except for the first one. Responses were given 
113 
through a mouse button (one mouse button for ‘‘same’’ and the other button for 
‘‘different’’), also counterbalanced across subjects. The subjects were specifically 
instructed to respond as quickly and accurately as possible while ignoring the sounds. In 
order to reduce artifacts originating from eye-blinks and movements during EEG 
recording, subjects were asked to minimize blinking and to focus on a central fixation 
cross between the two digits. Before each task, subjects performed practice blocks 
(composed by 10 trials) without any auditory stimuli until they reached a hit rate of at 
least 80% in each task.  
Figure 1. Example of trials stimulation sequence (above the line) and correct answers to the tasks (below 
the line) for the two tasks. A) Discrimination task (WM0), in which subjects had to decide whether the two 
digits on the screen were equal or different. B) Working memory task (WM1), in which the subjects had to 
compare the left digit on the screen with the left digit of the previous trial. WM0 – discrimination task; 
WM1 – working memory task.  
Each trial consisted of an auditory stimulus, irrelevant for the task, followed by a 
visual imperative stimulus after 350 ms (onset to onset), see figure 1. The total trial length 
varied from 1000 to 1500 ms (1250 ms on average; jitter +/–250 ms). The auditory 
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sequence consisted of repetitive standard tones (200 ms, including fade-in and fade-out 
of 10 ms each; 600 Hz; 85 dB; 80% probability), occasionally replaced by environmental 
novel sounds selected from a sample of 100 different exemplars (edited to have a 
duration of 200 ms, including fade-in and fade-out of 10 ms each; digitally recorded, low-
pass filtered at 10,000 Hz; 85 dB; 20% probability), such as those produced by a drill, 
hammer, rain, door, telephone ringing, and so forth (50). All sounds were randomly 
delivered binaurally through headphones (Sennheiser HD 202), and the only restrictions 
were that the first four stimuli of each block were standard tones, that two novel sounds 
never appeared consecutively and that each novel sound occurred only once in each task. 
The visual stimuli consisted of pairs of combinations of the digits 1 and 2 (11, 12, 21 or 
22), presented on a computer screen for 200 ms. The appearance probability was the 
same for every digit combination. The picture size was 357x441 pixels, with a vertical 
angle of 8º and a horizontal angle of 18º, accounting for two pictures presented 
simultaneously with the fixation cross in between. The distance from the subjects’ eyes to 
the screen was 100 cm. Overall, there were 400 standard trials and 100 novel trials in 
each of the two WM conditions.  
We recorded response time and hit rates for each trial with Presentation® 
(Neurobehavioral Systems, Inc). A correct response within the response window (until the 
sound onset of the subsequent trial) was counted as a hit. We computed distraction as 
the difference in hit rate or response time between auditory stimulus types (hit rate: 
WM0standard trials - WM0novel trials and WM1standard trials - WM1novel trials; 
response time: WM0novel trials - WM0standard trials and WM1novel trials - 
WM1standard trials) and working memory load costs as the difference in hit rate or 
response time between the WM load and the discrimination task (hit rate: WM0standard 
- WM1standard and WM0novel - WM1novel; response time: WM1standard -
WM0standard and WM1novel - WM0novel). 
EEG Recording and Analysis 
Electrophysiological activity was continuously recorded during task performance, 
from 64 scalp Ag/AgCl electrodes following the extended 10/10 convention. Elastic caps 
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with sintered electrodes and shielded wires were used. The horizontal and vertical 
electrooculograms (HEOG and VEOG) were recorded with electrodes placed at the outer 
canthus and below the right eye, respectively. An electrode placed on the tip of the nose 
was used as the common reference and the ground was located at the AFz position. The 
EEG and electrooculogram (EOG) were amplified and digitized at a sampling rate of 512 
Hz (Eemagine, ANT Software b.v., Enschede, the Netherlands). Impedances were kept at 5 
kΩ or below during the whole recording session. Recording was performed with an ANT 
amplifier of 64 channels (gain 20x; A/D resolution 22 bits, 71.526 nV per bit; filtering 0–
138.24 Hz; CMRR>90 dB).  
A digital finite impulse response (FIR) bandpass-filter from 0.01 to 30 Hz was 
applied using a Hamming window. ERPs were averaged offline for each auditory stimulus 
type and working memory condition, for an epoch of 1000 ms, including a 200 ms pre-
auditory-stimulus baseline. The first five epochs of each block and the epochs following a 
novel trial were excluded from averaging. Only epochs that corresponded to trials with 
correct responses were averaged.  
EOG correction was performed by manually selecting a large number of typical 
artifacts and accordingly applying a regression algorithm to compute propagation factors 
(Eeprobe 3.1, ANT Software BV, Enschede, the Netherlands). After EOG correction, 
epochs that contained EEG activity exceeding ±100 µV peak-to-peak amplitudes were 
rejected from further analyses. Since we included only trials with correct answers and hit 
rate was smaller for WM1, the final number of trials was smaller for WM1. The total 
number of trials included in the averages for each condition and auditory stimulus type 
was: 246 trials with standard sounds and 81 with novel sounds in WM0 and 213 trials 
with standard sounds and 64 trials with novel sounds in WM1. 
In this paradigm, subjects are specifically instructed to ignore the sounds. Hence, 
any related effects are necessarily involuntary or lead by exogenous attention. ERPs 
recorded during this auditory-visual distraction paradigm typically present first an 
auditory N1/mismatch negativity (N1/MMN) enhancement, reflecting a detection 
mechanism that leads to attention capture [46], followed by a novelty-P3 (nov-P3) that 
reflects the effective attention orientation [46,47,52]. Finally, the re-orienting negativity 
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(RON) reflects the attention re-orientation back to the task [53]. The target is visual and 
visual ERPs yield sensory (visual P1 and N1) and cognitive components related to target 
processing (N2b and P300). The N2b is a negative deflection originated by the relevant 
stimulus and the P300 reflects the processing of the task-relevant visual stimulus 
[51,54,55]. Typically, the task with working memory load is more difficult for the subjects, 
leading to a reduced P300 [51,54,55].  
To analyze distraction effects at the electrophysiological level, difference waves 
(dw) were calculated by subtracting the ERPs elicited in standard trials from those elicited 
in novel trials. These difference waves revealed an early-onset, long-lasting positive 
deflection that we assimilated to the novelty-P3. Novelty-P3 was measured as the mean 
amplitude in a time window ranging from 250 to 380 ms at F3, Fz, F4, C3, Cz, C4, P3, Pz 
and P4 electrodes.  
To analyze WM effects, we compared ERP measures only in standard trials. 
Specific auditory and visual components were elicited during task-performance: the 
auditory N1 and P2 and visual P1 and N1. Yet, since cognitive processing was of interest 
for the present study, we only analyzed N2b (560–645 ms, 210– 295 ms from visual 
stimulus presentation) and P300 (650–910 ms, 300–560 ms from visual stimulus 
presentation): F3, Fz, F4, C3, Cz and C4 for N2b and P3, Pz and P4 for P300. Moreover, 
since the P300 latency was different across WM conditions [F(1,21) =5.683, p=0.027; 
753±62 ms for WM1; 787±36 ms for WM0], we analyzed the amplitude of this component 
at different time windows for each condition (WM1: 650–875 ms; WM0-670– 910 ms). 
Endocrine Measurements 
We collected saliva samples by means of passive drool, using a short straw. 
Unstimulated whole saliva was used. We collected samples for DHEA, DHEAS and cortisol 
measurement before each task [before task (BT)], at 30 min [after task (AT)] and 60 min 
[washout (WO)]. The samples collected before the first task (i.e. before both tasks) were 
considered as the baseline. We chose the time points to collect the saliva samples in 
accordance to known cortisol raise and recovery times - raise 10 min after appropriate 
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stimulus, peak at 20–30 min and recover at 45– 60 min. Furthermore, synchronous 24 h 
profiles were described for DHEA and cortisol [56].  
Unbound DHEA and cortisol in the peripheral circulation penetrate into the saliva 
via intracellular mechanisms and salivary concentrations reflect serum concentrations 
[57,58]. DHEAS is not lipid soluble and cannot penetrate into the saliva by passive 
diffusion through cell membranes. Instead, it squeezes through the tight junctions 
between salivary glands. DHEAS concentrations in saliva are therefore dependent on 
serum concentration and salivary flow rate [57].  
Samples were refrigerated at 2–8ºC within 30 minutes after collection and they 
were stored at -20ºC within 4 h and until assayed. Each sample was measured in duplicate 
by using enzyme linked immunoassays: salivary DHEA and DHEAS enzyme immunoassay 
kits (Salimetrics Europe®, Ltd, Newmarket Suffolk, UK) and high sensitivity salivary cortisol 
enzyme immunoassay kits (Salimetrics®, LLC, State College, PA, USA). DHEA was 
measured in pg/mL and cortisol was measured in µg/dL. Due to the influence of saliva 
flow rates on DHEAS levels, the concentration of DHEAS (pg/mL) was multiplied by the 
flow rate (mL/min) and the corrected results were obtained as DHEAS measured per unit 
of time (pg/min). Intra- and interassay variation coefficients were less than 10% and 15%, 
in every case, respectively. Cortisol and DHEA were expressed as pmol/L by using the 
conversion factors 27590 and 3.467, respectively, and DHEAS was expressed as pmol/h by 
using the conversion factor 0.16284 (system of international units = conventional units x 
conversion factor). 
Statistical Analysis 
The Statistical Package for the Social Sciences Program (IBM SPSS Statistics, 
version 21) was used for data analyses. Results are presented as the mean ± standard 
error of the mean (SEM). The normal distribution of continuous variables was verified by 
the Kolmogorov-Smirnov Goodness of Fit Test and non-normal distributed variables were 
log (ln) transformed prior to the analysis. For the sake of simplicity, the results of non-
transformed variables are presented whenever we did not find any differences.  
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To explore the effects of WM load and auditory distraction on performance we 
performed repeated measures analyses of variance (ANOVAs) on hit rate and response 
time, including the within-subjects’ factors task (WM0 and WM1) and sound (standard 
and novel). Regarding electrophysiological responses, we examined the auditory ERPs to 
explore distraction effects and the visual ERPs to explore WM effects. To investigate the 
effects of auditory distraction on ERPs, we carried out repeated measures ANOVAs on the 
mean amplitude of the auditory P3 in the time window and electrodes considered above, 
with the within-subjects’ factors task (WM0 and WM1) and sound (standard and novel). 
To investigate WM effects on distraction ERPs, we carried out an ANOVA on the mean 
amplitude of the novelty-P3 in the time window and electrodes considered above with 
task (WM0 and WM1) as within-subjects factor. To investigate WM effects on 
electrophysiological responses, we included only standard trials and conducted ANOVAs 
on N2b and visP300 mean amplitude in the time windows and electrodes considered 
above, with task (WM0 and WM1) as within-subjects factor and task order (simply 
referred as order in the results) as between-subjects factor (WM0-WM1 or WM1-WM0; 
this factor is included because we used a blocked protocol, one task consisting exclusively 
in WM0 trials and the other consisting exclusively in WM1 trials, counterbalanced across 
subjects).  
To investigate the effects of WM manipulation on endocrine levels, we performed 
repeated measures ANOVAs on DHEA, DHEAS and cortisol levels, including the within-
subjects’ factors task (WM0 and WM1) and time (before task, after task and washout) 
and the between-subjects factor task order (WM0-WM1 or WM1-WM0). The endocrine 
relation to distraction and WM load effects at the behavioral and electrophysiological 
levels was investigated by repeated measures ANOVAs of behavior and ERP parameters, 
including baseline DHEA, DHEAS, cortisol or cortisol/DHEA ratio as covariates. Because 
the DHEA response (determined by the ratio after task/before task) differed between the 
two WM conditions, DHEA response in WM1 – DHEA response in WM0 (Δ DHEA 
response) was used as a measure of DHEA response attributed to WM load. This new 
variable was also tested as a covariate. Whenever the endocrine parameters covariated 
with the performance or ERP parameters, for each type of auditory stimuli or WM 
condition, we used Spearman’s Rank Order correlation coefficients to select the relevant 
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endocrine factors and understand the relations direction. DHEAS relations to 
performance and ERP parameters were not significant and therefore those results are not 
mentioned in the results section.  
ANOVA results were Greenhouse–Geisser corrected whenever the assumption of 
sphericity was violated. Post hoc tests were carried out wherever there were significant 
interactions between main factors. The Bonferroni correction was used for multiple 
comparisons. The limit of significance chosen was α=0.05. 
Results 
Performance 
Behavioral results for each task and auditory stimulus are presented in Figure 2. 
Overall hit rate was 83±2% in WM0 and 70±2% in WM1 (figure 2A) and this difference in 
hit rate was significant, as reflected by a main effect of task [F(1,22)=27.279, p<0.001]. 
Additionally, there was a main effect of task on response times [F(1,22)=8.760, p=0.007] 
with longer response times in WM1 [467±13 ms] than in WM0 [440±9 ms], see figure 2B. 
Thus, the WM load resulted in lower hit rates and longer response times. 
Regarding the effects of auditory distraction on performance, the results showed a 
main effect of auditory stimulus both on hit rate [F(1,22)=9.577, p=0.005, with lower hit 
rates for novel sounds (74±2%) than for standard ones (79±1%), see figure 2A], and 
response times [F(1,22)=43.451, p<0.001, with longer response times for novel sounds 
(476±11 ms) than for standard ones (431±10 ms), see figure 2B]. This means that novel 
sounds resulted in auditory distraction reflected by lower hit rates and longer response 
times. 
The interaction between task and auditory stimulus also had notable significant 
effects on hit rates [F(1,22)=5.557, p=0.028]. Post hoc analyses on each WM condition 
yielded significant effects of auditory distraction only in the working memory load task 
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[F(1,22)=8.697, p=0.007], see figure 2C. In that condition, hit rates were lower for novel 
sounds (65±4%) than for standards (74±1%). 
Figure 2. Performance results. A) Mean hit rate for each task and auditory stimulus type. B) Mean response 
time for each task and auditory stimulus type. C) Distraction costs for each task. Distraction = hit rate in 
standard minus novel trials or response time in novel minus standard trials. WM0 – discrimination task; 
WM1 – working memory task. Bars represent +/- standard error of the mean (SEM). 
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Event-Related Potentials 
Distraction effects. As can be seen in figure 3A, novel sounds elicited larger auditory P3 
mean amplitudes when compared to standard sounds, both in WM0 [F(1,22)=63.696, 
p<0.001; -3.3±0.5 µV in standard and +1.6±0.7 µV in novel trials] and in WM1 
[F(1,22)=98.333, p<0.001;  -4.1±0.4 µV in standard and +1.9±0.6 µV in novel trials], see 
figure 3B. This supports that a significant novelty P3 was elicited by novel sounds (figure 
3C). However, WM load did not influence the novelty-P3, as its amplitude was similar in 
both tasks [F(1,22)=3.381, p=0.079, 5.0±0.6 µV in WM0, and 5.9±0.6 µV in WM1]. Neither 
clear N1-enhancement/MMN nor RON was elicited. In sum, significant novelty-P3 
responses were elicited by novel sounds in both conditions, but without any significant 
difference between conditions. 
Working Memory Effects. The waveforms elicited by standard trials in the two tasks are 
presented in Figure 4. The N2b significantly increased in WM1 as compared to WM0 
[F(1,21)=6.738, p=0.017; -1.8±0.9 µV in WM0 and -3.3±0.6 µV in WM1] (see figure 4A and 
5B).  
The analysis of visP300 revealed a task x order interaction [F(1,21)=10.184, 
p=0.004], see figure 4C. Further analyses revealed a visP300 enhancement in the second 
task [t(22)=-3.163, p=0.005; 2.6±0.6 µV in the first task, and 4.8±0.8 µV in the second 
task], independently of the WM load content of that task (figure 4D). 
Overall, N2b was enhanced by WM load while the visP300 was enhanced in the 
second task, independently from working memory load. 
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Figure 3. Event Related Brain Potentials (ERPs). A) Grand average waveforms at Cz for both tasks (WM0 
and WM1) and type of sound (standard and novel). B) Auditory P3 (aud P3) amplitude for each task (WM0 
and WM1) and type of sound (standard and novel). C) Grand-average of novel minus standard difference 
waves at Cz. WM0 – discrimination task; WM1 – working memory task; NovP3 – novelty P3; s - seconds. 
Bars represent +/- standard error of the mean (SEM). 
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Figure 4. Standard Event-Related Potentials (ERPs) waveforms in the discrimination and working memory 
tasks. A) Standard ERPs in both tasks (both task orders). B) Mean N2b amplitude for each task. C) Standard 
ERPs in both tasks at Pz, according to the tasks order. D) Mean visual P300 amplitude according to the 
temporal sequence of tasks (first and second). WM0 – discrimination task; WM1 – working memory task; s 
– seconds; order WM0-WM1 – the discrimination task performed firstly and the working memory task
performed secondly; order WM1-WM0 – the working memory task performed firstly and the discrimination
task performed secondly. Bars represent +/- standard error of the mean (SEM).
Endocrine Baseline Levels and Response 
Baseline endocrine levels were: DHEA 790±155 pmol/L, DHEAS 984±120 pmol/h 
and cortisol 3412±622 pmol/L, with a normal distribution and no significant relation 
between them. These parameters were not significantly related to age and body mass 
index (BMI, kg/m2), and did not differ significantly according to the menstrual cycle phase 
(follicular, peri-ovulatory and luteal, based on self-reported menstrual cycle day) or 
between subjects taking and not taking hormonal contraception. DHEA and cortisol levels 
during the experimental procedure are shown in Figure 5.  
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In contrast to DHEAS levels, which were not affected by any of the factors (task, 
time or task order), and therefore won’t be reported any further, repeated measures 
ANOVA on DHEA levels revealed a task x order interaction [F(1,20)=6.215, p=0.022] and a 
task x time x order interaction [F(2,40)=9.839, p=0.002]. Further analyses revealed that 
DHEA levels rose after the performance of the second task as indicated by a time effect 
[F(2,40)=8.415, p=0.003; 596±94 pmol/L before task; 839±135 pmol/L after task; 929±156 
pmol/L at washout], see figure 5A.  
Regarding WM effects, post hoc analyses revealed that when the order was WM0-
WM1, DHEA levels were higher after WM1 than after WM0 [F(1,10)=9.041, p=0.013, 
711±139 pmol/L after WM0 and 1064±222 pmol/L after WM1]. The DHEA response 
[F(1,10)=10.676, p=0.008, 0.88 for WM0 and 1.60 for WM1] was also higher in WM1 than in 
WM0 (figure 5B). Nevertheless, when the order was WM1-WM0, DHEA levels after the 
second task [F(1,10)=6.006, p=0.034] and DHEA response [F(1,10)=4.855, p=0.052] were 
similar in the WM0 (the second task) and in the WM1 task. 
An repeated measures ANOVA on cortisol levels revealed a task x time x task order 
interaction [F(2,40)=11.809, p=0.002]. Post-hoc analyses for each task order separately 
showed that cortisol levels decreased after WM0 when the order was WM0-WM1. In fact, 
for this order, there was a time effect for WM0 [F(2,22)=9.544, p=0.007; cortisol levels were 
3725±855 pmol/L before task; 2704±579 pmol/L after task; 1766±359 pmol/L at 
washout], see figure 5C. In spite of this, the cortisol after task/before task ratio in WM0 
was not significantly different from the after task/before task ratio in WM1.  
DHEA and cortisol changes were directly related for both the WM0 [after 
task/before task: rs=0.615, n=22, p=0.002, figure 5D; washout/before task: rs=0.852, 
n=22, p<0.001] and WM1 task [after task/before task: rs=0.654, n=22, p=0.001, figure 5E; 
washout/before task: rs=0.656, n=22, p=0.001]. 
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Figure 5. Endocrine results. A) Mean DHEA levels for each task and order. B) DHEA response for each task 
and order. C) Mean cortisol levels for each task and order. D) DHEA and cortisol responses (after 
task/before task ratios) were directly related in the discrimination task. E) DHEA and cortisol responses 
were directly related in the working memory task. WM0 – discrimination task; WM1 – working memory 
task; DHEA response: DHEA after task/before task ratio; Cortisol response: Cortisol after task/before task 
ratio; order WM0-WM1 – the discrimination task performed firstly and the working memory task 
performed secondly; order WM1-WM0 – the working memory task performed firstly and the discrimination 




Endocrine Relations to Performance 
ANOVAs on hit rate and response time were used to select the endocrine 
parameters that covariated with performance (results are presented as supporting 
information, Table S1): baseline cortisol, baseline cortisol/DHEA ratio and ∆ DHEA 
response covariated with hit rates and ∆ DHEA response covariated with response times. 
Nevertheless, post hoc Spearman’s Rank Order correlations showed no significant 
relations between those endocrine parameters and performance.  
Endocrine Relations to Event-Related Potentials 
Distraction Effects. Endocrine relations to distraction were explored by using the novel 
minus standard difference waves for WM0 and WM1. There were no endocrine relations 
to novelty-P3 in WM0. However, in WM1, the novelty-P3 amplitude was enhanced in 
relation to higher baseline cortisol/DHEA ratios (rs=0.796, n=22, p<0.001; see figure 6).  
Working Memory Effects. The results showed that visP300 change between tasks was 
directly related to Δ DHEA response as supported by a significant interaction between 
visP300 amplitude x Δ DHEA response [F(1,20)=9.244, p=0.006] and a direct relation 
between visP300 enhancement and DHEA response increase attributed to WM load 
(rs=0.587, n=22, p=0.004; see Figure 7). The difference of visP300 latency between tasks 










Figure 7. The visP300 amplitude changed between tasks (WM0, WM1) in direct relation to DHEA 
response. WM0 – discrimination task; WM1 – working memory task. Δ DHEA response = DHEA response in 




The present study explores the relationships between cognitive performance and 
endogenous DHEA, DHEAS and cortisol. As expected, the audio-visual distraction 
paradigm including a manipulation of working memory, yielded typical effects observed in 
previous studies. Indeed, the WM load task was harder to perform, as revealed by lower 
hit rates and longer reaction times. Likewise, novel sounds distracted the participants, as 
reflected by lower hit rates and longer reaction times. Regarding brain responses to novel 
sounds in both WM0 and WM1 tasks, the results revealed an enhanced P3 deflection, 
indicating that novel sounds caused distraction when compared to standards. The N2b 
elicited by the task-relevant visual stimuli was enhanced under WM load as expected [51]. 
DHEA and cortisol responses were directly related (independently of the WM load 
content of the task). This is in agreement with the fact that corticotrophin releasing 
hormone (CRH) stimulates corticotrophin secretion and in turn corticotrophin is a 
stimulus for DHEA secretion [59,60], even if indirectly through the action of an 
unidentified DHEA androgen stimulating hormone [61,62,63].  
Nevertheless, we found important differences between DHEA and cortisol 
responses with WM load manipulation. DHEA levels increased with the performance of 
the second task independently of the task, suggesting either a cumulative effect or a 
latent interval before the response. Still, the increase in DHEA levels was more 
pronounced with WM load. Thus, the effect of a greater cognitive effort or specific effects 
of WM load on DHEA levels are suggested. Interestingly, this response is specific for DHEA 
and does not occur with cortisol and DHEAS. In fact, regarding cortisol, a decrease was 
found when the subjects were performing the discrimination task (WM0). Whatever the 
specific mechanisms may be, there is an interesting point: the distinctive pattern of 
cortisol and DHEA responses. Thus, cortisol decreases after a simple task if this task 
comes first and DHEA increases after a second cognitive task when this is a challenging 
task.  
Stangl et al. [64] demonstrated that DHEA administration increased DHEA levels 
and enhanced performance in a visual same-different task (without WM load) while 
cortisol levels remained constant. Also, those authors described baseline cortisol relations 
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to performance. However, other studies failed to provide systematic evidence that DHEA 
and DHEA administration enhanced short-term memory at the performance level [16,19]. 
In the present study, endogenous levels of DHEA, DHEAS and cortisol were measured and 
no significant relations were found with the accuracy or latency of the response. 
Nevertheless, a bigger sample of subjects may be necessary to uncover eventual 
relations.  
On the other hand, the present study demonstrated endocrine relations to the 
electrophysiological recordings. In the WM task, higher baseline cortisol/DHEA ratio was 
related to more processing of the distracting stimuli, as indexed by an enhanced novelty-
P3. This suggests that baseline cortisol enhances, whereas baseline DHEA prevents 
auditory distraction, and simultaneously suggests an anti-cortisol effect of DHEA. The fact 
that this relation became evident in the most stressful situation (WM load) agrees with 
previous evidence showing that DHEA has anti-cortisol effects under stress [12,14] or that 
these effects are more evident under stress.  
Regarding ERPs to the visual target stimuli, DHEA effects on WM load pointed 
towards increased visP300 amplitudes. In fact, the DHEA raise due to WM load was 
related with enhanced P300 amplitudes indicating enhanced memory update and 
suggesting a rapid DHEA behavioral effect.  
Endocrine responses to stimuli are commonly used and they usually provide 
higher sensitivity than baseline levels to detect pathological conditions or inter-subjects 
differences [29,65,66]. As an example, glucocorticoids responses to different stimuli can 
be used to measure the adrenals functional reserve (predicting their response to stress) 
or to characterize different phenotypes of the stress response (which were related to 
personality traits and pathological conditions) [67,68,69,70,71]. Accordingly, in the 
present study, the parameter related to working memory processing was DHEA response 
and not baseline DHEA. Also, apart from its slow genomic effects, corticosteroids are 
known to have rapid non-genomic central nervous system effects [35,39,40]. 
Alternatively, the relation between visual P300 amplitude and DHEA response 
could suggest that subjects with enhanced working memory update are the ones with 
higher DHEA responses. In that regard, other authors demonstrated that chronic stress 
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and higher cortisol levels were related with poorer memory [34,37,38] and reduced 
DHEAS response to a superimposed psychological stress [29]. Nevertheless, we found no 
relation between baseline cortisol and visual P300 amplitude, and therefore, an effect of 
chronic stress is not suggested.  
Wolf et al. [43] studied the effects of DHEA replacement on short term memory 
ERPs. They reported an increase in P3 amplitude after DHEA replacement, which reflects 
an enhancement of information updating. This is in accordance with our results, as we 
also observed that the physiological DHEA increase was related to an enhanced visP300.  
A short term increase in cortisol can damage hippocampal neurons and may 
impair memory [42]. This may be an oversimplification since specific types of 
hippocampal mediated memory may be impaired by stress but others may not [72,73]. 
Yet, and hypothesizing that DHEA might prevent memory impairment under stress, Wolf 
et al [74] found that DHEA replacement enhanced attention but did not prevent the 
decline in visual memory under an acute psychosocial stress. This result did not support 
the idea of a direct anti-glucocorticoid effect of DHEA in hippocampal mediated memory 
functions. In another study DHEA protected hippocampal neurons against excitatory 
amino acid-induced neurotoxicity [75]. Our results also support the idea of DHEA anti-
cortisol effects in distraction, but regarding working memory, we found relations with 
DHEA, not cortisol. Moreover, normal ranges of baseline cortisol were observed and 
cortisol levels did not rise with WM load, they just did not decrease.  
Recent results also suggest that repeated stress and consequent activation of the 
glucocorticoid receptors dampens prefrontal cortex glutamatergic transmission. Actually, 
it facilitates glutamate receptor turnover, which has a detrimental effect on prefrontal 
cortex-dependent cognitive processes [76] like WM. The present results agree with the 
known action of DHEA on glutamatergic receptors as well as with the idea that DHEA 
opposes cortisol detrimental effects during the performance of working memory tasks 
under stress. This last relation was evidenced by inverse relations of DHEA and cortisol to 
distraction.  
Nevertheless, working memory effects were related to the DHEA response but not 
to cortisol. Thus, regarding WM effects, an anti-cortisol effect of DHEA is not so evident 
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and other specific effects of DHEA may be present. As mentioned, besides their 
anticortisol effects, DHEA has Gamma Aminobutyric Acid Type A (GABAA) receptor 
antagonism and sigma 1 agonist effects [3,9,10] which might underlie or contribute to the 
effects found. In fact, both gabaminergic antagonism and glutamatergic agonism are 
known to improve cognitive function.  
Eventually in relation to DHEAS’ long half-life [2,3], its levels did not change with 
WM load manipulation. Also, we found no relations between baseline DHEAS and 
performance or ERPs. Nevertheless, we found no relations between baseline DHEA and 
performance or ERPs either. Instead, baseline cortisol/DHEA ratio and DHEA response 
relations to ERPs were found.  
DHEA metabolites also include other neuroactive steroids such as estradiol, 
estrone and testosterone [19,77], which may mediate part of the DHEA effects, namely 
after DHEA administration [78]. Estrogens, in particular estradiol, enhance working 
memory in women [79,80] and testosterone supplementation may enhance working 
memory in older men [81,82]. We did not measure DHEA metabolites, which may 
mediate some of its effects. Subsequently, we cannot exclude that those steroids may 
contribute or eventually be responsible for the performance and electrophysiological 
relations we found. Finally, as our study includes only female participants, the outreach of 
the results is limited only to women. DHEA and DHEAS are androgens and androgen 
levels, namely testosterone and DHEAS levels, are higher in men than in women [2,7]. 
Therefore, another group of participants would be necessary to study the 
electrophysiological correlates of DHEA and DHEAS in men. For further studies it would be 
relevant to study whether the results are identical or distinct according to gender. 
In summary, a higher cortisol/DHEA ratio was related to enhanced processing of 
the auditory distractor during the performance of a visual working memory task. This 
suggests that in women, DHEA may oppose cortisol effects in involuntary distraction, 
reducing the processing of the auditory distractor (novelty-P3). Regarding working 
memory, DHEA increased with the performance of consecutive cognitive tasks, and a 
higher DHEA response due to WM load was related to an enhancement of the task-
relevant information processing (visual P300). Overall, the results suggest that DHEA may 
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oppose cortisol effects reducing distraction and a higher DHEA response may enhance 
working memory at the electrophysiological level. 
Supporting Information 
Table S1. Endocrine relations to performance. ANOVAs of the performance parameters 
that covariated with endocrine measurements. Results represent the interaction between 
endocrine parameters and working memory (WM) condition and auditory stimulus. 
Baseline endocrine interactions are significant when p<0.013. ΔDHEA response=DHEA 
response in WM1 – DHEA response in WM0. WM0 – discrimination task; WM1 – working 
memory task. (DOCX) 
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Table S1: Endocrine relations to performance. 
  ANOVA  
Hit Rates 
Baseline Cortisol x Task (WM1, WM0) F (1,21)=5.956 p=0.024 
 Sound (standard, novel) F(1,21)=8.222 p=0.009 
 Task x Sound F(1, 21)=11.751 p=0.003 
Baseline Cortisol/DHEA ratio x Task F(1,20)=8.186 p=0.01 
 Sound F(1,20)=13.178 p=0.002 
 Task x Sound F(1,20)=17.609 p<0.001 
Δ DHEA response x Task F(1,20)=8.087 p=0.01 
 Sound F(1,20)=1.827 p=0.192 
 Task x Sound F(1,20)=5.671 p=0.027 
Response times 
Baseline Cortisol x Task F(1,21)=1.129 p=0.300 
 Sound F(1,21)=4.441 p=0.047 
 Task x Sound F(1,21)=3.038 p=0.096 
Baseline Cortisol/DHEA ratio x Task F(1,20)=0.467 P=0.502 
 Sound F(1,20)=6.489 p=0.019 
 Task x Sound F(1,20)=2.104 P=0.162 
Δ DHEA response x Task F(1,20)=3.304 p=0.084 
 Sound F(1,20)=2.349 p=0.141 
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Abstract 
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS) have 
been suggested to enhance working memory and attention. However, the administration 
of DHEA alone did not prove to have any beneficial results on memory or attention. The 
balance between both forms of the hormone might be crucial regarding the effects that 
DHEA and DHEAS exert on the central nervous system. We studied the DHEAS-to-DHEA 
ratio in relation to involuntary attention and working memory processing by recording 
the electroencephalogram of 22 young women while performing a working memory load 
task and a task without working memory load in an audio-visual oddball paradigm. DHEA 
and DHEAS were measured in saliva before each task. We found that a higher DHEAS-to-
DHEA ratio was related to enhanced auditory novelty-P3 amplitudes during performance 
of the working memory task. These results suggest that the balance between DHEAS and 
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DHEA levels modulates involuntary attention. In particular, a higher DHEAS-to-DHEA ratio 
might be related to an enhanced acoustic novelty processing without any detrimental 
effect on working memory processing. Moreover, these results suggest that high DHEAS-
to-DHEA ratio might enhance involuntary attention to the surrounding world during the 
performance of cognitive tasks, probably indicating an important protective mechanism. 
Key-words: dehydroepiandrosterone, dehydroepiandrosterone-sulfate, 
dehydroepiandrosterone-sulfate to dehydroepiandrosterone ratio, working memory, 
involuntary attention, distraction, novelty-P3, event-related potentials, sulfotransferase, 
sulfatase. 
Resumo 
Têm sido sugeridos efeitos benéficos da desidroepiandrosterona (DHEA) e da 
desidroepiandrosterona-sulfato (DHEAS) ao nível da memória e da atenção. Contudo, a 
administração isolada de DHEA, não mostrou efeitos benéficos na memória nem na 
atenção. O balanço entre ambas as formas da hormona poderá ser determinante para os 
efeitos da DHEA e DHEAS ao nível do sistema nervoso central. Neste estudo, explorámos 
qual é a relação da razão DHEAS/DHEA com a atenção involuntária e a memória de 
trabalho. Para isso, registámos o eletroencefalograma de 22 mulheres jovens adultas, 
enquanto realizavam uma tarefa com memória de trabalho e outra tarefa sem memória 
de trabalho, usando um paradigma de “oddball” audiovisual. Os níveis de DHEA e DHEAS 
foram medidos na saliva antes de cada tarefa. Durante a realização da tarefa com 
memória de trabalho, uma razão DHEAS/DHEA mais elevada relacionou-se com maiores 
amplitudes da deflexão P3-novidade (“novelty-P3”). Este resultado sugere que a atenção 
involuntária é modulada pelo balanço entre os níveis de DHEAS e DHEA. Em particular, 
uma razão DHEAS/DHEA mais elevada poderá estar relacionada com maior 
processamento da novidade acústica, sem um efeito deletério no processamento da 
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memória de trabalho. Estes resultados sugerem ainda, que uma razão DHEAS/DHEA 
elevada poderá promover a atenção involuntária em relação ao meio envolvente, durante 
a realização de tarefas cognitivas, o que poderá constituir um mecanismo protetor 
importante. 
 
Palavras chave: desidroepiandrosterona, desidroepiandrosterona-sulfato, razão 
DHEAS/DHEA, memória de trabalho, atenção involuntária, distração, P3-novidade, 




Dehydroepiandrosterone-sulfate-to-dehydroepiandrosterone balance in relation to 
memory and attention 
The physiological effects and mechanism of action of dehydroepiandrosterone 
(DHEA) and dehydroepiandrosterone-sulfate (DHEAS) is still a matter of debate, yet 
evidence has been accumulating concerning their relationship to cognition and the stress 
response. In particular, higher DHEAS concentrations were related to improved memory 
whereas low levels were found in Alzheimer’s disease (Weill-Engerer et al., 2002). Higher 
DHEA, DHEAS, DHEA-to-cortisol and DHEAS-to-cortisol levels were related to better 
cognitive function (van Niekerk et al., 2001; Carvalhaes-Neto et al., 2003; Davis et al., 
2008), improved attention (Wolf et al., 1998a), lower perceived stress and improved 
performance under stressful conditions (Morgan CA 3rd et al., 2009; Wemm et al., 2010; 
Russo et al., 2012) when compared to lower DHEA, DHEAS, DHEA-to-cortisol and DHEAS-
to-cortisol levels. Anti-cortisol effects of DHEA and DHEAS have been hypothesized to be 
contributing factors to these changes.  
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Most studies have not explored the effects of the differences between DHEAS and 
DHEA levels, even though sulfated steroids in general could act as endogenous 
neuromodulators (Gibbs et al., 2006) and the balance between DHEAS and DHEA levels 
could influence brain functioning and cognition (Maninger et al., 2009; Gibbs et al., 2006). 
Subjects with Alzheimer’s disease were shown to have reduced concentrations of DHEAS 
(Weill-Engerer et al., 2002) but increased concentrations of DHEA (Brown et al., 2003) in 
the central nervous system, or reduced conversion of DHEA into DHEAS and 
consequently, reduced DHEAS-to-DHEA ratios (Kim et al., 2003). On the other hand, 
steroid sulfatase inhibition in mice, increased DHEAS-to-DHEA ratios and impaired 
accuracy under attention demanding conditions (Davies et al., 2009). In addition, subjects 
with steroid sulfatase deficiency have higher rates of attention deficit hyperactivity 
disorder, with predominantly lack of attention symptoms (Kent et al., 2008). 
DHEA and DHEAS present in general a neurostimulatory effect. Nevertheless, 
DHEAS has a much more potent excitatory action than DHEA concerning glutamatergic 
agonism (Urani et al., 1998; Zou et al., 2000) and gabaminergic antagonism (Imamura and 
Prasad, 1998; Park-Chung et al., 1999), which may account for different effects of either 
form of the hormone (Monnet et al., 1995; Baulieu and Robel, 1998; Imamura and 
Prasad, 1998). In particular, working memory relies on glutamatergic transmission (Yuen 
et al., 2011). Therefore, DHEAS might have more potent enhancing effects on memory 
than DHEA and the evaluation of the DHEAS-to-DHEA ratio may uncover additional 
information that otherwise would not be revealed by the individual examination of either 
form of the hormone. 
Involuntary attention under working memory load 
Selective attention to stimuli in the surrounding world is fundamental for adaptive 
behavior (SanMiguel et al., 2008). Salient exogenous stimuli are known to capture 
attention involuntarily and endogenous mechanisms do voluntarily modulate brain 
responses to confront target stimuli (Arnott et al., 2001; Hopfinger and West, 2006). 
Nevertheless, attentional resources are limited, as evidenced by dual-task and task-
145 
switching experiments (Pashler, 1993; Pashler, 1994; Rogers and Monsell, 1995; Barcelo 
et al., 2006), and interactions between exogenous and endogenous mechanisms play a 
role in attention control (Yantis and Jonides, 1990; Pashler et al., 2001; SanMiguel et al., 
2008). Salient exogenous stimuli are known to capture attention involuntarily, causing 
reduced voluntary attention to the task relevant stimuli and therefore disrupting 
responses to target stimuli in a bottom-up way, and causing a deteriorating effect on 
performance (Yantis and Jonides, 1990, Escera et al., 1998; Escera et al. and 2000; Escera 
and Corral, 2007). On the other hand, involuntary attention to exogenous stimuli can also 
be modulated by voluntary top-down mechanisms adjusted to behavioral goals and 
cognitive load (Pashler et al., 2001; Lavie et al., 2004; Vuilleumier, 2005). The novelty-P3 
component elicited by salient exogenous stimuli and denoting the effective orientation of 
attention towards the distractor, is particularly sensitive to top-down mechanisms of 
attention (Escera et al., 2003; Escera et al., 1998) and to cognitive load (Lavie et al., 2004; 
SanMiguel et al., 2008). 
Working memory may play a special role on attention control. In fact, working 
memory modulates endogenous and exogenous mechanisms of attention (Hester and 
Garavan, 2005; SanMiguel et al., 2008), as it provides top-down signals to other brain 
structures (Miller, 2000; Fuster, 2001; Miller and Cohen, 2001) and also modulates 
involuntary attention processing at primary sensory areas of the cortex, effectively 
reducing responsiveness to a distractor (Pinsk et al., 2004; Spinks et al., 2004; Hopfinger 
and West, 2006; Postle, 2006; SanMiguel et al., 2008). Nevertheless, contradictory data 
exists regarding the direction of this influence, some results suggesting increased 
involuntary attention (distraction) with increased working memory load (DeFockert et al., 
2001; Lavie et al., 2004; Lavie, 2005; Lavie and DeFockert, 2005) while other results 
suggesting reduced involuntary attention during working memory load (Berti and 
Schroger, 2003; Postle, 2006; SanMiguel et al., 2008). Of note, although attentional 
resources are limited, being alert to relevant information from the surrounding world 
during the performance of a working memory task is important. For instance, being alert 
to signals that indicate danger can be critical for physical integrity. 
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DHEAS and DHEA relations to memory and attention at the electrophysiological level 
 Studies addressing DHEA and DHEAS effects on memory and attention at the 
electrophysiological level are scarce. Nevertheless, DHEA administration increased DHEAS 
levels and enhanced P300 amplitudes, reflecting enhanced information regarding to 
updating of short-term memory (Wolf et al., 1998b); higher DHEA levels were related to 
shorter P300 latencies (Braverman et al., 2009) when compared to lower DHEA levels; 
and higher increases in DHEA levels during the performance of a working memory task 
were related to enhanced P300 amplitudes (do Vale et al., 2014). Therefore, in 
accordance with results at the clinical level, the results at the electrophysiological level 
suggest a relationship between higher DHEA and DHEAS levels and improved memory. 
The electrophysiological correlates of the balance between DHEAS and DHEA with regard 
to working memory processing are unknown. Besides, the effects of DHEAS-to-DHEA 
balance in the control of involuntary attention during working memory tasks have yet to 
be explored. 
 
The aim of this study was to test whether the DHEAS-to-DHEA ratio has an 
influence on working memory and involuntary attention at the electrophysiological level. 
Our hypothesis was that the DHEAS-to-DHEA relation would modulate working memory 
processing and/or involuntary attention, and that these effects would be evident at the 
electrophysiological level. To test this hypothesis, we measured baseline DHEAS and 
DHEA and analyzed brain responses during the performance of a well-established 
auditory-visual distraction paradigm (Escera et al., 1998; Escera et al., 2000; Escera and 
Corral, 2007; SanMiguel et al., 2008; do Vale et al., 2014). The protocol included task 
irrelevant sounds, some of which were novel and aimed at causing distraction 
(involuntary attention) and a visual task which included working memory manipulation 
(SanMiguel et al., 2008; do Vale et al., 2014). In this paradigm, the unexpected auditory 
novel sounds were expected to deteriorate performance and elicit a novelty-P3 
enhancement (Escera et al., 1998; Escera et al., 2000; Friedman et al., 2001; do Vale et al., 
2014). The task with working memory load is more difficult to perform and therefore 
typically leads to a deterioration in performance and a reduction of the P300, reflecting a 
147 
lower processing of the task-relevant visual stimulus (Kok, 2001; Polich, 2007; SanMiguel 
et al., 2008; do Vale et al., 2014). 
Subjects and methods 
Subjects 
28 healthy females (18 to 25 years old, mostly undergraduate Psychology 
students) (do Vale et al., 2014) participated in the experiment. Because DHEAS levels 
differ according to gender, only women were included in the study. Non-corrected visual 
deficits, auditory deficits, neurologic, psychiatric, endocrine or oral diseases were 
exclusion criteria. Besides hormonal contraception, no other medications were allowed. 
Regular or binge alcohol consumption as well as smoking or illicit drug consumption were 
further exclusion criteria and subjects were asked not to consume alcohol in the twelve 
hours before the experimental protocol. Prior to the experimental session, the 
participants completed the State and Trait Anxiety Inventory (Spielberger et al., 1988) and 
all showed a normal range of state and trait anxiety levels (do Vale et al., 2014). Six 
subjects were discarded from the analysis due to technical problems with 
electroencephalogram (EEG) recordings or endocrine measurements. Therefore, 22 
subjects with complete data were retained for the analysis. In this group, mean age was 
20±0.5 years, all the participants were right-handed and presented a normal body mass 
index (21.9±0.5 kg/m2) and only three participants were under hormonal contraception. 
The experimental protocol was approved by the ethical committees of the 
University of Barcelona and Lisbon Medical School and it was conducted according to the 
principles of the Declaration of Helsinki. All subjects gave their written informed consent 
before entering the study. During the study protocol, DHEA, DHEAS and cortisol were 
both measured before and after the task. The results concerning the relationship 
between DHEA, DHEAS, cortisol and cortisol/DHEA ratio and working memory and 
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distraction at the behavioral and electrophysiological level were the subject of a previous 
study and were published elsewhere (do Vale et al., 2014). 
 
Task and procedure 
We used an adapted version of the paradigm used by SanMiguel et al. (2008). It 
consists of two visual tasks: one a discrimination task (no working memory load, WM0) 
and another one with a working memory load (WM1). The two tasks were performed two 
hours apart from each other (from onset to onset) and the order of the tasks were 
counterbalanced across the participants. Each task lasted about 15 minutes, and 
comprised of two blocks, containing 250 trials each. A short break was allowed between 
blocks (do Vale et al., 2014). 
The experiment was performed in the afternoon (beginning at 2-3 pm), with the 
participants sitting in a comfortable chair inside an electrically and acoustically shielded 
room. In the discrimination task (WM0) participants had to decide whether the two digits 
appearing on the screen were the same (11 and 22) or different (12 and 21); see figure 
1A. In the WM1 task (1-back task) participants had to decide whether the left or right 
digit (counterbalanced across participants) on the screen was the same as the left or right 
digit of the previous trial (figure 1B) (do Vale et al., 2014), therefore, keeping one digit in 
working memory until the next trial and answering for every pair of digits appearing on 
the screen. Responses were given through a mouse button (one mouse button for “same” 
and the other button for “different”), also counterbalanced across subjects. The 
participants were instructed to ignore the sounds and respond as quickly and accurately 
as possible. Furthermore, they were asked to minimize blinking and to focus on a central 
fixation cross (appearing between each two digits on the screen), in order to reduce eye-
blink and movement artifacts during EEG recording. Before each task, subjects performed 
practice blocks (composed of 10 trials) without any auditory stimuli until they reached a 
hit rate of at least 80% in each task (do Vale et al., 2014). 
 Each trial consisted of a task-irrelevant auditory stimulus, followed by a visual 
target stimulus (the interval between each auditory and visual stimulus was 350ms, onset 
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to onset); see figure 1. Trial length was 1250ms on average (varying from 1000 to 
1500ms; jitter +/-250ms). The auditory stimuli consisted of repetitive standard tones (200 
ms, including fade-in and fade-out of 10ms each; 600 Hz; 85dB; 80% probability), 
occasionally replaced by environmental novel sounds selected from a sample of 100 
different exemplars (edited to have a duration of 200ms, including fade-in and fade-out 
of 10ms each; digitally recorded, low-pass filtered sound at 10,000 Hz; 85dB; 20% 
probability), similar to those produced by a drill, hammer, rain, door, telephone ringing, 
and so forth (Escera et al., 2003; do Vale et al., 2014). All sounds were randomly delivered 
binaurally through headphones (Sennheiser HD 202), and the only restrictions were that 
the first four stimuli of each block were standard tones, that two novel sounds never 
appeared consecutively and that each novel sound occurred only once in each task. The 
visual stimuli consisted of pairs of digit combinations, with the digits 1 and 2 (11, 12, 21 or 
22), presented on a computer screen for 200ms. Appearance probability was the same for 
every digit combination. The picture size was 357x441 pixels, with a vertical angle of 8º 
and a horizontal angle of 18º, accounting for two pictures presented simultaneously with 
the fixation cross in between. The distance from the subjects’ eyes to the screen was 
100cm (do Vale et al., 2014). Each working memory setup (WM0 and WM1) consisted of 
500 trials (400 standard trials and 100 novel trials).  
 Response time and whether the participant gave the correct answer for each trial 
was registered with Presentation® (Neurobehavioral Systems Inc., Albany, CA, USA). A hit 
was considered if the participant pressed the correct mouse button during the response 
window (from image presentation until the onset of the next trial/sound). We computed 
distraction as the difference in hit rate or response time between auditory stimulus types 
(hit rate: WM0standard trials - WM0novel trials and WM1standard trials - WM1novel 
trials; response time: WM0novel trials - WM0standard trials and WM1novel trials - 
WM1standard trials). Working memory load costs were computed taking into 
consideration the difference in hit rate or response time between the WM load and the 
discrimination task (hit rate: WM0standard - WM1standard; response time: 
WM1standard - WM0standard) (do Vale et al., 2014). 
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Figure 1. Illustration of the stimulation sequence (above the line) and correct responses to the tasks (below 
the line) for the two conditions. A) Discrimination task (WM0), in which subjects had to decide whether the 
two digits on the screen were equal or different. B) Working memory task (WM1), in which the subjects had 
to compare the left digit on the screen with the left digit of the previous trial. WM0 – discrimination task; 
WM1 – working memory task (do Vale et al., 2014).  
EEG recording and analysis 
The electroencephalogram was continuously recorded during task performance, 
using 64 scalp Ag/AgCl electrodes contained in elastic caps, following the extended 10/10 
convention. The horizontal and vertical electrooculograms were recorded with electrodes 
placed at the outer canthus and below the right eye, respectively. An electrode placed on 
the tip of the nose was used as the common reference and the ground was located at the 
AFz position. The EEG and electrooculogram (EOG) were amplified and digitized at a 
sampling rate of 512Hz (Eemagine, ANT Software b.v., Enschede, the Netherlands). 
Impedances were kept at 5kΩ or below during the whole recording session. Recording 
was performed with an ANT amplifier of 64 channels (gain 20x; A/D resolution 22 bits, 
71.526nV per bit; filtering 0-138.24Hz; CMRR >90dB) (do Vale et al., 2014). 
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Continuous EEG data were bandpass filtered between 0.01 and 30Hz (with a 
digital finite impulse response filter using a Hamming window). Event-Related Potentials 
(ERPs) were averaged offline for each auditory stimulus type and working memory 
condition, for an epoch of 1000ms, including a 200ms pre-auditory-stimulus baseline (do 
Vale et al., 2014). Only the epochs with correct responses were retained to calculate the 
average. The first five epochs of each block, the epochs following a novel trial and the 
epochs with missed or wrong responses were excluded also from the total average. 
To perform EOG correction we manually selected a large number of typical 
artifacts and applied a regression algorithm to compute propagation factors (Eeprobe 3.1, 
ANT Software BV, Enschede, The Netherlands). After EOG correction, epochs that 
contained EEG activity exceeding ±100μV peak-to-peak amplitudes were excluded from 
averaging (do Vale et al., 2014). Because only trials with correct responses were included 
and the hit rate was smaller for the working memory load task, the final number of trials 
were smaller for the working memory load when compared with the discrimination task 
[t=6.320, p<0.001; 326 trials for the discrimination task and 272 trials for the working 
memory load task]. The mean number of trials included in the averages for each condition 
and auditory stimulus type were: 245 trials with standard sounds and 81 with novel 
sounds in the discrimination task and 210 trials with standard sounds and 62 trials with 
novel sounds in the working memory load task. 
As participants were specifically instructed to ignore the sounds, any related 
effects were necessarily involuntary or led by exogenous attention. ERPs recorded during 
this auditory-visual distraction paradigm typically present first an auditory N1-
enhancement (mismatch negativity), reflecting a detection mechanism that leads to 
attention capture (Escera et al., 1998), followed by a novelty-P3 (nov-P3) that reflects the 
effective attention orientation (Escera et al., 1998; Escera et al., 2000; Friedman et al., 
2001). Finally, the re-orienting negativity (RON) reflects the attention re-orientation back 
to the task (Schröger and Wolff, 1998). The target is visual and visual ERPs yield sensory 
(visual P1 and N1) and cognitive components related to target processing (N2b and P300). 
The P300 component reflects the processing of the task-relevant information of the visual 
stimulus (Kok, 2001; Polich, 2007; SanMiguel et al., 2008). The task with working memory 
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load is expected to be more difficult to perform, leading to a reduced P300, longer 
response time and lower hit rates (Kok, 2001; Polich, 2007; SanMiguel et al., 2008; do 
Vale et al., 2014). 
To analyze the effects of distraction on ERPs, difference waves were calculated by 
subtracting the ERPs elicited in standard trials from those elicited in novel trials. These 
difference waves revealed an early-onset, long-lasting positive deflection that we 
considered as integrating part of the novelty-P3 (do Vale et al., 2014). The novelty-P3 was 
measured as the mean amplitude and mean peak latency in a time window ranging from 
250 to 380 ms at F3, Fz, F4, C3, Cz, C4, P3, Pz and P4 electrodes (do Vale et al., 2014). To 
analyze the effects of working memory we compared ERP measurements in WM0 and 
WM1, using only standard trials. Specific auditory (N1 and P2) and visual (P1 and N1) 
components were elicited during task-performance, as expected. Nevertheless, because 
we aimed to study cognitive processing, we only analyzed the P300. This component was 
measured as the mean amplitude and mean peak latency in a time window ranging from 
650 to 910ms (300–560ms from visual stimulus presentation) at P3, Pz and P4 electrodes. 
Moreover, since the P300 latency was different for WM0 and WM1 conditions 
[F(1,21)=5.006, η2=0.193, p=0.036; 751±13ms for WM1; 783±7ms for WM0], the amplitude 
of this component was analyzed at different time windows for each condition (WM1: 650-
875ms; WM0-670-910ms) (do Vale et al., 2014). 
 
Endocrine measurements 
 Saliva samples were collected by passive drool before each task. Samples collected 
before the first task (i.e. before both tasks) were considered as baseline (do Vale et al., 
2014). Unlike DHEA, which is liposoluble and crosses cell membranes (Vining and 
McGinley, 1987; Ahn et al., 2007), DHEAS is not lipid soluble and penetrates into the 
saliva through tight junctions. Therefore, DHEAS concentrations in saliva depend on 
serum concentration and salivary flow rate (Vining and McGinley, 1987). 
Samples were refrigerated at 2-8ºC within 30 minutes after collection and stored 
at -20ºC within 4h until assayed (do Vale et al., 2014). Each sample was measured in 
153 
duplicate by using enzyme-linked immunoassays: salivary DHEA and DHEAS enzyme 
immunoassay kits (Salimetrics Europe®, Ltd, Newmarket Suffolk, UK). DHEA was 
measured in pg/mL. Due to the influence of saliva flow rates on DHEAS levels, the 
concentration of DHEAS (pg/mL) was multiplied by the flow rate (mL/min) and the 
corrected results were obtained as DHEAS measured per unit of time (pg/min). The 
minimal concentrations that can be distinguished from 0 with the used immunoassays are 
5pg/mL for DHEA and 43pg/mL for DHEAS. Intra- and interassay variation coefficients 
were less than 10% and 15%, in both cases, respectively. DHEA was expressed as pmol/L 
by using the conversion 3.467, and DHEAS was expressed as pmol/h by using the 
conversion factor 0.16284 (system of international units = conventional units x conversion 
factor). 
Statistical analysis 
Statistical analysis was performed with the Statistical Package for Social Sciences 
Program (IBM SPSS Statistics, version 21). Results are presented as mean ± standard error 
of the mean (SEM) and the normal distribution of continuous variables was verified by the 
Kolmogorov-Smirnov Goodness of Fit Test (do Vale et al., 2014). The effects of WM load 
and auditory distraction on performance were explored by performing repeated 
measures analyses of variance (ANOVAs) on the hit rate and response time, including the 
within subjects’ factors task (WM0 and WM1) and sound (standard and novel). The 
effects of WM load and auditory distraction on ERPs were explored by performing 
ANOVAs on auditory-P3 mean amplitude [including the within subjects’ factors task 
(WM0 and WM1) and sound (standard and novel)], novelty-P3 and visual P300, mean 
amplitude and peak latency [including the within subjects’ factor task (WM0 and WM1)] 
(do Vale et al., 2014). 
Pearson´s correlations were used to explore the relation between DHEAS/DHEA 
ratios and performance and electrophysiological responses. In both cases involuntary 
attention and working memory effects were considered. Concerning performance, we 
explored the relation between DHEAS/DHEA ratio and hit rate as well as response time 
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distraction (involuntary attention) costs in each condition (WM0 and WM1). We also 
examined the relation between DHEAS/DHEA ratio before WM1 and hit rate and 
response time costs of working memory. Regarding electrophysiological responses, in 
order to explore the relation between DHEAS/DHEA ratio and the effects of involuntary 
attention to novel sounds, we analyzed the relation between DHEAS/DHEA ratio before 
the performance of each condition and the respective novelty-P3 amplitudes and 
latencies. To explore the relation between DHEAS/DHEA ratio and working memory 
electrophysiological effects, the visual P300 amplitudes and latencies in WM1 minus 
WM0 were calculated (the resultant variables corresponded to working memory effects 
on visual P300 amplitudes and latencies) and their relationship to DHEAS/DHEA ratio 
before WM1 were also analyzed. The limit of significance chosen was α=0.05 and the 
Bonferroni correction was applied for multiple comparisons. In order to explore the 
relations between endocrine measurements and performance, as well as the relations 
between endocrine measurements and ERPs, four correlations regarding distraction and 
two correlations regarding working memory effects were tested. Effect size estimates of 
the results were expressed as eta squared (η2) for ANOVAs and correlation coefficients (r) 




Performance and event related potentials 
Performance and electrophysiological results were almost identical to those 
previously published, the main difference being to the fact that the present sample 
included one subject less (do Vale et al., 2014). There were main effects of task and the 
type of auditory stimulus on performance. Under working memory load, lower hit rates 
[F(1,21)=25.899, η2=0.552, p<0.001; hit rate was 83±2% in WM0 and 70±2% in WM1] and 
longer response times [F(1,21)=8.036, η2=0.277, p=0.010, response time was 440±9ms in 
WM0 and 467±14ms in WM1] were observed when compared to the discrimination task. 
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Novel sounds when compared to standard sounds, resulted in lower hit rates 
[F(1,21)=8.327, η2=0.284, p=0.009; hit rate was 79±1% for standard sounds and 74±2% for 
novel sounds] and longer response times [F(1,21)=39.683, η2=0.654, p<0.001; response 
time was 431±11ms for standard sounds and 476±11ms for novel sounds]. Besides, a 
significant interaction was observed between task and auditory stimulus type regarding 
hit rate [F(1,21)=5.292, η2=0.201, p=0.032], with lower hit rates for novel sounds when 
compared to standard sounds only in the working memory load task [F(1,21)=7.840, 
η2=0.272, corrected p=0.022 (uncorrected p=0.011); hit rate was 74±2% for standard 
sounds and 65±4% for novel sounds]. 
At the electrophysiological level, auditory distraction yielded significant novelty-P3 
responses, as indexed by a main effect of the type of stimulus on auditory P3 amplitude 
[F(1,21)=96.850, η2=0.822, p<0.001; -3.6±0.5µV for standard sounds and +1.6±0.5µV for 
novel sounds], see figure 2. Working memory manipulation had no significant effect on 
novelty-P3 amplitudes, novelty-P3 peak latencies or visual P300 amplitudes. As 
mentioned before, visual P300 peak latencies were shorter in the working memory load 
task than in the discriminatory task [F(1,21)=5.006, η2=0.193, p=0.036; 751±13ms in WM1 
and 783±7ms in WM0]. In both WM conditions, novelty-P3 amplitudes were not 
significantly related to visual P300 amplitudes and peak latencies. 
Endocrine levels and DHEAS-to-DHEA ratio relationship to performance and event-
related potentials 
Baseline DHEAS, DHEA and DHEAS/DHEA ratio were 984±120 pmol/h, 790±155 
pmol/L and 2.1±0.4, respectively. There was no significant difference between DHEAS, 
DHEA and DHEAS/DHEA ratios before each task. These parameters were not significantly 
related to age and body mass index (kg/m2), and did not differ significantly to the 
menstrual cycle phase or between subjects taking or not taking hormonal contraception.  
We found no significant relationship between DHEAS/DHEA ratios and 
performance parameters. Regarding event-related potentials, DHEAS/DHEA ratio before 
performance on WM1 was directly related to novelty-P3 amplitudes in the WM1 task 
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[r=+0.574, corrected p=0.010 (uncorrected p=0.005)], see figure 3. On the contrary, 
DHEAS/DHEA ratio was not related to novelty-P3 amplitudes or latencies in WM0, 
novelty-P3 latencies in WM1, visual P300 amplitudes or visual P300 latencies in the 
observed condition. Of note, the DHEAS/DHEA ratio was not related to novelty-P3 
amplitudes attributed to working memory load (novelty-P3 in WM1 – novelty-P3 in 
WM0). Also, novelty-P3 amplitudes in WM1 were significantly related to the 
DHEAS/DHEA ratio independently of visual P300 amplitudes [novelty-P3 amplitude in 
WM1 as dependent factor and DHEAS/DHEA ratio before WM1 (partial p=0.008) and 
visual P300 amplitude in WM1 (partial p=0.487) as independent factors]. 
Figure 2. Event-Related Potentials. A) Grand-average waveforms for standard sounds, novel sounds and 
novel minus standard difference waves for both tasks (WM0 and WM1). B) Scalp map distribution of 
auditory-P3 difference waves (250-380 ms) for both tasks (WM0 and WM1). WM0 - discrimination task; 




Figure 3. DHEAS/DHEA ratio relation to novelty-P3. A) DHEAS/DHEA ratio before the performance of the 
Working Memory load task was directly related to novelty-P3 amplitude during that task. B) Mean novelty-
P3 in subjects with high and low DHEAS/DHEA ratio for each condition. DHEAS/DHEA ratios were 
dichotomized around the median: values below and above the median were considered as low and high 
DHEAS/DHEA ratios, respectively. In the working memory task, subjects with high DHEAS/DHEA ratio 
presented higher novelty-P3 amplitudes than subjects with low DHEAS/DHEA ratio [t=2.366, p=0.028, 
df=21; novelty-P3 amplitude was +7.0±0.9 µV in subjects with high DHEAS/DHEA ratio and +4.4±0.7 µV in 
subjects with low DHEAS/DHEA ratio]. In the discrimination task this difference was not significant. WM0 – 




 The present study showed a relationship between DHEAS-to-DHEA balance and 
brain processing of exogenous stimuli during the performance of a working memory task.  
We used an auditory-visual distraction paradigm with task-irrelevant sounds and a visual 
target with working memory manipulation. As published previously (do Vale et al., 2014), 
158 
working memory load and auditory distraction deteriorated performance as expected. Hit 
rate was lower and response times were longer for the working memory task than in the 
discrimination task and response times were longer when accompanied with auditory 
distraction (SanMiguel et al., 2008; do Vale et al., 2014). In the working memory task, 
auditory distraction also caused significantly lower hit rates (do Vale et al., 2014). At the 
electrophysiological level, significant novelty-P3 deflections were observed in both tasks, 
inferring enhanced processing of the novel sounds when compared to standard sounds 
and thus suggesting increased distraction by novel sounds (SanMiguel et al., 2008; do 
Vale et al., 2014). Nevertheless, working memory manipulation had no significant effect 
on the electrophysiological response to auditory stimuli (do Vale et al., 2014).  
DHEAS-to-DHEA ratio and performance 
Clinical findings in patients with Alzheimer’s disease suggested beneficial effects of 
higher DHEAS-to-DHEA balance concerning memory (Weill-Engerer et al., 2002; Kim et al., 
2003; Brown et al., 2003; George et al., 2006). Moreover, the inhibition in the conversion 
of DHEAS to DHEA in rats, enhanced the hippocampal cholinergic function and improved 
memory (Rhodes et al., 1996; Li et al., 1997; Rhodes et al., 1997; Urani et al., 1998). 
However, most studies using DHEA administration to humans did not study or control the 
resultant DHEAS-to-DHEA ratios (Wolf et al., 1998a; Barnhart et al., 1999; van Niekerk et 
al., 2001; Evans et al., 2006; Goel and Cappola, 2011) which could have contributed to the 
inconclusive results of DHEA administration regarding memory and attention.  
On the other hand, reducing the conversion of DHEAS into DHEA in mice impaired 
accuracy under attention demanding conditions (Davies et al., 2009) and subjects with 
lower DHEA levels, lower DHEAS levels (Strous et al., 2001) or steroid sulfatase deficiency 
(and therefore higher DHEAS-to-DHEA ratios) had higher rates of attention deficit 
hyperactivity disorder (Kent et al., 2008). These findings are in agreement with the 
present results in which a higher DHEAS-to-DHEA ratio was related to an enhanced 
processing of the auditory distractor. Nevertheless, in the present study the participants 
had normal DHEAS and DHEA levels and we found no deleterious effects of higher DHEAS-
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to-DHEA ratio on working memory processing or performance. Of note, methylphenidate 
administered to boys with attention deficit hyperactivity disorder showed an increase in 
serum levels of both DHEAS and DHEA (proportionally more for DHEAS than DHEA) 
providing for a marked clinical improvement (Maayan et al., 2003). Therefore, besides 
DHEAS-to-DHEA ratio, DHEA and DHEAS levels seem important. 
 In the present study, no significant direct correlations between DHEAS-to-DHEA 
ratio and performance were observed. This might be due to the small number of 
participants. Furthermore, the DHEAS-to-DHEA ratio was related to the processing of the 
distracting task-irrelevant novel auditory stimuli. On the other hand, the DHEAS-to-DHEA 
ratio was not related to the task relevant visual stimuli processing, inferring that subjects 
with a higher DHEAS-to-DHEA ratio show an increased processing of the distracter which 
does not impact the task relevant processing and therefore does not lead to a 
deteriorated performance. Different processing strategies leading to a similar outcome 
might be employed between individuals with a high and low DHEAS-to-DHEA ratio. 
Individuals with an increased processing of non-task-related novelty might compensate 
distraction by making a greater effort in concentrating on the task. The increase in 
novelty-P3 and not the behavioral measures might therefore be a more direct index of 
DHEAS-to-DHEA balance. 
 
DHEAS-to-DHEA ratio relations to cerebral processing 
 At the electrophysiological level, a significant new finding was described in the 
present study. Specifically, a higher DHEAS-to-DHEA ratio was related to an enhanced 
novelty-P3 during the performance of a visual working memory task. This suggests the 
relation between higher DHEAS-to-DHEA ratio and enhanced acoustic novelty processing 
during visual working memory tasks and more generally, higher DHEAS-to-DHEA ratios 
might be related to enhanced involuntary attention to exogenous stimuli during the 
performance of a cognitively challenging task. In a different context, we had previously 
found a relation between DHEAS-to-DHEA balance and brain processing under implicit 
negative emotional content (do Vale et al., 2015a). Of note, DHEAS is the most abundant 
160 
hormone in the peripheral circulation and it is even more abundant in the brain. Yet, 
DHEAS and DHEA physiological effects are not established and their relations to brain 
processing are largely unknown (Baulieu and Robel, 1998; Komesaroff, 2008; Maninger et 
al., 2009). 
DHEA levels increase in response to stress (Lennartsson et al., 2012) and may have 
anti-cortisol effects (Browne et al., 1993; Herbert, 1997; Apostolova et al., 2005; 
Hennebert et al., 2007; Saponaro et al., 2007; Balazs et al., 2008; Sorwell and Urbanski, 
2010; Buoso et al., 2011; Russo et al., 2012). Higher DHEAS levels have been related to 
lower cortisol levels and reduced peak/baseline cortisol response to stress (do Vale et al., 
2011; Kimonides et al., 1998; Gruenewald et al., 2006). Moreover, an antagonism in 
DHEAS and cortisol synthesis and release by the adrenal gland in response to stress has 
also been hypothesized (Boudarene et al., 2002). On the other hand, baseline DHEAS 
levels were found to be directly related to baseline DHEA/cortisol ratios (do Vale et al., 
2015a) and thus, the DHEAS-to-DHEA ratios were inversely related to cortisol levels (do 
Vale et al., 2015b), suggesting some relation to lower stress levels. 
Therefore, higher DHEAS-to-DHEA ratios might be a measure of lower chronic 
stress and cumulative burden and therefore a lower allostatic load (McEwen, 2004). 
Hence, the present results suggest that subjects with high DHEAS-to-DHEA ratio might 
have low chronic stress levels and therefore more attentional resources available during 
the performance of working memory load tasks. Long term transcriptional effects of high 
DHEAS-to-DHEA ratio, either directly or related to the inhibition of cortisol transcriptional 
effects could eventually contribute to a long term increase in attentional resources. 
Interestingly, we found that cortisol levels alone did not explain these results as they 
were not inversely related to novelty-P3 processing during the performance of the same 
working memory load task (do Vale et al., 2014). 
The novelty-P3 is an index of the effective orienting of attention towards a 
distracting event (Escera et al., 1998; Escera et al., 2000; Friedman et al., 2001; SanMiguel 
et al., 2008; do Vale et al., 2014). Nevertheless, in the present study, the relation between 
higher DHEAS-to-DHEA ratio and increased involuntary acoustic novelty processing 
occurred with no deleterious effect on the visual target stimuli processing. In fact, no 
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relation between DHEAS-to-DHEA ratio and visual P300 amplitudes was found therefore 
suggesting that the increased involuntary attention to novel sounds did not distract the 
subjects from the visual working memory load task. Additionally, there was no relation to 
increased novelty-P3 or visual P300 latencies suggesting that the increased involuntary 
attention to novel sounds did not occur at the expense of longer stimulus evaluation 
times. In this context, the increased attention to unexpected novel sounds may be 
protective, maintaining an increased alertness to the surrounding world while voluntarily 
directing attention to the performance of the working memory load task. 
 Hence, the DHEAS-to-DHEA ratio may be an endogenous factor modulating 
exogenous attention mechanisms during the performance of cognitive tasks that require 
an active maintenance of information in working memory. Several studies have shown 
prefrontal cortex activation in working memory tasks, possibly inhibiting the processing of 
irrelevant information, leading to a reduction of distraction (Hopfinger et al., 2006; Pinsk 
et al., 2004; Spinks et al., 2004; Miller, 2000; Jarrold and Towse, 2006). In this regard, it 
was suggested that distractor stimuli could trigger prefrontal cortex activity and suppress 
the input of sensory information, thus preserving the contents of working memory from 
being disrupted by the distractor stimuli (Postle, 2005; SanMiguel et al., 2008). 
Nevertheless, the present results do suggest that high DHEAS-to-DHEA ratio may 
contribute to enhanced activation caused by irrelevant stimuli while not interfering with 
the sensory activation related to the task.  
 The relations of the DHEAS-to-DHEA ratio to brain processes seem to depend on 
either the type or the difficulty of the cognitive task. The DHEAS-to-DHEA ratio was 
related to novelty-P3 processing during a visual working memory task, but not during an 
easier visual discrimination task (no working memory load). In a previous study, using a 
visual emotionally neutral or negative context we did not find any relation between 
DHEAS-to-DHEA ratio and involuntary attention to novel sounds or emotionally neutral 
stimuli processing either, but higher DHEAS-to-DHEA ratios were related to reduced 
processing of negative emotional stimuli and shorter stimuli evaluation times (do Vale et 
al., 2015a). Taken together, previous findings at the clinical level and our 
electrophysiological results both point towards an important role of the sulfotransferase 
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(the enzyme that converts DHEA into DHEAS) and sulfatase (the enzyme that converts 
DHEAS into DHEA) activity. They also imply that evaluating and manipulating DHEAS-to-
DHEA ratios in future studies might be important to understand DHEA and DHEAS 
physiological effects. 
 
Limitations of the study 
In the present study, the participants were in different menstrual cycle phases and 
some were using hormonal contraception. DHEA and DHEAS levels can change along the 
menstrual cycle and with the use of hormonal contraception (Fern et al., 1978; Wiegratz 
et al., 2003). Nevertheless, considering the small sample size in the present study, the 
endocrine levels were not significantly different in relation to the menstrual cycle phase 
or the use of hormonal contraception. Moreover, given the randomized approach we 
used, the present results are expected to be independent of the menstrual cycle phase. In 
any case, even considering that endocrine levels change along the menstrual cycle or with 
the use of hormonal contraception, the relations we found between endocrine levels and 
brain processing cannot be invalidated. Finally, only female participants were included, 
limiting the outreach of the present study only to women. DHEAS levels differ between 
genders, therefore, another group of participants would be necessary to extend our 
conclusions also to men. Further studies would be relevant to prove whether the results 
are also identical in men.  
 
 In summary, in young women with normal DHEA levels, a high DHEAS-to-DHEA 
ratio was related to enhanced auditory novelty-P3 amplitudes during the performance of 
a visual working memory load task but was not related to visual P300 amplitudes, 
novelty-P3 latencies or visual P300 latencies. These results suggest that higher DHEAS-to-
DHEA ratios are related to enhanced acoustic novelty processing with no detrimental 
effect on working memory processing. Thus, it is proposed that higher DHEAS-to-DHEA 
ratios might enhance involuntary attention to the surrounding world during the 
performance of working memory load tasks, which again may be an important protective 
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mechanism. The present results also suggest the importance of the 
sulfotransferase/sulfatase activity in the modulation of DHEAS and DHEA effects in brain. 
Abbreviations 
DHEA- dehydroepiandrosterone; DHEAS - dehydroepiandrosterone-sulfate; EEG - 
electroencephalogram; ERPs - event-related potentials; WM0 - no working memory load 
(discrimination) condition; WM1 - working memory load condition. 
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Abstract 
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEAS) may 
have mood enhancement effects: higher DHEAS concentrations and DHEA/cortisol ratio 
have been related to lower depression scores and controlled trials of DHEA 
administration have reported significant antidepressant effects. The balance between 
DHEAS and DHEA has been suggested to influence brain functioning. We explored DHEAS, 
DHEA, cortisol, DHEA/cortisol and DHEAS/DHEA ratios relations to the processing of 
negative emotional stimuli at behavioral and brain levels by recording the 
electroencephalogram of 21 young women while performing a visual task with implicit 
neutral or negative emotional content in an audio-visual oddball paradigm. For each 
condition, salivary DHEA, DHEAS and cortisol were measured before performing the task 
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and at 30 and 60min. interval. DHEA increased after task performance, independently of 
the implicit emotional content. With implicit negative emotion, higher DHEAS/DHEA and 
DHEA/cortisol ratios before task performance were related to shorter visual P300 
latencies suggesting faster brain processing under a negative emotional context. In 
addition, higher DHEAS/DHEA ratios were related to reduced visual P300 amplitudes, 
indicating less processing of the negative emotional stimuli. With this study, we could 
show that at the electrophysiological level, higher DHEAS/DHEA and DHEA/cortisol ratios 
were related to shorter stimulus evaluation times suggesting less interference of the 
implicit negative content of the stimuli with the task. Furthermore, higher DHEAS/DHEA 
ratios were related to reduced processing of negative emotional stimuli which may 
eventually constitute a protective mechanism against negative information overload. 
Key-words: dehydroepiandrosterone; dehydroepiandrosterone-sulphate; cortisol; 
emotion processing; performance; dehydroepiandrosterone reactivity; auditory 
distraction; event-related-potentials. 
Resumo 
Alguns estudos sugerem que a desidroepiandrosterona (DHEA) e a 
desidroepiandrosterona-sulfato (DHEAS) podem ter efeitos benéficos ao nível do humor: 
concentrações mais elevadas de DHEAS e da razão DHEA/cortisol, têm sido associadas a 
menos sintomas depressivos e os estudos controlados com administração de DHEA, 
revelaram efeitos anti-depressivos significativos. Além disso, também tem sido sugerido 
que o balanço entre os níveis de DHEAS e DHEA pode influenciar o funcionamento 
cerebral. Neste estudo, explorámos as relações entre os níveis de DHEAS, DHEA, cortisol, 
DHEA/cortisol e DHEAS/DHEA e o processamento de estímulos emocionais negativos, a 
nível comportamental e cerebral. Foi gravado o eletroencefalograma de 21 jovens 
adultas, enquanto realizavam uma tarefa visual com conteúdo emocional implícito neutro 
ou negativo, usando um paradigma audiovisual (do tipo “oddball”). Para cada condição, 
foram medidas as concentrações de DHEA, DHEAS e cortisol na saliva, antes da tarefa e 
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aos 30 e 60 minutos. As concentrações de DHEA aumentaram após a realização das 
tarefas, independentemente do conteúdo emocional implícito. Razões DHEAS/DHEA e 
DHEA/cortisol mais elevadas antes da realização da tarefa com conteúdo emocional 
negativo, correlacionaram-se com latências da deflexão P300 visual mais curtas. Estes 
resultados sugerem que perante conteúdos emocionais negativos, as razões DHEAS/DHEA 
e DHEA/cortisol mais elevadas se associam a um processamento cerebral mais rápido. 
Além disso, razões DHEAS/DHEA mais elevadas, relacionaram-se com amplitudes mais 
reduzidas da deflexão P300 visual, indiciando um menor processamento dos estímulos 
emocionais negativos. Neste estudo, mostrámos que ao nível eletrofisiológico, razões 
DHEAS/DHEA e DHEA/cortisol mais elevadas, se relacionaram com avaliações do estímulo 
mais rápidas, sugerindo menor interferência do conteúdo emocional negativo, na 
realização da tarefa. Adicionalmente, razões DHEAS/DHEA mais elevadas relacionaram-se 
com menor processamento dos estímulos emocionais negativos, o que pode constituir 
um mecanismo protetor contra o excesso de informação negativa.  
Palavras-chave: desidroepiandrosterona, desidroepiandrosterona-sulfato, cortisol, 
processamento emocional, desempenho, reactividade da desidroepiandrosterona, 
distração auditiva, potenciais evocados.  
Introduction 
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEAS) 
are neuroactive steroids and their concentrations in the central nervous system are 
higher than in the peripheral circulation (Dong and Zheng, 2011; Lacroix et al., 1987). 
Although their physiological role and mechanisms of action are still a matter of debate 
(Komesaroff, 2008), a growing amount of evidence has been accumulating regarding their 
actions in the central nervous system. Concerning cognitive functions, higher DHEAS 
levels were related to improved memory (Barrett-Connor and Edelstein, 1994), whereas 
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low levels were found in Alzheimer’s disease (Weill-Engerer et al., 2002). Besides, higher 
DHEA, DHEAS or DHEA-to-cortisol levels were related to improved attention (Wolf et al., 
1997), lower perceived stress and also to improved performance under stressful 
conditions (Morgan et al., 2009; Russo et al., 2012).  
Furthermore, higher DHEAS concentrations and DHEA-to-cortisol ratios have been 
related to lower prevalence of depression, lower depression ratings and higher well-being 
scores (Barret-Connor and Edelstein, 1994; Barrett-Connor et al., 1999; Michael et al., 
2000; Young et al., 2002). The relation between DHEA levels alone and depression is less 
consistent. In fact, several groups have found that DHEA-to-cortisol ratios, rather than 
concentrations of either hormone alone, discriminated more accurately depressed from 
non-depressed individuals, with lower DHEA-to-cortisol ratios as seen in depression 
(Assies et al., 2004; Michael et al., 2000), in untreated depressed patients and in patients 
who remained depressed after several months (Goodyer et al., 1998).  
It was hence suggested that elevated DHEA and DHEAS relative to cortisol levels, 
may counteract the negative effects of high cortisol on mood (Goodyer et al., 1998; 
Kaminska et al., 2000). Moreover, controlled trials of DHEA therapy have reported 
significant positive effects on mood (Bloch et al., 1999; Schmidt et al., 2005; Wolkowitz et 
al. 1999). These mood improvements were related to increases in the circulating 
concentrations of DHEA and DHEAS and to increases in their ratios with cortisol. On the 
other hand, sulphated steroids in general possibly act as endogenous neuromodulators 
(Gibbs et al., 2006) and the balance between DHEAS and DHEA has also been suggested 
to influence brain functioning. In a study assessing both DHEA and DHEAS, depressed 
patients had low DHEAS but normal DHEA concentrations (Scott et al., 1999). In a 
different setting, but also pointing towards the importance of DHEAS to DHEA balance, it 
has been shown that subjects with Alzheimer’s disease have increased levels of DHEA in 
the central nervous system, but a reduced conversion of DHEA into DHEAS and 
consequently, reduced DHEAS/DHEA ratios (Kim et al., 2003). 
Glucocorticoids’ effects are not always deleterious. In fact, glucocorticoids have 
biphasic effects on fear conditioning: although mild or short lasting increases in 
glucocorticoids in relation to stress may have beneficial effects on attention and promote 
177 
adaptation, higher cortisol levels or long term increases have deleterious effects on 
executive functioning, attention, learning, memory and cognitive flexibility (Campeau et 
al., 2011; McEwen 2012). Again, anti-glucocorticoid effects of DHEA and DHEAS have 
been proposed in what concerns cognition and performance. 
DHEA and DHEAS present a general neurostimulatory effect, but DHEAS has a 
much more potent excitatory action than DHEA (Baulieu and Robel, 1998; Imamura and 
Prasad, 1998; Monnet et al., 1995; Dong and Zheng, 2011). At cellular level DHEAS 
antagonizes the neurotoxic effect of high doses of DHEA in mouse neuronal cultures (Gil-
ad et al., 2001) and DHEA is protective against the neurotoxic effects of corticosterone 
(Balazs et al., 2008). Hence, the simultaneous evaluation of DHEA, DHEAS and cortisol and 
the ratios of DHEA to cortisol and DHEAS to DHEA may uncover more information than 
the individual examination of either steroid alone. 
DHEA and DHEAS effects on cerebral regions specifically involved in emotional 
processing including the amygdale, hippocampus, insula and anterior cingulated cortex 
have been suggested. However, little research has explored the neural correlates of DHEA 
and DHEAS with respect to emotion and mood. In this regard, a study using LORETA 
showed that DHEA administration increased the activity in the anterior cingulate cortex 
(Alhaj et al., 2006). Another recent study using functional Magnetic Resonance Imaging 
(fMRI) found that DHEA reduces the activity in regions associated with the generation of 
negative emotion and enhances activity in regions linked to regulatory processes (Sripada 
et al., 2013).  
DHEA and DHEAS relations to emotional processing at the electrophysiological 
level are not known. Regarding cortisol, its administration increased the processing of 
angry faces in highly anxious individuals as indicated by increased amplitudes of early 
(P150) and late (P3) event-related potentials (van Peer et al., 2007). DHEA and DHEAS 
may modulate attention, cognition and mood while their response to emotional stimuli is 
mostly unexplored. 
The aim of the present study was to explore whether DHEA and DHEAS levels 
would have an influence on involuntary attention and emotional stimuli processing at the 
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performance and brain levels and, on the other hand, if an emotional challenge would 
alter DHEA and DHEAS levels. Furthermore, we wanted to examine the relation of DHEA 
and DHEAS with cortisol levels. The a priori hypotheses were: 1) higher endogenous 
DHEAS and DHEA levels as well as higher DHEA to cortisol and DHEAS to DHEA levels may 
protect from involuntary distraction and enhance brain processing and performance 
under a negative emotional context; 2) DHEAS and DHEA effects may be largely 
antagonistic from those of baseline cortisol; 3) in the short term, a negative emotional 
context might be a stimulus for DHEA and cortisol secretion.  
To test these hypotheses, we used a visual task with a neutral or negative 
emotional context and unexpected auditory novel sounds aimed to cause distraction. In 
this paradigm, the negative emotional context is expected to elicit an increased attention 
capture when compared to non-emotional faces (Öhman et al., 2001) and consequently 
deteriorate performance (Domínguez-Borràs et al., 2008). Furthermore, auditory 
distraction by novel sounds is expected to elicit a novelty P3 component in the 
electroencephalogram (EEG) and also deteriorate performance (Corral and Escera 2008; 
Domínguez-Borràs et al., 2008; Escera et al., 1998, 2000). We recorded performance 
parameters, the EEG and took saliva samples in order to determine the hormonal levels 
before and after the task. We explored DHEA, DHEAS, cortisol, DHEA/cortisol ratio and 
DHEAS/DHEA ratio relations to distraction and implicit negative emotion at the 
performance and electrophysiological levels.  
Participants and Methods 
Participants 
21 healthy female volunteers (university students) from 18 to 26 years (mean 
21±1), performed the study protocol. Only women were included as to ensure higher 
homogeneity in emotional processing (Garcia-Garcia et al., 2008) and androgen levels. All 
had normal or corrected-to-normal vision and none reported auditory deficits. There was 
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no history of neurologic, psychiatric, endocrine or oral diseases. Subjects were asked to 
refrain from alcohol intake in the twelve hours before the experimental protocol and 
tobacco and illicit drug consume were exclusion criteria. All participants gave their 
written informed consent. The experimental protocol was approved by the ethical 
committees of the University of Barcelona and Lisbon Medical School and was performed 
in accordance with the Declaration of Helsinki. 
Prior to the experimental session, subjects completed the State-Trait Anxiety 
Inventory (STAI; Spielberger et al., 1988) and all were within a normal range of state 
(mean 13±1) and trait (mean 17±1) anxiety levels. Mean body mass index (BMI) was 
22.3±0.8 kg/m2 and all participants presented a normal body mass index except one with 
grade 1 obesity. All except one participant were right-handed. Seven participants were in 
the follicular phase, three were in the peri-ovulatory phase and six were in the luteal 
phase, based on self-reported menstrual cycle day. Five subjects were using hormonal 
contraception, no other medications were allowed.  
Task and Procedure 
The experimental sessions were conducted in the afternoon, beginning at 2-3 pm. 
An adapted version of a well-established auditory-visual distraction task (Escera et al., 
1998, 2000) was presented with two different conditions, one featuring a neutral (NEU) 
and one featuring a negative emotional content (NEG), as implemented by Domínguez-
Borràs et al. (2008). Each condition lasted about 15 minutes and conditions were 
performed two hours apart (beginning to beginning). The order was counterbalanced 
across subjects. Each condition consisted of two separate blocks of 255 trials with a short 
interval between them.  
Participants sat in a comfortable chair in a dimly lit and electrically and acoustically 
shielded room. The task consisted of responding as fast and accurately as possible 
whether the two faces on the screen were equal or different by pressing the 
correspondent mouse button. The subjects were instructed to ignore the sounds. In order 
to reduce eye blinks and movements during EEG recording, subjects were asked to blink 
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as little as possible, and to focus on a central fixation cross between the two pictures. 
Responses were given through a mouse button (one mouse button for “the same” and 
the other button for “different”, counterbalanced across subjects) and the probability of 
both responses was the same. Before each experimental condition, subjects performed 
practice blocks (composed by 10 trials) using faces with a neutral expression only and 
without any auditory stimuli, until they reached a hit rate (HR) of at least 80%. 
In each trial, a task-irrelevant auditory stimulus was presented, followed after 300 
ms (onset-to-onset) by a visual imperative stimulus (figure 1). The total trial length varied 
from 1200 to 1600 ms (1400 ms on average; jitter +/-200 ms) and the response window 
until the end of the shortest trial was 1200 ms. The auditory sequence consisted of 
repetitive standard tones (duration of 200 ms, including fade-in and fade-out of 10ms 
each; 600 Hz; 85dB; probability of occurrence p = 80%), occasionally replaced by 
environmental novel sounds (p=20%). These novel sounds were selected from a sample of 
100 different specimens (edited to have a duration of 200 ms, including fade-in and fade-
out of 10ms each; digitally recorded, low-pass filtered at 10,000 Hz; 85dB), such as those 
produced by a drill, hammer, rain, door, telephone ringing, and so forth (Escera et al., 
2003). All sounds were delivered binaurally through headphones (Sennheiser HD 202) in a 
randomized order with the only restrictions that the first four stimuli of each block had to 
be standard tones, that two novel sounds never appeared consecutively and that each 
novel sound occurred only once in each condition. The visual stimuli were pairs of 
combinations of pictures of faces with either neutral (figure 1.A) or fearful (figure 1.B) 
expression, presented on a computer screen for 400ms. We used 12 pictures of faces 
with either neutral (NEU) or fearful (NEG) expression from the Ekman and Friesen (1976) 
database. All faces had exactly the same probability of occurrence and all had the same 
valence (NEU or NEG) in each block. The picture size was 356x488 pixels, the vertical 
angle 9º and the horizontal angle 17º, accounting for two pictures presented 
simultaneously with a fixation cross in between, and the distance from the subjects’ eyes 
to the screen was 100cm. 
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Figure 1: Trial Structure. A. Neutral emotional context (NEU). B. Negative emotional context (NEG). 
Performance and EEG Recording and Analysis 
Response time (RT) and whether the button press was correct, wrong or missed 
were recorded for each trial using Presentation® (Neurobehavioral Systems, Inc). A 
database was created with the mean response time for correct responses and hit rate 
(HR), separately for each condition (NEU and NEG) and auditory stimulus type (standard 
and novel). Distraction by novel sounds was computed as the difference in hit rate and 
response time between standard and novel auditory stimuli (hit rate: NEUstandard trials 
– NEUnovel trials and NEGstandard trials – NEGnovel trials; response time: NEUnovel
trials – NEUstandard trials and NEGnovel trials – NEGstandard trials). Performance 
disruption due to the processing of negative emotional stimuli was computed as the 
difference in hit rate and response time between conditions, as appropriate (hit rate: 
NEUstandard – NEGstandard and NEUnovel – NEGnovel; response time: NEGstandard – 
NEUstandard and NEGnovel – NEUnovel).  
EEG activity was continuously recorded, from 64 scalp Ag/AgCl electrodes 
following the extended 10/10 convention. It was amplified and digitalized at a sampling 
rate of 512 Hz (Eemagine, ANT Software b.v., Enschede, Netherlands). The horizontal and 
vertical electrooculogram (HEOG and VEOG) were recorded with electrodes placed at the 
outer canthus and below the right eye, respectively. An electrode placed on the tip of the 
nose was used as the common reference and the ground was located at the AFz position. 
Impedances were kept at 5 kΩ or below during the whole recording session. Recording 
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was performed with an ANT amplifier of 64 channels (gain 20x; A/D resolution 22 bits, 
71.526 nV per bit; filtering 0-138.24Hz; CMRR >90dB). 
EEG processing was performed off-line by using Eeprobe 3.1 (ANT Software BV, 
Enschede, Netherlands). A digital finite impulse response (FIR) bandpass-filter from 0.01 
to 30 Hz was applied using a Hamming window. ERPs were averaged for each auditory-
stimulus trial type and emotional condition, for an epoch of 1400 ms, comprising a pre-
auditory-stimulus baseline of 200 ms. The first five epochs of each block and epochs 
following a novel trial were excluded from averaging. Only epochs corresponding to trials 
with correct responses were included in further analyses. Electrooculogram (EOG) 
correction was performed by manually selecting a large number of typical artifacts and 
accordingly applying a regression algorithm to compute propagation factors (Eeprobe 3.1, 
ANT Software BV, Enschede, the Netherlands). After EOG correction any epochs 
containing EEG activity exceeding ±100μV peak-to-peak amplitudes were rejected from 
further analysis. On average, 84% of epochs (252 epochs) with standard sounds and 87% 
of epochs (87 epochs) with novel sounds in NEU and 86% of epochs (259 epochs) with 
standard sounds and 86% of epochs (86 epochs) with novel sounds in NEG were retained 
for averaging. 
In the employed paradigm the participants were specifically instructed to ignore 
the distraction stimuli (auditory), hence any related effects are necessarily involuntary or 
led by exogenous attention. ERPs recorded during auditory distraction are typically 
characterized by an auditory N1/mismatch negativity (N1/MMN) enhancement, reflecting 
a detection mechanism leading to attention capture, followed by a novelty-P3 (nov-P3) 
reflecting the effective orientation of attention (Escera et al., 1998 and 2000). The nov-P3 
component has been shown to be sensitive to the manipulation of the emotional context 
(Domínguez-Borràs et al., 2008) and attention (Escera et al., 1998). Subsequently, the re-
orienting negativity (RON) reflects the re-orientation of attention back to the task 
(Schröger and Wolff, 1998). The target stimuli in the present task were visual, and visual 
ERPs include the P300, which is a cognitive component related to target processing. The 
P300 (visP300) reflects the conscious processing of the visual stimulus and is sensitive to 
attention allocation (Domínguez-Borràs et al., 2008; Polich, 2007).  
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To analyze distraction effects, the ERPs elicited to the auditory stimuli were 
considered and difference waveforms (dw) were calculated by subtracting the ERPs 
elicited by standards from those elicited by novel sounds. These difference waveforms 
revealed an early-onset, long-lasting positive deflection that we assimilated to the 
novelty-P3. We measured the auditory P3 (aud-P3) and novelty-P3 (nov-P3) as the mean 
amplitude in the 210–470 ms time window at F3, Fz, F4, C3, Cz, C4, P3, Pz and P4 
electrodes.  
To analyze emotional effects, ERP measures in standard trials were compared. 
Specific components were elicited during task-performance, such as the auditory N1 and 
P2, visual N1 and P2 and the cognitive components N2b and visual P300. Since only 
cognitive processing was of interest for the present study, the visual P300 (650-1050 ms 
at F7, F3, FZ, F4, F8, T7, C3, CZ, C4, T8, P7, P3, PZ, P4 and P8, 350-750 ms from stimulus 
presentation) was analyzed. Mean amplitudes for the considered time windows and 
electrodes were computed for each deflection. 
Endocrine measurements 
Saliva samples were collected by passive drool, using a short straw. Unstimulated 
whole saliva was used. For each condition, samples were collected for DHEA, DHEAS and 
cortisol measurement before task (BF), at 30 min (30 min after the beginning of the task, 
10 to 15 min after the end of the task) and 60 min (60 min after the beginning of the task, 
40 to 45 min after the end of the task). The samples collected before the first condition 
(i.e. before both the neutral and the negative condition), were considered as the baseline. 
Time points to collect the saliva samples were chosen in accordance to known cortisol 
raise and recovery times (raise 10 min after appropriate stimulus, peak at 20-30 min and 
recovery at 45-60 min after the end of the stimulus) (Martins et al., 2001, 2002 and 2004; 
do Vale et al., 2011). Furthermore, synchronous 24h profiles were described for DHEA 
and cortisol and DHEA half-life is less than 30min (Rosenfeld et al., 1975). For this reason, 
the second condition was started two hours after the first one to allow cortisol and DHEA 
levels to recover from the influence of the first condition (return to a “baseline” level).  
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Unbound DHEA and cortisol in the peripheral circulation penetrate into the saliva 
via intracellular mechanisms and salivary concentrations reflect serum concentrations 
(Ahn et al., 2007; Vining and McGinley, 1987). DHEAS is not lipid soluble and cannot 
penetrate into the saliva by passive diffusion through cell membranes. Instead, it 
squeezes through the tight junctions between salivary glands. DHEAS concentrations in 
saliva are therefore dependent on serum concentration and salivary flow rate (Vining and 
McGinley, 1987).  
Samples were refrigerated at 2-8º C within 30 min after collection and were stored 
at -20ºC within 4h and until assayed. Each sample was measured in duplicate using 
enzyme-linked immunoassays: salivary DHEA and DHEAS enzyme immunoassay kits 
(Salimetrics Europe®, Ltd, Newmarket Suffolk, UK) and high sensitivity salivary cortisol 
enzyme immunoassay kits (Salimetrics®, LLC, State College, PA, USA). DHEA was 
measured in pg/mL and cortisol was measured in µg/dL. Due to the influence of saliva 
flow rates on DHEAS levels, the concentration of DHEAS (pg/mL) was multiplied by the 
flow rate (mL/min) and the corrected results were obtained as DHEAS measured per unit 
of time (pg/min). The minimal concentrations that can be distinguished from 0 with the 
used immunoassays are 5pg/mL for DHEA, <0.003µg/dL for cortisol and <43pg/mL for 
DHEAS. Intra- and interassay coefficients of variation were less than 10% and 15% in 
every case, respectively. 
Statistical Analysis 
The Statistical Package for the Social Sciences Program (IBM SPSS Statistics, 
version 21) was used for data analysis. Results are presented as the mean ± standard 
error of the mean (SEM). The normal distribution of continuous variables was verified by 
the Kolmogorov-Smirnov goodness of fit test. 
To explore the effects of the implicit emotional content and auditory distraction 
on performance, repeated measures analyses of variance (ANOVA) were performed on 
hit rate and response time, including the within-subjects’ factors emotional condition 
(NEU and NEG) and type of auditory stimulus (standard and novel). Regarding brain 
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responses, ERPs time-locked to the auditory stimuli were analyzed to explore distraction 
effects. ERPs time-locked to the visual stimuli (the faces) were analyzed to explore 
emotional context effects. To investigate the effects of the emotional context and 
auditory distraction on brain responses to auditory stimuli, repeated measures ANOVAs 
were carried out on auditory P3 mean amplitude in the time window and electrodes 
considered above, including the within-subjects’ factors emotional condition (NEU and 
NEG) and type of auditory stimulus (standard and novel). To investigate the effects of the 
emotional context on brain responses to visual stimuli, only standards were included and 
ANOVAs were performed on the visual P300 mean amplitude in the time windows and 
electrodes considered above, with emotional condition (NEU and NEG) as within-subjects 
factor. To investigate the effects of emotional context manipulation on endocrine levels, 
repeated measures ANOVAs were performed on DHEA, DHEAS and cortisol levels, 
including the within-subjects’ factors emotional condition (NEU and NEG) and 
measurement time (before task, at 30min and 60 min).  
To investigate the endocrine relation to distraction and emotional context effects 
at the behavioral level, the previous repeated measures ANOVAs of behavior parameters 
were repeated, including baseline DHEA, DHEAS, cortisol, DHEA/cortisol ratio or 
DHEAS/DHEA ratio as covariates. Whenever the endocrine parameters covariated with 
the performance or ERP parameters for each type of auditory stimuli or emotional 
condition, we performed simple or multiple regression analyses to select the relevant 
independent endocrine factors and/or to understand the direction of the relationship. 
Lastly, as visual P300 peak latency in both emotional contexts was not directly related, in 
order to find the relation between visual P300 peak latency and endocrine parameters, 
linear and multiple regression analyses were used with the endocrine parameters as 
independent variables. 
ANOVA results were Greenhouse–Geisser corrected whenever the assumption of 
sphericity was violated. The limit of significance chosen was α=0.05. Post hoc tests were 
carried out wherever there were significant interactions between main factors and the 
Bonferroni correction was applied for multiple comparisons. For the endocrine relations 
to performance or ERPs the alpha therefore was set to 0.01 as the effects were tested for 
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five variables (cortisol, DHEA, DHEAS, DHEA/cortisol ratio and DHEAS/DHEA ratio). Effect 
size estimates of the results were expressed as eta squared (η2) for ANOVAs and 
correlation coefficients (r) for regression analyses. 
Results 
Performance 
Behavioral results for each condition and trial type are presented in Figure 2. 
There was a main effect of emotional context on response time [F(1,20)=17.51, p<0.001, 
η2=0.47], with longer response times under the emotionally negative context (433±17 ms) 
than under the neutral one (379±12 ms). Furthermore, there was a main effect of trial 
type on response time [F(1,20)=31.88, p<0.001, η2=0.61], with longer response times for 
novel (423±13 ms) than for standard (389±14ms) trials, indicating that the novel sounds 
caused distraction of visual task performance (figure 2.A). Overall hit rate was 88±1 % and 
did not change significantly with the emotional context or trial type (figure 2.B).  
Event-Related Potentials 
Distraction Effects. No clear N1-enhancement/MMN nor RON was elicited and therefore 
our analysis focused only on the nov-P3. In fact, the nov-P3 was significantly elicited as 
supported by the significant differences of the mean amplitudes in the auditory P3 
latency window for standard and novel trials [F(1,20=169.09, p<0.001, η2=0.89; -2.3±0.4 µV 
in standard and +1.7±0.5 µV in novel trials], see figure 3.A and 3.B. However, there were 
no effects of emotional context on the auditory P3 (see figure 3.C), as no significant 
interaction between emotional context and auditory stimulus type was found. 
Emotional Context Effects. The waveforms elicited by standard trials in the two 
emotional contexts are presented in figure 3.D. No significant emotional effects were 
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observed on visual P300 as its amplitude was similar in both conditions. Also, there were 
no significant latency differences in P300, between emotional conditions.  
 
Figure 2: Performance results. A. Mean response times for each condition [neutral (NEU) or negative 
context (NEG)] and auditory stimulus type (standard or novel). B. Mean hit rates for each condition and 
auditory stimulus type. Error bars represent ±1 standard error of the mean (SEM).  
 
Endocrine Baseline Levels and Reactivity 
 Baseline endocrine levels were: DHEA 254±41 pg/mL, DHEAS 5856±690 pg/min 
and cortisol 764±100 pg/mL, following a normal distribution. Baseline DHEA level was 
directly related to baseline cortisol level (r=+0.63, p=0.002, n=21). There was no 
significant relation between baseline DHEAS and DHEA or DHEAS and cortisol level. 
Nevertheless, baseline DHEAS levels were directly related to baseline DHEA/cortisol ratio 
(r=+0.56, p=0.008, n=21). Baseline endocrine parameters were not related to age or body 
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mass index and did not differ according to menstrual cycle phase or between subjects 
taking and not taking hormonal contraception. 
DHEA, DHEAS and cortisol mean levels for each condition and sample time are 
presented in figure 4. The repeated measures ANOVA on DHEA levels revealed a main 
effect of measurement time on DHEA levels [F(2,40)= 5.94, p=0.007, η2=0.24; mean levels 
were 243±42 pg/mL before task, 258±41 pg/mL at 30 min and 309±45 pg/mL at 60 min], 
see figure 4.A and 4.B. There was no significant relation between emotional context and 
DHEA levels. Moreover, there was no interaction between DHEAS (figure 4.C) or cortisol 
levels (figure 4.D) and the emotional context or measurement time. 
Figure 3:  Event-Related Potentials (ERPs). A. Grand average waveforms at Cz for each emotional context 
(neutral and negative) and type of sound (standard and novel). B. Mean auditory P3 (aud P3) amplitude for 
each emotional context and type of sound. C. Grand average of novel minus standard difference waveforms 
at Cz for each emotional context. D. Grand average ERPs for neutral and negative context (only standard 
trials). NEG: negative emotional context; NEU: neutral emotional context; aud: auditory event related 
potentials; vis: visual event related potentials.  
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Figure 4: Endocrine results. A. DHEA mean levels for each condition and measurement time. B. DHEA levels 
before task, at 30 min and 60 min. C. DHEAS mean levels for each condition and measurement time. D. 
Cortisol mean levels for each condition and measurement time. Error bars represent ±1 SEM. The shadow 
indicates the period of task performance. NEG: negative emotional context; NEU: neutral emotional 
context. 
Endocrine Relations to Performance and Event-Related Potentials 
We found no significant relations between performance (hit rate and response 
times) and endocrine parameters. Regarding event-related potentials, no significant 
relations were found between endocrine parameters and distraction effects. 
Nevertheless, significant relations were found between endocrine parameters and 
emotional context. Higher DHEAS/DHEA ratios before performing the emotionally 
negative condition were related to reduced visual P300 amplitudes in this condition. This 
was revealed by a significant interaction between visual P300 amplitudes and 
DHEAS/DHEA ratios [F(1,19)=9.38, p=0.006, η2=0.33] with higher DHEAS/DHEA ratios in 
relation to reduced visual P300 amplitudes attributed to the negative context (r=-0,58, 
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p=0.006, n=21; see figure 5.A). Concerning visual P300 peak latency, higher DHEA/cortisol 
(partial r=-0.56, p=0.003, n=21) and DHEAS/DHEA (partial r=-0.60, p=0.004, n=21) ratios 
before performing the negative emotional context block, were related to shorter visual 
P300 peak latencies (figure 5.B and 5.C), together explaining 52% of the latency 
variability. Remarkably, smaller visual P300 amplitudes attributed to the negative context 
were related to shorter visual P300 peak latencies (r=+0.53, n=21, p=0.015). 
Figure 5: Endocrine relations to Event-Related Potentials. A. Higher DHEAS/DHEA ratios before performing 
the negative emotional context block were related to reduced interference with the task due to the 
processing of the implicit negative content of the stimuli as shown by reduced visual P300 amplitudes. B 
and C. Higher DHEA/cortisol and DHEAS/DHEA ratios before performing the negative emotional context 
block, were related to shorter visual P300 peak latencies. Δ vis P300 amplitude: mean visual P300 amplitude 
in the negative minus neutral context. 
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Discussion 
The present study revealed relations between dehydroepiandrosterone (DHEA), its 
sulphated form (DHEAS) and brain processing under an emotionally negative context 
induced by images of fearful faces, suggesting that these neurosteroids may modulate the 
processing of emotionally negative information. Although the sounds as well as the 
emotional content of the pictures were irrelevant for the task, the results suggest that the 
subjects were unable to fully ignore them as indicated by significant effects on 
performance and brain responses. The distraction effect of task irrelevant auditory stimuli 
as well as the behavioral disruption due to the processing of task irrelevant negative 
emotional stimuli have been shown before by other authors (Escera et al., 1998, 2000; 
Domínguez-Borràs et al., 2008, 2009; Öhman et al., 2001), whereas the relation between 
the neurosteroids and emotional processing at the brain level is a new finding.  
Novel sounds led to distraction as shown by longer response times and the 
elicitation of a significant novelty P3. Conversely, no clear N1-enhancement/MMN was 
observed in our results, probably due to a very early P3 onset, causing an overlap 
between the components. Recent studies have shown that small deviant stimuli, and 
hence large novel sounds, may activate deviance-detection mechanisms as early as 20 ms 
from sound onset (see Slabu et al., 2010; Escera and Malmierca, 2014) and therefore 
attention switching may have had occurred before the supratemporal activation giving 
rise to the typical N1-enhancement/MMN trigger response (Yago et al., 2001). 
Additionally, in the negative emotional context, response times were longer than in the 
neutral context which implicates that the novel sounds effectively caused distraction and 
the emotionally negative context effectively disrupted performance. However, the 
emotional context did not significantly modulate the electrophysiological response to 
auditory distraction, contrasting with previous studies (Domínguez-Borràs et al., 2008; 
García-García et al., 2008) which found an enhancement of the visual P300 for 
emotionally negative stimuli (Domínguez-Borràs et al., 2008). Nevertheless, in studies 
using faces, some authors have found visual P300 enhancement by fearful faces (Luo et 
al., 2010), while others reported no changes in P300 amplitude (Balconi and Lucchiari, 
192 
2005) as in the present study. Importantly, in the present study, the emotional content of 
the images was not relevant for the task.  
DHEA levels increased after the performance of both conditions, independent of 
the emotional context of the task. Interestingly, a previous study showed that 
corticotrophin releasing hormone (CRH) levels increased with another cognitive task: the 
visualization of emotionally significant movies (Martins et al., 2010). In turn, the present 
results suggest that cognitive tasks are a stimulus for DHEA secretion and may lead to a 
higher DHEA/cortisol ratio. Moreover, it suggests that DHEA is not just a stress hormone 
and that some differential regulation of DHEA and cortisol exists. In fact, CRH stimulates 
corticotrophin secretion and in turn corticotrophin is a stimulus for cortisol and DHEA 
secretion (Nieschlag et al., 1973). This may explain the direct relation we found between 
cortisol and DHEA levels.  
Boudarene et al. (2002) studied subjects without mental disorders and varying 
levels of anxiety, and found that the level of anxiety was related to the profile of 
endocrine response after the performance of cognitive tasks: subjects with high anxiety 
levels in the STAI test had increased cortisol reactivity and subjects with low anxiety levels 
showed an exclusive increase in DHEAS levels. The authors suggested that the antagonism 
in DHEAS and cortisol might be related to competition in their synthesis and its release by 
the adrenal gland. This agrees with the results in the present study, in which all the 
subjects had low anxiety levels and a DHEA raise but no cortisol response in relation to 
the cognitive task (in both emotional conditions), was found. For non-pathological 
conditions and low levels of anxiety, this might eventually represent an adaptive 
mechanism that includes higher DHEA than cortisol responses and anti-cortisol effects of 
DHEA. DHEA increase however was identical for both emotional contexts, so that DHEA 
increase alone is not expected to be related to performance or electrophysiological 
effects of the emotional context.   
No significant relation was found between response times or hit rates and 
endocrine measurements. A larger sample may be necessary to uncover endocrine 
relations to performance. Nevertheless, an interesting finding of the present study 
consists in endocrine relations to brain responses. A higher DHEA/cortisol ratio was 
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related to lower visual P300 latencies in the negative emotional context, suggesting DHEA 
to be protective from an interference of the implicit negative content of the stimuli with 
the task which might represent an anti-glucocorticoid effect of DHEA. In the negative 
condition, higher DHEAS/DHEA ratios were also related to lower visual P300 latencies, 
thus, a higher proportion of DHEA respective to cortisol and a higher proportion of 
sulphated to non-sulphated form of DHEA may protect from any interference with the 
task caused by the processing of the implicit emotional content of the stimuli. 
In agreement, higher DHEA levels have been previously found to be related to 
shorter P300 latencies (Braverman and Blum, 2003; Braverman et al., 2009). A protective 
effect of DHEA and DHEAS could eventually be mediated by anti-cortisol effects and/or 
neuromodulatory effects of these hormones. Wang et al. (2013) associating a prolonged 
P300 latency with an attentional bias to negative stimuli in high trait anxiety subjects, 
who are expected to have higher cortisol levels. On the contrary, in the present study 
examining subjects with low trait anxiety, higher DHEA/cortisol ratios were related to 
shorter P300 latencies in the negative condition. Higher DHEA/cortisol could be related to 
less interference with the task caused by the implicit stressful content of the stimuli, in 
agreement with the hypothesis of anti-cortisol effects of DHEA and suggesting a 
protective mechanism against the deleterious consequences of stress. The present results 
also agree with studies at the cellular level, in which DHEA was protective against the 
neurotoxic effects of corticosterone (Balazs et al., 2008). 
Lastly, the visual P300 amplitude increments in the negative emotional context as 
compared to the neutral one, were inversely related to DHEAS/DHEA ratios, suggesting 
that the processing of the task-irrelevant negative content of the stimuli might eventually 
be reduced by DHEAS. Even though the participants of the study were healthy and 
depression was not screened by any specific inventory, women in particular have been 
shown to be specialy sensitive to threatening stimuli and it has been hypothesized that 
this might be related to the higher prevalence of affective disorders in women (Kemp et 
al., 2004). Enhanced negative affect is an integral characteristic of depressive disorders 
and negative mood can be experimentally induced using various procedures, among 
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others by presenting images of faces with emotional expressions (Dyck et al., 2011; 
Schneider et al., 1994 and 1997).  
 Although the mechanisms underlying mood persistence in major depressive 
disorder remain poorly understood, cognitive theories hypothesize that depressed 
patients have cognitive biases for emotional information, which help perpetuate 
depressive symptoms (Beck, 1967; Gotlib and Joormann, 2010). The present results 
suggest that the processing of negative emotional stimuli may be reduced in relation to 
higher DHEAS/DHEA levels, which might eventually be involved in protective mechanisms 
against a negative attention bias and undermine the relation between higher DHEAS 
levels and lower frequencies of depression, lower depression ratings and better well 
being scores previously described by other authors (Barret-Connor and Edelstein, 1994; 
Barrett-Connor et al., 1999). In line with this hypothesis, subjects with higher 
DHEAS/DHEA ratio would process less and have less memory updating of the implicit 
negative content of the stimuli and would thus have a reduced attentional bias towards 
these stimuli, which might promote wellbeing and contribute to protection from 
depressive states. 
Emotional stimuli usually capture attention more effectively than non-emotional 
ones (Öhman et al., 2001) and have an impact on cognitive functions even when they are 
task-irrelevant (Domínguez-Borràs et al., 2008). On the other hand, it is hypothesized that 
protective mechanisms filter out irrelevant sensory inputs protecting the higher brain 
functions from sensory overload (Braff and Geyer, 1990). Taken together, our findings 
concerning visual P300 latency and visual P300 amplitude under an emotionally negative 
context showed a relation between higher DHEA/cortisol and DHEAS/DHEA ratios and 
less processing of the negative emotional stimuli and less disruption by the processing of 
negative emotional stimuli. These results also suggest that DHEA and DHEAS potentially 
play a role or contribute to protective mechanisms filtering out negative information 
overload. 
 A simultaneous relation to latency reduction and decrease in P300 amplitude may 
seem contradictory at first sight, nevertheless, as the task consisted in deciding whether 
two faces with the same emotional expression were equal or different (while the 
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emotional expression was irrelevant), less processing of the task-irrelevant emotional 
content – related to higher DHEAS/DHEA ratios - might be reflected in smaller P300 
amplitudes and at the same time shorter P300 latencies due to a more efficient 
processing of the task-relevant visual information and less interference resulting from the 
task-irrelevant emotion. In other words, the P300 amplitude might be reduced as a 
reflection of less neuronal recruitment due to less allocation of attentional resources to 
the task-irrelevant emotion, while P300 latencies might be reduced due to a decreased 
stimulus evaluation time, likewise due to less processing of the task-irrelevant emotional 
content of the images. This interpretation is consistent with the direct relation we found 
between reduced P300 amplitudes and shorter P300 latencies. Furthermore, it is 
consistent with previous studies showing that emotional stimuli elicit an enhanced P300 
as compared to neutral stimuli (Schupp et al., 2004) and longer P300 latencies for 
negative emotional target stimuli (Fichtenholtz et al., 2007) as compared to neutral 
stimuli. Additionally, emotional stimuli outside the attentional focus have been shown not 
to elicit an enhanced P300 (MacNamara and Hajcak, 2009). 
Endocrine relations to auditory distraction were not found in the present study: 
DHEA, DHEAS and cortisol were not related to the novelty-P3, suggesting that their levels 
do not modulate auditory distraction processing under an emotionally negative context. 
This differs from our previous findings concerning auditory distraction under working 
memory load, in which we found that the novelty-P3 amplitude was enhanced in relation 
to higher baseline cortisol/DHEA ratios (do Vale et al., 2014). It also suggests that the 
influence of the endocrine parameters on auditory distraction, may depend on the 
cognitive task involved. 
The present results also highlight the relevance of the balance between DHEA, 
DHEAS and cortisol concerning the processing of negative emotions. Importantly, these 
results agree with findings at the clinical level, in which higher DHEAS concentrations and 
DHEA-to-cortisol ratios but not DHEA levels alone were related to less frequent 
depression, less depressive mood and higher wellbeing scores (Barrett-Connor et al., 
1999; Michael et al., 2000; Young et al., 2002). Although DHEA and DHEAS can be 
converted into each other and general common effects are expected for the sulphated 
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and non-sulphated form of the hormone (Baulieu and Robel, 1998; Dong and Zheng, 
2011; Maninger et al., 2009), several differences exist in their mechanism of action. For 
instance, DHEAS has a much more potent excitatory action by NMDA agonism and 
gabaminergic antagonism than DHEA, which may account for some differential effects 
(Baulieu and Robel, 1998; Imamura and Prasad, 1998; Monnet et al., 1995). Moreover, as 
stated, sulphated steroids in general possibly act as endogenous neuromodulators (Gibbs 
et al., 2006) and the balance between DHEAS and DHEA might influence brain 
functioning. Previous studies at the cellular and molecular level showed that DHEAS had 
neuroprotective effects mediated through GABA-A receptor antagonism (Majewska, 
1992), DHEAS stimulated dopamine release from rat hypothalamic cells (Murray and 
Gillies, 1997) and DHEAS antagonized the neurotoxic effect of high doses of DHEA (Gil-ad 
et al., 2001). These studies suggest potential mechanisms by which DHEAS could have 
more potent anti-depressant effects than DHEA and agree with the present finding that 
higher DHEAS/DHEA ratios were related to reduced processing of the negative emotional 
content. 
In the present study, the participants were in different menstrual cycle phases and 
some were using hormonal contraception. This is a limitation, as DHEA, DHEAS and 
cortisol levels can change along the menstrual cycle and with the use of hormonal 
contraception (Fern et al., 1978; Wiegratz et al., 2003). Nevertheless, eventually in 
relation to the small sample size, in the present study, the endocrine levels were not 
significantly different according to the menstrual cycle phase or the use of hormonal 
contraception. But even considering that DHEA, DHEAS or cortisol levels could change 
along the menstrual cycle or with the use of hormonal contraception, the relations found 
between endocrine levels and emotional stimuli processing would not be invalidated. In 
any case, given the randomized approach we used concerning the menstrual cycle phase, 
the present results are expected to be independent of the menstrual cycle phase. Finally, 
the fact that only female participants were included, limit the outreach of the present 
study only to women. DHEAS levels differ between genders, therefore, another group of 
participants would be necessary to extend our conclusions also to men. For further 





 In a nutshell, in women, during the processing of stimuli with negative emotional 
content, higher DHEA/cortisol and DHEAS/DHEA ratios were related to shorter visual 
P300 latencies, suggesting a relation of these endocrine parameters with shorter stimulus 
evaluation time and less interference with the task at hand due to the processing of the 
task-irrelevant negative content of the visual stimuli. Additionally, higher DHEAS/DHEA 
ratios were related to reduced visual P300 amplitudes suggesting less processing of the 
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In this thesis we studied DHEA and DHEAS behavioral correlates both at the 
personality, performance and electrophysiological level. Relations to personality, working 
memory, negative emotional processing and involuntary attention were explored. 
Furthermore, the relation between baseline DHEAS levels and pituitary-adrenal axis 
reactivity was tested, as well as the DHEA and DHEAS response to the performance of 
cognitive tasks.  
 
DHEA and DHEAS baseline levels and reactivity 
 The first study was a retrospective one, in which the relation between DHEAS and 
pituitary-adrenal axis reactivity in adult humans of both genders was explored. We used 
several specific diagnostic groups. Nevertheless, only results remaining significant 
independent of age and diagnostic group were reported. In this study, only DHEAS and 
not DHEA measurements were used. We expected a stronger relation between DHEAS 
and more stable parameters like age, gender and basal hypothalamic-pituitary-adrenal 
(HPA) axis activity as that hormone has a longer half-life. On the contrary, acute changes 
might have been more easily detected with DHEA, namely after CRH administration. 
In this study, DHEAS levels were significantly higher (37%) in males, as expected (2; 
12; 13; 690; 691). The mean age was 33 years old (ranging from 18 to 57 years old) and 
DHEAS levels were inversely related to age as it was also extensively described in the 
literature (2; 122; 232; 692; 693; 694). We found a 1.4% mean decline in DHEAS levels per 
year while other authors had previously described a decline of about 2% per year during 
adulthood and higher decline rates in post-menopausal women and older men (12; 691; 
695). Age explained 20% of DHEAS variability, gender explained 4% of DHEAS variability 
(men were only 13% of the participants in this study) and age and gender together 
explained 27% of DHEAS variability.  
DHEAS levels were also significantly and directly related to baseline ACTH, 
independent of age, gender and diagnostic group. ACTH explained 14% of DHEAS 
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variability. Age, gender and ACTH together accounted for 34% of DHEAS variability. ACTH 
is not a major factor for DHEAS and DHEA production, and is generally not considered as a 
relevant factor for baseline DHEAS levels. In fact, chronic stress is generally associated 
with increased cortisol levels and decreased DHEAS levels. Moreover, it should be noted 
that despite the ACTH response, no DHEAS response was found in the CRH test, even 
though dexamethasone suppression is known to decrease both cortisol and DHEAS (271). 
All this point to the complexity of the relation between ACTH and DHEAS, especially 
taking into consideration that a putative cortical androgen stimulating hormone (CASH) is 
still to be identified. 
Nevertheless, opposite to findings in chronic stress, in the acute set, CRH 
stimulates corticotrophin and corticotrophin may be a stimulus for both cortisol, DHEA 
(152; 696) and DHEAS (8; 271) secretion, even if ACTH effects on DHEA and DHEAS are 
mediated through some unidentified CASH (697; 698; 699). In the present study, despite 
the ACTH response, mean DHEAS levels did not change in the CRH test, suggesting no 
acute effect of ACTH on DHEAS levels. Also, ACTH responses were not related to DHEAS 
responses. Taking into account the high DHEAS levels and long DHEAS half-life, a longer 
ACTH rise may be necessary to increase DHEAS levels (2), DHEAS may be slower than 
cortisol response (we only measured DHEAS at 0, 30 and 60min intervals) or the effects of 
ACTH in DHEAS secretion may be long time effects, as ACTH is also a trophic hormone 
regarding adrenal androgen secretion (700). However, although DHEAS mean levels did 
not change in response to CRH, individually DHEAS response was variable (–73 μg/dL to 
+317 μg/dL, and only two participants showed an increase higher than 37 µg/dL). In most
subjects (75%), DHEAS levels changed less than 10%. Only 16% and 5% of the subjects had 
a variation in DHEAS level that was higher than 15% and 30% of baseline levels 
respectively.  
Due to its long half-life, important short time changes in DHEAS levels were 
unexpected. Intra and interassay variation coefficients could eventually account for most 
individual changes in DHEAS concentrations, nevertheless, individual mean values during 
the CRH test were related to personality traits, which points against that hypothesis. The 
smaller changes could eventually be justified by adrenal synthesis. Nevertheless, big 
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changes in DHEAS were not expected to rely only on adrenal synthesis and the two 
extreme cases could eventually correspond to outliers. On the other hand, besides 
adrenal synthesis, brain synthesis, transport from brain to periphery and the activity of 
the sulfotransferase and sulfatase, could eventually contribute to the observed changes in 
DHEAS levels. In fact, DHEAS concentrations in the brain are several times higher than in 
the peripheral circulation and the efflux of DHEAS across the blood-brain barrier was 
determined to be tenfold greater than its influx (701). Hence, the peripheral levels of 
DHEAS could also be related to its levels in the brain, but only a small portion of central 
DHEAS is expected to cross the blood brain barrier (0.3%) (83; 85). Regarding the activity 
of the sulfotransferase/sulfatase, it can rapidly convert DHEA to DHEAS and vice versa 
(160).  
Other authors had previously found that besides individual levels of DHEAS, mean 
DHEAS levels could also change in response to stressful stimuli (271; 8). Maninger et al. 
(271) studied monkeys and found significant increases in DHEAS mean levels, 30 min after 
an acute stress (mean levels were around 12 µg/dL at baseline, 15 µg/dL at 30min and 
more than 20 µg/dL at around 120min, corresponding to mean increases of 25% at 30min 
and more than 66% at 120min). Lennartsson et al. (8) studied men and women and also 
found significant changes in mean DHEA and DHEAS levels in response to acute stress, 
with large inter-individual variation in the magnitude of that response. In another study, 
Lennartson et al. (11) also explored DHEA, DHEAS and cortisol responses to stress in 
human subjects. In the low perceived stress group, they found mean changes in DHEAS 
levels of about 1 µmol/L (37 µg/dL), with 95% confidence in intervals ranging from 0.60 to 
1.8 µmol/L (22 to 66 µg/dL). The relative change (percentage increase) of DHEA was 
greater than the relative change in DHEAS, but given the fact that DHEAS concentrations 
were about 300 times higher than DHEA concentrations, the absolute amount of increase 
in concentration of DHEAS during acute stress was much larger than for DHEA. The delta 
DHEAS accounted for the majority of the total increase in DHEA and DHEAS put together 
(by average 98% in that study). Also, in a study of adolescent girls with 
hyperandrogenism, using CRH infusion over 3h, it was found that DHEA increased 5-fold 
and DHEAS increased by 46% (on average) during the CRH infusion (154). 
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The fact that in our study, individual changes in DHEAS responses were related to 
personality parameters whereas there were no mean changes in DHEAS levels, raises the 
eventual hypothesis of the existence of different subgroups of DHEAS reactivity. 
Considering the fact that mean levels did not change, some additional intermediary factor 
could eventually exist, which we did not measure and which might explain the 
modulation or even determine the direction of the DHEAS response to CRH. For instance, 
Boudarene et al. (278) found that subjects with low anxiety levels showed an exclusive 
increase in DHEAS in response to cognitive stress, while subjects with higher anxiety had 
higher cortisol reactivity. Although we did not evaluate anxiety level in this specific study, 
cortisol mean levels increased in response to CRH and we found a direct relation between 
cortisol and DHEAS responses (not considering baseline cortisol and DHEAS levels). In fact, 
although higher baseline DHEAS levels were related to lower peak/baseline cortisol 
responses, DHEAS peak/baseline responses to CRH were also directly related to 
peak/baseline cortisol responses (r=+0.29, p<0.05) whereas DHEAS peak/baseline 
responses were not related to peak/baseline ACTH responses. Therefore, to us, a 
competition in the synthesis and release of DHEAS and cortisol, as Boudarene et al. 
hypothesized (278), does not seem a probable mechanism that could explain the 
individual differences in DHEAS responses. 
In the human fetal and adult pituitary, CRH acts via protein kinase A (PKA). In 
human fetal adrenal cells, CRH increases messenger ribonucleic acid encoding 17alpha-
hydroxylase/17,20 lyase (P450c17), but not 3β-HSD/Δ4-5 isomerase (702; 699). On the 
other hand, 3β-HSD expression is stimulated by ACTH. PKC, but not PKA inhibitors block 
CRH-stimulated P450c17 induction, whereas PKA inhibitors block ACTH-stimulated 
cortisol. Thus, it was suggested that in the human fetal adrenal, CRH is coupled to the 
phospholipase C-inositol phosphate second messenger system and preferentially induces 
the expression of P450c17 and DHEAS via PKC. CRH would act through PKA to increase 
pituitary ACTH response, and then ACTH would stimulate the expression of enzymes 
involved in cortisol synthesis whereas CRH would more directly induce adrenal enzymes 
involved in DHEAS synthesis though PKC. This could provide a potential mechanism for 
CRH stimulation of DHEAS response, independent of ACTH response and therefore 
distinct of cortisol response (702). Also, there is no significant decline in ACTH or cortisol 
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responses to CRH with aging whereas there is an ACTH-independent decline in DHEA 
response to CRH, again suggesting distinct regulatory mechanisms (703). Nevertheless, 
this is not so simple, because ACTH is also a major tropic hormone for adrenal androgen 
secretion, and plays a role in increasing cortisol and DHEA responses to CRH (700). 
In the CRH test, we found that baseline ACTH was strongly and directly related to 
the peak ACTH response and was also directly related to the peak cortisol response and in 
turn baseline cortisol was also strongly related to the peak cortisol response suggesting 
that baseline HPA axis activity was a strong determinant in the response to CRH. ACTH 
was not related to ACTH or cortisol peak/baseline ratio suggesting that ACTH does not 
modulate the intensity of the response, but only that those subjects with higher baseline 
ACTH and cortisol levels naturally reach higher peak ACTH and cortisol levels. The 
influence of DHEAS seemed much subtler. Baseline DHEAS was not related to the peak 
ACTH or peak cortisol response in the CRH test. Similarly, it was not related to 
peak/baseline ACTH response in CRH test but it was inversely related to the peak/baseline 
cortisol response (after age, gender, baseline ACTH and baseline cortisol correction). 
Those results suggest that DHEAS may reduce the magnitude of the cortisol response 
independently of baseline ACTH or cortisol levels. This finding agrees with previous 
evidence that DHEAS may down-regulate cortisol levels (13; 232; 687; 704). 
The reduction of glucocorticoid receptors, the inhibition of glucocorticoid receptor 
dependent transcription activity and the inhibition of 11β-HSD type 1 have been 
hypothesized as possible mechanisms of DHEA anti-cortisol effects. The last one could 
account for reduced cortisol levels, but would not explain why subjects with higher 
DHEAS levels would have reduced cortisol responses to CRH. Eventually, one hypothesis 
could be that long term higher DHEAS levels might modulate the adrenal capacity to 
respond to an acute stress or that subjects with higher baseline DHEAS levels were the 
ones that responded to CRH with reduced cortisol response. In fact, other authors found 
that DHEA acted directly on the rat zona fasciculata-reticularis cells to diminish 
corticosterone secretion by inhibition of the post cyclic Adenosine Monophosphate 
(cAMP) pathway, and decreasing the function of steroidogenic enzymes in P450scc as 
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well as StAR protein expression. More specifically, DHEA attenuated forskolin-stimulated 
SF-1 phosphorylation to affect StAR protein expression (705). 
Then we obtained DHEA, DHEAS and cortisol measurements in two groups of 
healthy young adult female participants before and after the performance of cognitive 
tasks, one group with Working Memory load manipulation and another with emotional 
context manipulation. In these groups, DHEA, DHEAS and cortisol levels were not related 
to age or body mass index, which was not unexpected given the homogeneity of the 
sample regarding these two parameters (mean age was 20±0.5 and 21±1 years old and 
body mass index was 21.8±0.5 kg/m2 and 22.3±0.8 kg/m2).  
As expected, the concentrations of DHEA, DHEAS and cortisol were distinct from 
those found in peripheral blood. We found salivary concentrations of DHEA about 3-11%, 
concentrations of DHEAS about 0.3-1.7% and concentrations of cortisol about 1.0-4.3% (in 
molar ratios), when compared to those expected for peripheral blood (using common 
reference levels). Mean cortisol-to-DHEA molar ratios were about 7 and mean DHEAS-to-
DHEA ratios were around 2.1 when using DHEAS in pmol/h and DHEA in pmol/L (molar 
ratios using pmol/L for both hormones were around 46). Ota and collaborators described 
mean cortisol-to-DHEA ratios in the saliva between 9 to 21 (706; 707). In the peripheral 
circulation cortisol-to-DHEA ratios were about 5-10-20 and DHEAS-to-DHEA ratios were 
100-300 (82).
DHEA and DHEAS concentrations in human brain tissue (homogenates) were 
higher than plasma concentrations, but cerebrospinal fluid concentrations were lower 
than plasma concentrations (82). DHEA was described to be 5% of plasma concentrations 
and cortisol was described to be 6% of plasma concentrations (82). DHEAS was expected 
to penetrate less into the cerebrospinal fluid than DHEA (0.03% of circulating DHEAS was 
expected to cross the blood brain barrier) (83), but the efflux of DHEAS out of the brain 
was also estimated to be tenfold greater than its influx (85) and in adults, the levels of 
DHEAS in the cerebrospinal fluid were still higher than those of DHEA (82). DHEAS-to-
DHEA molar ratio was estimated to be about 100-300 in plasma and 2 in the 
cerebrospinal fluid (82). On the contrary, cortisol-to-DHEA ratio was expected to be 
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similar or a little higher in the cerebrospinal fluid and saliva than in the peripheral 
circulation (82). 
Gooddyer et al. studied blood and saliva of adolescents (84) and proposed a 
similar relationship as that described by Guazzo et al. between blood and cerebrospinal 
fluid levels of DHEA, DHEAS and cortisol (82). It was even suggested that transport into 
the brain and saliva might be, to some extent, comparable and that salivary levels may 
thus give a reasonable representation of those found in the cerebrospinal fluid (82). We 
found a higher DHEAS-to-DHEA molar ratio than those authors. Nevertheless, we used 
corrected for salivary flow rate levels of DHEAS and in that case a similar DHEAS-to-DHEA 
ratio was found (12; 82). In fact, it was described that DHEAS may squeeze through the 
tight junctions between salivary glands (and DHEAS concentrations in saliva are 
dependent on serum concentration and salivary flow rate) (74). We found saliva-to-blood 
ratio of DHEA within the expected level when compared to the one described by Guazzo 
et al. (82). Of note, our DHEA levels were within the salivary reference levels but we did 
not actually measure blood levels in our study, just compared salivary levels with 
common reference levels. 
In the two groups that we used saliva measurements, DHEA and cortisol baseline 
levels were directly related. On the other hand, baseline DHEAS levels (in saliva) were 
directly related to baseline DHEA/cortisol ratios and thus, DHEAS/DHEA levels were 
inversely related to cortisol levels (rs=-0.526, p<0.001, n=43), suggesting a relation 
between higher DHEAS/DHEA ratios and lower stress levels. It also suggested that higher 
baseline DHEAS-to-DHEA ratios could eventually be a measure of lower chronic stress or 
cumulative burden, meaning lower allostatic load (290). It is interesting to note that we 
found a direct relation between DHEA and cortisol baseline levels, but we did not find a 
significant relation between DHEAS and cortisol baseline levels, also suggesting a distinct 
regulation of DHEA and DHEAS levels (considering the correction for the saliva flow rate, 
DHEAS was not related to DHEA, although if we had considered both measurements in 
pg/mL, DHEA and DHEAS levels were directly related – r=+0.514, p<0.001, n=44). The 
sulfotransferase and sulfatase as well as the membrane transport systems may also 
regulate and modulate DHEAS levels in different compartments contributing to those 
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differences (48; 54; 58; 62; 63). Besides, we recently found that (in the saliva of these 
same subjects), baseline DHEAS levels were directly related to baseline CRH (r=+378, 
p=0.005, n=54) but not to cortisol or DHEA levels, whereas cortisol levels were not 
significantly related to CRH or DHEAS levels (708).  
It was not unexpected that CRH was not a significant factor for cortisol levels, 
since peripheral CRH is not a measure of hypothalamic levels (277; 709; 710). CRH could 
eventually stimulate DHEA synthesis through ACTH or another unknown factor 
contributing to the direct relation between DHEA and cortisol levels. On the other hand, a 
direct relation between peripheral CRH and DHEAS levels was found, which was 
independent of cortisol levels (708), therefore suggesting a relation independent of 
hypothalamic CRH. Chronic stress situations are usually accompanied by increased CRH 
and reduced DHEAS levels. Nevertheless, CRH and DHEAS have both neurostimulant 
effects. We studied healthy non-chronically stressed subjects. Besides, as mentioned 
before, CRH may act through PKA to increase pituitary ACTH response, which stimulates 
the expression of enzymes involved in cortisol synthesis whereas CRH may more directly 
induce adrenal enzymes involved in DHEAS synthesis though PKC. This could provide a 
potential mechanism for CRH stimulation of DHEAS response, independent of ACTH 
response, and therefore distinct to cortisol stress response (702). Together with our 
findings, it raises the hypothesis if DHEA might partially respond to ACTH (although the 
response was not equal to the cortisol response, it was directly related), whereas the 
conversion of DHEA into DHEAS could have a more distinct regulation. As mentioned, we 
also found a direct relation between DHEA-to-cortisol ratio and DHEAS levels and an 
inverse relation between DHEAS-to-DHEA ratio and cortisol. Therefore, higher DHEAS 
levels could be a measure of the balance between DHEA and cortisol while higher 
conversion of DHEA into DHEAS would occur in subjects with lower stress/cortisol level.  
As mentioned, DHEA and cortisol baseline levels were directly related. Moreover, 
with the performance of cognitive tasks with Working Memory (WM) manipulation, DHEA 
and cortisol responses were also directly related, independently of the Working Memory 
load content of the task. This is in agreement with the fact that CRH stimulates 
corticotrophin secretion and in turn corticotrophin is a stimulus for DHEA secretion (152; 
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696), even if indirectly through the action of a hypothesized DHEA androgen stimulating 
hormone (697; 698; 699). In fact, DHEA levels were shown to increase in response to 
stress (8) and anti-cortisol effects have been hypothesized to justify it (269; 318; 319). 
Nevertheless, we found important differences between DHEA and cortisol responses to 
Working Memory load manipulation. DHEA levels increased with the performance of the 
second task, independent of the task, suggesting either a cumulative effect or a latent 
interval before the response. Still, the increase in DHEA levels was more pronounced with 
WM load. Thus, the effect of a greater cognitive effort or specific effects of WM load on 
DHEA levels were suggested. Interestingly, this response was specific for DHEA and does 
not occur with cortisol and DHEAS. In fact, regarding cortisol, a decrease was found when 
the subjects were performing the discriminatory task (no Working Memory load). 
Whatever the specific mechanisms involved, there is an interesting point: the distinctive 
pattern of cortisol and DHEA responses. Thus, cortisol decreases after a simple task if this 
task comes first and DHEA increases after a second cognitive task when this is a 
challenging task. 
In the group of participants who performed the protocol with emotional context 
manipulation (one task with neutral and another one with negative emotional context), 
DHEA levels increased after the performance of both conditions, independent of the 
emotional context of the task. Interestingly, a previous study showed that CRH levels 
increased with another cognitive task: the visualization of emotionally significant movies 
(276). In turn, the present results suggest that cognitive tasks are a stimulus for DHEA 
secretion and may lead to a higher DHEA/cortisol ratio. Although CRH stimulates 
corticotrophin secretion and in turn corticotrophin is a stimulus for cortisol and DHEA 
secretion (152), thus explaining the direct relation we found between cortisol and DHEA 
levels, these results furthermore suggest that DHEA was not just a stress hormone and 
that some differential regulation of DHEA and cortisol exists. 
Boudarene et al. (278) studied subjects without mental disorders and varying 
levels of anxiety, and found that the level of anxiety was related to the profile of 
endocrine response after the performance of cognitive tasks: subjects with high anxiety 
levels in the State-Trait Anxiety Inventory (STAI) test had increased cortisol reactivity and 
214 
subjects with low anxiety levels showed an exclusive increase in DHEAS levels. The 
authors suggested that the antagonism in DHEAS and cortisol might be related to 
competition in their synthesis and its release by the adrenal gland. Although the 
underlying mechanism is not clarified, these results agree with the results in the present 
study, in which all the subjects were found to have low anxiety levels and a DHEA raise 
but no cortisol response was observed in relation to the cognitive task (in both emotional 
conditions). For non-pathological conditions and low levels of anxiety, this might 
eventually represent an adaptive mechanism that includes higher DHEA than cortisol 
responses and anti-cortisol effects of DHEA. DHEA increase however was identical for 
both emotional contexts, so that DHEA increase alone was not expected to be related to 
performance or electrophysiological effects of the emotional context. Opposite to the 
observed DHEA responses, DHEAS mean levels did not change with working memory load 
or emotional manipulation.  
DHEAS relation to Personality 
We expected a stronger relation between DHEAS (than DHEA) and more stable 
parameters as personality as that hormone has a longer half-life. We explored the 
relations between DHEAS and Type A personality and superordinate trait (Neurotic Triad, 
Psychotic Dyad and Behavior-Deviant) scores obtained from the MMPI (688). Type A 
personality was conventionally defined by using the specific group of 11 items selected 
from the MMPI; Neurotic Triad: hypochondriasis + depression + hysteria; Psychotic Dyad: 
paranoia + schizophrenia; and Behavior-Deviant triad: psychopathic deviate + masculinity-
femininity + hypomania (688). Lower DHEAS levels were related to higher Neurotic Triad 
scores. However, that relation was no longer significant after age correction, and in fact, 
age was directly related to Neurotic Triad score. This was surprising, not only because 
personality is generally considered as a stable personal characteristic established at a very 
early stage of life but also because our sample was young. Nevertheless, aging was 
previously described to be related to increased Neurotic Triad scores (711) and decreased 
DHEAS baseline levels and that seems to be the reason for this spurious relation between 
DHEAS and Neurotic Triad scores. 
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Higher DHEAS levels have been previously described in subjects with greater 
sensation-seeking and monotony-avoidant traits (357) and lower Type A behavior scores 
(355). In the present study, baseline DHEAS levels were not significantly related to any of 
the selected psychometric variables, pointing to the lower sensitivity of baseline 
endocrine levels. However, DHEAS reactivity in the CRH test was significantly related to 
Behavior Deviant triad and Type A personality and both relations persisted independent 
of age, gender and diagnostic group. Endocrine reactivity in the CRH test, regarding the 
ACTH and cortisol response, had been previously shown to be related to other 
psychometric variables (340; 341; 342; 344; 712; 713). In our study, higher DHEAS 
responses were associated with higher Type A behavior and Behavior Deviant triad 
(psychopathic deviation + hypomania + masculinity-femininity) scores and more 
specifically with psychopathic deviate score. Although the present results point towards a 
relation between DHEAS and the same group of personality traits that have previously 
been described, the relations do not follow in the same direction. Nevertheless, the 
relation between baseline DHEAS levels and DHEAS response is not necessarily direct. On 
the contrary, subjects with higher cortisol levels in the chronic set may have lower cortisol 
responses under stress. 
DHEA and DHEAS relations to Working Memory processing and involuntary attention 
We explored the relationships between cognitive performance and endogenous 
DHEA, DHEAS and cortisol. As expected, the audio-visual distraction paradigm including a 
manipulation of working memory, yielded typical effects as observed in previous studies. 
Indeed, the WM load task was harder to perform, as revealed by lower hit rates and 
longer reaction times. Likewise, novel sounds distracted the participants, as reflected by 
lower hit rates and longer reaction times. Regarding brain responses to novel sounds in 
both the discrimination (no WM load) and Working Memory load (WM load) tasks, the 
results revealed a novelty-P3 deflection, indicating that novel sounds caused distraction 
when compared to standards. The N2b elicited by the task-relevant visual stimuli was 
enhanced under WM load as expected (508). 
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 Stangl et al. (714) demonstrated that DHEA administration increased DHEA levels 
and enhanced performance in a visual, same-different task (without WM load) while 
cortisol levels remained constant. However, other studies failed to provide systematic 
evidence that DHEA or DHEA administration enhanced short-term memory at the 
performance level (328; 331). In the present study, endogenous levels of DHEA, DHEAS 
and cortisol were measured and no significant relations were found to the accuracy or 
latency of the response. Nevertheless, a bigger sample of subjects may be necessary to 
uncover eventual relationship at the performance level. 
 On the other hand, this study demonstrated endocrine relations to the 
electrophysiological recordings. Rapid effects of DHEA or DHEAS reflected at the 
electrophysiological level could eventually result from rapid non-genomic effects of these 
hormones, by acting at ionic channels like NMDA and GABA-A membrane receptors. On 
the other hand, one could also hypothesize that long term changes in DHEA and DHEAS 
could eventually promote genomic effects that could then potentially modulate 
electrophysiological responses. Against these long term effects, no high affinity nuclear 
receptor of DHEA was identified so far, and direct genomic effects of DHEA and DHEAS 
are unknown. Nevertheless, DHEA and DHEAS may modulate, for instance 
glucocorticoids’ effects, which are known to have genomic effects. Moreover, DHEA and 
DHEAS were shown to increase neurite growth and therefore suggested to influence in 
cortical organization (15).  
In the WM task, we found that higher baseline cortisol/DHEA ratio was related to 
more processing of the distracting stimuli, as indexed by an enhanced novelty-P3. This 
suggests that baseline cortisol enhances, whereas baseline DHEA prevents auditory 
distraction (meaning involuntary attention to exogenous novel sounds), and 
simultaneously suggesting an anti-cortisol effect of DHEA. The fact that this relation 
became evident in the most stressful situation (WM load) agrees with previous evidence 
showing that DHEA has anti-cortisol effects under stress (283; 318) or that these effects 
are more evident under stress. 
 High cortisol levels or long term increases in cortisol levels are expected to 
decrease working memory performance whereas mild or short-lasting increases in 
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cortisol have been described to have beneficial effects on attention and memory (220; 
633; 634; 635; 636; 637; 638). We studied healthy subjects with normal anxiety scores (as 
evaluated by the Stait-Trait Anxiety Inventory) and normal cortisol levels. Nevertheless, 
higher cortisol-to-DHEA ratios were related to enhanced involuntary attention processing 
and simultaneously with a trend towards reduced processing of the target stimuli.  
We also explored the relationship between DHEAS-to-DHEA balance and brain 
processing of exogenous stimuli during the performance of a working memory task. 
Higher DHEAS-to-DHEA ratios were also related to enhanced novelty-P3 during the 
performance of the visual working memory task. This suggested a relationship between 
higher DHEAS-to-DHEA ratios and enhanced acoustic novelty processing during visual 
working memory tasks and more generally, that higher DHEAS-to-DHEA ratios might 
eventually be related to enhanced involuntary attention to exogenous stimuli (auditory 
distraction) during the performance of working memory tasks. 
Clinical findings in patients with Alzheimer’s disease already suggested beneficial 
effects of higher DHEAS-to-DHEA balance concerning memory (107; 447; 451). In fact, 
DHEA and DHEAS present a general neurostimulatory effect: presynaptic actions include 
glutamate, acetylcholine and norepinephrine release and postsynaptic actions include 
sigma 1 receptor agonism with subsequent N-methyl-D-aspartate (NMDA) receptor 
activation, γ-aminobutyric acid type A (GABA-A) receptor antagonism and inhibition of 
voltage-gated calcium currents (3; 7; 120). As mentioned, DHEAS has a much more potent 
excitatory action than DHEA concerning NMDA agonism (209; 315) and gabaminergic 
antagonism (184; 715) which may account for differential effects of both forms of the 
hormone (1; 184; 196). Furthermore, inhibiting the conversion of DHEAS to DHEA was 
shown to enhance cholinergic function in the hippocampus and improve memory in rats 
(208; 209; 210; 452) and DHEAS antagonized the neurotoxic effect of DHEA in 
neuroblastoma cells (238). The findings at the clinical level and the ones in our studies 
both point towards the importance of the sulfotransferase (the enzyme that converts 
DHEA into DHEAS) activity. 
On the other hand, reducing the conversion of DHEAS into DHEA in mice impaired 
accuracy under attention demanding conditions (320) and subjects with lower DHEA 
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levels, lower DHEAS levels (716) or steroid sulfatase deficiency have higher rates of 
attention deficit hyperactivity disorder (322), therefore suggesting a relation between 
DHEAS deficiency, DHEA deficiency and high DHEAS-to-DHEA ratio and more distraction. 
These findings agree with the present findings in which a higher DHEAS-to-DHEA ratio 
was related to an enhanced processing of the auditory distractor. Nevertheless, in the 
present study the participants had normal DHEAS and DHEA levels and no deleterious 
effects of higher DHEAS-to-DHEA ratio on working memory processing or performance 
were found. Besides, methylphenidate [a central stimulant which increases oxidative 
stress namely lipid peroxidation and brain derived neurotrophic factor amongst others 
(717; 718)] administered to boys with attention deficit hyperactivity disorder had been 
shown to increase serum levels of both DHEAS and DHEA and simultaneously causing 
marked clinical improvement (323). 
Novelty-P3 is an index of the effective orienting of attention towards the 
distracting event (477; 479; 480). We found a trend for a relation between higher 
cortisol/DHEA ratios and reduced visual P300 amplitudes attributed to working memory 
load (rs=-0.52, p=0.014, n=22), suggesting that higher cortisol-to-DHEA ratios increased 
distraction from the visual working memory task. Nevertheless, the relation between 
higher DHEAS-to-DHEA ratios and increased involuntary auditory novelty processing 
occurred with no deleterious effect on the visual target stimuli processing. In fact, there 
was no relation between DHEAS-to-DHEA ratios and visual P300 amplitudes, therefore 
suggesting that the increased involuntary attention to novel sounds did not distract the 
subjects from the visual working memory load task. Additionally, there was no increase in 
novelty-P3 or visual P300 latencies and therefore, the increased involuntary attention to 
novel sounds did not occur at the expenses of longer stimulus evaluation times. In this 
context, the increased attention to unexpected novel sounds may be protective, 
maintaining involuntary attention to the surrounding world while voluntarily directing 
attention to the performance of the working memory load task. 
Hence, DHEAS-to-DHEA balance may constitute an endogenous factor modulating 
exogenous attention mechanisms during the performance of cognitive tasks that require 
an active maintenance of information in working memory. The present results suggest 
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that subjects with higher baseline DHEAS-to-DHEA ratios might eventually have more 
attention resources available during the performance of working memory load tasks. 
Long term transcriptional effects of higher DHEAS-to-DHEA ratios, either directly or by 
inhibiting cortisol transcriptional effects could eventually contribute to long term increase 
of attentional resources. We also found a significant relationship between higher DHEAS-
to-DHEA ratios and lower cortisol levels (719) [therefore suggesting lower chronic stress 
and lower cumulative burden or lower allostatic load (290) in subjects with higher DHEAS-
to-DHEA ratios]. Nevertheless, cortisol levels alone did not have the same meaning as 
they were not inversely related to novelty-P3 processing during the performance of the 
same working memory load task (720).  
It has been suggested that working memory results in prefrontal cortex activation 
and, in turn, a reduction of distraction (514; 520; 522; 523; 721). Moreover, it was also 
suggested that distractor stimuli could trigger prefrontal cortex activity and suppress the 
input of sensory information, thus preserving the contents of working memory from 
being disrupted by the distractor stimuli (722). Nevertheless, the present results suggest 
that higher DHEAS-to-DHEA levels may contribute to enhanced activation caused by 
irrelevant stimuli while contributing to maintained sensory activation related to the task. 
Interestingly (although its meaning is not known), working memory, attention and 
emotion involve prefrontal cortex activity (519; 520; 521; 597), DHEAS concentrations are 
lower and DHEA concentrations are higher in the prefrontal lobe when compared to the 
posterior brain areas (4). It has also been suggested relationships between DHEAS and 
DHEA, working memory, attention and emotional processes (293; 294; 295; 317; 451; 
720; 723).  
Moreover, the relations of DHEAS-to-DHEA ratio to brain processes seem to 
depend on the cognitive task involved. DHEAS-to-DHEA ratio was related to novelty-P3 
processing during a visual working memory load task, but not during the visual 
discrimination task (no working memory load task). In the study using a visual emotionally 
negative context we also found no relation between DHEAS-to-DHEA ratio and 
involuntary attention to novel sounds, but higher DHEAS-to-DHEA ratios were related to 
reduced processing of negative emotional stimuli and shorter stimuli evaluation time. 
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Distinct patterns of receptors and neurotransmitters in different brain structures and 
circuits as well as circuit interactions may originate different effects of DHEA and DHEAS 
(233; 234) in different cognitive functions. Also, different DHEAS-to-DHEA gradients may 
eventually exist in different brain structures (4) involved in different functions, which 
could also contribute to these differences, but then little is known. 
 Regarding ERPs to the visual target stimuli, DHEA effects on WM load pointed 
towards increased visual P300 amplitudes. In fact, the rise in DHEA due to WM load was 
related to enhanced P300 amplitudes indicating enhanced memory update and 
suggesting a rapid DHEA behavioral effect. Endocrine responses to stimuli are commonly 
used and they usually provide higher sensitivity than baseline levels to detect pathological 
conditions or inter-subject differences (11; 339; 724). As an example, glucocorticoids 
responses to different stimuli can be used to measure the adrenals functional reserve 
(predicting their response to stress) or to characterize different phenotypes of the stress 
response (which were related to personality traits and pathological conditions) (725; 340; 
341; 342; 726). Accordingly, in the present study, the parameter related to working 
memory processing was DHEA response and not baseline DHEA. Also, apart from its slow 
genomic effects, corticosteroids are known to have rapid non-genomic central nervous 
system effects (220; 638; 639).  
 Alternatively, the relation between visual P300 amplitude and DHEA response 
could suggest that subjects with enhanced working memory update are the ones with 
higher DHEA responses. In that regard, other authors demonstrated that chronic stress 
and higher cortisol levels were related to poorer memory (634; 636; 637) and reduced 
DHEAS responses to a superimposed psychological stress (11). Nevertheless, we found no 
relation between baseline cortisol and visual P300 amplitude, and therefore, an effect of 
chronic stress was not suggested. Wolf et al. (24) studied the effects of DHEA 
replacement on short term memory ERPs. They reported an increase in P3 amplitude 
after DHEA replacement, which reflected an enhancement of information updating. This 
is in accordance with our results, as we also observed that the physiological DHEA 
increase was related to an enhanced visual P300. 
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A short term increase in cortisol can damage hippocampal neurons and may 
impair memory (574). This may be an oversimplification since specific types of 
hippocampal mediated memory may be impaired by stress but others may not (727; 728). 
Yet, and hypothesizing that DHEA might prevent memory impairment under stress, Wolf 
et al. (327) found that DHEA replacement enhanced attention but did not prevent the 
decline in visual memory under an acute psychosocial stress. This result did not support 
the idea of a direct anti-glucocorticoid effect of DHEA in hippocampal mediated memory 
functions. In another study DHEA protected hippocampal neurons against excitatory 
amino acid-induced neurotoxicity (232). Our results also supported the idea of DHEA anti-
cortisol effects in distraction, but regarding working memory, we found a relationship 
with DHEA, not cortisol. Moreover, normal ranges of baseline cortisol were observed and 
cortisol levels did not rise with WM load, nor did they decrease. 
Recent results also suggest that repeated stress and consequent activation of the 
glucocorticoid receptors dampens prefrontal cortex glutamatergic transmission. Actually, 
it facilitates glutamate receptor turnover, which has a detrimental effect on prefrontal 
cortex-dependent cognitive processes (729) like Working Memory. The present results 
agree with the known action of DHEA on glutamatergic receptors as well as with the idea 
that DHEA opposes cortisol detrimental effects during the performance of working 
memory tasks under stress. This last relationship was evidenced by inverse relation of 
DHEA and cortisol to distraction. 
Nevertheless, working memory effects were related to the DHEA response but not 
to cortisol. Thus, regarding WM effects, an anti-cortisol effect of DHEA was not so evident 
but other specific effects of DHEA may be present. As mentioned, besides their 
anticortisol effects, DHEA has Gamma Aminobutyric Acid Type A (GABA-A) receptor 
antagonism and sigma 1 agonist effects (1; 3; 7) which might underlie or contribute to the 
effects found. In fact, both gabaminergic antagonism and glutamatergic agonism are 
known to improve cognitive function. 
Of note, we found no relation between baseline DHEA or DHEAS and performance 
or ERPs. Instead, baseline cortisol/DHEA ratio, DHEAS/DHEA ratio and DHEA response 
relationship to ERPs were found. If DHEA and DHEAS have mostly modulatory effects over 
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ion channels and anti-cortisol mechanisms of action instead of specific receptors and 
effects, and if DHEAS also function as a pro-hormone regarding these cognitive effects, 
that by itself might contribute to the relevance of baseline cortisol/DHEA and 
DHEAS/DHEA ratios instead of baseline DHEA or DHEAS levels alone. 
DHEA and DHEAS relations to emotional processing 
The study with emotional context manipulation revealed relations between DHEA, 
its sulfated form (DHEAS) and brain processing under an emotionally negative context 
induced by images of fearful faces, suggesting that these neurosteroids may modulate the 
processing of emotionally negative information. Although the sounds as well as the 
emotional content of the pictures were irrelevant for the task, the results suggest that the 
subjects were unable to fully ignore them as indicated by significant effects on 
performance and brain responses. The distraction effect of task irrelevant auditory stimuli 
as well as the behavioral disruption due to the processing of task irrelevant negative 
emotional stimuli have been shown before by other authors (477; 479; 509; 534; 535), 
whereas the relation between these neurosteroids and emotional processing at the brain 
level is a new finding. 
Novel sounds led to distraction as shown by longer response times and the 
elicitation of a significant novelty-P3. Conversely, no clear N1-enhancement/MMN was 
observed in our results, probably due to a very early P3 onset, causing an overlap 
between the components. Recent studies have shown that small deviant stimuli, and 
hence large novel sounds, may activate deviance-detection mechanisms as early as 20 ms 
from sound onset (730; 731) and therefore attention switching may have had occurred 
before the supratemporal activation giving rise to the typical N1-enhancement/MMN 
trigger response (732). Additionally, in the negative emotional context, response times 
were longer than in the neutral context which implicated that the novel sounds 
effectively caused distraction and the emotionally negative context effectively disrupted 
performance. However, the emotional context did not significantly modulate the 
electrophysiological response to auditory distraction, contrasting with previous studies 
223 
 
(509; 544) which found an enhancement of the novelty-P3 and also found an 
enhancement of the visual P300 for emotionally negative stimuli (509). Nevertheless, in 
studies using faces, some authors have found visual P300 enhancement to fearful faces 
(542), while others reported no changes in P300 amplitude (543) as in the present study. 
Importantly, in the present study, the emotional content of the images was not relevant 
for the task.  
No significant relation was found between response times or hit rates and 
endocrine measurements. As mentioned before, a larger sample may be necessary to 
uncover endocrine relationship to performance. Nevertheless, interesting findings of this 
study were the endocrine relationships to brain responses. A higher DHEA/cortisol ratio 
was related to lower visual P300 latencies in the negative emotional context, suggesting 
DHEA to be protective from an interference of the implicit negative content of the stimuli 
with the task which might represent an anti-glucocorticoid effect of DHEA. In the negative 
condition, higher DHEAS/DHEA ratios were also related to lower visual P300 latencies, 
thus, a higher proportion of DHEA respective to cortisol and a higher proportion of 
sulfated to non-sulfated form of DHEA may provide protection from any interference with 
the task caused by the processing of the implicit emotional content of the stimuli. 
In agreement, higher DHEA levels have been previously found to be related to 
shorter P300 latencies (625; 733). A protective effect of DHEA and DHEAS could 
eventually be mediated by anti-cortisol effects and/or neuromodulatory effects of these 
hormones. Wang et al. (734) associated a prolonged P300 latency with an attentional bias 
to negative stimuli in high trait anxiety subjects, who were expected to have higher 
cortisol levels. On the contrary, in the present study, examining subjects with low trait 
anxiety, higher DHEA/cortisol ratios were related to shorter P300 latencies in the negative 
condition. Higher DHEA/cortisol could be related to less interference with the task caused 
by the implicit stressful content of the stimuli, in agreement with the hypothesis of anti-
cortisol effects of DHEA and suggesting a protective mechanism against the deleterious 
consequences of stress. The present results also agree with studies at the cellular level, in 
which DHEA was protective against the neurotoxic effects of corticosterone (262). 
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Lastly, the visual P300 amplitude increments in the negative emotional context as 
compared to the neutral one, were inversely related to DHEAS/DHEA ratios, suggesting 
that the processing of the task-irrelevant negative content of the stimuli might eventually 
be reduced by a higher proportion of DHEAS in relation to DHEA. Even though the 
participants of the study were healthy and depression was not screened by any specific 
inventory, women in particular have been shown to be especially sensitive to threatening 
stimuli and it has been hypothesized that this might be related to the higher prevalence 
of affective disorders in women (735). Enhanced negative affect is an integral 
characteristic of depressive disorders and negative mood can be experimentally induced 
using various procedures, among others by presenting images of faces with emotional 
expressions (736; 737; 738).  
Although the mechanisms underlying mood persistence in major depressive 
disorder remain poorly understood, cognitive theories hypothesize that depressed 
patients have cognitive biases for emotional information, which help perpetuate 
depressive symptoms (739; 740). The present results suggest that the processing of 
negative emotional stimuli may be reduced in relation to higher DHEAS/DHEA levels, 
which might eventually be involved in protective mechanisms against a negative attention 
bias and undermine the relation between higher DHEAS levels and lower frequencies of 
depression, lower depression ratings and better wellbeing scores previously described by 
other authors (18; 20). In line with this hypothesis, subjects with higher DHEAS/DHEA 
ratio would process less and have less memory updating of the implicit negative content 
of the stimuli and would thus have a reduced attentional bias towards these stimuli, 
which might promote wellbeing and contribute to protection from depressive states. 
Emotional stimuli usually capture attention more effectively than non-emotional 
ones (534) and have an impact on cognitive functions even when they are task-irrelevant 
(509). On the other hand, it is hypothesized that protective mechanisms filter out 
irrelevant sensory inputs protecting the higher brain functions from sensory overload 
(741). Taken together, our findings concerning visual P300 latency and visual P300 
amplitude under an emotionally negative context showed a relation between higher 
DHEA/cortisol and DHEAS/DHEA ratios and lower processing of the negative emotional 
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stimuli and less disruption by the processing of negative emotional stimuli. These results 
also suggest that DHEA and DHEAS potentially play a role or contribute to protective 
mechanisms filtering out negative information overload. 
 A simultaneous relation to latency reduction and decrease in P300 amplitude may 
seem contradictory at first sight, nevertheless, as the task consisted in deciding whether 
two faces with the same emotional expression were equal or different (while the 
emotional expression was irrelevant), lower processing of the task-irrelevant emotional 
content – related to higher DHEAS/DHEA ratios - was reflected in smaller P300 amplitudes 
and at the same time shorter P300 latencies, providing a more efficient processing of the 
task-relevant visual information, and less interference resulting from the task-irrelevant 
emotion. In other words, the P300 amplitude might be reduced as a reflection of less 
neuronal recruitment due to less allocation of attentional resources to the task-irrelevant 
emotion, while P300 latencies might be reduced due to a decreased stimulus evaluation 
time, likewise due to less processing of the task-irrelevant emotional content of the 
images. This interpretation is consistent with the direct relation we found between 
reduced P300 amplitudes and shorter P300 latencies. Furthermore, it is consistent with 
previous studies showing that emotional stimuli elicit an enhanced P300 (742) and longer 
P300 latencies for negative emotional target stimuli (743) when compared to neutral 
stimuli. Additionally, emotional stimuli outside the attentional focus have been shown not 
to elicit an enhanced P300 (744). 
 Endocrine relationship to auditory distraction was not found in the present study: 
DHEA, DHEAS, cortisol, DHEA-to-cortisol or DHEAS-to-DHEA ratio were not related to the 
novelty-P3, suggesting that their levels did not modulate auditory distraction processing 
under an emotionally negative context. This differs from our previous findings concerning 
auditory distraction under working memory load, in which we found that the novelty-P3 
amplitude was enhanced in relation to higher baseline cortisol/DHEA ratios and higher 
DHEAS/DHEA ratios. As mentioned, it also suggests that the influence of the endocrine 
parameters on auditory distraction, may depend on the cognitive task involved. 
 Again, the present results also highlighted the relevance of the balance between 
DHEA, DHEAS and cortisol, concerning the processing of negative emotions. Importantly, 
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these results agree with findings at the clinical level, in which higher DHEAS 
concentrations and DHEA-to-cortisol ratios but not DHEA levels alone were related to less 
frequent depression, less depressive mood and higher well-being scores (20; 365; 366). As 
mentioned before, although DHEA and DHEAS can be converted into each other and 
general common effects can be expected for the sulfated and non-sulfated form of the 
hormone (1; 3; 7), several differences exist in their mechanism of action. DHEAS has a 
much more potent excitatory action by NMDA agonism and gabaminergic antagonism 
than DHEA (1; 184; 196) and sulfated steroids possibly act as endogenous 
neuromodulators (207). Therefore, the balance between DHEAS and DHEA might 
influence brain functioning. Previous studies at the cellular and molecular level showed 
that DHEAS had neuroprotective effects mediated through GABA-A receptor antagonism 
(185), DHEAS stimulated dopamine release from rat hypothalamic cells (252) and that 
DHEAS antagonized the neurotoxic effect of high doses of DHEA (238). These studies 
suggest potential mechanisms by which DHEAS could have more potent anti-depressant 
effects than DHEA and agree with the present finding that higher DHEAS/DHEA ratios are 
related to reduced processing of the negative emotional content. 
Integrating the present results with previous knowledge of DHEA and DHEAS regulation 
and physiological effects 
Some authors defend that there is an unidentified adrenal androgen stimulating 
hormone (AASH) (697; 698; 699) whereas others defend the notion that adrenal 
androgen synthesis depends on the relative activities of adrenal enzymes and DHEA 
sulfotransferase activity and that ACTH alone is involved in this process (152; 696). 
Concerning the modulation of glucocorticoid and adrenal androgen levels, the literature 
suggests that in the chronic setting, ACTH may be an adrenal trophic factor, therefore 
increasing cortisol, DHEA and DHEAS synthesis (700). The present results agree with those 
results, as baseline ACTH levels explained part of baseline DHEAS levels, even if only a 
minor part of DHEAS variability was explained by baseline ACTH levels (745). An acute 
increase in ACTH levels may preferentially stimulate cortisol synthesis and to a lower 
extend it might also stimulate DHEA synthesis, whereas CRH may stimulate pituitary ACTH 
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and also directly stimulate adrenal DHEAS synthesis (154; 702). This would also agree with 
the direct relation we found between cortisol and DHEA, both baseline and reactivity, 
although the relative responses of cortisol, DHEA and DHEAS were different (719; 720; 
723; 745). Because only a minor part of baseline DHEAS variability was explained by 
baseline ACTH and different responses of DHEA and cortisol were found our results 
suggest other regulating factor(s) besides ACTH (720; 723; 745). 
 One hypothesis to integrate the present findings with previous research would be 
that chronic stress could eventually promote higher chronic CRH levels, with pituitary 
chronic stimulation of ACTH synthesis, higher adrenal cortisol-to-DHEA production, and 
therefore lower baseline DHEAS and subjects with higher baseline cortisol would also 
have lower DHEA to DHEAS conversion. Without chronic stress (low anxiety subjects), low 
baseline CRH could eventually lead to low baseline ACTH and directly stimulate the 
adrenal to preferentially produce more DHEA than cortisol and therefore also higher 
DHEAS levels and higher DHEA to DHEAS conversion. That would also agree with our 
findings, in which subjects with higher DHEA-to-cortisol ratio were the ones with higher 
DHEAS levels and subjects with higher cortisol levels had lower DHEAS-to-DHEA ratios 
(719; 720; 723). As CRH effects may occur at the level of enzymatic synthesis (699; 702), 
these may be long term effects and it is to be expected that long term stress may affect 
the acute response of the adrenal to a stressful event (11). Nevertheless, in subjects with 
low anxiety trait and state, we found that higher baseline CRH was also directly related to 
higher baseline DHEAS, independently of baseline cortisol or DHEA levels (708). 
Therefore, it agrees with other studies that suggested that CRH may directly 
(independently of ACTH) stimulate DHEAS synthesis (702). Nevertheless, we found no 
rapid changes in CRH (data not shown) or DHEAS levels in response to cognitive tasks 
when DHEA levels changed, suggesting that CRH may not be the major stimulus for DHEA 
secretion in these situations. 
 Subjects with high chronic stress are known to respond with less ACTH surge but 
increased adrenal cortisol response. Additionally, in the present hypothesis, those 
subjects could eventually respond with proportionally less DHEA and DHEAS. On the 
contrary, subjects without chronic stress, would respond with more ACTH but the adrenal 
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would be prepared to produce proportionally less cortisol and more DHEA in response to 
an acute ACTH surge as compared to chronic stress subjects, and the CRH surge would 
also stimulate the adrenal to produce proportionally more DHEAS. Also, higher DHEA and 
DHEAS would reduce the acute cortisol response to a stressful event (13; 232; 687; 704) 
by modulating enzyme activity (705), which also agrees with our results (745). The 
sulfotransferase and sulfatase levels and activity could also contribute to modulating 
DHEAS-to-DHEA levels. For instance, the sulfotransferase was shown to be down-
regulated during infection, inflammation and the euthyroid sick syndrome (174; 175; 
176). The liver could also contribute to the balance between DHEAS and DHEA, and the 
brain, by having higher DHEAS and DHEA levels than the peripheral blood, it could also 
contribute to peripheral levels of these hormones, in particular concerning peripheral 
DHEA levels (as this is expected to easily cross the blood brain barrier). In the brain, 
eventually, higher oxidative stress might induce more DHEA synthesis and decrease the 
DHEAS-to-DHEA ratio (109; 110). 
Stressful stimuli, namely psychological ones, stimulate DHEA and cortisol 
secretion. Interestingly, we found that DHEA increased in response to cognitive tasks 
performance (720; 723). This could result from stress inherent to those tasks, but DHEA 
and not cortisol increase was found, suggesting a preferential DHEA rather than cortisol 
response in low anxiety subjects (720; 723). Moreover, the increase in DHEA was higher 
for the working memory load task, also suggesting a possible specific effect of working 
memory tasks (720). In any case, the present results suggest that cognitive tasks may 
constitute a stimulus for DHEA secretion and may eventually increase DHEA-to-cortisol 
ratios. Furthermore, a distinct regulation of DHEA and cortisol secretion also seems 
apparent. 
The rapid effects of DHEA and DHEAS may occur through the modulation of 
membrane ion channels, receptors and neurotransmitters (3; 7). Cortisol is also known to 
have rapid effects through such mechanisms (220). DHEA and DHEAS differ in a sulfate 
group, therefore, different effects on ion channels are expected. On the other hand, 
baseline levels, may traduce long term effects, even organizational ones (189; 242), either 
through the modulation of cortisol effects (231; 262; 263) or through the modulation of 
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enzyme activity or genomic processes (3; 7), even if there is no specific membrane or 
nuclear receptor (7). For instance, these hormones may modulate cortisol genomic 
effects (231). Also, the balance between DHEA and cortisol and DHEAS and DHEA may 
traduce either different or opposite effects of these hormones or eventually that these 
ratios may involve some unknown regulatory factor. Endocrine phenotypes are 
established early in life, meaning that each person has a typical baseline and reactivity 
endocrine pattern, which is relatively stable, while inter-individual differences are higher 
(339). Personality is also established early in life and relatively stable (338) and we found 
a relation between DHEAS reactivity and personality profile, in particular related to 
behavior deviant triad and type A personality. 
 Concerning central effects, mainly relations to attention, memory and humor have 
been suggested for DHEA and DHEAS. Although most studies with DHEA reposition failed 
to find beneficial results in memory, results found in literature suggest that higher 
endogenous DHEAS, DHEAS-to-DHEA and DHEA-to-cortisol ratios may enhance working 
memory (7). In particular, lower DHEAS-to-DHEA ratios were found in Alzheimer’s disease 
(107; 447; 451), whereas higher DHEAS-to-DHEA ratios (in sulfatase deficiency) were 
found in attention deficit disorder (322), thus suggesting that higher DHEAS levels may be 
important for long term memory but also that high DHEAS or low DHEA may enhance 
distraction. We found that higher DHEA reactivity was related to enhanced working 
memory (720). On the contrary, higher cortisol-to-DHEA and DHEAS-to-DHEA were 
related to enhanced distraction, but (in the present results), whereas higher cortisol-to-
DHEA might compromise the processing of a concomitant working memory task, maybe a 
higher DHEAS-to-DHEA would not. Therefore, anti-cortisol effects of DHEA were 
suggested regarding distraction whereas specific rapid DHEA effects were suggested 
regarding working memory processing. We found no relation between DHEAS levels alone 
and working memory processing. 
 The present results agree with previous studies which suggest that DHEA, DHEAS 
and cortisol may modulate memory processes and eventually oppose some deleterious 
effects of high cortisol levels on memory. Previous studies suggest that mild or short-
lasting increases in cortisol due to stress generally have beneficial effects on attention 
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and memory, whereas high cortisol levels or long term increases are related to poorer 
prefrontal cortex working memory, poorer executive functioning, poorer learning and less 
cognitive flexibility (220; 633; 634; 636; 637; 638; 639; 641; 644). Higher DHEA levels have 
also been related to higher hippocampal volume, increased cortical thickness of the 
prefrontal cortex and other areas involved in memory processes as well as early 
activation of the anterior cingulate cortex, whereas higher cortisol levels were correlated 
to lower hippocampal volume and reduced memory capacities (448). The effects of 
cortisol on memory also depend on timing, with stress immediately before or after a 
stimuli enhancing memory, whereas a stress prior to retrieval may impair memory (573). 
DHEA and DHEAS baseline levels and reactivity might eventually influence different 
phases of memory processes, but little is known.  
Concerning humor, higher DHEAS or DHEA-to-cortisol ratios have been proposed 
to be related to less depression ratings and small DHEA reposition studies also support 
that effect (362; 383; 384; 385). Our study suggests that higher DHEA-to-cortisol and 
higher DHEAS-to-DHEA may protect against interference/disruption by the negative 
content of the stimuli and higher DHEAS-to-DHEA ratio may be related to less processing 
of the negative content of the stimuli (723). Less attention to negative stimuli may 
eventually be protective against depressive states and undermine the relation between 
higher DHEAS levels and less depression found in clinical studies.  
Concerning emotional processing, cortisol increases the processing and memory 
for emotional stimuli (648). Previous studies associated chronic increases in cortisol levels 
to more errors in the categorization of emotional stimuli, increased activity in the 
hippocampus and altered prefrontal cortex function (647). On the other hand, the 
present study and previous neuroimaging studies, suggest that DHEA and DHEAS may 
downregulate the negative emotions induced by aversive stimuli (25; 723). During 
emotional processes, higher DHEA levels were previously related to reduced activity in 
the amygdala and hippocampus (which were involved in the generation of negative 
emotions) and an increased connectivity between these two regions (25). 
 The fact that DHEA and DHEAS have neuro-excitatory and simultaneously anti-
stress effects seems contradictory at first sight. Nevertheless, eventually due to its rapid 
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effects, modulating membrane receptors (norepinephrine release, GABA-A antagonism 
and glutamatergic agonism for instance) are neuro-excitatory, while simultaneous anti-
cortisol effects may be “anti-stress”. It also suggests a different paradigm for these 
hormones: in part, they would cause the subjects to be “active but without stress” (in 
what concerns cortisol effects). DHEAS could eventually be more neuro-excitatory 
(possibly due to its sulfate group; and it is known to have more potent GABA-A 
antagonism and glutamatergic agonism) whereas DHEA might eventually be more “anti-
cortisol” (most opposite to cortisol effects were found for DHEA instead of DHEAS; DHEA 
and cortisol are lipophilic and can cross cell membranes; molar concentrations of DHEA 
and cortisol bear similarity much more than DHEAS and cortisol concentrations). 
 
Limitations of the studies 
 In the study exploring DHEAS relations to CRH test and personality the participants 
belonged to different diagnostic groups. Nevertheless, the diagnostic group was taken 
into account during the statistical analysis. Moreover, this was a retrospective study and 
we did not have DHEA measurements, which would be expected to show higher short 
time changes during the CRH test. 
In the studies addressing endocrine relation to working memory, emotional 
processing and involuntary attention at the performance and electrophysiological level 
we measured DHEA, cortisol and DHEAS in the saliva and not in the brain. Nevertheless, 
DHEA and cortisol are lipophilic and saliva levels are expected to be comparable to serum 
(74; 746), cerebrospinal fluid (747) and brain tissue levels (748). DHEAS is hydrophilic and 
does not readily cross the blood-brain-barrier or cell membranes. Nevertheless, DHEAS 
concentrations in the brain are several times higher than in the peripheral circulation and 
the efflux of DHEAS across the blood-brain barrier was determined to be tenfold greater 
than its influx (701). On the other hand, only a small proportion of DHEAS is expected to 
cross the blood brain barrier and most DHEAS in the peripheral circulation has its origin in 
the adrenals (27; 28). Therefore, we cannot say whether peripheral levels of DHEAS are 
related to its levels in the brain. Yet, peripheral levels of DHEA and DHEAS levels were 
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found to be directly related to cerebrospinal fluid levels (82) and as mentioned before, it 
was suggested by Guazzo et al. that salivary levels may give a reasonable representation 
of DHEA, DHEAS and cortisol levels in the cerebrospinal fluid (82). DHEA metabolites also 
include other neuroactive steroids such as estradiol, estrone and testosterone (178; 331), 
which may mediate part of the DHEA effects (749). Estrogens, and in particular estradiol, 
enhance working memory in women (750; 751). We did not measure DHEA metabolites, 
which may mediate some of its effects. Subsequently, we cannot exclude that those 
steroids may contribute or eventually be responsible for the electrophysiological relations 
we found. 
Furthermore, in these studies addressing working memory, emotional processing 
and attention, the two groups of participants were in different menstrual cycle phases 
and some were using hormonal contraception. DHEA, DHEAS and cortisol levels can 
change along the menstrual cycle and with the use of hormonal contraception (752; 753). 
Nevertheless, eventually in relation to the small sample size, in these studies, the 
endocrine levels were not significantly different in relation to the menstrual cycle phase 
or the use of hormonal contraception. But even considering that DHEA, DHEAS or cortisol 
levels could change along the menstrual cycle or with the use of hormonal contraception, 
the relations we found between endocrine levels and working memory, emotional stimuli 
or auditory distraction processing would not be invalidated. In any case, given the 
randomized approach we used concerning the menstrual cycle phase, the present results 
are expected to be independent of the menstrual cycle phase. Finally, the fact that only 
female participants were included in these studies, limit the outreach of the present 
study only to women. DHEAS levels differ between genders (2; 754), therefore, another 
group of participants would be necessary to extend our conclusions also to men. For 





Baseline ACTH levels were directly related to baseline DHEAS levels, suggesting 
that ACTH modulates DHEAS levels. Baseline DHEAS levels were inversely related to the 
intensity of the cortisol response in the CRH test (taking into account cortisol baseline 
levels). Therefore, a relation between higher baseline DHEAS levels and lower magnitude 
of the cortisol response to stress is suggested. A relation between DHEAS and personality 
is also suggested as DHEAS reactivity was directly related to Behavior Deviant triad and 
Type A behavior. On the other hand, in women, DHEA levels increased after the 
performance of cognitive tasks, independent of the emotional context of the task and to a 
larger extent after a working memory load rather than on a discriminatory task. These 
results suggest that cognitive tasks may be a stimulus for DHEA secretion. Moreover, a 
simple stress response is not suggested as there was no concomitant increase in cortisol 
levels. 
 A higher cortisol/DHEA ratio was related to enhanced processing of the auditory 
distractor during the performance of a visual working memory task. This suggests that in 
women, DHEA may oppose cortisol effects in involuntary distraction, reducing the 
processing of the auditory distractor (novelty-P3). Furthermore, higher DHEAS-to-DHEA 
ratios were related to enhanced auditory novelty-P3 amplitudes during the performance 
of a visual working memory load task but were not related to visual P300 amplitudes, 
novelty-P3 latencies or visual P300 latencies. These results suggest that higher DHEAS-to-
DHEA ratios may be related to enhanced acoustic novelty processing with no detrimental 
effect in working memory processing. More generally, it is suggested that higher DHEAS-
to-DHEA ratios may enhance involuntary attention to the surrounding world during the 
performance of working memory load tasks, which may be an important protective 
mechanism. Regarding working memory, a higher DHEA response due to Working 
Memory load was related to an enhancement of the task-relevant information processing 
(visual P300), suggesting an eventual rapid effect of DHEA. Overall, the results suggest 
that DHEA may oppose cortisol effects reducing distraction, higher DHEAS-to-DHEA 
balance may increase involuntary attention with no reduction in working memory and a 
higher DHEA response may enhance working memory at the electrophysiological level. 
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Also in women, during the processing of stimuli with negative emotional content, 
higher DHEA/cortisol and DHEAS/DHEA ratios were related to shorter visual P300 
latencies, suggesting a relation of these endocrine parameters with shorter stimulus 
evaluation time and less interference with the task at hand due to the processing of the 
task-irrelevant negative content of the visual stimuli. Additionally, higher DHEAS/DHEA 
ratios were related to reduced visual P300 amplitudes suggesting less processing of the 
negative information, which might constitute a protective mechanism against negative 
information overload. The present results also suggest the importance of the 
sulfotransferase and sulfatase activity in the modulation of DHEAS and DHEA brain 
effects. 
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Future research and clinical perspectives 
In the future, knowledge of DHEA action and reposition effects may bring 
additional clinical utility to its measurement and eventually uncover therapeutic 
usefulness. For future research it would be important to study the relation between DHEA 
and DHEAS and memory, attention and emotional processing also in men. Men have 
higher levels of DHEAS in the peripheral circulation while DHEA levels are identical to that 
in women, so, particular aspects may exist. Furthermore, we found several trends in what 
concerns the relation between DHEA and performance. Studies with a larger number of 
participants would be important to confirm the present results and might reveal 
significant behavioral relations of DHEA and DHEAS with memory, attention and 
emotions. We did not measure the DHEA response to CRH, which could add some 
information regarding the relation between these hormones and the ACTH and cortisol 
responses. We did not measure other hormones that could contribute to the present 
relations between DHEA or DHEAS and personality or brain processing. Further research 
could also address DHEA and DHEAS active derivatives and other neurosteroids. 
Studies in older people (in whom DHEA and DHEAS levels decrease), in ill and 
recovering persons (in whom DHEAS levels may change in a short period of time), in 
patients with adrenal insufficiency (in whom peripheral DHEAS levels are low) and in 
patients with hepatic failure (in whom sulfotransferase activity may be affected) may 
provide further evidence of DHEA and DHEAS brain and behavioral effects. Measuring the 
temporal evolution of DHEA, DHEAS, cortisol and CRH levels during acute medical illness 
and recovery (during the neuroendocrine adaptation syndrome and recovery) and if 
possible simultaneously evaluating rapid differences in electrophysiological, 
neurofunctional or performance parameters may also eventually provide further 
evidence of short time DHEA and DHEAS changes and their possible effects in illness. It 
would also be interesting to study short term changes in DHEA-to-cortisol and DHEAS-to-
DHEA ratios in those study groups. 
Previous reposition studies in humans using oral DHEA were inconclusive or 
brought insufficient results. In fact, contradictory results exist regarding memory. The 
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present and previous results point towards an effect of the DHEAS-to-DHEA ratio and that 
could justify the contradictory results of DHEA reposition studies regarding memory. 
Therefore, reposition studies measuring not only DHEA but both DHEA, DHEAS and 
cortisol and their ratios before and after treatment could eventually bring new 
information regarding the effects of DHEA treatment in memory and particularly in 
Alzheimer's disease. A different point raised by the present studies is whether the 
performance of cognitive tasks may raise DHEA levels in the long term and whether this 
could prevent DHEA decline with age, a point that was also not studied. The present 
results also suggest that subjects with higher DHEAS levels may have lower cortisol stress 
responses, therefore, it might be useful to study whether DHEA reposition could protect 
from deleterious effects of high cortisol levels or cortisol peaks, namely regarding 
memory, but also concerning other diseases like the cardiovascular ones. 
Concerning humor, although coherent and pointing towards positive anti-
depressive effects of DHEA reposition, a small number of participants with depression 
were studied. Therefore, larger reposition studies and also simultaneously measuring 
DHEA, DHEAS and cortisol levels, might reveal important information. In the future, if the 
existing preliminary results are confirmed, DHEA treatment could be an anti-depressive 
drug candidate. If reposition studies point towards an important effect of DHEAS-to-DHEA 
ratio, then the modulation of the sulfotransferase activity needs to be studied and if 
possible, addressed. 
The present results may help in understanding DHEA and DHEAS physiological 
effects and future research may establish if there is a place for the use of DHEA and 
DHEAS levels as clinical indicators for brain processing, personality or the stress response 
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Abstract OBJECTIVES: Dehydroepiandrosterone-sulphate (DHEAS) physiologic relevance 
remains controversial. However, several central nervous system and behavioural 
effects of DHEAS have been described. We explored the relation between DHEAS 
and both pituitary-adrenal axis reactivity and personality in human subjects.
DESIGN: We studied 120 consecutive patients assisted at the out patient endocrine 
department of a public central hospital before medical treatment. Personality was 
evaluated with the Minnesota Multiphasic Personality Inventory (MMPI) and the 
pituitary-adrenal axis reactivity was assessed with the CRH test.
RESULTS: Baseline DHEAS was inversely related to peak/basal cortisol (parcial 
r=–0.454, p<0.05) response to CRH infusion. DHEAS reactivity in the CRH test 
was directly related to the Deviant Behaviour triad (BD) (r=0.257, p<0.05) and 
type A personality (AP) (r=0.295, p<0.05). Basal ACTH was directly related to 
baseline DHEAS (r=0.366, p<0.001) and together with age and gender explained 
34% of DHEAS variability. 
CONCLUSIONS: DHEAS may be a protective factor against an excessive cortisol 
response when people are under stress situations. Personality may be related to 
DHEAS reactivity. 
Abreviations: 
AP  - Type A Personality
AUC  - Area Under the Curve
AUC/h  - Area Under the Curve/hour
BD  - Behaviour Deviant Triad
GABA-A  - Gamma-Aminobutyric Acid Type A Receptor
K-S - Kolmogorov-Smirnov
MMPI - Minnesota Multiphasic Personality Inventory
NMDA - N-methyl-D-aspartate receptor
NT - Neurotic Triad
PD - Psychotic Dyad
sd - standard deviation
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DHEAS, Personality and Stress
INTRODUCTION
In humans dehydroepiandrosterone-sulphate (DHEAS) 
is the most abundant hormone in the peripheral circu-
lation. Its normal levels (2–10 μmol/L) are more than 
20 times those of cortisol or thyroxine, more than 100 
times those of testosterone, growth hormone and pro-
lactin and more than 10,000 times those of aldosterone, 
estradiol or insulin. On the other hand, most laboratory 
animals have only negligible amounts of DHEAS. Even 
primates have much lower levels than humans (Berr et 
al. 1996).
DHEA is mostly synthesised in the adrenals and 
gonads, either as the final androgen-like compound or 
as an intermediate in the synthesis of androgens. How-
ever, it is also synthesised in the central nervous system 
(Paul & Purdy 1992; Berr et al. 1996; Baulieu & Robel 
1998; Reddy & Kulkarni 1998; Labrie et al. 2003; Sicard 
et al. 2007). A sulphotransferase reversibly converts 
DHEA into DHEAS, and the sulphated form is by far 
the most abundant in the peripheral circulation. Never-
theless, the nonsulphated form is, however, much more 
lipossoluble and may easily cross biologic membranes 
presenting a much larger distribution that includes 
the central nervous system (Berr et al. 1996; Sicard et 
al. 2007). DHEA has a short half-life – 1 to 3 hours – 
as opposed to DHEAS that has a long half-life – 10 to 
20 hours (Legrain et al. 2000; Muniyappa et al. 2006; 
Komesaroff 2008). 
No definitive factors regulating DHEAS synthesis 
have been so far identified. 
DHEAS physiological effects and teleological mean-
ing are unclear and controversial. At the clinical level 
DHEAS levels are higher in males and dramatically 
decrease with age – in the seventh decade they are 
about 20% of those in the third decade (Berr et al. 1996; 
Kimonides et al. 1998; Laughlin & Barrett-Connor 2000; 
Tannenbaum et al. 2004; Sicard et al. 2007). Further-
more, DHEAS levels relate to morbidity and mortality 
even after age correction (Berr et al. 1996; Gruenewald 
et al. 2006; Sicard et al. 2007). Either specific effects or 
more generally a cortisol antagonism has been invoked 
to account for those associations (Akinola & Mendes 
2008; Wemm et al. 2010).
Regarding DHEAS effects, initial evidence resulted 
mainly from large observational studies on the elderly 
and post menopausal women – The Rancho Bernardo 
Study, Baltimore Longitudinal Study of Aging and Per-
sonnes Agées Quid (PAQUID) – studies with DHEAS 
replacement in the elderly – DHEAge Study – and 
smaller clinical studies of patients with primary adre-
nal failure (Barrett-Connor & Edelstein 1994; Berr et al. 
1996; Wolf et al. 1997; Barrett-Connor et al. 1999; Bau-
lieu et al. 2000; Schlienger et al. 2002; Legrain & Girard 
2003; Hougaku et al. 2006; O’Donnell et al. 2006). Nev-
ertheless, during the last years, more and more evidence 
regarding DHEAS effects in adolescents and adults has 
been collected. 
Similarly to other neurosteroids specific central ner-
vous system effects have been described for DHEAS. 
DHEAS seems to modulate cognitive function and 
higher levels of this hormone are related to better 
results regarding memory, learning and resilience 
(Barrett-Connor & Edelstein 1994; Morley et al. 1997; 
Compagnone & Mellon 1998; Reddy & Kulkarni 1998; 
Morrow 2007; Sicard et al. 2007; Wemm et al. 2010); to 
higher well being scores and less depression (Moralès 
et al. 1994; Wolf et al. 1997; Barrett-Connor et al. 1999; 
Schlienger et al. 2002; Dallman et al. 2003; Akinola & 
Mendes 2008) and to higher resistance to the deleteri-
ous effects of a stressful situation (Reddy & Kulkarni 
1998; Morrow 2007; Morgan et al. 2009; Yoon et al. 
2009). 
At the molecular level DHEAS has a general 
neurostimulatory effect via gabaminergic antagonism 
[Gamma-Aminobutyric Acid Type A Receptor (GABA-
A) antagonism] and glutaminergic agonism [N-methyl-
D-aspartate receptor (NMDA) sigma-1 agonism]
(Paul & Purdy 1992; Baulieu & Robel 1998; Reddy &
Kulkarni 1998; Morrow 2007). Neurotrophic effects
have also been described and DHEA and DHEAS
may contribute to neocortical organization (Baulieu
& Robel 1998; Compagnone & Mellon 1998; Beck &
Handa 2004; Suzuki et al. 2004). Moreover, DHEA and
DHEAS neuroprotective effects after hypoxia have been
documented and lower levels of those hormones in
older adults could contribute to the enhanced cerebral
vulnerability to vascular lesion or other neural insults
(Kimonides et al. 1998).
The concept of endocrine phenotypes in endocrine 
research assumes that with regard to hormone levels, 
intersubject variability is much larger than intrasu-
bject variability throughout the time (Bertagna et al. 
1994; Coste et al. 1994). It is also postulated that these 
endocrine phenotypes are established at the beginning 
of one’s life. A second related concept is that one of 
endocrine plasticity, meaning that endocrine responses 
nonrandomly change throughout the time according 
to previous experiences (Chrousos et al. 1988; Chrou-
sos 1992; Levine 1993). In what concerns behavioural 
endocrine research personality traits are also indi-
vidual features established quite early in life. A relation 
between cortisol and the hypothalamic-pituitary-adre-
nal axis reactivity and personality has been established 
(Chrousos et al. 1988; Chrousos 1992; Kirshbaum et al. 
1992; Levine 1993; Bertagna et al. 1994; Castanon & 
Morméde 1994; George et al. 2010; Wirtz et al. 2010); 
however, this relation was less studied in what concerns 
DHEAS (Thomas et al. 1994).
The Minnesota Multiphasic Personality Inventory 
(MMPI) is well validated in the general population 
and, in addition to its importance in the psychiatric 
setting, it can also be used to interpret classic person-
ality dimensions (Costa et al. 1986). In the corticotro-
pin-releasing hormone (CRH) test, pituitary-adrenal 
response to CRH administration is classically measured 
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with ACTH and cortisol determinations as an index of 
the stress response. The CRH test has been extensively 
used in psychoneuroendocrine research of several 
psychiatric and psychosomatic disorders (Gold et al. 
1986; Demitrack et al. 1991; Chrousos & Gold 1992) 
and previous studies from our research team found out 
significant relations between personality and pituitary-
adrenal response to CRH administration in common 
clinical disorders (Martins et al. 2001; Martins et al. 
2002; Martins et al. 2004). 
The above evidence suggests the existence of a rela-
tion between DHEAS and behaviour, namely with 
personality and stress response. In the current study 
we explored the relation between DHEAS and both 
personality traits and pituitary-adrenal axis reactivity 
in humans.
PATIENTS AND METHODS
We analysed retrospectively the records of 120 con-
secutive patients in which CRH test and personality 
evaluation with the MMPI were included in the clinical 
workout. Patients belong to several diagnostic groups. 
Clinical condition was not further taken into account 
for this study but diagnostic group was retained as a 
baseline variable in the statistical analysis, so that only 
significant results after correction for this potential 
confounding variable are reported. The study proto-
col was approved by he Hospital Ethical Committee 
and informed written consent was obtained for every 
patient. The data used was obtained before beginning 
medical treatment.
Age, gender, height and weight without shoes or 
coats were recorded. 
The Portuguese translation of the MMPI (Montene-
gro 1982) was filled by the participants after one of the 
authors’ complete and detailed instructions. The par-
ticipants remained alone in a quiet room for the entire 
procedure. Scores were obtained according to MMPI 
authors’ instructions. To avoid the use of multiple com-
parisons, only conventionally defined type A personal-
ity (AP) and superordinate traits were used – neurotic 
triad (NT): hypochondriasis (Hs) + depression (D) + 
hysteria (Hy); psychotic dyad (PD): paranoia (Pa) + 
schizophrenia (Sc) and behaviour-deviant triad (BD): 
psychopathic deviate (Pd) + masculinity-femininity 
(Mf) + hypomania (Ma) (Butcher et al. 1990; Greene 
1991). The original MMPI version was used instead of 
the revised one (MMPI-2) since the MMPI-2 transla-
tion had not been validated yet.
The CRH test was performed the following week, 
after an overnight fast. In all cases a venous line was 
obtained in the antecubital region, the participant 
lying in the supine position; after a 15 to 20 min period 
of adaptation a venous blood sample was collected 
– time  0. CRH was then slowly infused in 1 to 2min
(human CRH, 100 μg, CRH Ferring GmHb, Kiel, Ger-
many); further blood samples were obtained at 15, 30,
60 and 120 min. All samples were immediately refriger-
ated at +4 °C and sent to the Endocrine Laboratory after 
test completion. ACTH and cortisol were measured at 
0, 15, 30, 60 and 120 min, DHEAS was measured at 0, 
30 and 60 min and prolactin (PRL) was only measured 
at baseline.
Immunoradiometric assay (IRMA) and enzyme-
linked immunoassay (ELISA) methods were used for 
ACTH (IRMA, Nichols Institute, San Juan Capist-
rano, CA), PRL (IRMA, Diagnostc Products Corpora-
tion, Los Angeles, CA), DHEAS and cortisol (ELISA, 
Diagnostic Products Corporation, Los Angeles, CA) 
measurements which were performed in the hospital 
central laboratory. Intra- and interassay variation coef-
ficients were less than 10% in every case. 
Statistical analysis was carried out with the use 
of the Statistical Package for the Social Sciences Pro-
gram (SPSS, version 16.0). Results are presented as 
the mean±standard deviation (sd) or as percentage 
as appropriate. The area under the curve (AUC) was 
computed according to the trapezoidal rule (Rowland 
& Tozer 1995). Mean values per hour were computed. 
The normal distribution of continuous variables was 
verified by the Kolmogorov-Smirnov (K-S) goodness 
of fit test. Non normal distributed variables were log 
transformed prior to analysis. However, for the sake 
of simplicity when no differences were found, results 
regarding the non-transformed variables are presented. 
The Chi-Square test was used to compare the distri-
bution of non-continuous variables between selected 
groups, factorial analysis of variance (ANOVA) to 
compare continuous variables between selected groups 
and Multiple linear regression analysis to explore the 
relation between continuous variables. The limit of sta-
tistical significance was selected at 0.05. 
RESULTS
All patients results are summarized in Tables 1–3. 
Basal DHEAS was different among diagnostic 
groups – F(4,119)=3.959, p<0.005 – with hirsute sub-
jects presenting significantly higher basal DHEAS 
values – 237±113 μg/dL – when compared to all other 
diagnostic groups. There were no differences in ACTH, 
cortisol and PRL among diagnostic groups.
Mean baseline DHEAS was 158±99 [20–554] μg/dL 
and presented a distribution not significantly different 
from the normal one, K-S test Z=0.862, ns. 
DHEAS levels were higher in males when compared 
to females – 207±87 μg/dL vs 151 ±99 μg/dL, t=2.088, 
p<0.05. DHEAS levels were inversely related to age 
– r=0.444, p<0.001, even after gender correction, the
regression equation being DHEAS=272.493–3.736
× age. Together gender and age accounted for 27% of
DHEAS variability. DHEAS levels were not significantly 
related to body mass index (BMI) or body weight.
DHEAS levels were significantly related to ACTH 
– r=+0.366, p<0.001 – and PRL – r=+0.233, p<0.05
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– but not to cortisol. However, ACTH and PRL were
interrelated and when both variables were included
in the analysis only ACTH remained as a significant
factor. This relation persists even after age, gender and
diagnostic group correction. Age, gender and ACTH
account for 34% of DHEAS variability.
Baseline ACTH was significantly related to the 
peak ACTH (r=+0.490, p<0.001) and peak cortisol 
(r=+0.246, p<0.05) responses during the CRH test. 
Baseline cortisol was strongly related to the peak corti-
sol response (r=+0.782, p<0.001). Baseline DHEAS was 
not related to the peak ACTH or peak cortisol response 
in the CRH test but baseline DHEAS was inversely 
related to the peak/baseline cortisol response (parcial 
r=–0.454, p<0.05) after age, gender, baseline ACTH and 
baseline cortisol correction (multiple linear correlation 
including peak/baseline cortisol, age, gender, baseline 
ACTH and baseline cortisol, total r=0.631, p<0.005) 
(Figure 1). DHEAS was not related to peak/baseline 
ACTH response.
Baseline DHEAS was inversely related to NT score – 
r=–0.355, p<0.001 – but not to PD or BD triad. However, 
this relation was no longer significant when age correc-
tion was carried out; in fact, age was directly related 
to NT – r=+0.443, p<0.001. Nevertheless, the DHEAS 
response in the CRH test (evaluated as the AUC) 
was significantly and directly related to BD triad and 
type A personality – simple linear correlation respec-
tively r=+0.257, p<0.05 and r=+0.295, p<0.05 (Figure 
2 and 3) – and that relation remains significant even 
after age and diagnostic group correction. As noted, 
DHEAS average levels have not significantly changed 
after the CRH test. Despite this, DHEAS response was 
highly variable in what concerns the individual level 
(–73 μg/dL to +317 μg/dL).
DISCUSSION
This is an observational retrospective study, whose 
objective is to explore the relation between DHEAS and 
both personality and pituitary-adrenal axis reactivity in 
adult humans.
We used several specific diagnostic groups. As noted 
before only results remaining significant independently 
of age and diagnostic group are reported.
Only DHEAS and not DHEA measurements were 
used. We expected a stronger relation between DHEAS 
and more stable parameters as age, gender, basal hypo-
thalamic-pituitary-adrenal (HPA) axis activity and per-
sonality as that hormone has a longer half-life. On the 
contrary, acute changes might be more easily detected 
with DHEA, namely after CRH administration.
The predominance of female participants (87%) 
reflects the population assisted in the Endocrine outpa-
tient department. Even so, DHEAS levels were signifi-
cantly higher (37%) in males, as it was expected (Berr et 
al. 1996; Baulieu et al. 2000; Laughlin & Barrett-Conner 
2000; Tannenbaum et al. 2004; Gruenewald et al. 2006).
The mean age was 33 years old (the sample was 
18 to 57 years old) and DHEAS levels were inversely 
related to age as it has extensively been described in the 
literature (Berr et al. 1996; Lane et al. 1997; Morley et 
al. 1997; Kimonides et al. 1998; Legrain & Girard 2003; 
Sicard et al. 2007). We found a 1.4% mean decline in 
DHEAS levels per year while other authors had previ-
ously described a decline of about 2% per year during 
adulthood and higher decline rates in post-menopausal 
women and older men (Laughlin & Barrett-Connor 
2000; Tannenbaum et al. 2004; Labrie et al. 2005).
Age explained 20% of DHEAS variability, gender 
explained 4% of DHEAS variability and age and gender 
together explained 27% of DHEAS variability. Both fac-





Age (years) 33±12 [18–57]
Gender F/M (%) 87/13
BMI (kg/m2) 27.7±9.0 [14.5–60.1]
DHEAS (μg/dL) 35–430 158±99 [20–554]
ACTH (pg/mL) 0–46 19±14 [1–90]
PRL (ng/mL) 2–29 11±7 [2–33]
Cortisol (μg/dL) 4–23 18±9 [4–51]







0’ 21±16 19±9 177±106
15’ 52±74 b 22±8 c –
30’ 50±58 c 23±8 c 177±114
60’ 31±31 a 24±9 c 176±107
120’ 16±18 a 18±10 –
AUC 32±36 b 22±8 c 176±107
AUC units are pg/mL.h for ACTH, μg/dL.h for cortisol, and μg/dL.h 
for DHEAS.
Value different from basal, a p<0.05, b p<0.01, c p<0.001
Tab. 3. Superordinate traits and AP score (MMPI).
Mean±sd
Neurotic Triad (NT) score 164±30
Psychotic Dyad (PD) score 115±22
Behaviour-Deviant triad (BD) score 158±23
Type A Personality (AP) (%) 38±16
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tors have been extensively identified as relevant factors 
for DHEAS levels.
DHEAS levels were also significantly and directly 
related to basal ACTH independently of age, gender and 
diagnostic group; ACTH explains 14% of DHEAS vari-
ability. Age, gender and ACTH accounted for 34% of 
DHEAS variability. This is a relatively new finding since 
ACTH had not been generally considered as a relevant 
factor both for DHEAS and adrenal androgen produc-
tion. In fact, chronic stress is generally associated with 
increased cortisol levels and decreased DHEAS levels. 
Moreover, it should be noted that despite the ACTH 
response, no DHEAS response was found in the CRH 
test, even if dexamethasone suppression decreases both 
cortisol and DHEAS. All this points out the complexity 
of the relation between ACTH and DHEAS until a puta-
tive cortical androgen stimulating hormone (CASH) is 
still to be identified.
As a group, and despite the ACTH response, mean 
DHEAS levels did not change in the CRH test sug-
gesting no acute effect of ACTH on DHEAS levels. 
Taking into account the high DHEAS levels and long 
DHEAS half-life, it may be necessary a longer ACTH 
rise to increase DHEAS levels (Berr et al. 1996). How-
ever, individually DHEAS response was highly variable. 
Baseline ACTH was strongly and directly related to the 
peak ACTH response and was also directly related to 
the peak cortisol response and baseline cortisol was 
strongly related to the peak cortisol response suggest-
ing that baseline HPA axis activity is a strong determi-
nant of the response to CRH. In more detail, baseline 
ACTH levels seem to be a major determinant of either 
ACTH or cortisol response. An interesting finding is 
the fact that baseline ACTH is related to both ACTH or 
cortisol peak levels but not to ACTH or cortisol peak/
baseline ratio suggesting that ACTH does not modu-
late the intensity of the response, but only that those 
subjects with higher baseline ACTH and cortisol levels 
naturally reach higher peak ACTH and cortisol levels. 
The influence of DHEAS seems much more subtle. 
Baseline DHEAS was not related to the peak ACTH or 
peak cortisol response in the CRH test. Similarly, it was 
not related to peak/baseline ACTH response in CRH 
test but it was inversely related to the peak/baseline 
cortisol response (after age, gender, baseline ACTH 
and baseline cortisol correction). Those results suggest 
that DHEAS may reduce the magnitude of the cortisol 
response independently of baseline ACTH or cortisol 
levels. There is some previous evidence that DHEAS 
may indeed down-regulate cortisol levels (Kimonides et 
al. 1998; Gruenewald et al. 2006; Morrow 2007; Akinola 
& Mendes 2008).
Lower DHEAS was related to higher NT scores. The 
relation between DHEAS and NT score persisted after 
diagnostic group correction. However, that relation was 
no longer significant after age correction, and in fact, 
age was directly related to NT score. This is rather sur-
prising not only because personality is generally con-
Fig. 1. Relation between baseline DHEAS and peak/baseline 
cortisol response in CRH test.
Fig. 2. Relation between DHEAS reactivity and BD triad.
Fig. 3. Relation between DHEAS reactivity and type A Personality.
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sidered as a stable personal characteristic established at 
a very early stage of life but also because this is a rather 
young sample. On the other hand, it seems plausible 
that aging, bringing about morbidity and mortality 
of both the patient and their relationships, should be 
associated with increased hypochondriac and depres-
sive scores, two of the three components of the neurotic 
triad. Whatever the reason may be, aging is associ-
ated with increased NT scores (Zuckerman 1994) and 
decreased DHEAS baseline levels and that seems to be 
the reason for the spurious relation between DHEAS 
and NT. Disappointingly, baseline DHEAS levels were 
not significantly related to any of the selected psycho-
metric variables and this points out the insensitivity of 
baseline endocrine levels. 
However, DHEAS reactivity in the CRH test is sig-
nificantly related to BD triad and Type A personality 
and both relations persist independently from age, 
gender and diagnostic group. As noted before neuroen-
docrine reactivity in the CRH test (regarding the ACTH 
and cortisol response) has been previously shown to be 
related to other psychometric variables. The apparent 
paradox is that although there does not seem to be any 
DHEAS response in the CRH test (evaluated by the 
mean), the DHEAS response is significantly related 
to psychometric variables. In fact, although the mean 
DHEAS does not change in the CRH test, individually 
considered peak DHEAS – baseline DHEAS changes 
deeply from –73 to + 317 μg/mL. In short, higher 
DHEAS responses are associated with Type A behav-
iour and BD triad (psychopathic deviation + hypoma-
nia + masculinity-femininity) and more specifically 
with Pd score (data not shown).
To conclude we found that DHEAS significantly 
changes according to gender and age. Moreover, we 
also noticed that: 1) baseline DHEAS is significantly 
modulated by ACTH; 2) baseline DHEAS significantly 
modulates the intensity of the cortisol response in 
the CRH test; 3) DHEAS reactivity is a factor for BD 
triad and Type A behaviour. In short, baseline DHEAS 
relates to stress response and DHEAS reactivity relates 
to personality.
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Abstract
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEAS) have been reported to have memory
enhancement effects in humans. A neuro-stimulatory action and an anti-cortisol mechanism of action may contribute to
that relation. In order to study DHEA, DHEAS and cortisol relations to working memory and distraction, we recorded the
electroencephalogram of 23 young women performing a discrimination (no working memory load) or 1-back (working
memory load) task in an audio-visual oddball paradigm. We measured salivary DHEA, DHEAS and cortisol both before each
task and at 30 and 60 min. Under working memory load, a higher baseline cortisol/DHEA ratio was related to higher
distraction as indexed by an enhanced novelty P3. This suggests that cortisol may lead to increased distraction whereas
DHEA may hinder distraction by leading to less processing of the distractor. An increased DHEA production with
consecutive cognitive tasks was found and higher DHEA responses attributed to working memory load were related to
enhanced working memory processing as indexed by an enhanced visual P300. Overall, the results suggest that in women
DHEA may oppose cortisol effects reducing distraction and that a higher DHEA response may enhance working memory at
the electrophysiological level.
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Introduction
Dehydroepiandrosterone-sulphate (DHEAS) is the most abun-
dant steroid in the peripheral circulation and it is much more
abundant in humans than in any other species [1,2,3,4,5,6,7].
Circulating levels dramatically decrease with aging. Moreover,
lower levels are related to higher morbidity and mortality ratios
even when corrected for age [2,8].
DHEA is mostly synthesized in the adrenals whereas the gonads
represent a minor source of this hormone. However, DHEA is also
synthesized in the central nervous system [3], where its concen-
trations are higher than in the peripheral circulation [3,9,10]. In
both peripheral and central compartments a sulpho-transferase
reversibly converts DHEA to DHEAS, restricting its distribution
and prolonging its half-life [2,3].
Several central effects concerning cognitive performance and
stress response have been described for DHEA and DHEAS.
Higher levels were related to increased memory and attention
scores [9,11] and improved performance in stressful conditions
[12,13,14], whereas low levels were found in Alzheimer’s disease
[15]. However, DHEA administration in older subjects showed
inconclusive results [5,16,17,18,19].
On the other hand, stressful stimuli also modulate DHEA and
DHEAS levels: acute stress is related to an increase in DHEA and
DHEAS levels [20,21,22,23] whereas chronic stress decreases
baseline DHEA and DHEAS levels [24,25,26,27,28], as well as the
acute DHEAS response to a superimposed psychological stress
[29]. Yet, a direct influence of cognitive processing on DHEA or
DHEAS levels has not been studied.
At the molecular level, DHEA and DHEAS have a general
neuro-stimulatory effect: presynaptic actions include glutamate,
acetylcholine and norepinephrine release and postsynaptic actions
include sigma 1 receptor agonism with subsequent N-methyl-D-
aspartate (NMDA) receptor activation, gabaminergic antagonism
and inhibition of voltage-gated calcium currents [3,9,10]. Never-
theless, DHEA and DHEAS molecular effects are not exactly the
same and several studies suggest that the balance between them
may influence brain functioning [9,30]. As an example, DHEAS
has more potent antagonistic effects at the c-aminobutyric acid
type A receptor (GABAA receptor) than DHEA [31,32]. Hence,
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the simultaneous evaluation of DHEA and DHEAS may uncover
more information than the individual examination of either form
of that steroid.
Concerning glucocorticoids, whereas mild or short-lasting
increases in cortisol due to stress may protect the body, promote
adaptation and have beneficial effects on attention and memory,
higher cortisol levels or long term increases are related to poorer
executive functioning, poorer learning and memory and less
cognitive flexibility [33,34,35,36,37,38,39]. In particular, working
memory (WM) depends on prefrontal cortex activity, which is
modulated by glucocorticoids: prefrontal cortex-dependent work-
ing memory is enhanced by acute stress and inhibited by chronic
stress [35,40]. The relation between glucocorticoids and cognitive
functioning is bidirectional: glucocorticoids impact cognitive
function and cognitive processing has been shown to influence
glucocorticoid secretion [41].
Several levels of evidence suggest that DHEA and DHEAS may
counterbalance cortisol effects: a higher DHEA/cortisol ratio has
been related to better performance under stress [14] and DHEAS
antagonized the memory deteriorating neurotoxic effects of
cortisol in the hippocampus [10,42]. More generally, DHEA
and DHEAS decrease with aging, whereas cortisol does not.
Consequently, the cortisol/DHEA ratio increases and may be
involved both in the cognitive impairments and in the particular
vulnerability to stress damage that seems to characterize the
elderly [5,9,42].
The aim of the present study was to test whether DHEA and
DHEAS levels are modulated by WM load and whether these
endocrine levels are related to distraction and WM at the
electrophysiological level, as evidence for their neurophysiologic
effects using Event-Related Brain Potentials (ERPs) is scarce
[43,44,45]. The specific a priori hypotheses were: 1) higher
endogenous DHEA and DHEAS levels may prevent involuntary
distraction and enhance cognitive performance; 2) DHEA and
DHEAS putatively beneficial effects may be translated at the
neurophysiological level; 3) DHEA and DHEAS effects may be
largely antagonistic from those of high baseline cortisol; and 4)
WM load may be a stimulus for DHEA and DHEAS production.
To test these hypotheses we measured the relation between
DHEA, DHEAS and cortisol on one hand and the cognitive
performance and brain responses, using a well-established
auditory-visual distraction paradigm [46,47,48] on the other.
The protocol includes task irrelevant sounds, some of which are




The experimental protocol was approved by the ethical
committees of the University of Barcelona and Lisbon Medical
School and it was conducted according to the principles of the
Declaration of Helsinki. All the subjects gave their written
informed consent before entering the study.
Subjects
28 healthy female volunteers (undergraduated Psychology
students) performed the study protocol. In order to ensure a
higher homogeneity in androgen levels, only women were
included. The subjects were young (18 to 25 years old, mean
2060.5 years old) and presented a normal body mass index
(21.860.5 kg/m2). All the participants had a normal or corrected-
to-normal vision and none reported auditory deficits. None of the
participants reported a past history of neurologic, psychiatric,
endocrine or oral diseases. All the subjects were right-handed.
Four subjects were under hormonal contraception. No other
medications were allowed. Regular or binge alcohol consumption
were exclusion criteria and subjects were asked not to consume
alcohol in the twelve hours before the experimental protocol.
Regular tobacco consumption as well as illicit drug consumption
were further exclusion criteria. Prior to the experimental session,
subjects completed the State-Trait Anxiety Inventory [49] and all
showed a normal range of state and trait anxiety levels. Five
subjects were discarded from the analysis due to technical
problems with electroencephalogram (EEG) recordings or endo-
crine measurements.
Task and Procedure
The experimental sessions were held in the afternoon, beginning
at 2–3 pm. An adapted version of a well-established auditory-
visual distraction task [46,47,50] was presented, based on the
protocol used by SanMiguel et al. (2008) [51]. In this protocol, two
visual tasks were performed: one task without working memory
load (WM0) and another one with working memory load (WM1).
In the present experiment, the two tasks were performed two hours
apart from each other (from onset to onset) and the order of the
tasks was counterbalanced across participants. Each task lasted
about 15 minutes, and consisted of two blocks of 250 trials each
(plus five initial trials that were excluded from the analyses). A
short pause was allowed between blocks.
Participants sat in a comfortable chair in a dimly lit and
electrically and acoustically shielded room. In the discrimination
task (WM0) subjects had to decide whether the two digits
appearing on the screen were the same (11 and 22) or different
(12 and 21), see figure 1A. In the WM1 task (1-back task) subjects
had to decide whether the left or right digit (counterbalanced
across subjects) on the screen was the same as the left or right digit
of the previous trial (figure 1B). Thus, they had to keep one digit in
working memory until the next trial, answering to every trial,
except for the first one. Responses were given through a mouse
button (one mouse button for ‘‘same’’ and the other button for
‘‘different’’), also counterbalanced across subjects. The subjects
were specifically instructed to respond as quickly and accurately as
possible while ignoring the sounds. In order to reduce artifacts
originating from eye-blinks and movements during EEG record-
ing, subjects were asked to minimize blinking and to focus on a
central fixation cross between the two digits. Before each task,
subjects performed practice blocks (composed by 10 trials) without
any auditory stimuli until they reached a hit rate of at least 80% in
each task.
Each trial consisted of an auditory stimulus, irrelevant for the
task, followed by a visual imperative stimulus after 350 ms (onset
to onset), see figure 1. The total trial length varied from 1000 to
1500 ms (1250 ms on average; jitter +/–250 ms). The auditory
sequence consisted of repetitive standard tones (200 ms, including
fade-in and fade-out of 10 ms each; 600 Hz; 85 dB; 80%
probability), occasionally replaced by environmental novel sounds
selected from a sample of 100 different exemplars (edited to have a
duration of 200 ms, including fade-in and fade-out of 10 ms each;
digitally recorded, low-pass filtered at 10,000 Hz; 85 dB; 20%
probability), such as those produced by a drill, hammer, rain,
door, telephone ringing, and so forth (50). All sounds were
randomly delivered binaurally through headphones (Sennheiser
HD 202), and the only restrictions were that the first four stimuli of
each block were standard tones, that two novel sounds never
appeared consecutively and that each novel sound occurred only
once in each task. The visual stimuli consisted of pairs of
combinations of the digits 1 and 2 (11, 12, 21 or 22), presented on
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a computer screen for 200 ms. The appearance probability was
the same for every digit combination. The picture size was
3576441 pixels, with a vertical angle of 8u and a horizontal angle
of 18u, accounting for two pictures presented simultaneously with
the fixation cross in between. The distance from the subjects’ eyes
to the screen was 100 cm. Overall, there were 400 standard trials
and 100 novel trials in each of the two WM conditions.
We recorded response time and hit rates for each trial with
PresentationH (Neurobehavioral Systems, Inc). A correct response
within the response window (until the sound onset of the
subsequent trial) was counted as a hit. We computed distraction
as the difference in hit rate or response time between auditory
stimulus types (hit rate: WM0standard trials 2 WM0novel trials
and WM1standard trials 2 WM1novel trials; response time:
WM0novel trials 2 WM0standard trials and WM1novel trials 2
WM1standard trials) and working memory load costs as the
difference in hit rate or response time between the WM load and
the discrimination task (hit rate: WM0standard 2 WM1standard
and WM0novel 2 WM1novel; response time: WM1standard 2
WM0standard and WM1novel 2 WM0novel).
EEG Recording and Analysis
Electrophysiological activity was continuously recorded during
task performance, from 64 scalp Ag/AgCl electrodes following the
extended 10/10 convention. Elastic caps with sintered electrodes
and shielded wires were used. The horizontal and vertical
electrooculograms (HEOG and VEOG) were recorded with
electrodes placed at the outer canthus and below the right eye,
respectively. An electrode placed on the tip of the nose was used as
the common reference and the ground was located at the AFz
position. The EEG and electrooculogram (EOG) were amplified
and digitized at a sampling rate of 512 Hz (Eemagine, ANT
Software b.v., Enschede, the Netherlands). Impedances were kept
at 5 kV or below during the whole recording session. Recording
was performed with an ANT amplifier of 64 channels (gain 20x;
A/D resolution 22 bits, 71.526 nV per bit; filtering 0–138.24 Hz;
CMRR.90 dB).
A digital finite impulse response (FIR) bandpass-filter from 0.01
to 30 Hz was applied using a Hamming window. ERPs were
averaged offline for each auditory stimulus type and working
memory condition, for an epoch of 1000 ms, including a 200 ms
pre-auditory-stimulus baseline. The first five epochs of each block
and the epochs following a novel trial were excluded from
averaging. Only epochs that corresponded to trials with correct
responses were averaged.
EOG correction was performed by manually selecting a large
number of typical artifacts and accordingly applying a regression
algorithm to compute propagation factors (Eeprobe 3.1, ANT
Software BV, Enschede, the Netherlands). After EOG correction,
epochs that contained EEG activity exceeding 6100 mV peak-to-
peak amplitudes were rejected from further analyses. Since we
included only trials with correct answers and hit rate was smaller
Figure 1. Example of trials stimulation sequence (above the line) and correct answers to the tasks (below the line) for the two tasks.
A) Discrimination task (WM0), in which subjects had to decide whether the two digits on the screen were equal or different. B) Working memory task
(WM1), in which the subjects had to compare the left digit on the screen with the left digit of the previous trial. WM0 – discrimination task; WM1 –
working memory task.
doi:10.1371/journal.pone.0104869.g001
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for WM1, the final number of trials was smaller for WM1. The
total number of trials included in the averages for each condition
and auditory stimulus type was: 246 trials with standard sounds
and 81 with novel sounds in WM0 and 213 trials with standard
sounds and 64 trials with novel sounds in WM1.
In this paradigm, subjects are specifically instructed to ignore
the sounds. Hence, any related effects are necessarily involuntary
or lead by exogenous attention. ERPs recorded during this
auditory-visual distraction paradigm typically present first an
auditory N1/mismatch negativity (N1/MMN) enhancement,
reflecting a detection mechanism that leads to attention capture
Figure 2. Performance results. A) Mean hit rate for each task and auditory stimulus type. B) Mean response time for each task and auditory
stimulus type. C) Distraction costs for each task. Distraction = hit rate in standard minus novel trials or response time in novel minus standard trials.
WM0 – discrimination task; WM1 – working memory task. Bars represent +/– standard error of the mean (SEM).
doi:10.1371/journal.pone.0104869.g002
Figure 3. Event Related Brain Potentials (ERPs). A) Grand average waveforms at Cz for both tasks (WM0 and WM1) and type of sound (standard
and novel). B) Auditory P3 (aud P3) amplitude for each task (WM0 and WM1) and type of sound (standard and novel). C) Grand-average of novel
minus standard difference waves at Cz. WM0 – discrimination task; WM1 – working memory task; NovP3 – novelty P3; s - seconds. Bars represent +/–
standard error of the mean (SEM).
doi:10.1371/journal.pone.0104869.g003
DHEA Relations to Working Memory and Distraction
PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e104869
[46], followed by a novelty-P3 (nov-P3) that reflects the effective
attention orientation [46,47,52]. Finally, the re-orienting negativ-
ity (RON) reflects the attention re-orientation back to the task
[53]. The target is visual and visual ERPs yield sensory (visual P1
and N1) and cognitive components related to target processing
(N2b and P300). The N2b is a negative deflection originated by
the relevant stimulus and the P300 reflects the processing of the
task-relevant visual stimulus [51,54,55]. Typically the task with
working memory load is more difficult for the subjects, leading to a
reduced P300 [51,54,55].
To analyze distraction effects at the electrophysiological level,
difference waves (dw) were calculated by subtracting the ERPs
elicited in standard trials from those elicited in novel trials. These
difference waves revealed an early-onset, long-lasting positive
deflection that we assimilated to the novelty-P3. Novelty-P3 was
measured as the mean amplitude in a time window ranging from
250 to 380 ms at F3, Fz, F4, C3, Cz, C4, P3, Pz and P4 electrodes.
To analyze WM effects we compared ERP measures only in
standard trials. Specific auditory and visual components were
elicited during task-performance: the auditory N1 and P2 and
visual P1 and N1. Yet, since cognitive processing was of interest for
the present study, we only analyzed N2b (560–645 ms, 210–
295 ms from visual stimulus presentation) and P300 (650–910 ms,
300–560 ms from visual stimulus presentation): F3, Fz, F4, C3, Cz
and C4 for N2b and P3, Pz and P4 for P300. Moreover, since the
P300 latency was different across WM conditions [F(1,21) = 5.683,
p = 0.027; 753662 ms for WM1; 787636 ms for WM0], we
analyzed the amplitude of this component at different time
windows for each condition (WM1: 650–875 ms; WM0-670–
910 ms).
Figure 4. Standard Event-Related Potentials (ERPs) waveforms in the discrimination and working memory tasks. A) Standard ERPs in
both tasks (both task orders). B) Mean N2b amplitude for each task. C) Standard ERPs in both tasks at Pz, according to the tasks order. D) Mean visual
P300 amplitude according to the temporal sequence of tasks (first and second). WM0 – discrimination task; WM1 – working memory task; s – seconds;
order WM0-WM1 – the discrimination task performed firstly and the working memory task performed secondly; order WM1-WM0 – the working
memory task performed firstly and the discrimination task performed secondly. Bars represent +/2 standard error of the mean (SEM).
doi:10.1371/journal.pone.0104869.g004
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Figure 5. Endocrine results. A) Mean DHEA levels for each task and order. B) DHEA response for each task and order. C) Mean cortisol levels for
each task and order. D) DHEA and cortisol responses (after task/before task ratios) were directly related in the discrimination task. E) DHEA and
cortisol responses were directly related in the working memory task. WM0 – discrimination task; WM1 – working memory task; DHEA response: DHEA
after task/before task ratio; Cortisol response: Cortisol after task/before task ratio; order WM0-WM1 – the discrimination task performed firstly and the
working memory task performed secondly; order WM1-WM0 – the working memory task performed firstly and the discrimination task performed
secondly. Error bars represent +/2 standard error of the mean (SEM).
doi:10.1371/journal.pone.0104869.g005
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Endocrine Measurements
We collected saliva samples by means of passive drool, using a
short straw. Unstimulated whole saliva was used. We collected
samples for DHEA, DHEAS and cortisol measurement before
each task [before task (BT)], at 30 min [after task (AT)] and
60 min [washout (WO)]. The samples collected before the first
task (i.e. before both tasks) were considered as the baseline. We
chose the time points to collect the saliva samples in accordance to
known cortisol raise and recovery times-raise 10 min after
appropriate stimulus, peak at 20–30 min and recover at 45–
60 min. Furthermore, synchronous 24 h profiles were described
for DHEA and cortisol [56].
Unbound DHEA and cortisol in the peripheral circulation
penetrate into the saliva via intracellular mechanisms and salivary
concentrations reflect serum concentrations [57,58]. DHEAS is
not lipid soluble and cannot penetrate into the saliva by passive
diffusion through cell membranes. Instead, it squeezes through the
tight junctions between salivary glands. DHEAS concentrations in
saliva are therefore dependent on serum concentration and
salivary flow rate [57].
Samples were refrigerated at 2–8uC within 30 minutes after
collection and they were stored at 220uC within 4 h and until
assayed. Each sample was measured in duplicate by using enzyme-
linked immunoassays: salivary DHEA and DHEAS enzyme
immunoassay kits (Salimetrics EuropeH, Ltd, Newmarket Suffolk,
UK) and high sensitivity salivary cortisol enzyme immunoassay
kits (SalimetricsH, LLC, State College, PA, USA). DHEA was
measured in pg/mL and cortisol was measured in mg/dL. Due to
the influence of saliva flow rates on DHEAS levels, the
concentration of DHEAS (pg/mL) was multiplied by the flow
rate (mL/min) and the corrected results were obtained as DHEAS
measured per unit of time (pg/min). Intra- and interassay variation
coefficients were less than 10% and 15%, in every case,
respectively. Cortisol and DHEA were expressed as pmol/L by
using the conversion factors 27590 and 0.3467, respectively, and
DHEAS was expressed as pmol/h by using the conversion factor
0.16284 (system of international units = conventional units6con-
version factor).
Statistical Analysis
The Statistical Package for the Social Sciences Program (IBM
SPSS Statistics, version 21) was used for data analyses. Results are
presented as the mean 6 standard error of the mean (SEM). The
normal distribution of continuous variables was verified by the
Kolmogorov-Smirnov Goodness of Fit Test and non-normal
distributed variables were log (ln) transformed prior to the analysis.
Figure 6. Baseline cortisol/DHEA ratio was directly related to novelty-P3 under Working Memory load.
doi:10.1371/journal.pone.0104869.g006
DHEA Relations to Working Memory and Distraction
PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e104869
For the sake of simplicity, the results of non-transformed variables
are presented whenever we did not find any differences.
To explore the effects of WM load and auditory distraction on
performance we performed repeated measures analyses of
variance (ANOVAs) on hit rate and response time, including the
within-subjects factors task (WM0 and WM1) and sound (standard
and novel). Regarding electrophysiological responses, we exam-
ined the auditory ERPs to explore distraction effects and the visual
ERPs to explore WM effects. To investigate the effects of auditory
distraction on ERPs, we carried out repeated measures ANOVAs
on the mean amplitude of the auditory P3 in the time window and
electrodes considered above, with the within-subjects factors task
(WM0 and WM1) and sound (standard and novel). To investigate
WM effects on distraction ERPs, we carried out an ANOVA on
the mean amplitude of the novelty-P3 in the time window and
electrodes considered above with task (WM0 and WM1) as within-
subjects factor. To investigate WM effects on electrophysiological
responses, we included only standard trials and conducted
ANOVAs on N2b and visP300 mean amplitude in the time
windows and electrodes considered above, with task (WM0 and
WM1) as within-subjects factor and task order (simply referred as
order in the results) as between-subjects factor (WM0-WM1 or
WM1-WM0; this factor is included because we used a blocked
protocol, one task consisting exclusively in WM0 trials and the
other consisting exclusively in WM1 trials, counterbalanced across
subjects).
To investigate the effects of WM manipulation on endocrine
levels, we performed repeated measures ANOVAs on DHEA,
DHEAS and cortisol levels, including the within-subjects factors
task (WM0 and WM1) and time (before task, after task and
washout) and the between-subjects factor task order (WM02WM1
or WM12WM0). The endocrine relation to distraction and WM
load effects at the behavioral and electrophysiological levels was
investigated by repeated measures ANOVAs of behavior and ERP
parameters, including baseline DHEA, DHEAS, cortisol or
cortisol/DHEA ratio as covariates. Because the DHEA response
(determined by the ratio after task/before task) differed between
the two WM conditions, DHEA response in WM1 – DHEA
response in WM0 (D DHEA response) was used as a measure of
DHEA response attributed to WM load. This new variable was
also tested as a covariate. Whenever the endocrine parameters
covariated with the performance or ERP parameters, for each type
Figure 7. The visP300 amplitude changed between tasks (WM0, WM1) in direct relation to DHEA response. WM0 – discrimination task;
WM1 – working memory task. D DHEA response = DHEA response in WM1 – DHEA response in WM0; D visP300 = mean visual P300 in WM1 - mean
visual P300 in WM0.
doi:10.1371/journal.pone.0104869.g007
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of auditory stimuli or WM condition, we used Spearman’s Rank
Order correlation coefficients to select the relevant endocrine
factors and understand the relations direction. DHEAS relations
to performance and ERP parameters were not significant and
therefore those results are not mentioned in the results section.
ANOVA results were Greenhouse–Geisser corrected whenever
the assumption of sphericity was violated. Post hoc tests were
carried out wherever there were significant interactions between
main factors. The Bonferroni correction was used for multiple
comparisons. The limit of significance chosen was a= 0.05.
Results
Performance
Behavioral results for each task and auditory stimulus are
presented in Figure 2. Overall hit rate was 8362% in WM0 and
7062% in WM1 (figure 2A) and this difference in hit rate was
significant, as reflected by a main effect of task [F(1,22) = 27.279,
p,0.001]. Additionally, there was a main effect of task on
response times [F(1,22) = 8.760, p = 0.007] with longer response
times in WM1 [467613 ms] than in WM0 [44069 ms], see
figure 2B. Thus, the WM load resulted in lower hit rates and
longer response times.
Regarding the effects of auditory distraction on performance,
the results showed a main effect of auditory stimulus both on hit
rate [F(1,22) = 9.577, p = 0.005, with lower hit rates for novel
sounds (7462%) than for standard ones (7961%), see figure 2A],
and response times [F(1,22) = 43.451, p,0.001, with longer
response times for novel sounds (476611 ms) than for standard
ones (431610 ms), see figure 2B]. This means that novel sounds
resulted in auditory distraction reflected by lower hit rates and
longer response times.
The interaction between task and auditory stimulus also had
notable significant effects on hit rates [F(1,22) = 5.557, p = 0.028].
Post hoc analyses on each WM condition yielded significant effects
of auditory distraction only in the working memory load task
[F(1,22) = 8.697, p = 0.007], see figure 2C. In that condition, hit
rates were lower for novel sounds (6564%) than for standards
(7461%).
Event-Related Potentials
Distraction effects. As can be seen in figure 3A, novel
sounds elicited larger auditory P3 mean amplitudes when
compared to standard sounds, both in WM0 [F(1,22) = 63.696,
p,0.001; 23.360.5 mV in standard and +1.660.7 mV in novel
trials] and in WM1 [F(1,22) = 98.333, p,0.001; 24.160.4 mV in
standard and +1.960.6 mV in novel trials], see figure 3B. This
supports that a significant novelty P3 was elicited by novel sounds
(figure 3C). However, WM load did not influence the novelty-P3,
as its amplitude was similar in both tasks [F(1,22) = 3.381, p = 0.079,
5.060.6 mV in WM0, and 5.960.6 mV in WM1]. Neither clear
N1-enhancement/MMN nor RON was elicited. In sum, signifi-
cant novelty-P3 responses were elicited by novel sounds in both
conditions, but without any significant difference between
conditions.
Working Memory Effects. The waveforms elicited by
standard trials in the two tasks are presented in Figure 4. The
N2b significantly increased in WM1 as compared to WM0
[F(1,21) = 6.738, p = 0.017; 21.860.9 mV in WM0 and
23.360.6 mV in WM1] (see figure 4A and 5B).
The analysis of visP300 revealed a task6order interaction
[F(1,21) = 10.184, p = 0.004], see figure 4C. Further analyses
revealed a visP300 enhancement in the second task [t(22) =
23.163, p = 0.005; 2.660.6 mV in the first task, and 4.860.8 mV
in the second task], independently of the WM load content of that
task (figure 4D).
Overall, N2b was enhanced by WM load while the visP300 was
enhanced in the second task, independently from working memory
load.
Endocrine Baseline Levels and Response
Baseline endocrine levels were: DHEA 79.0615.5 pmol/L,
DHEAS 9846120 pmol/h and cortisol 34126622 pmol/L, with
a normal distribution and no significant relation between them.
These parameters were not significantly related to age and body
mass index (BMI, kg/m2), and did not differ significantly
according to the menstrual cycle phase (follicular, peri-ovulatory
and luteal, based on self reported menstrual cycle day) or between
subjects taking and not taking hormonal contraception. DHEA
and cortisol levels during the experimental procedure are shown in
Figure 5.
In contrast to DHEAS levels, which were not affected by any of
the factors (task, time or task order), and therefore won’t be
reported any further, repeated measures ANOVA on DHEA levels
revealed a task6order interaction [F(1,20) = 6.215, p = 0.022] and a
task6time6order interaction [F(2,40) = 9.839, p = 0.002]. Further
analyses revealed that DHEA levels rose after the performance of
the second task as indicated by a time effect [F(2,40) = 8.415,
p = 0.003; 59.669.4 pmol/L before task; 83.9613.5 pmol/L after
task; 92.9615.6 pmol/L at washout], see figure 5A.
Regarding WM effects, post hoc analyses revealed that when the
order was WM0-WM1, DHEA levels were higher after WM1 than
after WM0 [F(1,10) = 9.041, p = 0.013, 71.1613.9 pmol/L after
WM0 and 106.4622.2 pmol/L after WM1]. The DHEA
response [F(1,10) = 10.676, p = 0.008, 0.88 for WM0 and 1.60 for
WM1] was also higher in WM1 than in WM0 (figure 5B).
Nevertheless, when the order was WM12WM0, DHEA levels
after the second task [F(1,10) = 6.006, p = 0.034] and DHEA
response [F(1,10) = 4.855, p = 0.052] were similar in the WM0
(the second task) and in the WM1 task.
An repeated measures ANOVA on cortisol levels revealed a
task6time6task order interaction [F(2,40) = 11.809, p = 0.002].
Post-hoc analyses for each task order separately showed that
cortisol levels decreased after WM0 when the order was WM02
WM1. In fact, for this order, there was a time effect for WM0
[F(2,22) = 9.544, p = 0.007; cortisol levels were 37256855 pmol/L
before task; 27046579 pmol/L after task; 17666359 pmol/L at
washout], see figure 5C. In spite of this, the cortisol after task/
before task ratio in WM0 was not significantly different from the
after task/before task ratio in WM1.
DHEA and cortisol changes were directly related for both the
WM0 [after task/before task: rs = 0.615, n = 22, p = 0.002,
figure 5D; washout/before task: rs = 0.852, n = 22, p,0.001]
and WM1 task [after task/before task: rs = 0.654, n = 22,
p = 0.001, figure 5E; washout/before task: rs = 0.656, n = 22,
p = 0.001].
Endocrine Relations to Performance
ANOVAs on hit rate and response time were used to select the
endocrine parameters that covariated with performance (results
are presented as supporting information, Table S1): baseline
cortisol, baseline cortisol/DHEA ratio and D DHEA response
covariated with hit rates and D DHEA response covariated with
response times. Nevertheless, post hoc Spearman’s Rank Order
correlations showed no significant relations between those
endocrine parameters and performance.
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Endocrine Relations to Event-Related Potentials
Distraction Effects. Endocrine relations to distraction were
explored by using the novel minus standard difference waves for
WM0 and WM1. There were no endocrine relations to novelty-P3
in WM0. However, in WM1, the novelty-P3 amplitude was
enhanced in relation to higher baseline cortisol/DHEA ratios
(rs = 0.796, n = 22, p,0.001; see figure 6).
Working Memory Effects. The results showed that visP300
change between tasks was directly related to D DHEA response as
supported by a significant interaction between visP300 ampli-
tude6D DHEA response [F(1,20) = 9.244, p = 0.006] and a direct
relation between visP300 enhancement and DHEA response
increase attributed to WM load (rs = 0.587, n = 22, p = 0.004; see
Figure 7). The difference of visP300 latency between tasks was not
related to the endocrine parameters.
Discussion
The present study explores the relationships between cognitive
performance and endogenous DHEA, DHEAS and cortisol. As
expected, the audio-visual distraction paradigm including a
manipulation of working memory, yielded typical effects observed
in previous studies. Indeed, the WM load task was harder to
perform, as revealed by lower hit rates and longer reaction times.
Likewise, novel sounds distracted the participants, as reflected by
lower hit rates and longer reaction times. Regarding brain
responses to novel sounds in both WM0 and WM1 tasks, the
results revealed an enhanced P3 deflection, indicating that novel
sounds caused distraction when compared to standards. The N2b
elicited by the task-relevant visual stimuli was enhanced under
WM load as expected [51].
DHEA and cortisol responses were directly related (indepen-
dently of the WM load content of the task). This is in agreement
with the fact that corticotrophin releasing hormone (CRH)
stimulates corticotrophin secretion and in turn corticotrophin is
a stimulus for DHEA secretion [59,60], even if indirectly through
the action of an unidentified DHEA androgen stimulating
hormone [61,62,63].
Nevertheless, we found important differences between DHEA
and cortisol responses with WM load manipulation. DHEA levels
increased with the performance of the second task independently
of the task, suggesting either a cumulative effect or a latent interval
before the response. Still, the increase in DHEA levels was more
pronounced with WM load. Thus, the effect of a greater cognitive
effort or specific effects of WM load on DHEA levels are
suggested. Interestingly, this response is specific for DHEA and
does not occur with cortisol and DHEAS. In fact, regarding
cortisol, a decrease was found when the subjects were performing
the discrimination task (WM0). Whatever the specific mechanisms
may be, there is an interesting point: the distinctive pattern of
cortisol and DHEA responses. Thus, cortisol decreases after a
simple task if this task comes first and DHEA increases after a
second cognitive task when this is a challenging task.
Stangl et al. [64] demonstrated that DHEA administration
increased DHEA levels and enhanced performance in a visual
same-different task (without WM load) while cortisol levels
remained constant. Also, those authors described baseline cortisol
relations to performance. However, other studies failed to provide
systematic evidence that DHEA and DHEA administration
enhanced short-term memory at the performance level [16,19].
In the present study, endogenous levels of DHEA, DHEAS and
cortisol were measured and no significant relations were found
with the accuracy or latency of the response. Nevertheless, a bigger
sample of subjects may be necessary to uncover eventual relations.
On the other hand, the present study demonstrated endocrine
relations to the electrophysiological recordings. In the WM task,
higher baseline cortisol/DHEA ratio was related to more
processing of the distracting stimuli, as indexed by an enhanced
novelty-P3. This suggests that baseline cortisol enhances, whereas
baseline DHEA prevents auditory distraction, and simultaneously
suggests an anti-cortisol effect of DHEA. The fact that this relation
became evident in the most stressful situation (WM load) agrees
with previous evidence showing that DHEA has anti-cortisol
effects under stress [12,14] or that these effects are more evident
under stress.
Regarding ERPs to the visual target stimuli, DHEA effects on
WM load pointed towards increased visP300 amplitudes. In fact,
the DHEA raise due to WM load was related with enhanced P300
amplitudes indicating enhanced memory update and suggesting a
rapid DHEA behavioral effect.
Endocrine responses to stimuli are commonly used and they
usually provide higher sensitivity than baseline levels to detect
pathological conditions or inter-subjects differences [29,65,66]. As
an example, glucocorticoids responses to different stimuli can be
used to measure the adrenals functional reserve (predicting their
response to stress) or to characterize different phenotypes of the
stress response (which were related to personality traits and
pathological conditions) [67,68,69,70,71]. Accordingly, in the
present study, the parameter related to working memory
processing was DHEA response and not baseline DHEA. Also,
apart from its slow genomic effects, corticosteroids are known to
have rapid non-genomic central nervous system effects [35,39,40].
Alternatively, the relation between visual P300 amplitude and
DHEA response could suggest that subjects with enhanced
working memory update are the ones with higher DHEA
responses. In that regard, other authors demonstrated that chronic
stress and higher cortisol levels were related with poorer memory
[34,37,38] and reduced DHEAS response to a superimposed
psychological stress [29]. Nevertheless, we found no relation
between baseline cortisol and visual P300 amplitude, and
therefore, an effect of chronic stress is not suggested.
Wolf et al. [43] studied the effects of DHEA replacement on
short term memory ERPs. They reported an increase in P3
amplitude after DHEA replacement, which reflects an enhance-
ment of information updating. This is in accordance with our
results, as we also observed that the physiological DHEA increase
was related to an enhanced visP300.
A short term increase in cortisol can damage hippocampal
neurons and may impair memory [42]. This may be an
oversimplification since specific types of hippocampal mediated
memory may be impaired by stress but others may not [72,73].
Yet, and hypothesizing that DHEA might prevent memory
impairment under stress, Wolf et al [74] found that DHEA
replacement enhanced attention but did not prevent the decline in
visual memory under an acute psychosocial stress. This result did
not support the idea of a direct anti-glucocorticoid effect of DHEA
in hippocampal mediated memory functions. In another study
DHEA protected hippocampal neurons against excitatory amino
acid-induced neurotoxicity [75]. Our results also support the idea
of DHEA anti-cortisol effects in distraction, but regarding working
memory, we found relations with DHEA, not cortisol. Moreover,
normal ranges of baseline cortisol were observed and cortisol levels
did not rise with WM load, they just did not decrease.
Recent results also suggest that repeated stress and consequent
activation of the glucocorticoid receptors dampens prefrontal
cortex glutamatergic transmission. Actually, it facilitates glutamate
receptor turnover, which has a detrimental effect on prefrontal
cortex-dependent cognitive processes [76] like WM. The present
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results agree with the known action of DHEA on glutamatergic
receptors as well as with the idea that DHEA opposes cortisol
detrimental effects during the performance of working memory
tasks under stress. This last relation was evidenced by inverse
relations of DHEA and cortisol to distraction.
Nevertheless, working memory effects were related to the
DHEA response but not to cortisol. Thus, regarding WM effects,
an anti-cortisol effect of DHEA is not so evident and other specific
effects of DHEA may be present. As mentioned, besides their anti-
cortisol effects, DHEA has Gamma Aminobutyric Acid Type A
(GABAA) receptor antagonism and sigma 1 agonist effects [3,9,10]
which might underlie or contribute to the effects found. In fact,
both gabaminergic antagonism and glutamatergic agonism are
known to improve cognitive function.
Eventually in relation to DHEAS’ long half-life [2,3], its levels
did not change with WM load manipulation. Also, we found no
relations between baseline DHEAS and performance or ERPs.
Nevertheless, we found no relations between baseline DHEA and
performance or ERPs either. Instead, baseline cortisol/DHEA
ratio and DHEA response relations to ERPs were found.
DHEA metabolites also include other neuroactive steroids such
as estradiol, estrone and testosterone [19,77], which may mediate
part of the DHEA effects, namely after DHEA administration
[78]. Estrogens, in particular estradiol, enhance working memory
in women [79,80] and testosterone supplementation may enhance
working memory in older men [81,82]. We did not measure
DHEA metabolites, which may mediate some of its effects.
Subsequently, we cannot exclude that those steroids may
contribute or eventually be responsible for the performance and
electrophysiological relations we found. Finally, as our study
includes only female participants, the outreach of the results is
limited only to women. DHEA and DHEAS are androgens and
androgen levels, namely testosterone and DHEAS levels, are
higher in men than in women [2,7]. Therefore, another group of
participants would be necessary to study the electrophysiological
correlates of DHEA and DHEAS in men. For further studies it
would be relevant to study whether the results are identical or
distinct according to gender.
In summary, a higher cortisol/DHEA ratio was related to
enhanced processing of the auditory distractor during the
performance of a visual working memory task. This suggests that
in women, DHEA may oppose cortisol effects in involuntary
distraction, reducing the processing of the auditory distractor
(novelty-P3). Regarding working memory, DHEA increased with
the performance of consecutive cognitive tasks, and a higher
DHEA response due to WM load was related to an enhancement
of the task-relevant information processing (visual P300). Overall,
the results suggest that DHEA may oppose cortisol effects reducing
distraction and a higher DHEA response may enhance working
memory at the electrophysiological level.
Supporting Information
Table S1 Endocrine relations to performance. ANOVAs
of the performance parameters that covariated with endocrine
measurements. Results represent the interaction between endo-
crine parameters and working memory (WM) condition and
auditory stimulus. Baseline endocrine interactions are significant
when p,0.013. D DHEA response = DHEA response in WM1 –
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Table S1: Endocrine relations to performance 
ANOVA 
Hit Rates 
Baseline Cortisol x Task (WM1, WM0) F (1,21)=5.956 p=0.024 
Sound (standard, novel) F(1,21)=8.222 p=0.009 
Task x Sound F(1, 21)=11.751 p=0.003 
Baseline Cortisol/DHEA ratio x Task F(1,20)=8.186 p=0.01 
Sound F(1,20)=13.178 p=0.002 
Task x Sound F(1,20)=17.609 p<0.001 
Δ DHEA response x Task F(1,20)=8.087 p=0.01 
Sound F(1,20)=1.827 p=0.192 
Task x Sound F(1,20)=5.671 p=0.027 
Response times 
Baseline Cortisol x Task F(1,21)=1.129 p=0.300 
Sound F(1,21)=4.441 p=0.047 
Task x Sound F(1,21)=3.038 p=0.096 
Baseline Cortisol/DHEA ratio x Task F(1,20)=0.467 P=0.502 
Sound F(1,20)=6.489 p=0.019 
Task x Sound F(1,20)=2.104 P=0.162 
Δ DHEA response x Task F(1,20)=3.304 p=0.084 
Sound F(1,20)=2.349 p=0.141 
Task x Sound F(1,20)=10.734 p=0.004 
Correction: The Relationship between Dehydroepiandrosterone (DHEA), Working Memory and 
Distraction – A Behavioral and Electrophysiological Approach. 
Sónia do Vale, Lenka Selinger, João Martin Martins, Ana Coelho Gomes, Manuel Bicho, Isabel do Carmo, 
Carles Escera 
Published: August 8, 2014. http://dx.doi.org/10.1371/journal.pone.0104869 
The factor used to convert DHEA measurements from conventional units to the system of 
international units should be 3.467 instead of 0.3467 (this error is in the last sentence of the “Subjects 
and Methods” section, “Endocrine Measurements” subsection). Therefore, DHEA levels in the “Results” 
section, “Endocrine Baseline Levels and Response” subsection, should read 10 times higher, as follows. 
First sentence of the first paragraph: Baseline endocrine levels were: DHEA 790±155 pmol/L, DHEAS 
984±120 pmol/h and cortisol 3412±622 pmol/L, with a normal distribution and no significant relation 
between them. 
Last sentence of the second paragraph: Further analyses revealed that DHEA levels rose after the 
performance of the second task as indicated by a time effect [F(2,40) =8.415, p=0.003; 596±94 pmol/L 
before task; 839±135 pmol/L after task; 929±156 pmol/L at washout], see figure 5A. 
First sentence of the third paragraph: Regarding WM effects, post hoc analyses revealed that when the 
order was WM0-WM1, DHEA levels were higher after WM1 than after WM0 [F(1,10) =9.041, p=0.013, 
711±139 pmol/L after WM0 and 1064±222 pmol/L after WM1]. 
Figure 5.A: DHEA values should read 10 times higher, therefore “x10” is missing in the top of DHEA axis. 
Figure 6: Baseline cortisol/DHEA ratio axis should be 0, 10, 20, 30 and 40 instead of 0, 100, 200, 300 and 
400.  
Figure 5.D has got a typographical error: it should be rs=0.615 (as stated in the text) instead of 
rs=0.165. 
These errors do not significantly affect the results and they do not affect the conclusions of the 
work. The authors apologize for these errors. 
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Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS)may havemood enhancement ef-
fects: higher DHEAS concentrations and DHEA/cortisol ratio have been related to lower depression scores and con-
trolled trials of DHEA administration have reported significant antidepressant effects. The balance between DHEAS
and DHEA has been suggested to influence brain functioning. We explored DHEAS, DHEA, cortisol, DHEA/cortisol
and DHEAS/DHEA ratios relations to the processing of negative emotional stimuli at behavioral and brain levels
by recording the electroencephalogram of 21 young women while performing a visual task with implicit neutral
or negative emotional content in an audio–visual oddball paradigm. For each condition, salivary DHEA, DHEAS
and cortisol were measured before performing the task and at 30 and 60 min intervals. DHEA increased after task
performance, independent of the implicit emotional content. With implicit negative emotion, higher DHEAS/
DHEA and DHEA/cortisol ratios before task performance were related to shorter visual P300 latencies suggesting
faster brain processing under a negative emotional context. In addition, higher DHEAS/DHEA ratios were related
to reduced visual P300 amplitudes, indicating less processing of the negative emotional stimuli. With this study,
we could show that at the electrophysiological level, higher DHEAS/DHEA and DHEA/cortisol ratios were related
to shorter stimulus evaluation times suggesting less interference of the implicit negative content of the stimuli
with the task. Furthermore, higher DHEAS/DHEA ratios were related to reduced processing of negative emotional
stimuli which may eventually constitute a protective mechanism against negative information overload.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-
sulfate (DHEAS) are neuroactive steroids and their concentrations
in the central nervous system are higher than in the peripheral circula-
tion (Dong and Zheng, 2011; Lacroix et al., 1987). Although their phys-
iological role and mechanisms of action are still a matter of debate
(Komesaroff, 2008), a growing amount of evidence has been accumu-
lating regarding their actions in the central nervous system. Concerning
cognitive functions, higher DHEAS levels were related to improved
memory (Barrett-Connor and Edelstein, 1994), whereas low levels
were found in Alzheimer's disease (Weill-Engerer et al., 2002). Besides,
higher DHEA, DHEAS or DHEA-to-cortisol levels were related to
improved attention (Wolf et al., 1997), lower perceived stress and
also to improved performance under stressful conditions (Morgan
et al., 2009; Russo et al., 2012).
Furthermore, higher DHEAS concentrations and DHEA-to-cortisol
ratios have been related to lower prevalence of depression, lower de-
pression ratings and higher well-being scores (Barrett-Connor and
Edelstein, 1994; Barrett-Connor et al., 1999; Michael et al., 2000;
Young et al., 2002). The relation betweenDHEA levels alone and depres-
sion is less consistent. In fact, several groups have found that DHEA-to-
cortisol ratios, rather than concentrations of either hormone alone, dis-
criminated more accurately depressed from non-depressed individuals,
with lower DHEA-to-cortisol ratios as seen in depression (Assies et al.,
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2004; Michael et al., 2000), in untreated depressed patients and in
patients who remained depressed after several months (Goodyer
et al., 1998).
It was hence suggested that elevated DHEA and DHEAS relative to
cortisol levels, may counteract the negative effects of high cortisol on
mood (Goodyer et al., 1998; Kaminska et al., 2000). Moreover, con-
trolled trials of DHEA therapy have reported significant positive effects
on mood (Bloch et al., 1999; Schmidt et al., 2005; Wolkowitz et al.,
1999). These mood improvements were related to increases in the cir-
culating concentrations of DHEA andDHEAS and to increases in their ra-
tios with cortisol. On the other hand, sulfated steroids in general
possibly act as endogenous neuromodulators (Gibbs et al., 2006) and
the balance between DHEAS andDHEA has also been suggested to influ-
ence brain functioning. In a study assessing both DHEA and DHEAS, de-
pressed patients had low DHEAS but normal DHEA concentrations
(Scott et al., 1999). In a different setting, but also pointing towards the
importance of DHEAS to DHEA balance, it has been shown that subjects
with Alzheimer's disease have increased levels of DHEA in the central
nervous system, but a reduced conversion of DHEA into DHEAS and
consequently, reduced DHEAS/DHEA ratios (Kim et al., 2003).
Glucocorticoids' effects are not always deleterious. In fact, glucocor-
ticoids have biphasic effects on fear conditioning: although mild or
short lasting increases in glucocorticoids in relation to stress may have
beneficial effects on attention and promote adaptation, higher cortisol
levels or long term increases have deleterious effects on executive func-
tioning, attention, learning, memory and cognitive flexibility (Campeau
et al., 2011; McEwen, 2012). Again, anti-glucocorticoid effects of DHEA
and DHEAS have been proposed in what concerns cognition and
performance.
DHEA and DHEAS present a general neurostimulatory effect, but
DHEAS has a much more potent excitatory action than DHEA (Baulieu
and Robel, 1998; Imamura and Prasad, 1998; Monnet et al., 1995; Dong
and Zheng, 2011). At the cellular level DHEAS antagonizes the neurotoxic
effect of high doses of DHEA in mouse neuronal cultures (Gil-ad et al.,
2001) and DHEA is protective against the neurotoxic effects of corticoste-
rone (Balazs et al., 2008). Hence, the simultaneous evaluation of DHEA,
DHEAS and cortisol and the ratios of DHEA-to-cortisol and DHEAS-to-
DHEA may uncover more information than the individual examination
of either steroid alone.
DHEA and DHEAS effects on cerebral regions specifically involved in
emotional processing including the amygdale, hippocampus, insula and
anterior cingulated cortex have been suggested. However, little re-
search has explored the neural correlates of DHEA and DHEAS with re-
spect to emotion and mood. In this regard, a study using LORETA
showed that DHEA administration increased the activity in the anterior
cingulate cortex (Alhaj et al., 2006). Another recent study using func-
tional Magnetic Resonance Imaging (fMRI) found that DHEA reduces
the activity in regions associated with the generation of negative emo-
tion and enhances activity in regions linked to regulatory processes
(Sripada et al., 2013).
DHEA and DHEAS relations to emotional processing at the electro-
physiological level are not known. Regarding cortisol, its administration
increased the processing of angry faces in highly anxious individuals as
indicated by increased amplitudes of early (P150) and late (P3) event-
related potentials (van Peer et al., 2007). DHEA and DHEAS may modu-
late attention, cognition and mood while their response to emotional
stimuli is mostly unexplored.
The aim of the present study was to explore whether DHEA and
DHEAS levels would have an influence on involuntary attention and
emotional stimuli processing at the performance and brain levels and,
on the other hand, if an emotional challenge would alter DHEA and
DHEAS levels. Furthermore, we wanted to examine the relation of
DHEA and DHEAS with cortisol levels. The a priori hypotheses were:
1) higher endogenous DHEAS and DHEA levels as well as higher
DHEA-to-cortisol and DHEAS-to-DHEA levels may protect from invol-
untary distraction and enhance brain processing and performance
under a negative emotional context; 2) DHEAS and DHEA effects may
be largely antagonistic from those of baseline cortisol; 3) in the short
term, a negative emotional context might be a stimulus for DHEA and
cortisol secretion.
To test these hypotheseswe used a visual taskwith a neutral or neg-
ative emotional context and unexpected auditory novel sounds aimed
to cause distraction. In this paradigm, the negative emotional context
is expected to elicit an increased attention capture when compared to
non-emotional faces (Öhman et al., 2001) and consequently deteriorate
performance (Domínguez-Borràs et al., 2008). Furthermore, auditory
distraction by novel sounds is expected to elicit a novelty-P3 compo-
nent in the electroencephalogram (EEG) and also deteriorate perfor-
mance (Corral and Escera, 2008; Domínguez-Borràs et al., 2008;
Escera et al., 1998, 2000). We recorded performance parameters, the
EEG and took saliva samples in order to determine the hormonal levels
before and after the task. We explored DHEA, DHEAS, cortisol, DHEA/
cortisol ratio andDHEAS/DHEA ratio relations to distraction and implicit
negative emotion at the performance and electrophysiological levels.
Participants and methods
Participants
21 healthy female volunteers (university students) from 18 to
26 years (mean 21 ± 1), performed the study protocol. Only women
were included as to ensure higher homogeneity in emotional processing
(Garcia-Garcia et al., 2008) and androgen levels. All had normal or
corrected-to-normal vision and none reported auditory deficits. There
was no history of neurologic, psychiatric, endocrine or oral diseases.
Subjects were asked to refrain from alcohol intake in the 12 h before
the experimental protocol and tobacco and illicit drug consumption
were exclusion criteria. All participants gave their written informed
consent. The experimental protocol was approved by the ethical
committees of the University of Barcelona and Lisbon Medical School
and was performed in accordance with the Declaration of Helsinki.
Prior to the experimental session, subjects completed the State-Trait
Anxiety Inventory (STAI; Spielberger et al., 1988) and all were within a
normal range of state (mean 13 ± 1) and trait (mean 17 ± 1) anxiety
levels. Mean body mass index (BMI) was 22.3 ± 0.8 kg/m2 and all par-
ticipants presented a normal body mass index except one with grade 1
obesity. All except one participant were right-handed. Seven partici-
pants were in the follicular phase, three were in the peri-ovulatory
phase and sixwere in the luteal phase, based on self reportedmenstrual
cycle day. Five subjects were using hormonal contraception, no other
medications were allowed.
Task and procedure
The experimental sessions were conducted in the afternoon, begin-
ning at 2–3 pm. An adapted version of awell-established auditory–visu-
al distraction task (Escera et al., 1998, 2000) was presented with two
different conditions, one featuring a neutral (NEU) and one featuring a
negative emotional content (NEG), as implemented by Domínguez-
Borràs et al (2008). Each condition lasted about 15 min and conditions
were performed 2 h apart (beginning to beginning). The order was
counterbalanced across subjects. Each condition consisted of two
separate blocks of 255 trials with a short interval between them.
Participants sat in a comfortable chair in a dimly lit and electrically
and acoustically shielded room. The task consisted of responding as
fast and accurately as possible whether the two faces on the screen
were equal or different by pressing the correspondent mouse button.
The subjects were instructed to ignore the sounds. In order to reduce
eye blinks and movements during EEG recording, subjects were asked
to blink as little as possible, and to focus on a central fixation cross be-
tween the two pictures. Responses were given through a mouse button
(one mouse button for “the same” and the other button for “different”,
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counterbalanced across subjects) and the probability of both responses
was the same. Before each experimental condition, subjects performed
practice blocks (composed of 10 trials) using faces with a neutral
expression only and without any auditory stimuli, until they reached a
hit rate (HR) of at least 80%.
In each trial, a task-irrelevant auditory stimulus was presented,
followed after 300 ms (onset-to-onset) by a visual imperative stimulus
(Fig. 1). The total trial length varied from 1200 to 1600 ms (1400ms on
average; jitter +/− 200 ms) and the response window until the end of
the shortest trial was 1200 ms. The auditory sequence consisted of
repetitive standard tones (duration of 200 ms, including fade-in
and fade-out of 10 ms each; 600 Hz; 85 dB; probability of occurrence
p = 80%), occasionally replaced by environmental novel sounds (p =
20%). These novel sounds were selected from a sample of 100 different
specimens (edited to have a duration of 200 ms, including fade-in and
fade-out of 10 ms each; digitally recorded, low-pass filtered at
10,000 Hz; 85 dB), such as those produced by a drill, hammer, rain,
door, telephone ringing, and so forth (Escera et al., 2003). All sounds
were delivered binaurally through headphones (Sennheiser HD 202)
in a randomized order with the only restrictions that the first four
stimuli of each block had to be standard tones, that two novel sounds
never appeared consecutively and that each novel sound occurred
only once in each condition. The visual stimuli were pairs of combi-
nations of pictures of faces with either neutral (Fig. 1.A) or fearful
(Fig. 1.B) expression, presented on a computer screen for 400 ms.
We used 12 pictures of faces with either neutral (NEU) or fearful
(NEG) expression from the Ekman and Friesen (1976) database. All
faces had exactly the same probability of occurrence and all had
the same valence (NEU or NEG) in each block. The picture size was
356 × 488 pixels, the vertical angle 9° and the horizontal angle 17°,
accounting for two pictures presented simultaneously with a fixa-
tion cross in between, and the distance from the subjects' eyes to
the screen was 100 cm.
Performance and EEG recording and analysis
Response time (RT) andwhether the button press was correct, wrong
ormissedwere recorded for each trial using Presentation® (Neurobehav-
ioral Systems, Inc). A database was created with the mean response time
for correct responses and hit rate (HR), separately for each condition
(NEU and NEG) and auditory stimulus type (standard and novel).
Distraction by novel sounds was computed as the difference in hit rate
and response time between standard and novel auditory stimuli
(hit rate: NEUstandard trials − NEUnovel trials and NEGstandard
trials− NEGnovel trials; response time: NEUnovel trials − NEUstandard
trials and NEGnovel trials−NEGstandard trials). Performance disruption
due to the processing of negative emotional stimuli was computed as
the difference in hit rate and response time between conditions, as ap-
propriate (hit rate: NEUstandard − NEGstandard and NEUnovel −
NEGnovel; response time: NEGstandard − NEUstandard and
NEGnovel − NEUnovel).
EEG activity was continuously recorded, from 64 scalp Ag/AgCl elec-
trodes following the extended 10/10 convention. It was amplified and
digitalized at a sampling rate of 512 Hz (Eemagine, ANT Software b.v.,
Enschede, Netherlands). The horizontal and vertical electrooculogram
(HEOG and VEOG) were recorded with electrodes placed at the outer
canthus and below the right eye, respectively. An electrode placed on
the tip of the nose was used as the common reference and the ground
was located at the AFz position. Impedances were kept at 5 kΩ or
below during the whole recording session. Recording was performed
with an ANT amplifier of 64 channels (gain 20×; A/D resolution 22
bits, 71.526 nV per bit; filtering 0–138.24 Hz; CMRR N 90 dB).
EEG processing was performed off-line by using Eeprobe 3.1 (ANT
Software BV, Enschede, Netherlands). A digital finite impulse re-
sponse (FIR) bandpass-filter from 0.01 to 30 Hz was applied using a
Hamming window. ERPs were averaged for each auditory-stimulus
trial type and emotional condition, for an epoch of 1400ms, compris-
ing a pre-auditory-stimulus baseline of 200 ms. The first five epochs
of each block and epochs following a novel trial were excluded from
averaging. Only epochs corresponding to trials with correct re-
sponses were included in further analyses. Electrooculogram (EOG)
correction was performed by manually selecting a large number of
typical artifacts and accordingly applying a regression algorithm to
compute propagation factors (Eeprobe 3.1, ANT Software BV, En-
schede, the Netherlands). After EOG correction any epochs contain-
ing EEG activity exceeding ±100 μV peak-to-peak amplitudes were
rejected from further analysis. On average, 84% of epochs (252
epochs) with standard sounds and 87% of epochs (87 epochs) with
novel sounds in NEU and 86% of epochs (259 epochs) with standard
sounds and 86% of epochs (86 epochs) with novel sounds in NEG
were retained for averaging.
In the employed paradigm the participants were specifically
instructed to ignore the distraction stimuli (auditory), hence any related
effects are necessarily involuntary or led by exogenous attention. ERPs
recorded during auditory distraction are typically characterized by an
auditory N1/mismatch negativity (N1/MMN) enhancement, reflecting
a detection mechanism leading to attention capture, followed by a
novelty-P3 (nov-P3) reflecting the effective orientation of attention
(Escera et al., 1998, 2000). The nov-P3 component has been shown
to be sensitive to the manipulation of the emotional context
(Domínguez-Borràs et al., 2008) and attention (Escera et al., 1998). Sub-
sequently, the re-orienting negativity (RON) reflects the re-orientation
of attention back to the task (Schröger and Wolff, 1998). The target
stimuli in the present task were visual, and visual ERPs include the
Fig. 1. Trial structure. A. Neutral emotional context (NEU). B. Negative emotional context (NEG).
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P300, which is a cognitive component related to target processing. The
P300 (visP300) reflects the conscious processing of the visual stimulus
and is sensitive to attention allocation (Domínguez-Borràs et al., 2008;
Polich, 2007).
To analyze distraction effects, the ERPs elicited to the auditory stim-
uli were considered and difference waveforms (dw) were calculated by
subtracting the ERPs elicited by standards from those elicited by novel
sounds. These difference waveforms revealed an early-onset, long-
lasting positive deflection that we assimilated to the novelty-P3. We
measured the auditory P3 (aud-P3) and novelty-P3 (nov-P3) as the
mean amplitude and mean peak latency in the 210–470 ms time win-
dow at F3, Fz, F4, C3, Cz, C4, P3, Pz and P4 electrodes.
To analyze emotional effects, ERP measures in standard trials
were compared. Specific components were elicited during task-
performance, such as the auditory N1 and P2, visual N1 and P2 and
the cognitive components N2b and visual P300. Since only cognitive
processing was of interest for the present study, the visual P300 (650–
1050 ms at F7, F3, FZ, F4, F8, T7, C3, CZ, C4, T8, P7, P3, PZ, P4 and P8,
350–750 ms from stimulus presentation) was analyzed. Mean ampli-
tudes and mean peak latencies for the considered time window and
electrodes were computed for each deflection.
Endocrine measurements
Saliva samples were collected by passive drool, using a short straw.
Unstimulated whole saliva was used. For each condition, samples
were collected for DHEA, DHEAS and cortisol measurement before
task (BF), at 30 min (30 min after the beginning of the task, 10 to
15min after the end of the task) and 60min (60min after the beginning
of the task, 40 to 45min after the end of the task). The samples collected
before the first condition (i.e. before both the neutral and the negative
condition), were considered as the baseline. Time points to collect the
saliva samples were chosen in accordance to known cortisol raise and
recovery times (raise 10 min after appropriate stimulus, peak at 20–
30 min and recovery at 45–60 min after the end of the stimulus)
(Martins et al., 2001, 2002, 2004; doVale et al., 2011). Furthermore, syn-
chronous 24 h profiles were described for DHEA and cortisol and DHEA
half-life is less than 30 min (Rosenfeld et al., 1975). For this reason, the
second condition was started 2 h after the first one to allow cortisol and
DHEA levels to recover from the influence of the first condition (return
to a “baseline” level).
Unbound DHEA and cortisol in the peripheral circulation pene-
trate into the saliva via intracellular mechanisms and salivary con-
centrations reflect serum concentrations (Ahn et al., 2007; Vining
and McGinley, 1987). DHEAS is not lipid soluble and cannot pene-
trate into the saliva by passive diffusion through cell membranes.
Instead, it squeezes through the tight junctions between salivary
glands. DHEAS concentrations in saliva are therefore dependent on
serum concentration and salivary flow rate (Vining and McGinley,
1987).
Samples were refrigerated at 2–8 °C within 30 min after collection
and were stored at −20 °C within 4 h and until assayed. Each sample
was measured in duplicate using enzyme-linked immunoassays:
salivary DHEA and DHEAS enzyme immunoassay kits (Salimetrics
Europe®, Ltd, Newmarket Suffolk, UK) and high sensitivity salivary
cortisol enzyme immunoassay kits (Salimetrics®, LLC, State College,
PA, USA). DHEA was measured in pg/mL and cortisol was measured
in μg/dL. Due to the influence of saliva flow rates on DHEAS levels,
the concentration of DHEAS (pg/mL) was multiplied by the flow
rate (mL/min) and the corrected results were obtained as DHEAS mea-
sured per unit of time (pg/min). Theminimal concentrations that can be
distinguished from 0 with the used immunoassays are 5 pg/mL for
DHEA, b0.003 μg/dL for cortisol and b43 pg/mL for DHEAS. Intra- and
interassay coefficients of variation were less than 10% and 15% in
every case, respectively.
Statistical analysis
The Statistical Package for the Social Sciences Program (IBM SPSS
Statistics, version 21) was used for data analysis. Results are presented
as the mean ± standard error of the mean (SEM). The normal distribu-
tion of continuous variables was verified by the Kolmogorov–Smirnov
goodness of fit test.
To explore the effects of the implicit emotional content and auditory
distraction on performance, repeated measures analyses of variance
(ANOVA) were performed on hit rate and response time, including the
within-subjects factors emotional condition (NEU and NEG) and type
of auditory stimulus (standard and novel). Regarding brain responses,
ERPs time-locked to the auditory stimuli were analyzed to explore dis-
traction effects. ERPs time-locked to the visual stimuli (the faces) were
analyzed to explore emotional context effects. To investigate the effects
of the emotional context and auditory distraction on brain responses to
auditory stimuli, repeated measures ANOVAs were carried out on audi-
tory P3 mean amplitude in the timewindow and electrodes considered
above, including the within-subjects factors emotional condition (NEU
and NEG) and type of auditory stimulus (standard and novel). To inves-
tigate the effects of the emotional context on brain responses to visual
stimuli, only standards were included and ANOVAs were performed
on the visual P300mean amplitude in the timewindows and electrodes
considered above, with emotional condition (NEU and NEG) as within-
subjects factor. To investigate the effects of emotional context manipu-
lation on endocrine levels, repeatedmeasures ANOVAswere performed
on DHEA, DHEAS and cortisol levels, including the within-subjects
factors emotional condition (NEU and NEG) and measurement time
(before task, at 30 min and 60 min).
To investigate the endocrine relation to distraction and emotional
context effects at the behavioral level, the previous repeated measures
ANOVAs of behavior parameters were repeated, including baseline
DHEA, DHEAS, cortisol, DHEA/cortisol ratio or DHEAS/DHEA ratio as
covariates. Whenever the endocrine parameters covariated with the
performance or ERP parameters for each type of auditory stimuli or
emotional condition, we performed simple or multiple regression anal-
yses to select the relevant independent endocrine factors and/or to un-
derstand the direction of the relationship. Lastly, as visual P300 peak
latency in both emotional contexts was not directly related, in order
to find the relation between visual P300 peak latency and endocrine
parameters, linear and multiple regression analyses were used with
the endocrine parameters as independent variables.
ANOVA results were Greenhouse–Geisser corrected whenever the
assumption of sphericity was violated. The limit of significance chosen
wasα=0.05. Post hoc tests were carried out wherever there were sig-
nificant interactions between main factors and the Bonferroni correc-
tion was applied for multiple comparisons. For the endocrine relations
to performance or ERPs the alpha thereforewas set to 0.01 as the effects
were tested for five variables (cortisol, DHEA, DHEAS, DHEA/cortisol
ratio and DHEAS/DHEA ratio). Effect size estimates of the results were
expressed as eta squared (η2) for ANOVAs and correlation coefficients
(r) for regression analyses.
Results
Performance
Behavioral results for each condition and trial type are presented in
Fig. 2. There was a main effect of emotional context on response time
[F(1,20) = 17.51, p b 0.001, η2 = 0.47], with longer response times
under the emotionally negative context (433 ± 17 ms) than under
the neutral one (379 ± 12 ms). Furthermore, there was a main effect
of trial type on response time [F(1,20) = 31.88, p b 0.001, η2 = 0.61],
with longer response times for novel (423 ± 13 ms) than for standard
(389±14ms) trials, indicating that the novel sounds causeddistraction
of visual task performance (Fig. 2.A). Overall hit rate was 88 ± 1% and
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No clear N1-enhancement/MMNnor RONwas elicited and therefore
our analysis focused only on the nov-P3. In fact, the nov-P3 was signif-
icantly elicited as supported by the significant differences of the mean
amplitudes in the auditory P3 latency window for standard and novel
trials [F(1,20) = 169.09, p b 0.001, η2 = 0.89;−2.3 ± 0.4 μV in standard
and +1.7 ± 0.5 μV in novel trials], see Fig. 3.A and B. However, there
were no effects of emotional context on the auditory P3 (see Fig. 3.C),
as no significant interaction between emotional context and auditory
stimulus type was found.
Emotional context effects
The waveforms elicited by standard trials in the two emotional
contexts are presented in Fig. 3.D. No significant emotional effects
were observed on visual P300 as its amplitude was similar in both
conditions. Also, there were no significant latency differences in P300,
between emotional conditions.
Endocrine baseline levels and reactivity
Baseline endocrine levels were: DHEA 254 ± 41 pg/mL, DHEAS
5856 ± 690 pg/min and cortisol 764 ± 100 pg/mL, following a normal
distribution. Baseline DHEA level was directly related to baseline
cortisol level (r =+0.63, p = 0.002, n = 21). There was no significant
relation between baseline DHEAS and DHEA or DHEAS and cortisol
level. Nevertheless, baseline DHEAS levels were directly related to
baseline DHEA/cortisol ratio (r = +0.56, p = 0.008, n = 21). Baseline
endocrine parameters were not related to age or body mass index and
did not differ according to menstrual cycle phase or between subjects
taking and not taking hormonal contraception.
DHEA, DHEAS and cortisol mean levels for each condition and sam-
ple time are presented in Fig. 4. The repeated measures ANOVA on
DHEA levels revealed a main effect of measurement time on DHEA
levels [F(2,40) = 5.94, p = 0.007, η2 = 0.24; mean levels were 243 ±
42 pg/mL before task, 258 ± 41 pg/mL at 30 min and 309 ± 45 pg/mL
at 60min], see Fig. 4.A and B. There was no significant relation between
emotional context and DHEA levels. Moreover, there was no interaction
between DHEAS (Fig. 4.C) or cortisol levels (Fig. 4.D) and the emotional
context or measurement time.
Endocrine relations to performance and event-related potentials
We found no significant relations between performance (hit rate
and response times) and endocrine parameters. Regarding event-
related potentials, no significant relations were found between endo-
crine parameters and distraction effects. Nevertheless, significant rela-
tions were found between endocrine parameters and emotional
context. Higher DHEAS/DHEA ratios before performing the emotionally
negative condition were related to reduced visual P300 amplitudes in
this condition. Thiswas revealed by a significant interaction between vi-
sual P300 amplitudes and DHEAS/DHEA ratios [F(1,19) = 9.38, p =
0.006, η2=0.33]with higher DHEAS/DHEA ratios in relation to reduced
visual P300 amplitudes attributed to the negative context (r = −0.58,
p = 0.006, n = 21; see Fig. 5.A). Concerning visual P300 peak latency,
higher DHEA/cortisol (partial r = −0.56, p = 0.003, n = 21) and
DHEAS/DHEA (partial r = −0.60, p = 0.004, n = 21) ratios before
performing the negative emotional context block, were related to
shorter visual P300 peak latencies (Fig. 5.B and C), together explaining
52% of the latency variability. Remarkably, smaller visual P300 ampli-
tudes attributed to the negative context were related to shorter visual
P300 peak latencies (r = +0.53, n = 21, p = 0.015).
Discussion
The present study revealed relations between dehydroepiandroster-
one (DHEA), its sulfated form (DHEAS) and brain processing under an
emotionally negative context induced by images of fearful faces,
suggesting that these neurosteroids may modulate the processing of
emotionally negative information. Although the sounds as well as the
emotional content of the pictures were irrelevant for the task, the
results suggest that the subjects were unable to fully ignore them as
indicated by significant effects on performance and brain responses.
The distraction effect of task irrelevant auditory stimuli as well as the
behavioral disruption due to the processing of task irrelevant negative
emotional stimuli have been shown before by other authors (Escera
et al., 1998, 2000; Domínguez-Borràs et al., 2008, 2009; Öhman et al.,
2001), whereas the relation between the neurosteroids and emotional
processing at the brain level is a new finding.
Novel sounds led to distraction as shown by longer response times
and the elicitation of a significant novelty-P3. Conversely, no clear N1-
enhancement/MMN was observed in our results, probably due to a
very early P3 onset, causing an overlap between the components. Re-
cent studies have shown that small deviant stimuli, and hence large
novel sounds, may activate deviance-detection mechanisms as early as
20 ms from sound onset (see Slabu et al., 2010; Escera and Malmierca,
2014) and therefore attention switching may have had occurred
before the supratemporal activation giving rise to the typical N1-
enhancement/MMN trigger response (Yago et al., 2001). Additionally,
in the negative emotional context, response times were longer than in
the neutral context which implicates that the novel sounds effectively
caused distraction and the emotionally negative context effectively






































Fig. 2. Performance results. A. Mean response times for each condition [neutral (NEU) or
negative context (NEG)] and auditory stimulus type (standard or novel). B. Mean hit
rates for each condition and auditory stimulus type. Error bars represent ±1 standard
error of the mean (SEM).
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Fig. 3. Event-related potentials (ERPs). A. Grand average waveforms at Cz for each emotional context (neutral and negative) and type of sound (standard and novel). B. Mean auditory P3
(aud P3) amplitude for each emotional context and type of sound. C. Grand average of novelminus standard differencewaveforms at Cz for each emotional context. D. Grand average ERPs









































































Fig. 4. Endocrine results. A. DHEAmean levels for each condition and measurement time. B. DHEA levels before task, at 30 min and 60 min. C. DHEAS mean levels for each condition and
measurement time. D. Cortisol mean levels for each condition and measurement time. Error bars represent±1 SEM. The shadow indicates the period of task performance. NEG: negative
emotional context; NEU: neutral emotional context.
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significantly modulate the electrophysiological response to auditory
distraction, contrasting with previous studies (Domínguez-Borràs
et al., 2008; Garcia-Garcia et al., 2008) which found an enhancement
of the visual P300 for emotionally negative stimuli (Domínguez-Borràs
et al., 2008). Nevertheless, in studies using faces, some authors have
found visual P300 enhancement by fearful faces (Luo et al., 2010),
while others reported no changes in P300 amplitude (Balconi and
Lucchiari, 2005) as in the present study. Importantly, in the present
study, the emotional content of the imageswas not relevant for the task.
DHEA levels increased after the performance of both conditions, in-
dependent of the emotional context of the task. Interestingly, a previous
study showed that corticotrophin releasing hormone (CRH) levels
increased with another cognitive task: the visualization of emotionally
significantmovies (Martins et al., 2010). In turn, the present results sug-
gest that cognitive tasks are a stimulus for DHEA secretion andmay lead
to a higher DHEA/cortisol ratio. Moreover, it suggests that DHEA is not
just a stress hormone and that some differential regulation of DHEA
and cortisol exists. In fact CRH stimulates corticotrophin secretion and
in turn corticotrophin is a stimulus for cortisol and DHEA secretion
(Nieschlag et al., 1973). This may explain the direct relation we found
between cortisol and DHEA levels.
Boudarene et al. (2002) studied subjects without mental disorders
and varying levels of anxiety, and found that the level of anxietywas re-
lated to the profile of endocrine response after the performance of cog-
nitive tasks: subjects with high anxiety levels in the STAI test had
increased cortisol reactivity and subjects with low anxiety levels
showed an exclusive increase in DHEAS levels. The authors suggested
that the antagonism in DHEAS and cortisol might be related to compe-
tition in their synthesis and its release by the adrenal gland. This agrees
with the results in the present study, in which all the subjects had low
anxiety levels and a DHEA raise but no cortisol response in relation to
the cognitive task (in both emotional conditions), was found. For non-
pathological conditions and low levels of anxiety, this might eventually
represent an adaptive mechanism that includes higher DHEA than
cortisol responses and anti-cortisol effects of DHEA. DHEA increase
however was identical for both emotional contexts, so that DHEA
increase alone is not expected to be related to performance or electro-
physiological effects of the emotional context.
No significant relation was found between response times or hit
rates and endocrine measurements. A larger sample may be necessary
to uncover endocrine relations to performance. Nevertheless, an inter-
esting finding of the present study consists in endocrine relations to
brain responses. A higher DHEA/cortisol ratio was related to lower visu-
al P300 latencies in the negative emotional context, suggesting DHEA to
be protective froman interference of the implicit negative content of the
stimuli with the task which might represent an anti-glucocorticoid ef-
fect of DHEA. In the negative condition, higher DHEAS/DHEA ratios
were also related to lower visual P300 latencies, thus, a higher propor-
tion of DHEA respective to cortisol and a higher proportion of sulfated
to non-sulfated form of DHEA may protect from any interference with
the task caused by the processing of the implicit emotional content of
the stimuli.
In agreement, higher DHEA levels have been previously found to be
related to shorter P300 latencies (Braverman and Blum, 2003;
Braverman et al., 2009). A protective effect of DHEA and DHEAS could
eventually bemediated by anti-cortisol effects and/or neuromodulatory
effects of these hormones. Wang et al. (2013) associated a prolonged
P300 latency with an attentional bias to negative stimuli in high trait
anxiety subjects, who are expected to have higher cortisol levels. On
the contrary, in the present study examining subjects with low trait
anxiety, higher DHEA/cortisol ratios were related to shorter P300 laten-
cies in the negative condition. Higher DHEA/cortisol could be related to
less interferencewith the task caused by the implicit stressful content of
the stimuli, in agreement with the hypothesis of anti-cortisol effects of
DHEA and suggesting a protective mechanism against the deleterious
consequences of stress. The present results also agree with studies at
the cellular level, in which DHEA was protective against the neurotoxic
effects of corticosterone (Balazs et al., 2008).
Lastly, the visual P300 amplitude increments in the negative emo-
tional context as compared to the neutral one, were inversely related
to DHEAS/DHEA ratios, suggesting that the processing of the task-
irrelevant negative content of the stimuli might eventually be reduced
by DHEAS. Even though the participants of the study were healthy
and depression was not screened by any specific inventory, women in
particular have been shown to be specially sensitive to threatening
stimuli and it has been hypothesized that this might be related to the
higher prevalence of affective disorders in women (Kemp et al., 2004).







































































Fig. 5. Endocrine relations to event-related potentials. A. Higher DHEAS/DHEA ratios be-
fore performing the negative emotional context block were related to reduced interfer-
ence with the task due to the processing of the implicit negative content of the stimuli
as shown by reduced visual P300 amplitudes. B and C. Higher DHEA/cortisol and
DHEAS/DHEA ratios before performing the negative emotional context block, were related
to shorter visual P300 peak latencies. Δ vis P300 amplitude: mean visual P300 amplitude
in the negative minus neutral context.
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disorders and negative mood can be experimentally induced using
various procedures, among others by presenting images of faces with
emotional expressions (Dyck et al., 2011; Schneider et al., 1994, 1997).
Although the mechanisms underlying mood persistence in major
depressive disorder remain poorly understood, cognitive theories hy-
pothesize that depressed patients have cognitive biases for emotional
information, which help perpetuate depressive symptoms (Beck,
1967; Gotlib and Joormann, 2010). The present results suggest that
the processing of negative emotional stimulimay be reduced in relation
to higher DHEAS/DHEA levels, which might eventually be involved in
protectivemechanisms against a negative attention bias and undermine
the relation between higher DHEAS levels and lower frequencies of de-
pression, lower depression ratings and better well-being scores previ-
ously described by other authors (Barrett-Connor and Edelstein, 1994;
Barrett-Connor et al., 1999). In line with this hypothesis, subjects with
higher DHEAS/DHEA ratio would process less and have less memory
updating of the implicit negative content of the stimuli and would
thus have a reduced attentional bias towards these stimuli, which
might promotewell-being and contribute to protection fromdepressive
states.
Emotional stimuli usually capture attention more effectively than
non-emotional ones (Öhman et al., 2001) and have an impact on cogni-
tive functions even when they are task-irrelevant (Domínguez-Borràs
et al., 2008). On the other hand, it is hypothesized that protective
mechanisms filter out irrelevant sensory inputs protecting the higher
brain functions from sensory overload (Braff and Geyer, 1990). Taken
together, our findings concerning visual P300 latency and visual P300
amplitude under an emotionally negative context showed a relation
between higher DHEA/cortisol and DHEAS/DHEA ratios and less
processing of the negative emotional stimuli and less disruption by
the processing of negative emotional stimuli. These results also suggest
that DHEA and DHEAS potentially play a role or contribute to protective
mechanisms filtering out negative information overload.
A simultaneous relation to latency reduction and decrease in P300
amplitude may seem contradictory at first sight, nevertheless, as the
task consisted in deciding whether two faces with the same emotional
expression were equal or different (while the emotional expression
was irrelevant), less processing of the task-irrelevant emotional con-
tent – related to higher DHEAS/DHEA ratios – might be reflected in
smaller P300 amplitudes and at the same time shorter P300 latencies
due to a more efficient processing of the task-relevant visual informa-
tion and less interference resulting from the task-irrelevant emotion.
In other words, the P300 amplitude might be reduced as a reflection
of less neuronal recruitment due to less allocation of attentional re-
sources to the task-irrelevant emotion, while P300 latencies might be
reduced due to a decreased stimulus evaluation time, likewise due to
less processing of the task-irrelevant emotional content of the images.
This interpretation is consistent with the direct relation we found
between reduced P300 amplitudes and shorter P300 latencies.
Furthermore, it is consistent with previous studies showing that
emotional stimuli elicit an enhanced P300 as compared to neutral
stimuli (Schupp et al., 2004) and longer P300 latencies for negative
emotional target stimuli (Fichtenholtz et al., 2007) as compared to
neutral stimuli. Additionally, emotional stimuli outside the atten-
tional focus have been shown not to elicit an enhanced P300
(MacNamara and Hajcak, 2009).
Endocrine relations to auditory distraction were not found in the
present study: DHEA, DHEAS and cortisol were not related to the
novelty-P3, suggesting that their levels do not modulate auditory dis-
traction processing under an emotionally negative context. This differs
fromour previous findings concerning auditory distraction underwork-
ingmemory load, inwhichwe found that the novelty-P3 amplitudewas
enhanced in relation to higher baseline cortisol/DHEA ratios (do Vale
et al., 2014). It also suggests that the influence of the endocrine
parameters on auditory distraction, may depend on the cognitive task
involved.
The present results also highlight the relevance of the balance be-
tween DHEA, DHEAS and cortisol concerning the processing of negative
emotions. Importantly, these results agree with findings at the clinical
level, in which higher DHEAS concentrations and DHEA-to-cortisol ra-
tios but not DHEA levels alone were related to less frequent depression,
less depressive mood and higher well-being scores (Barrett-Connor
et al., 1999; Michael et al., 2000; Young et al., 2002). Although DHEA
and DHEAS can be converted into each other and general common ef-
fects are expected for the sulfated and non-sulfated form of the hor-
mone (Baulieu and Robel, 1998; Dong and Zheng, 2011; Maninger
et al., 2009), several differences exist in their mechanism of action. For
instance, DHEAS has a much more potent excitatory action by NMDA
agonism and gabaminergic antagonism than DHEA, whichmay account
for some differential effects (Baulieu and Robel, 1998; Imamura and
Prasad, 1998;Monnet et al., 1995).Moreover, as stated, sulfated steroids
in general possibly act as endogenous neuromodulators (Gibbs et al.,
2006) and the balance between DHEAS and DHEA might influence
brain functioning. Previous studies at the cellular and molecular level
showed that DHEAS had neuroprotective effects mediated through
GABA-A receptor antagonism (Majewska, 1992), DHEAS stimulated do-
pamine release from rat hypothalamic cells (Murray and Gillies, 1997)
and DHEAS antagonized the neurotoxic effect of high doses of DHEA
(Gil-ad et al., 2001). These studies suggest potential mechanisms by
which DHEAS could have more potent anti-depressant effects than
DHEA and agree with the present finding that higher DHEAS/DHEA ra-
tios were related to reduced processing of the negative emotional
content.
In the present study, the participants were in different menstrual
cycle phases and some were using hormonal contraception. This is a
limitation, as DHEA, DHEAS and cortisol levels can change along the
menstrual cycle and with the use of hormonal contraception (Fern
et al., 1978; Wiegratz et al., 2003). Nevertheless, eventually in relation
to the small sample size, in the present study, the endocrine levels
were not significantly different according to the menstrual cycle phase
or the use of hormonal contraception. But even considering that
DHEA, DHEAS or cortisol levels could change along the menstrual
cycle or with the use of hormonal contraception, the relations found be-
tween endocrine levels and emotional stimuli processing would not be
invalidated. In any case, given the randomized approach we used
concerning the menstrual cycle phase, the present results are expected
to be independent of the menstrual cycle phase. Finally, the fact that
only female participants were included, limit the outreach of the
present study only to women. DHEAS levels differ between genders,
therefore, another group of participants would be necessary to extend
our conclusions also to men. For further studies, it would be relevant
to study whether the results are identical in men.
Conclusions
In a nutshell, in women, during the processing of stimuli with nega-
tive emotional content, higher DHEA/cortisol and DHEAS/DHEA ratios
were related to shorter visual P300 latencies, suggesting a relation of
these endocrine parameters with shorter stimulus evaluation time and
less interference with the task at hand due to the processing of the
task-irrelevant negative content of the visual stimuli. Additionally,
higher DHEAS/DHEA ratios were related to reduced visual P300 ampli-
tudes suggesting less processing of the negative information, which
might constitute a protective mechanism against negative information
overload.
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